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The ovine Maedi Visna Virus (MVV) and the Human Immunodeficiency Virus Type 1 (HIV-1) are
members of the lentiviririae retrovirus subfamily. Lentiviruses possess a complex genomic organisation,
encoding several genes with a regulatory or auxiliary function. Alternative splicing of the genomic-length
primary transcript is used to express this complexity. mRNA expression is subject to temporal regulation in
both MVV and HIV-1. In HIV-1 a highly basic protein. Rev, mediates this regulation. Rev function requires
binding to a highly structured RNA target, the Rev responsive element (RRE), and may involve facilitation of
RNA nucleocytoplasmic export. Rev/RRE interaction is essential for virus replication. There is little overall
sequence homology between lentivirus Rev proteins. However, functionally important basic and leucine-rich
motifs are conserved. These domains are found within the putative MVV Rev protein, and a predicted RRE-
like structure is present in a similar genomic location to that in HIV-1.
To compare the mode of action of MVV Rev with that of HIV-1 Rev, a series of functional assays were
planned. The rev gene of a British isolate of MVV (EV-1) was cloned and sequenced. Recombinant Rev was
expressed as a fusion protein in yeast and bacterial systems. A polyclonal antiserum directed against a
synthetic Rev polypeptide was generated to aid purification. Expression in yeast was characterised by a low
product yield, due to the highly toxic nature of the Rev fusion protein. Alternative expression and
purification protocols were unable to greatly improve the yield and purity of product. The bacterial pGEX
system, in which Rev was fused to glutathione S-transferase (GSTRev), was employed as an alternative.
Purification by affinity chromatography resulted in an improved yield and purity of product. Partial instability of
the fusion protein may have resulted in observed contamination.
Binding of GSTRev to RNA corresponding to the predicted RRE was assayed by filter binding
experiments. A specific vector context and low temperature were required to generate high quality RNA.
GSTRev bound with high affinity to RRE-RNA, but not to RNA corresponding to antisense RRE. Addition of
a non-specific competitor RNA reduced binding to antisense, but not sense, RNA.
Rev is the least well conserved protein amongst sequenced isolates of MVV. To test for the
functional conservation of the Rev/RRE axis, the cross reactivity of Rev function on heterologous RREs was
examined by transient transfection assay. Whilst cross-strain functional reciprocity was observed, both the
EV-1 and 1514 isolate Rev proteins demonstrated greatest activity on cognate RRE. Co-divergence of the
rev gene and RRE structure of each strain has therefore occurred. MVV Rev was able to function through
the RRE of the closely related caprine arthritis encephalitis virus. These results may have implications for the
possible development of anti-lentiviral gene therapy based on frans-dominant, inhibitory Rev molecules.
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The lentivirinae subfamily of exogenous, non-oncogenic retroviruses establish life-long
infections in host organisms. These viruses are so named due to the extended asymptomatic
period, insidious onset and relentless nature of disease (lentus: slow Latin). Lentiviruses share
the ability to persist within the host during the asymptomatic period despite vigorous immune
responses. Cells of the immune system are targets for infection, and resulting destruction and/or
dysregulation of the immune system is responsible for pathology. Retroviruses possess an RNA
genome, and replicate via a DNA intermediate, which characteristically integrates into the host
genome to form the provirus.
The prototypic member of the lentivirus genus is the ovine Maedi-Visna virus (MVV).
Importation of sheep inapparently infected with MVV was responsible for epidemics of
progressive interstitial pneumonia (maedi in Icelandic) and progressive paralysis (visna in
Icelandic) which devastated Icelandic sheep flocks between 1939 and 1952 (Sigurdsson, 1954).
The single viral aetiology of these diseases was demonstrated in 1967 (Gudnadottir and Palsson,
1967). MVV is also known as ovine progressive pneumonia virus (OPPV) (Cutlip and Laird, 1976)
or ovine lentivirus (OvLV) (Lairmore etal., 1986). Other members of the lentivirus genus include
equine infectious anaemia virus (EIAV) (Dreguss and Lombard, 1954), bovine immunodeficiency
virus (BIV) (Van der Maaten etal., 1972), caprine arthritis encephalitis virus (CAEV) (Crawford et
al., 1980), simian immunodeficiency virus (SIV) (Daniel etal., 1985), feline immunodeficiency
virus (FIV) (Pederson et al., 1987), and human immunodeficiency virus (HIV) type 1 (Barre-
Sinoussi et al., 1983) and type 2 (Clavel et al., 1986). The field of lentivirus research was
stimulated by the lentiviral classification of HIV-1, the primary aetiological agent of the current
human pandemic of acquired immunodeficiency syndrome (AIDS) (Chiu et al., 1985).
Subsequent research effort has focused on HIV. Throughout this thesis the literature
concerning HIV will be extensively quoted.
1.2 Lentiviral Phylogeny
Traditional approaches to the decipherment of the evolutionary relationships of the
lentiviruses have been based on phylogenetic tree analysis using sequence data obtained from
conserved sections of the genome, for example the reverse transcriptase region of pol (see
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figure 1.1). This is hindered by the extremely high evolutionary rates achieved by lentiviruses
(~106 fold faster than the DNA genomes of 'higher' organisms) (Gojobori et al., 1990). A
consensus has emerged that the primate lentiviruses form five groups within a distinct clade (see
legend to figure 1.1) (Huet et at., 1990; Myers etal., 1992; Hirsch eta!., 1993), and that the ovine
and caprine lentiviruses form a second clade (Querat et at., 1990). The relatively recent time scale
for lentiviral radiation is supported by most authors. Querat and colleagues suggest that the
divergence of the ungulate and primate viruses occurred -430 years ago (1990). However, the
position of the non-primate lentiviruses remains uncertain.

























The evolutionary relationships of the lentivirus family. An adaptation from published evolutionary tree
analyses, based on data from gag coding sequences (Garvey etal., 1990; Querat etal., 1990; Myers et
al., 1992: Hirsch et at., 1993). Analyses concur on the relationships of the primate viruses; the position of
the non-primate viruses is less clear. Question marks (?) identify divergence points of greatest
uncertainty. Branch length is for clarity only, and is not to scale. SIV sequences isolated from African green
monkeys (agm), mandrills (mnd), chimpanzee (cpz), rhesus macaques (mac), African Sykes' monkey (syk)
and sooty mangabeys (smm). Consensus clades are marked with Roman numerals (l-VI). These groups,
and prototype viruses are: I - HIV-1, I I - HIV-2, 111 - SlVgy^, I V - SIVagm, V - SIVmncj and VI - MVV.
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1.3 Pathology of MVV Infection
MVV infection is characterised by a prolonged prepatent period of between one to three
years, although longer periods are possible (Sigurdsson, 1954). Subsequent clinical disease is
generally progressive in nature, with any degree of regression of symptoms accompanied by
inevitable recrudescence. Pathological lesions are typically of inflammatory origin, and may occur
in a number of organs. Death normally occurs within 6-12 months of the onset of symptoms.
Animals suffering MVV disease typically present with loss of condition and respiratory
distress (maedi). This is due to a lymphoproliferative interstitial pneumonia. Heavy accumulation
of inflammatory cells within the pulmonary septa reduces the efficiency of gaseous exchange.
The lung may swell to four times its normal mass (Sigurdsson, 1954). Severe lung disease may
result in smooth muscle hyperplasia and the formation of lymphoid follicles with active germinal
centres (Lairmore etal., 1986).
Neurological disease (visna) occurs as a complication of maedi. It is characterised by
locomotive dysfunction, leading to hind limb paralysis and occasionally paraplegia (Sigurdsson
et at., 1957). Inflammatory lesions within the central nervous system (CNS) lead to demyelination
and gliosis (Sigurdsson etal., 1957; Stowring et at., 1985). Although lesions may extend into the
grey matter, destruction of neurones is rare (Sigurdsson and Palsson, 1958). Meningitis may also
occur (Oliver et at., 1981).
Pathology in the mammary gland is similar to that in the lung, with chronic infiltration of
inflammatory cells in the parenchyma and formation of germinal centres leading to chronic mastitis
(Van der Molen etal., 1985).
Chronic arthritis may occur as a further complication of maedi. Pathology in the joint
involves swelling and calcification of soft tissue, perivascular lymphocytic infiltration and a degree
of fibrosis and ossification (Oliver et at., 1981). Arthritis is the dominant disease manifestation in
adult goats of infection with CAEV (Crawford etal., 1980). The carpal joint is typically affected,
and in severe cases joint deformation may render limbs useless. CAEV disease also has
pulmonary, neurological and mammary gland forms, although, unlike visna, caprine encephalitis is
generally manifest in young animals and has a rapid course (Cork et a!., 1974).
It is unclear how viral replication relates to pathogenesis. It is clear that in the MVV
infected sheep, pathological lesions are closely associated with sites of active virus expression
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(Brodie etal., 1995). The severity of CNS lesions can be reduced by host immunosuppression
before infection (Nathanson etal., 1976). Viral antigens are likely to drive the immune response,
leading to inflammatory infiltration. Pathology might be the result of chronic stimulation of the
immune system.
1.4 MVV Genomic Organisation
Information as to the genetic structure of MVV has been obtained by the sequencing of
viral isolates. To date, six isolates of MVV have been sequenced. These are four variants of the
Icelandic neurovirulent strain KV1514 (Sonigo etal., 1985; Braun etal., 1987; Staskus et al.,
1991b; Andresson etal., 1993), the British isolate EV-1 (Sargan etal., 1991) and the South
African SA-OMVV (Querat etal., 1990). These viruses demonstrate similar structures, although
there is a high degree of sequence divergence. The EV-1 isolate has a 9203 base genome
(Sargan et al., 1991), and is representative of all sequenced isolates. Figure 1.2 illustrates the
genomic structure of MVV: for comparison the structure of HIV-1 and the distantly related
oncovirus, Fluman T-Cell Leukaemia Virus Type 1 (FtTLV-1) (Poeisz etal., 1980) are also shown.
The basic features of retrovirus genomes are present. These include the flanking long terminal
repeats (LTR), composed of the U3, R and U5 regions. U5 contains the complementary site for
binding of the cellular tRNA (tRNA-| 2lys) and U3 a polypurine tract, both of which are required for
completion of viral replication (Sonigo etal., 1985). Also contained within the LTR are sequences
which direct and regulate the transcription of the viral genome.
MVV encodes six open reading frames (ORF) for the expression of viral proteins. Three
of these, gag, poland env, are homologous to genes common to all retroviruses. The remaining
ORFs encode proteins with a putative regulatory or auxiliary function. This genomic complexity is
a hallmark of the lentivirus genus. The additional ORFs are located between pol and env, and in
the 3' env /LTR region. In MVV, these additional ORFs give rise to the proteins Tat, Rev and
Vif.There is an additional ORF(W) in SA-OMVV. There is no evidence, however, for translation of
this ORF (Querat etal., 1990).
1.5 Viral Proteins
MVV expresses the basic complement of structural and enzymatic proteins common to
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Figure 1.2: Genomic Organisation of Complex Retroviruses
The genomic structures of the lentiviruses, Maedi Visna virus (MVV) and Human
Immunodeficiency virus type 1 (HIV-1), and of the oncovirus Human T-Cell Leukaemia virus type 1
(HTLV-1) are shown. Structures are to scale. Genomes are delineated by the long terminal
repeats (LTR). This region contains three subdomains, U5, R and U3. Genes encoding structural
(gag, env) or enzymatic (pot) proteins are shown. The pro (protease) coding region of the
lentiviruses is contained within the pol gene, but is out of frame with pol in HTLV-1.
Regulatory/auxiliary genes are present between the pol/env genes, and at the 3' end of the
genomes. Bipartite genes are marked (tat/tax: light stippling, rev/rex: dark stippling) The tripartite
























































all retroviruses. These proteins are encoded by the gag, po/and env genes (Baltimore, 1974).
Much of the data concerning MVV proteins is derived from the work of Vigne and colleagues
(1982). However, the full range of viral activities remains to be completely characterised, and in
several instances these have been inferred from comparison of the MVV coding capacity with
that of other retroviruses.
The general strategy of retroviral protein expression is the production of polyprotein
precursors from which functional activity is released by proteolysis. The major precursor of the
MVV gag polypeptides is a non-glycosylated protein of 55kDa (Pr559a9) (Vigne etal., 1982).
This is processed to generate the virion internal structural proteins. The matrix protein (MA, p16)
interacts with the envelope. The HIV-1 equivalent, p17, directs the nuclear import of the viral pre-
integration complex during the infection process (Bukrinsky etal., 1993). The particle core is
formed by multimerisation of the capsid protein (CA, p25). The highly basic nucleocapsid protein
(NC, p14) binds to the viral genomic RNA within the core. MVV has no equivalent of the carboxy-
terminal proximal Gag protein, p6, found in primate lentiviruses.
Gag sequences are also contained within a second 150kDa molecule (Vigne et al.,
1982). By analogy with other retroviruses, this is believed to be a Gag/Pol polyprotein precursor
(Pr1509a9"Po1), which is generated by a ribosomal frame shift event. A polypurine tract and RNA
hairpin located within the gag!polgene overlap mediates shifting of the ribosomal complex into
the -1 reading frame. The ratio of Gag to Pol products is set by the frequency of this event. Pol
derived polypeptides have enzymatic activities, including reverse transcriptase, protease and
integrase. The MVV reverse transcriptase is Mg2+dependent (Lin and Thormar, 1970) a property
shared by all lentiviral enzymes, which distinguishes them from the Mn2+ dependence of type-C
oncoviruses. MVV also contains a putative deoxyuridine triphosphatase (dUTPase) activity, a
feature shared with CAEV, FIV and EIAV (McClure etal., 1987; Elder et al., 1992), but not by the
primate or bovine lentiviruses. Loss of functional dUTPase activity is associated with severe
restriction of viral replication in primary cells though not established cell lines in both FIV
(Wagaman etal., 1993) and EIAV (Lichtenstein etal., 1995). dUTPase may act to both reduce the
rate of misincorporation of dUTP for dTTP during DNA synthesis, and to increase the pool of
dTTP in non-dividing cells where the concentration of dNTPs is low. MVV integrase activity has
been characterised (Katzman and Sudol, 1994); however, production of the predicted protease
has yet to be demonstrated.
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A glycosylated 150kDa protein is the precursor of the MVV envelope proteins
(Pr150env) (Vigne eta!., 1982). There are 28 potential N-linked glycosylation sites within the Env
protein (Sonigo et al., 1985), and three hydrophobic regions characteristic of retroviruses
(Kiyokawa et al., 1984). The first of these acts as a signal peptide to target Pr150env to the cell
membrane. It is not known whether this peptide is subsequently removed from the mature
protein. A protease cleavage site divides Env into two components, the surface glycoprotein
(SU) gp135, and the transmembrane protein (TM) gp46 (Vigne et al., 1982). Gp135 is the
putative ligand for the MVV cellular receptor, whereas gp46 is thought to mediate fusion.
Products of the small ORFs have been identified in MVV infected cells. These are Tat
(10-11kDa) (Davis and Clements, 1989), Rev (19kDa) (Mazarin et al., 1990) and Vif (29kDa)
(Audoly et al., 1992). These proteins will be discussed in detail later.
1.6 The Viral Lifecycle
Infection of a potential host cell is initiated by binding of the virion to a cellular receptor.
Two putative receptor molecules for MVV have been described; an unidentified 50kDa protein
(Crane etal., 1991) and ovine MHC class II (Dalziel et al., 1991). This antigen may form one
component of the cellular receptor, since expression of class II is insufficient to mediate MVV
susceptibility. The cellular receptor must be widely distributed; MVV infection has been reported
in various cell types, including cells within the choroid plexus (Brahic et al., 1981),
oligodendrocytes and astrocytes in the CNS (Stowring etal., 1985) and bronchiolar epithelial
(Geballe et al., 1985) cells. The major target for MVV in vivo, however, are cells of the
monocyte/macrophage lineage (Narayan et al., 1982; Gendelman et al., 1985). MVV does not
replicate within T lymphocytes (Gorrell et al., 1992), a property shared by CAEV and EIAV, and
one which differentiates these viruses from the primate, feline and bovine immunodeficiency
viruses, for which T lymphocytes are a major host cell (Narayan and Clements, 1989). The cellular
receptor for HIV-1 infection, CD4, has been characterised (Dalgleish et al., 1984).
Binding to the cellular receptor is followed by fusion of the virion with the cell membrane,
entry and uncoating. Reverse transcription of the genomic RNA then proceeds, primed by the
binding of tRNA'ys1i2to the primer binding site in the LTR (Coffin, 1990); in HIV-1 this may occur
within a virion-derived particle, demonstrating the importance of uncoating (Zhang et al., 1995).
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The double stranded DNA product of reverse transcription is the substrate for integration into the
host genome. However, the role of integration in MVV infection is uncertain. A failure to detect
integrated provirus in in vitro infected cells has been reported (Harris etal., 1984). Vigne and co¬
workers did, however, observe integration during infection of foetal cornea cells (1985).
Moreover, integrase deficient mutants of CAEV and HIV-1 are not infectious (Turelli etal., 1994;
Wiskerchen and Muesing, 1995). This supports the supposition that integration is an obligate
step in the retroviral life cycle; re-examination of the MVV integration state using more
sophisticated PCR analysis may resolve the issue.
1.6.1 In Vitro Replication
The integrated provirus is transcribed by the cellular RNA polymerase II. From this stage,
the replicative cycles in vivo and in vitro diverge. In vitro infection of permissive cells, such as
choroid plexus fibroblasts results in massive RNA amplification (up to 4000 copies per cell)
(Brahic et ai, 1981) and extensive cytopathic effect (syncytia formation) induced by the
production of viral Env protein. Virion formation requires packaging of two copies of the viral
genomic RNA and the Gag and Pol proteins to form a viral capsid, which is surrounded by Env
containing plasma membrane. The retrovirion is functionally diploid. The RNA packaging signal
has not been described for MVV, however in other retroviruses, including HIV-1, an area of
extensive predicted secondary structure in the 5' untranslated region (y) has been shown to
bind specifically to the Gag nucleocapsid polypeptide (Lever et at., 1989; Darlix etal., 1990;
Harrison and Lever, 1992). Mature extracellular MVV virions are pleiomorphic, with diameters in
the range 90-130nm, and possess condensed nucleoid cores (Thormar, 1961; Coward etal.,
1970).
1.6.2 The In Vivo Life Cycle: Restricted Replication
The lytic replicative cycle is not demonstrated by virally infected cells isolated from the
host animal. Co-cultivation with permissive cells is required to recover virus from in vivo derived
cells. Thus viral replication appears to be subject to an in vivo block: this phenomenon has been
termed 'restricted replication' (Haase etal., 1977; Brahic et at., 1981). It has been hypothesised
that restricted expression is the mechanism which allows lentiviral persistence in the host despite
a vigorous specific immune response, and also explains the prolonged prepatent period (Haase,
1986).
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The viral structural proteins appear to form the major targets for both the humoral and cell
mediated immune responses against both MVV and HIV infection (Schrier etal., 1989; Blacklaws
et al., 1994); however there is some evidence to suggest the presence of cytotoxic T cells
directed against the regulatory protein Net (Culmann etal., 1989). Infected cells not expressing
structural proteins might thus avoid immune system surveillance. This could be achieved by
suppressed transcription or by a post-transcriptional mechanism, possibly based on the
maintenance of subthreshold levels of the viral regulatory protein, Rev (see 1.11). It is thus
possible to distinguish restricted replication (the presence of viral RNA and possibly regulatory
proteins but no structural proteins) from true latency (little or no viral RNA) at the single cell level.
Results from early studies of animals infected with high experimental doses of MVV are
consistent with the restriction hypothesis. Thus, intracranial injection with MVV was found to
result in extensive (18%) infection of choroid plexus cells with viral DNA: however, structural
proteins were detected in only a small fraction (0.1%) of these cells (Haase etal., 1977). In a
similar experiment, Brahic and colleagues observed viral infection of 1-3% of choroid plexus cells
(1981). Viral RNA was detected in a similar proportion of cells, at copy numbers 100-fold lower
than observed in lytic infection. Thus it was suggested that restricted transcription was at least
partially responsible for the replicative block in vivo.
Infected monocytes derived from the blood-stream and CNS of naturally infected animals
also display restricted replication. Differentiation of monocytes into tissue macrophages induces
the transition from restricted to productive replication phases in both MVV and CAEV infection
(Narayan etal., 1983; Gendelman et al., 1986). This mobile population of cells may thus act as the
primary disseminating agents of MVV infection throughout the host organism: the Trojan Horse'
hypothesis (Peluso et al., 1985). Monocyte precursor cells within the bone marrow containing
latently integrated provirus may form a reservoir for infection: infected monoblasts with very few
viral RNA copies have been reported (Gendelman et al., 1985).
The use of PCR based in situ localisation techniques have allowed the observation of
previously undetectable single genomic copies of viral DNA. A reservoir of infection has been
detected within the lymphoid organs of HIV infected individuals (Embretson et al., 1993;
Pantaleo etal., 1993). It is clear that the majority of infected cells in lymphoid tissue (99-99.75%)
are in a latent state, expressing no viral RNA (Embretson etal., 1993). Using a pulmonary model
of MVV infection, Haase and co-workers detected viral DNA in the majority of bronchiolar
epithelial cells; however, only a fraction of these (10%) contained viral RNA, and this was present
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at low copy number (Staskus et al., 1991a). However, in both HIV and MVV infected individuals,
there appears to be a small population of cells undergoing productive infection at all stages
throughout infection: there is therefore no true clinical latency (Staskus etal., 1991a; Pantaleo
eta!., 1993). That these cells might be more numerous in the MVV infected host may be a
consequence of higher basal level transcription in this virus (see section 1.10.tat). Seeding of
the periphery with latently infected cells results in productive infection on cell differentiation
(monocytes) or activation (lymphocytes). In turn, this may result in immune-mediated disease. In
MVV infection this may take the form of dysregulation of the immune response, with immune cell
infiltration and inappropriate release of mediating factors such as cytokines.
1.7 Viral Transcription
The MVV proviral LTR contains both promoter and enhancer activity (Hess etal., 1985).
Constructs containing a reporter gene under the control of the LTR are expressed in activated
macrophages in transfected animals (Small etal., 1989; Clements et al., 1994). Thus it is likely
that the regulation of MVV expression due to the activation state of the host cell is a function of
sequences within the LTR. Putative elements have been mapped to the enhancer region within
the U3 section of the LTR, and consist of potential binding sites for the transcription factors AP-1
and AP-4 (Hess et al., 1989). The 1514 isolate of MVV contains six degenerate copies of the AP-
1 site, four of which are contained within two 43bp repeat sequences. Only the TATA box
proximal AP-1 site matches the consensus sequence. This site binds the AP-1 factor (a dimer of
the factors Fos and Jun) (Gabuzda et al., 1989; Shih et al., 1992). Induction of cell activation,
either by stimulation with serum or phorbol ester or during differentiation of monocytes into
macrophages, is associated with rapid upregulation of the levels of these factors (Shih etal.,
1992). This supports the hypothesis that the In vivo restriction of viral expression is
predominantly a transcriptional phenomenon. Significant variation in the sequence of the
enhancer elements has been noted; in the British isolate EV-1 there is only one 43bp repeat and
the TATA box proximal AP-1 site does not conform to consensus (Sargan et al., 1995). Moreover,
studies have found a lack of AP-1 binding activity to the EV-1 LTR, and implicated a novel ~40kDa
transcriptional factor in the regulation of EV-1 LTR activity (Sutton et al., submitted).
Transcription in activated cells or during lytic infection in vitro produces a genomic length,
9.4kb transcript. Differential splicing of the primary transcript results in the generation of a
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Figure 1.3: Transcript Pattern of Maedi Visna Virus
A
Genomic structure of Maedi Visna Virus. Numbers refer to genomic size (in kb). The
bipartite gene, rev, is stippled. Major elucidated splice sites are depicted: filled triangles: splice
donor sites, open triangles: splice acceptor sites. Position of sites based on data from Vigne el
al., 1987; Sargan and Bennet, 1989. Minor splice sites have been located (Sargan and Bennet,
1989): Observed variations in transcript size (for example 1.2-1.4kb rev mRNA) are explained by
utilisation of these alternative sites.
B
Major exons. Numbering derived from Vigne et al., 1987.
C
Major subgenomic mRNA species. Coding regions are depicted as open boxes. Exons 1
and 2 are non coding. Potential translation product of each species is shown, together with
predicted mRNA size. Two size classes are evident: singly spliced 3.5-4.6kb RNA and multiply
spliced 1.2-1,6kb RNA. Three of the mRNAs are bicistronic; there is evidence for translation o
both Tat and Rev from a single multiply spliced transcript in an in vitro translation system (Davis anc
Clements, 1989). Multiply spliced transcripts with three or four exons have been reported: the
































complex pattern of sub-genomic mRNAs (Vigne et al., 1987; Sargan and Bennet, 1989)
characteristic of Antiviruses, including HIV-1 (Muesing et al., 1985), and of other 'complex'
retroviruses, including HTLV-1 (Seiki et al., 1985). Alternative splicing is one mechanism which
allows a high proportion of the retroviral genome to encode protein: only a single set of
regulatory/processing signals are required. Such economy is characteristic of RNA viruses. The
basic transcript pattern of MVV is illustrated by figure 1.3. All transcripts contain common 5' and 3'
sequences (Vigne et al., 1987). Three size classes of mRNA are discernible; 9.4kb genomic
v-i rvs SC. to
RNA encoding Gag and Pol, 3.7-4.8kb singly spliced RNA encoding Env and Vif and 1.2 and
1.6kb multiply spliced mRNA encoding the putative regulatory proteins Rev (Mazarin etal., 1988)
and Tat (Davis and Clements, 1989) respectively. The complexity of the Antiviral transcription
pattern (HIV-1 expresses over 20 distinct mRNA species) necessitates the presence of efficient
regulatory mechanisms. In all retroviruses, c/s-acting signals control the efficiency of alternative
splicing events (see 1.13.3). However, in MVV the accumulation of transcripts is subject to
temporal regulation. Specifically, viral RNA is enriched for multiply spliced transcripts early after
infection; singly spliced and unspliced message accumulates at later time points (Vigne et al.,
1987; Sargan et al., 1994). A similar biphasic pattern is observed in HIV-1 and HTLV-1 infected
cells (Hidaka etal., 1988; Kim etal., 1989a). In HIV-1, the genes rev, tat and net are early gene
products, and the remaining auxiliary genes are expressed in the late phase. Regulation of
mRNA accumulation allows efficient separation of regulatory/amplification and assembly phases,
and may play an essential role in viral persistence. Temporal regulation of viral RNAs is a feature of
a number of DNA viruses, including the herpesviruses and adenovirus, and is achieved by the
presence of stage-specific promoters. A similar strategy has been proposed to have been
adopted by the spuma-retrovirus subfamily (Lochelt etal., 1993). In contrast, regulation in the
other complex retroviruses occurs at the post-transcriptional level and is mediated by an RNA
binding protein, Rev (section 1.10).
1.8 Lentivirus Auxiliary Genes
The presence of several small proteins with a regulatory or auxiliary function is
characteristic of a group of retroviruses which have been termed 'complex' (Cullen^, 1991). In
addition to the Antiviruses, this grouping includes certain oncoviruses (prototype HTLV-1) and
the spumaviruses (prototype, Human Foamy Virus: HFV) (Achong etal., 1971). The extent of the
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evolutionary distance between these viruses suggests that auxiliary gene products with similar
functions are likely the product of convergent evolution, and are not derived from genes found in
a common ancestral virus. Recombination, transduction of cellular genes ('gene capture') and
duplication are all possible mechanisms for the genesis of the auxiliary genes (Myers etal., 1992;
Tristem etal., 1992; Kubota etal., 1994). The greatest array of auxiliary genes is displayed by the
lentiviruses. Table 1.1 lists the complement of genes found in each of the studied lentiviral
species.




tat rev nef vif vpr vpu vpx
HIV-1/SIVcpz Y-1 Y Y Y Y Y N
HIV-2/SIVmac Y-1 Y Y Y Y N Y
SIVagm Y-1 Y Y Y Nc N Yc
SIVmnd/SIVsyk Y-1 Y Y Y Y N N
MVV Y-2 Y Na Y Nd N N
CAEV Y-2 Y N Y Nd N N
EIAV Y-1 Y N N N N N
BIV Y-1 Y N Y Ne N N
FIV Y-2 Y Nb Y N N N
Presence of each of the seven authenticated in vivo auxiliary gene products of lentiviruses in the genome
of each phylogenetic group is illustrated. Y: gene present, N: gene not present. Additional information -
tat: 1 - tat/TAR system, 2 - TAR independent system (see 1.9). nef: a - genome contains region with
potential to encode sequence with degree of homology to nef (Sargan et al., 1991): not translated in all
strains: b - report of nef activity in the TM2 FIV strain (Miyazawa et al., 1993), no confirmation, vpr: c - vpx
gene of SIVagm suggested reclassification as vpr based on sequence homology (Tristem et al., 1992); d -
degree of homology between tat and HIV/SIV vpr in these viruses (Myers et al., 1992) (1.9.3); e - BIV vpw
or vpy suggested possible homologues of vpr (Gonda etal., 1992): no evidence for In vivo translation of
these ORFs.
Homologous genes do not always share extensive sequence similarity, and may be
identified by function, possession of characteristic domain structure and genomic location. Two
of these genes, tat and rev are common to all of these viruses. Functional homologues of tat and
rev are found in the complex oncoviruses (tax and rex respectively) and of tat in the
spumaviruses (taf).
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Tat and rev are the best characterised of the regulatory/auxiliary gene class, due in large
measure to the fact that functional copies of these genes are an essential requirement for HIV-1
replication (Dayton etal., 1986; Fisher eta/., 1986; Sadaie etal., 1988; Terwilliger etal., 1988).
Study of the remaining genes has been hampered by the lack of easily identifiable negative
phenotypes. Ablation of these genes is associated with reduced, but not completely attenuated,
viral replication. This phenomenon has led to these genes being termed 'auxiliary' or 'accessory',
and their activities 'facilitating' as opposed to the essential tat and rev. However, the conservation
of these genes implies strong selective pressure in their favour. The recent finding that
attenuated auxiliary genes are associated with the failure of disease progression in certain HIV+
individuals points to the importance of these genes in viral pathogenesis (Michael eta/., 1995a).
Other experiments have strongly suggested that the importance of these gene products lies in
the establishment and persistence of infection in the natural host environment (Kestler eta/.,
1991; Lang etal., 1993). Thus, elucidation of the functional mechanisms of the auxiliary proteins
is essential for a full understanding of lentiviral pathogenesis. In this review all non-structural
genes of the complex retroviruses will be termed auxiliary.
It is possible that a putative 'ancestral lentivirus' contained a basic complement of auxiliary
genes (tat, rev, vifand possibly vpi). EIAV may have secondarily lost the viflocus. Moreover, the
presence of additional complexity in the primate lentiviruses supports their classification as a
distinct sub-group (see section 1.2) (Myers etal., 1992). It will be interesting to identify the role of
these genes in primate viral replication, and whether the non-primate viruses lack these
functions, or possess compensatory activity elsewhere in their genomes. Further phylogenetic
data may be derived by elucidation of the functional interchangeability of the auxiliary proteins.
A review of the information presently available concerning the lentivirus auxiliary genes
follows. In vivo expression of the putative genes vpw, vpy and tmx of BIV (Garvey etal., 1990)
and ttm of EIAV (Beisel et al., 1993) has yet to be demonstrated, and therefore these genes
have not been included in this review.
1.8.1 Vif
Loss of function of the 23kDa Vif (virion infectivity factor) protein of HIV-1 is associated
with a 100-1000 fold decrease in the efficiency of cell free viral transmission (Fisher et al., 1987;
Strebel et al., 1987). The requirement for vif activity varies with cell type. Broadly, Vif is essential
for replication in primary cells (restricted cells), but may be dispensable for replication in
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transformed cell lines (permissive cells) (Gabuzda et al., 1992a; Gabuzda et al., 1994). The vif
defect is conferred upon a virus by the producer cell. Thus vif mutant viruses produced in
restricted cells are unable to replicate in any target cell, whereas mutants produced in permissive
cells can replicate in any target for at least one replicative cycle. It is assumed that permissive cells
contain a factor with Vif-like activity, and/or that restricted cells possess a replication inhibition
factor neutralised by Vif. Cell fusion experiments have so far failed to identify such factors
(Borman et al., 1995).Variations between cell lines with respect to categorisation may be
responsible for divergent reports on the mechanism of Vif action.
Vif function has been shown to be required at a late stage of infection (Blanc et al.,
1993). The protein is present in both a soluble cytosolic form, and tightly associated with the
cytoplasmic face of cellular membranes (Goncalves et al., 1994). This is consistent with an effect
of Vif on the assembly and maturation of virion particles. Hoglund and colleagues (1994) have
demonstrated that Vif deficient particles recovered from restrictive cells have heterogeneous
morphology and contain abnormal core structures. Viral protein content is also abnormal in both a
quantitative and qualitative fashion. Specifically, there is a decrease in envelope (Sakai et al.,
1993) and polymerase gene products, and a block in proteolytic processing of the Pr559a9
precursor molecule (Borman etal., 1995; Simm et al., 1995). Vif is therefore involved in the
correct incorporation and assembly of viral structural proteins into the virion, and may facilitate the
processing of precursor molecules. How Vif affects this process is not known. A report that Vif
contains cysteine protease activity, and acts to modify the cytoplasmic domain of the
transmembrane protein gp41 (Guy et al., 1991) has not been confirmed (Gabuzda et al., 1992b;
von Schwedler etal., 1993).
The block to replication of defective virions is likely to occur during viral entry as a
consequence of the particle abnormalities (Courcoul et al., 1995). It may involve reduced or
abnormal membrane fusion, uncoating, core stability or transport following internalisation.
Borman and co-workers (1995) were able to partially rescue a vif mutant virus by pseudotyping
with murine leukaemia virus envelope, suggesting that the mutant defect is manifest in envelope
mediated infection mechanisms: binding, fusion or entry. However, several groups report the
unhindered entry of vif mutants into cells (Ma etal., 1990). Defective viruses are reported to be
unable to complete the process of reverse transcription (Sova and Volsky, 1993; von Schwedler
etal., 1993). This may be manifest as an indirect effect. Completion of reverse transcription may
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occur within a partially uncoated core structure: disruption of this structure is likely to impair the
enzymatic process. Thus, it appears that Vif modulates particle maturation in such a way that viral
infectivity is enhanced by the stimulation of efficient reverse transcription.
A hydrophobic carboxy-terminal region of Vif may be involved in membrane interactions.
This region contains a motif conserved amongst almost all lentiviral Vif proteins, with the
consensus sequence SLQXLA (Oberste and Gonda, 1992). Conservation of this motif points to
a degree of functional conservation of the Vif protein. Loss of Vif function is associated with a
similar phenotype to that of HIV-1 in HIV-2 (Michaels etal., 1993), SIVmac (Gibbs etal., 1994) and
FIV (Tomonaga et al., 1992). The Vif proteins of SIVmac and HIV-1 demonstrate functional
reciprocity in the HUT78 cell line (Simon et al., 1995); this property is not shared by the Vif
proteins of BIV, FIV and MVV. This may be due to a failure of the non-primate lentivirus proteins
to interact correctly with the HIV-1 viral proteins which are the putative targets for Vif. However,
vif mutant HIV-1 and HIV-2 viruses show differential replication in certain cell lines, suggesting that
they have different requirements for cellular factors (Reddy etal., 1995b). The 29kDa product of
the MVV vif gene has been shown to localise to the cytoplasm of infected cells, although no
association with cellular membranes was found (Audoly et al., 1992). Vif is essential for efficient
replication of CAEV in primary macrophages (Harmache et al., 1995a). Deletion of CAEV Vif is
associated with a defect in the late stage of virus production; however, these authors did not
identify a reduction in viral infectivity. Although this might suggest a divergence in mechanism
between HIV-1 and CAEV Vif proteins, the uncertainty over the distribution of Vif-permissive and
restrictive cell lines for non-primate lentiviruses makes interpretation of this data difficult.
1.8.2 Nef
The nef gene is found only in primate lentiviruses. The 25-27kDa product is modified by
myristoylation of an amino-terminal glycine residue, which results in association of this
cytoplasmic protein with the plasma membrane of infected cells (Franchini et al., 1986; Yu and
Felsted, 1992). The function of Nef is one of the most controversial aspects of lentivirus
molecular biology. Early studies proposed a role for Nef in the repression of transcription from
the HIV-1 proviral LTR (Ahmad and Venkatesan, 1988; Niederman et al., 1989), hence the term
nef (n egative factor). However, subsequent analysis failed to confirm these results (Kim S.etal.,
1989), and instead identified an enhancement of viral replication kinetics in a wide range of host
cells in the presence of a functional nef gene (de Ronde etal., 1992; Terwilliger et al., 1991).
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This effect may be attributable to an increase in the intrinsic infectivity of progeny viral particles
produced in the presence of Nef (Miller etal., 1994). Nef has not been found within the virion,
suggesting that it may act through post-translational modifications to the viral structural proteins:
reminiscent of the role of Vif. Recently, two groups have reported that proviral DNA synthesis in
cells infected with nef deleted (Anef) HIV-1 proceeds 5-10 fold less efficiently than wild type
(Aiken and Trono, 1995; Schwartz et at., 1995). The apparently normal viral RNA and protein
content, and normal reverse transcriptase activity of isolated particles suggests that the Anef
defect is due to the existence of a suboptimal environment for DNA synthesis. Inappropriate
internalisation or uncoating of the viral core due to the absence of a Nef mediated modulation
might explain this phenomenon. A highly conserved proline repeat motif with the sequence
(PXX)4 is required for enhancement of infectivity, and may bind a cellular serine kinase (Sawai et
al., 1994). Recruitment of a kinase by Nef may result in modifications to the viral structural
proteins.
A second biological function of Nef is the specific removal of cell surface CD4 molecules
by endocytosis into early endosomes, with subsequent degradation (Garcia and Miller, 1991;
Anderson etal., 1993; Aiken etal., 1994). Removal of surface receptor may prevent deleterious
viral superinfection (Benson et al., 1993), and aid dispersal of progeny virions. However,
mutational analysis has demonstrated dissociation of this activity from viral infectivity
enhancement (Goldsmith etal., 1995).
Surface CD4 is involved in signal transduction resulting in activation of T lymphocytes by
antigen stimulation. Downregulation of CD4 may alter the activation state of cells. There are
directly contradictory reports as to the affect of Nef on cell activation (Bandres and Ratner, 1994;
Skowronski etal., 1993). A possible explanation for this lies in the findings of Baur etal. (1994),
that Nef promotes activation when expressed at the cell surface, but is inhibitory when present in
the cytoplasm. This effect is presumably mediated by interactions with different sets of cellular
proteins. The influence of such activities on viral replication and pathogenesis is unclear.
The nef gene of SIVmac appears to be functionally analogous to HIV-1 nef. There is
sufficient conservation between the proteins to allow the functional substitution of the SIVmac
nef gene with that of HIV-1 (Sinclair et al., 1995). Studies with SIVmac infection of rhesus
monkeys (Macaca mulatta) have demonstrated the essential nature of Nef for viral spread and
pathogenicity in infected animals (Kestler etal., 1991). Moreover, the most successful vaccines
developed to date against SIV infection have been live viruses with attenuating nef mutations
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(Daniel et at., 1992). Subtle effects of Nef on infectivity and T lymphocyte physiology, difficult to
interpret in vitro, may be of great importance in vivo.
Nef specific transcripts may represent 90% of mRNAs expressed early in infection
(Klotman et at., 1992). Such high level expression might have significance for early antiviral
immune responses. Nef contains several epitopes recognised by cytotoxic T lymphocytes, and
these are found in the majority of HIV-1 infected individuals (Culmann et at., 1989; Hadida etal.,
1992). The significance of these cells is unknown.
1.8.3 Vpr
Viral Protein R (Vpr), is the 12-15kDa product of the R ORF common to all primate
lentiviruses (except possibly SIVagm, see table 1.1) (Wong-Staal etal., 1987). The phenotype
associated with Vpr is host cell dependent. The emerging consensus is that Vpr conveys an
advantage in terms of rapidity of replication and higher progeny virus titres in primary cells
(Westervelt et at., 1992; Balotta et at., 1993; Connor etal., 1995). Lack of functional Vpr is
associated with moderate to complete attenuation of viral replication in monocytes and
macrophages (Balliet etal., 1994). Vpr deletion has no significant effect on viral replication in
immortalised cell lines ( Hattori et a!., 1990). Vpr may be dispensable for growth in all cell types in
HIV-2 and SIVmac (Gibbs et al., 1994); this may be due to compensatory activity of the Vpx
protein (see below).
Vpr is unique amongst HIV-1 auxiliary proteins in being incorporated into the virion (Yuan
et al., 1990), and is present in approximately equimolar quantities to Gag (Paxton et al., 1993).
Interaction with the carboxy-terminal Gag protein p6 is both necessary and sufficient for
incorporation of Vpr into nascent virions (Kondo etal., 1995).
Vpr locates specifically to the nuclear matrix and perinuclear regions in transfected cells
(Lu et al., 1993). Nuclear localisation may be a function of a leucine/isoleucine rich motif in the
central region of Vpr (Zhao et al., 1994), and may be mediated by interaction with a cellular
protein.
Several functional activities are associated with Vpr. Incorporation in the virion strongly
suggests an involvement in the early phase of infection. One hypothesis is that the nucleophilic
Vpr protein ensures nuclear import of the replicative pre-integration complex, which allows
replication in non-dividing cells such as macrophages (Heinzinger et al., 1994).
Post integration events may also be influenced by Vpr. Purified, recombinant Vpr can
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reactivate HIV-1 expression trom latently infected cell lines and induce an increase in
permissiveness to HIV replication amongst a range of both transformed and primary cells (Levy
et at., 1995). Cohen and co-workers (1990) demonstrated modest (3-fold) activation of HIV-1 LTR
and heterologous promoters by Vpr. The amino-terminal region of Vpr contains a motif with some
homology to the acidic activation domain of a range of frans-activating factors, including MVV Tat
(1.9.2). By analogy with these proteins, the activity of Vpr is probably mediated by interaction with
cellular factors. Vpr frans-activation of the viral promoter may have significance at periods during
infection when Tat is limiting, especially immediately post integration. Alternatively, Vpr mediated
frans-activation of cellular genes may be responsible for the ability of Vpr to alter the state of cells,
with consequential increases in permissiveness for viral replication. Vpr can inhibit proliferation of
a wide range of cells, including T lymphocytes, by inducing arrest in the G2 phase of the cell cycle
(Rogel etat., 1995), and induce differentiation in others (for example the rhabdomyosarcoma cell
line TE671, Levy et at., 1993). HIV-1 clones are able to establish persistent infections in w'froonly
in the absence of a functional vprgene (Nishino etal., 1991; Planelles etal., 1995), suggesting
that Vpr impairs the multiplication or viability of infected cells.
The in vivo functional significance of such activity is uncertain. Arrest in G2 may establish
a suitable milieu for viral replication, and prevent the re-entry of cells into G0 quiescence. Host cell
differentiation is linked to increased viral permissiveness (Rich etal., 1992). Exogenous Vpr may
establish a reservoir of permissive cells at an initial stage of infection before its effects are
reduced by humoral immunity. Vpr is present within the serum and cerebro-spinal fluid of AIDS
patients (Levy etal., 1994). Dysregulation or differentiation of uninfected cells may contribute to
pathology: loss of muscle precursor populations for example, may explain AIDS associated
wasting (Levy etal., 1995). A similar effect on immune cell precursors may contribute to depletion
of mature immune cells.
Studies with mutated vpr genes in SIVmac infection have reported that vpr is
dispensable for the establishment of infection and pathogenicity (Gibbs etal., 1995; Hoch etal.,
1995), although some delay in progression to disease may occur (Lang etal., 1993). Hoch and
co-workers did, however, indicate that there might be a more vigorous humoral immune response
against the virus in the absence of vpr. Cells chronically infected with Avprvirus might be better
targets for the immune system. This, in turn, could allow the immune system to contain the
infection for a longer period. The relative contribution of each function of Vpr may vary according
to host cell type.
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1.8.4 Vpx
A 14-16 kDa protein has been identified as the product of the X ORF of the HIV-
2/SIVmac/SIVsm group of lentiviruses (Franchini etal., 1988). Vpx has significant homology with
vprand may have arisen due to a gene duplication event in the relatively recent evolutionary past
(Tristem etal., 1990). This suggests the possibility of a duplicative or overlapping functional role
for these genes; a hypothesis strengthened by the fact that, like Vpr, Vpx is packaged into
mature virions (Flenderson et al., 1988, Yu etal., 1988). Furthermore, a similar phenotype is
associated with ablation of Vpr and Vpx expression: similar cell type specific effects are observed
( Flu etal., 1989; Marcon etal., 1991 ;Yu etal., 1991; Gibbs etal., 1994). Gibbs etal. (1994) found
that A vpx SIVmac viruses demonstrated a significantly greater degree of attenuation than Avpr
mutants: deletion of both vpr and vpx severely attenuated viral replication. Infection of rhesus
monkeys with vpxdeleted SIVmac23g virus resulted in a reduction in viral load but did not prevent
progression to AIDS (Gibbs etal., 1995).
The nature of the attenuation of replication by vpx deletion is unknown. Both the
presence of Vpx within the virion and its localisation within the cytoplasm of infected cells
(Kappes et al., 1993) suggest an involvement in the early events of replication. A 5-10 fold
reduction in DNA synthesis within a single replicative cycle is associated with loss of Vpx function
(Kappes et al., 1991). A role for Vpx in reverse transcription is therefore possible. Binding of
purified Vpx to polyethenoadenylic acid (Henderson et al., 1988) is suggestive of a role in
stabilising RNA and DNA interactions during reverse transcription.
Further study is required to demonstrate the similarity of Vpx and Vpr. It is possible that
divergence is taking place, with novel functions co-existing with overlapping ones. The relative
contributions of Vpr and Vpx in HIV-2/SIV infections could vary in different viral backgrounds and
host cell types. Vpx may be 'dominant' in the SIVmac239 strain used by Gibbs and co-workers
(1994).
1.8.5 Vpu
Viral protein U (Vpu) is a 16kDa protein unique to the HIV-1/SIVcpz group of primate
lentiviruses. Vpu is an oligomeric transmembrane phosphoprotein (Strebel etal., 1989; Maldarelli
et al., 1993), with two elucidated functions.
Replication of viruses deficient for Vpu expression is associated with decreased
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production of progeny virions, and a concomitant accumulation of viral proteins within infected
cells (Strebel et al., 1988; Terwilliger et at., 1989). The Vpu mutant phenotype is also
characterised by the presence of abnormal viral particles, and by aberrant budding from
intracytoplasmic membranes (Klimkait et al., 1990). Thus, Vpu facilitates the correct assembly
and/or final release of virions. The affect of ablation of Vpu on viral replication is dependent on
host cell type: replication is strongly attenuated in certain transformed cell lines and in primary
monocytes/macrophages (Balliet eta!., 1994; Yao etal., 1992), but little affected in others, for
example COS-7 cells (Gottlinger etal., 1991). Vpu can mediate the enhanced release of capsids
containing Gag-Pol precursor proteins from divergent retroviruses, including MVV and Moloney
murine leukaemia virus (Gottlinger et al., 1993); activity is therefore unlikely to involve specific
interactions with capsid proteins. Vpu has biochemical and structural homology with several
ortho- and para-myxovirus proteins which are involved in virion release, including influenza A
virus M2. M2 has been shown to act as an ion channel by forming multimeric pore structures
within Golgi membranes (Pinto etal., 1992). Thus, by analogy, Vpu may alter luminal conditions
with respect to pH or ion balance which in turn leads to modification of the capsid precursor
proteins to ensure efficient assembly and release. The putative modification may also be
mediated by cellular factors, obviating the need for Vpu in other retroviruses, or in certain host
cell types.
A second function of Vpu has recently been elucidated. During export from the cell, the
viral precursor envelope protein gp160 is trapped within the endoplasmic reticulum (ER) by the
formation of complexes with its ligand molecule, CD4, preventing efficient processing and export
(Jabbar and Nayak, 1990). Expression of Vpu, which localises to the perinuclear membrane
compartments within the cytoplasm (Klimkait et al., 1990), alleviates the block in gp160
processing by inducing the degradation of CD4 (Willey etal., 1992). The half life of CD4
molecules in the presence of Vpu is reduced from six hours to twelve minutes (Lenburg and
Landau, 1993). Conformational changes in CD4 triggered by Vpu binding might be responsible
for degradation, perhaps by entry of the altered protein into the ER pathway for the proteolysis of
misfolded proteins (Vincent etal., 1993; Bour etal., 1995).
The functional significance of the two roles of Vpu are incompletely understood. They
appear to be mediated as independent events (Schubert and Strebel, 1994). In particular, cells
of the monocyte/macrophage lineage express little CD4 and display budding of particles from
intracytoplasmic vesicles in the absence or presence of Vpu (Orenstein etal., 1988). Yet viral
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replication in macrophages is particularly susceptible to loss of Vpu function. It is possible that
this is due to other, as yet, uncharacterised functions of Vpu.
1.9 Tat
All lentiviruses encode a small, regulatory protein, Tat, which mediates trans-activation of
the viral U3 promoter. There is evidence to suggest that lentiviruses differ in both the mechanism
of frans-activation and in their requirement for Tat activity. Broadly, lentiviruses divide into two
groups with respect to Tat: those for which Tat is an absolute requirement, correlating with high
trans-activating activity (HIV-1, HIV-2, SIV, BIV and EIAV), and those (MVV, CAEV, FIV) where Tat
may be dispensable for replication in culture, correlating with low level trans-activation. This
division may be due to the characteristics of basal (- tat) transcription, such that in the latter group
basal transcription may be sufficient to support replication, and may reflect fundamental
differences in the mechanism of frans-activation.
1.9.1 HIV-1 Tat
HIV-1 tat (tat-1) is an 86 residue, highly basic protein encoded by two exons. Tat-1 has a
modular structure, with a number of protein domains responsible for mediating different activities
(figure 1,4a). Modular structure is a characteristic of transcriptional activators (Ptashne, 1988). A
highly basic central motif is required for target binding in vitro (Calnan et at., 1991), and is also
responsible for targeting of Tat-1 to the nucleus, and in particular, the nucleolus of infected cells
(Hauber etal., 1989). The 47 amino terminal residues, comprising an acidic terminal region, the
cysteine and 'core' motifs, are required for function, and form the 'activation' or 'effector' domain
of Tat (Rice and Carlotti, 1990).
The basal activity of the HIV-1 promoter is low in most cells (Jones et at., 1986). Tat-1
induces transcription from the promoter by 40-3000 fold, depending on cell type (Arya etal.,
1985; Sodroski etal., 1985). This activity is dependent on binding to TAR (trans-activation
response element), an RNA stem-loop structure present in all nascent viral transcripts. Tat/TAR
interaction is essential for HIV-1 replication (Fisher et a!., 1986). TAR is located within the R region
of the LTR, immediately downstream of the transcriptional initiation site (bases +1 to +44). A
highly conserved trinucleotide pyrimidine bulge within TAR is the site of Tat binding (Dingwall et
a!., 1990). The bulge may induce a bend in the RNA helix to allow Tat access to the major groove,
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Figure 1.4: Structure of the MVV and HIV-1 Tat Proteins
A
Domain organisation of the Tat proteins of HIV-1 and MVV. Delineating residue position
of each domain are shown. The putative activation domain of each protein is marked. A cysteine
"F r
rich region provides the single region of amino acid homology. NH2: amino reminus, COOI-
carboxy terminus.
B
Amino acid homology within cysteine-rich domains. Top: HIV-1 Tat sequence, residue
11-30. Bottom: MVV Tat sequence, residues 65-81. Identical residues are shown in bold. Gap
in sequence are depicted by a dash.
C
Alignment of sections of the putative activation domains of the transcriptional tram
activators, herpes simplex virus type 1 (HSV-1) VP16, and MVV Tat (from Carruth et al., 1994
The amino terminal portion of the HIV-1 Vpr protein, which may have frans-activating activit
(section 1.8.3) is also shown. The carboxy-terminal proximal regions display greatest sequenc
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resulting in a stable interaction.
Tat-1 activity leads to an increase in the steady state level of LTR directed transcripts
(Peterlin etal., 1986). However, the precise mechanism of Tat activity is incompletely understood
and remains controversial. Analysis of viral RNA produced in the absence of Tat-1 has shown that
most transcripts terminate close to the initiation site, consisting largely of the TAR structure
(Feinberg etal., 1991). Tat-1 function is associated with an increase in the number of full-length
transcripts with little change in the number of short ones (Kao etal., 1987). Expression of the
transcription factor TFIIF, believed to have a role in increasing polymerase processivity, obviates
the requirement for Tat-1 (Kato et al., 1992). The poor efficiency of elongation of the basal
transcriptional complex is a result of the assembly of a poorly processive complex in the absence
of Tat (Kessler and Matthews, 1992). This is presumably mediated by elements within the LTR.
Thus, the HIV-1 LTR has been described as an 'attenuated' promoter (Jones and Peterlin, 1994),
and Tat-1 as an 'RNA sequence specific processivity factor' (Cullen, 1991).
There is also evidence for a second mechanism of Tat-1 activity: direct increase in the
rate of transcription initiation from the viral LTR (Kao etal., 1987; Rice and Matthews, 1988). This
activity is almost completely analogous to the action of conventional transcriptional activators
(reviewed in Roeder, 1991), and suggests that Tat-1 can co-operate with cellular transcription
factors to maximise the rate of initiation. The mechanism of increased initiation is not fully
understood. Binding of Tat-1 to the TATA binding protein (TBP), a component of the TFIID basal
transcription complex, has been demonstrated, and is necessary for Tat-1 activity (Kashanchi et
al., 1994; Zhou and Sharp, 1995). Tat-1 binding was found to enhance TFIID interactions with the
promoter.
Laspia and co-workers (1989) have provided evidence to support both models of Tat
function. Indeed, it is likely these events are linked, with the tormation of the transcriptional
complex influencing its subsequent activity. A full appreciation of the activity of Tat will await the
evaluation of the role of cellular co-factors. A strong candidate for a Tat co-activator has recently
been reported. This is a protein kinase (TAK: tat associated kinase) which has been shown to
interact with the activation domain of Tat-1 and Tat-2 (Herrmann and Rice, 1995). The ability of
mutant Tat proteins to interact with TAK was found to correlate with trans-activation ability. A
known substrate for TAK is RNA polymerase II. Phosphorylation has been proposed to trigger
the transition from the initiation to the elongation phase of transcription (Dahmus and Dynan,
1992). Several other Tat and TAR binding proteins have been described (reviewed in Antoni et
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al., 1994): in most cases the functional significance of interaction remains to be determined.
A bimodal mechanism for Tat-1 activity is suggested by the data presently available.
Thus, Tat may upregulate the rate of formation of initiating ribonucleoprotein complexes by
means of direct interaction with specific components, for example TBP. Subsequently, binding of
Tat-1 to the nascent RNA may promote elongation over initiation by recruiting TAK to the
complex.
Whilst the reductionist approach has yielded some success in delineating Tat function, it
may be insufficient to explain the full role of this protein. In particular, the increase in the steady
state levels of viral mRNA resulting from Tat activity is insufficient to account fully for the positive
effect of Tat on protein expression and viral replication (in HIV-1: Cullen, 1986; Feinberg et al.,
1986) (in MVV: Gdovin and Clements, 1992). Tat may therefore possess a post-transcriptional
role. Experiments studying HIV-1 Tat activity in Xenopus oocytes demonstrated the requirement
for Tat to 'activate' transcripts to allow efficient translation (Braddock et al., 1989). This
observation has not been repeated in human cells, however (Chin eta!., 1991). Huang and
colleagues (1994) have observed reduced infectivity and cytopathicity of HIV-1 containing a
deleted fafgene but with a compensatory trans-activating function, suggesting a discrete role for
Tat-1 in viral infectivity.
The Tat/TAR axis is preserved by HIV-2 and SIV, and by the distantly related BIV and
EIAV. The Tat proteins of HIV-1, HIV-2 and SIVmac can functionally complement one another
(Viglianti and Mullins, 1988; Tong-Starksen et al., 1993). Whilst the BIV Tat/TAR system
possesses many of the elements of trans-activation found in the primate lentiviruses (Pallansch
et al., 1992; Carpenter et al., 1993) EIAV is more diverse. There is no bulge within the TAR of
EIAV (Carvalho and Derse, 1991), and the Tat protein (eTat) has a simpler structure, with an
activation domain consisting solely of the conserved core motif (Carroll et al., 1991). Although
eTat cannot functionally substitute for Tat-1, a chimaera consisting of eTat core and Tat-1 basic
motifs can direct weak frans-activation of the HIV-1 promoter (Derse eta!., 1991). This suggests
that these proteins function by interacting with the same cellular components.
1.9.2 MVV Tat
MVV Tat (vTat) is the prototype of the second group of trans-activators. MVV Tat is a
10kDa protein encoded by a single exon and possesses a distinct domain structure from Tat-1
(Davis and Clements, 1989; figure 1.4a). The only homologous region is the cysteine rich motif
25
(figure 1.4b). The relatively modest frans-activating ability of vTat (5-30 fold induction)(Hess etal.,
1989; Gourdou etal., 1989) is partially due to high basal activity of the MVV LTR (Hess et at.,
1985; Davis and Clements, 1989). The LTR may thus be sufficiently processive in its own right.
There is no TAR-like region in the LTR. Instead, vTat activity may require sequences within the
LTR enhancer region, in particular the TATA box proximal AP-1 site and the neighbouring AP-4
site found in the 1514 viral strain (Hess et al., 1989; Gdovin and Clements, 1992). There is no
consensus AP-1 site in the EV-1 MVV isolate (Sargan etal., 1995): instead an uncharacterised
cellular factor binds an overlapping site (Sutton etal., 1995). The effect of this on vTat activity in
this virus is unknown.
There is no evidence to suggest that vTat binds directly to DNA (Gdovin and Clements,
1992; Neuveut etal., 1993). vTat may thus function by an indirect mechanism. Other viral trans-
activators function in this manner, by modulating the activity of cellular factors to recruit them to
the viral promoter. The adenovirus E1A , herpes simplex virus VP16 (reviewed by Jones et al.,
1988) and HTLV-ITax proteins are examples (Wagner and Green, 1993).
The transcriptional factors Fos and Jun form a heterocomplex which can bind at the TATA
box proximal AP-1 site of MVV (Shih et al., 1992). A role for these factors in vTat frans-activation is
suggested by the failure of Jun deficient F9 teratocarcinoma cells to support vTat function, and
by the finding that vTat elevates the expression of Jun in transfected cells (Neuveut et al., 1993).
Thus, vTat may directly interact with Jun and Fos, altering their binding specificities to encourage
interaction with the viral promoter. This is analogous to the activity of Tax, which binds a subset of
the bZIP (basic region-leucine zipper domain) cellular transcription factors, including CREB and
CREM (Adya et al., 1994), and stabilises their dimerisation (Baranger etal., 1995; Perini etal.,
1995).
A vTat/GAL 4 DNA binding domain chimaera has been shown to direct activation via the
recognition site for GAL 4 (Carruth et al., 1994). The full length vTat protein demonstrated
characteristically modest frans-activating ability in this system (2-4 fold). The 38 amino-terminal
residues of vTat were found to have potent activity (600 fold frans-activation) if directly fused to
GAL4, and are suggested to form an activation domain. This region of vTat has a degree of
homology with the acidic activation domains of a number of transcriptional trans-activators. The
aligned hydrophobic residues and overall negative charge of this domain is demonstrated by
herpes simplex virus VP16 and by the Vpr protein of primate lentiviruses (figure 1.4b) (see
section 1.8.3). Acidic activation domains are implicated in binding to basal transcription factors,
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including TBP (Greenblatt etal., 1994). The ability of Tat-1 to compete specifically with chimaeric
vTat/GAL4 in this system (Carruth et al., 1994), demonstrates that the activation domains of these
proteins may interact with a common cellular co-factor(s); TBP is a strong candidate. This activity
may be common to both groups of lentiviral Tat proteins.
A possible model for vTat function is suggested. In quiescent cells, low concentrations of
vTat are effectively repressed by an intramolecular interaction with a leucine rich negative
regulatory element (residues 39-53) (Carruth et al., 1994). On cell activation or differentiation,
elevated levels of Fos and/or Jun bind to the leucine rich motif of vTat (these factors possess a
leucine zipper motif), inducing conformational changes which release the activity of the activation
domain. Furthermore, binding to Fos/Jun directs vTat to promoters containing AP-1 sites,
including the proviral LTR. vTat may function by both stabilising Fos/Jun dimerisation and binding
to DNA, and by direct interaction with other components of the basal transcription complex,
including TBP.
Several features of MVV transcription and Tat biology are shared by CAEV and FIV. Both
of these viruses have promoters with high basal activity and the putative Tat proteins possess
moderate frans-activating ability (2-8 fold) (Sparger et al., 1992; Saltarelli et al., 1993), and act
through AP-1 and AP-4 sites located within the U3 region (Hess et al., 1986). The domain
structure of vTat is shared by the CAEV protein, enabling these proteins to functionally
complement one another (Saltarelli et al., 1993). Harmache et al. (1995b) found that tat is
dispensable for viral replication both in vitro and during experimental infection of goats. FIV tat
(ORF A) has been shown to be dispensable for growth in transformed cell lines, although
deletion of tat is associated with a severely impaired phenotype in primary lymphocytes
(Tomonaga et al., 1993). It seems probable that the role of Tat in these viruses is not primarily as
an LTR trans-activator.
1.10 Rev
Sodroski and co-workers (1986) observed that mutations around the HIV-1 tat second
exon, which could not be complemented by exogenous Tat, resulted in attenuated structural
gene expression without affecting tat expression. This mutant phenotype mimics the early phase
of productive infection (1.7) suggesting that a gene responsible for temporal regulation was
defined by the mutation. The gene was identified and named art (anti-repressor trans-activator),
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due to the activity ot the gene product in relieving repression of structural gene expression. A
second group also located this gene, although they suggested the name trs (trans-regulator of
splicing) because of a proposed role in the inhibition of splicing (Feinberg etal., 1986). The
actual effect of the gene was discovered when it was shown that art/trs defective proviruses
failed to accumulate cytoplasmic structural gene (9 and 4kb) mRNAs, but that total cellular levels
of RNA species were essentially unchanged in the presence or absence of art/trs (Malim etat.,
1988; Arrigo et at., 1989; Hammarskjold et at., 1989). Complementation with a functional gene
restored structural gene expression by relieving the block to cytoplasmic expression of the
cognate mRNA. The name rev(regulator of expression of viral proteins) has subsequently been
adopted (Gallo etal., 1988).
Rev is a post-transcriptional trans-activator of structural gene expression and is essential
for productive infection (Sadaie etal., 1988). Its effect is mediated via the Rev Response
element (RRE), a region of RNA secondary structure within the envgene (Malim et at., 1989c).
This is spliced out of the rev independent 2kb mRNAs. The RRE is present in the full length
(9kb) gag/pol and singly spliced (4kb)env/vpu, v//and vpr transcripts in HIV-1; expression of
these transcripts is Rev dependent (Sodroski et at., 1986; Knight et at, 1987; Schwartz et a/.,
1991; Garret etal., 1991). Rev accumulation during infection results from the action of Tat on viral
transcription. Transcripts are spliced to completion, or retained and degraded in the nucleus, in
the absence of Rev. Once a sufficient level of activity is reached, Rev overcomes the effect of
inhibitory sequences present in the mRNA encoding the structural proteins by one or more of
the following proposed mechanisms: inhibition of splicing, promotion of nucleocytoplasmic
export, increasing stability and/or translatability of these transcripts (Rosen eta/., 1988; Chang
and Sharp, 1989; Emerman etal., 1989; Felber etal., 1989; Arrigo and Chen, 1991; Pomerantz
etal., 1992). Direct binding and oligomerisation of Rev on the RRE is necessary, but not
sufficient for function, which also requires interaction with one or more cellular co-factors (Daly et
a!., 1989; Berger et a!., 1991; Malim et al., 1991). Rev therefore initiates the expression of
structural proteins, acting as a switch between early and late phases of the viral replicative cycle.
A rev gene is present in the genomes of all lentiviruses, and a homologous gene, rex, is
encoded by the FITLV-1 oncovirus group (Inoue et al., 1986). Rex also acts to facilitate the
cytoplasmic accumulation of incompletely spliced RNAs (Flidaka et al, 1988). This activity is
essential for viral replication (Rosenblatt et al., 1988) and is mediated by a structured region
within the viral LTR, the Rex responsive element (RxRE) (Hanly etal., 1989).
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1.11 Rev Biochemistry: Definition of Functional Domains
Rev/Rex proteins are characteristically small, nuclear phosphoproteins. The size range of
these proteins is from 82 residues (SIVagm) to 189 residues (HTLV-I). Most Rev/Rex proteins
migrate anomalously slowly on SDS-PAGE gels, due to the high content of basic residues and/or
to post-translational modifications. Considerable progress has been made towards a biochemical
characterisation of HIV-1 Rev, the prototypic protein of the family, and of the Rex protein of HTLV-
1. Analysis of domain structure is of importance to facilitate elucidation of functional mechanisms.
HIV-1 Rev consists of 116 amino acid residues, and is encoded by a series of multiply
spliced transcripts (Schwartz et al., 1990). The first coding exon is located in the centre of the
genome, between pol and env, and contributes the 24 amino-terminal protein residues. The
second exon, situated at the 3' end of env, but in a different reading frame register, encodes
residues 25-116 (Sodroski et al, 1986). The protein migrates on SDS-PAGE gels with an
apparent molecular weight of 19kDa (Knight eta!., 1987). Extensive mutational analysis has led
to the definition of two major functional domains within HIV-1 Rev (figure 1.5). The first consists of
-40 amino terminal residues, and is characterised by an arginine-rich central core. This motif
(residues 34-50) functions both as a nucleolar localisation signal, and as the RNA sequence-
specific binding element. Less distinct flanking sequences are essential for in vitro
multimerisation of the Rev protein on its target RNA. Mutations within this amino terminal domain
typically reveal a recessive negative phenotype. In contrast, a second functional domain of Rev
has been delineated by a series of trans-dominant negative mutants spanning residues 81-88
(Mermer et al., 1989). These mutants retain normal RNA binding, multimerisation and localisation
activities, yet are functionally negative. It has been proposed that this domain, which contains a
number of critically spaced leucine residues, interacts with a cellular co-factor critical for Rev
activity (Malim etal., 1991). Rev therefore demonstrates a modular organisation similar to that of
transcriptional activators (Ptashne, 1988; see also tat,section 1.9), i.e. a binding domain which
mediates specificity, and an effector or activation domain which translates binding into a
functional event. The amino-terminal 14 and carboxy-terminal 25 residues of HIV-1 Rev are
dispensable for activity (Perkins etal., 1989; Malim etal., 1989b; Hope etal., 1990).
Rev activity has also been found residing within a 28kDa phosphoprotein, Tev (Benko
et al., 1990). This protein contains the Tat first exon, Rev second exon and a novel coding exon
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Figure 1.5: Modular Organisation of the HIV-1 Rev Protein
Domain structure of the Rev protein of HIV-1. The amino acid sequence of the RN
binding and activation domains are highlighted. Region of predicted secondary structure (
helix) are shown. NH2: amino terminus, COOH: carboxy-terminus. NLS: nuclear localisatio































within Env. The apparently normal Rev activity of Tev implies that the first exon-specific residues
of Rev are not essential for activity; however it is possible that the Tat/Env residues of Tev provide
compensatory activity. Tev is not required for HIV-1 replication (Purcell and Martin, 1993).
The 27kDa HTLV Rex protein demonstrates a similar, though less discrete, domain
structure to that of Rev (Bohnlein S. et al, 1991). The amino-terminal proximal 19 residues form a
highly basic domain, which mediates nuclear localisation and RNA binding (Siomi et al., 1988;
Bogerd et al., 1991). An activation domain, containing reiterated leucine residues, is present
within the central region of the molecule (Hope et al., 1991; Weichselbraun etal., 1992).
1.11.1 THE AMINO TERMINAL DOMAIN
1 .11.1.1 RNA Binding
HIV-1 Rev is a sequence specific RNA binding protein (Daly etal., 1989; Zapp and
Green, 1989). Mutations within the highly basic amino-terminal domain of Rev eliminate this
activity (Malim et al., 1989b; Olsen et al., 1990; Zapp et al., 1991). Synthetic peptides
corresponding to this domain are able to bind target RNA in In vitro assays with an affinity and
specificity only slightly lower that that of the full length protein (Kjems et al., 1992; Tan et al.,
1993). Moreover, Rev specific binding characteristics can be transferred to Rex by fusion to Rev
residues 33-46 (Bohnlein etal., 1991), demonstrating that this region is sufficient for sequence
specific binding. Scanning mutagenesis analysis of the arginine-rich (10/17 residues are
arginine) binding domain has been performed in order to identify critical residues. Tan and
colleagues (1993) found that substitution of individual arginine residues within a Rev peptide led
to a reduction in specific binding; however, Hammerschmid et al. (1994) were able to replace
each residue within the domain with leucine with no apparent reduction in binding. These
apparently contradictory results may be explained by the fact that the latfer study utilised full
length Rev protein. Thus, individual mutations may be more tolerated in the context of the intact
molecule, perhaps due to contributory interactions by residues outside the minimal domain. A
degree of functional redundancy therefore resides within Rev. These, and other studies using
protease protection analysis (Kjems et al., 1992; Jensen et al., 1995) have identified those
residues which make specific contacts with target RNA, and those which contribute structural
information to the protein. Those residues outlined in bold are believed to contact the RNA:
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Rev belongs to a class of RNA binding molecules characterised by an arginine-rich motif
(Lazinski et al., 1989). This group also includes HIV-1 Tat, bacteriophage N anti-terminating
proteins and non-specific RNA binding molecules such as histones. There is little sequence
homology within this class beyond a preponderance of arginine residues. Reiterated arginines
have a high affinity, but no specificity, for guanine-rich sequences via electrostatic interactions
(Daly et al., 1993a). Competition experiments suggest that Rev is essentially a poly(G) binding
protein (Daly etal., 1993a). Non-arginine residues within the basic domain presumably contribute
discriminatory interactions as a secondary event to initial arginine-guanine contact.
Analysis of Rev structure by circular dichroism has suggested that the protein contains a
high degree (40-48%) of ex-helical content (Nalin et al., 1990; Wingfield et al., 1991). This is
predicted to take the form of a helix-loop-heiix motif in the amino-terminal portion of the molecule
(helix 1: residues 8-26, loop 27-33, helix 2: 34-59) (Auer etal., 1994). Recently, Tan and co¬
workers have shown that the efficiency of binding to the RRE of a binding domain peptide is
directly proportional to the helical content of the peptide (Tan etal., 1993). The basic domain is
predicted to form a helix in both the isolated peptide and in the context of the full length
molecule. The helix may make contact with the RNA within a major groove distorted by non-
canonical base pairing (see section 1.12).
Multiple arginine residues also comprise the RNA binding domain of HTLV Rex proteins
(Bogerd etal., 1991). Substitution with lysines abrogates binding, as does alteration of the
interspersed non-basic residues (Hammes and Greene, 1993). Helix destabilising proline
residues within the basic domain suggest that Rex contacts RNA in a distinct manner from that of
Rev (Tan and Frankel, 1995).
1.11.1.2 Subcellular Localisation
Subcellular localisation of HIV-1 and HIV-2 Rev and HTLV-I Rex proteins within the nuclei,
and accumulation within the nucleoli, of transiently transfected cells is mediated by the arginine-
rich domains of these proteins (Cullen et al., 1988; Siomi et al., 1988; Perkins et al., 1989; Dillon
et al., 1991). Nuclear (NLS) and nucleolar (NOS) targeting signals within Rev are distinct
(Cochrane etal., 1990b).The SV40 T antigen NLS (sequence PKKKRKV) is the prototype of a
class characterised by highly basic content and short size (Kalderon et al., 1984). The Rev NLS
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belongs to this group: the pentapeptide RRRRW (residues 41-45) is sufficient to direct the
nuclear targeting of the normally cytoplasmic protein (3-galactosidase (Perkins et al., 1989).
Residues flanking this peptide are required for nucleolar targeting. Whilst the entire basic domain
(35-50) has been proposed to function as a minimal nucleolar localisation signal (NOS) (Miyazaki
et al., 1992), other groups have demonstrated that elements amino-proximal to this motif are
necessary for efficient localisation (Hope et al., 1990b; Venkatesh etal., 1990).
The demonstration that the specific RNA binding motif coincided with the putative
NLS/NOS meant that the significance of localisation is difficult to assess. However, a serine for
tryptophan substitution at residue 45 abolishes nuclear localisation while preserving other
functions: this mutant is inactivating, demonstrating the requirement for nuclear localisation for
Rev function (Hammerschmid et al., 1994). The relevance of nucleolar localisation to function has
been studied by generating chimaeric Rev/heterologous RNA binding proteins and assaying for
Rev activity on an RNA target containing a cognate recognition sequence for the heterologous
protein. The bacteriophage MS2 RNA binding protein and its operator sequence have been
used (McDonald et al., 1992; Venkatesan et al., 1992). This system allows Rev function to be
studied independently from RNA binding. McDonald and colleagues found that a mutant which
localised to the nucleoplasm but was excluded from the nucleolus possessed full function,
arguing against the functional importance of nucleolar targeting.
Since nucleoli are not discrete, membrane limited organelles, accumulation implies
binding to a nucleolar component. The overlap of the localisation and RNA binding domains
suggests that nucleolar distribution is due to low affinity binding to ribosomal RNA (Felber etal.,
1989). RNase treatment of isolated nuclei abolishes Rev nucleolar binding (D'Agostino et al.,
1995) Alternatively, Rev may bind to a nucleolar protein. The basic domain has been implicated in
high specificity binding to two acidic stretches within the abundant nucleolar protein B23
(Fankhauser etal., 1991). This evolutionally conserved, 38kDa protein shuttles rapidly between
the nucleus and cytoplasm, and is believed to chaperone the import of ribosomal components to
the nucleolus, the site of ribosome biogenesis (Borer etal., 1989). Peptides corresponding to
the NOS (residues 37-47) and to the SV40 T antigen NLS, bind with high affinity and specificity
to B23 in in vitro assays (Szebeni et al., 1995). A peptide corresponding to the Rex NOS
(residues 1-19) also binds B23 (Adachi et al., 1993). Rev nucleolar distribution overlaps that of
B23 (Luznik etal., 1995). It may be that Rev/Rex can 'hijack' B23 in order to gain rapid access to
the nucleus, or that B23 acts as a nucleolar receptor for Rev. Active rRNA synthesis and nucleolar
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integrity are required for Rev nuclear localisation (Richard etal., 1994; D'Agostino etal., 1995),
suggesting that Rev might be stored within the nucleolus by binding to both B23 and ribosomal
RNA, until target RNA is available.
1.11.1.3 Multimerisation
A third function of the amino terminal region of Rev was characterised on the basis that
mutations flanking the arginine-rich motif abrogated in vivo activity while preserving both
localisation and in vitro RRE binding (Berger et al., 1991). Such mutations were found to prevent
Rev multimerisation on the RNA target, and spanned a bipartite domain including residues 18-31
and 51-57 (Malim and Cullen, 1991, Zapp etal., 1991). Mutations outside of this domain do not
interfere with in vitro multimerisation, as observed by the ability of Rev to form multiple,
differentially migrating ribonucleoprotein complexes in gel mobility shift assays (Olsen etal.,
1990). Recent reports have suggested, however, that in vivo multimerisation may require
different sequence specificities. Using an in vivo assay for Rev association based on Rev/Tat
chimaeras, Cullen and colleagues demonstrated that the activation domain mutant RevMlO was
unable to multimerise in vivo, despite wild type activity in vitro (Madore et al., 1994). Mutations in
the pre-defined multimerisation domain were partially active. It was concluded that in vivo
complex formation requires stabilisation through bridging interactions with a cellular co-factor
mediated by the activation domain. Similar conclusions were reached following a study of in vivo
HTLV-I Rex association (Bogerd and Greene, 1993). Proteins with mutated leucine-rich domains
were found to be deficient in multimerisation. It therefore appears that in vitro assays measure the
intrinsic ability of Rev/Rex to multimerise on the RRE, but that such complexes are non-functional
without the stabilising effect of the cellular co-factor.
1.11.2 THE ACTIVATION DOMAIN
The HIV-1 Rev activation or effector domain is a discrete, independent region of 9-10
residues (Mermer etal., 1990). Mutations within this domain abolish Rev response (Benko etal.,
1990). All other domains of Rev are dispensable for activity if Rev is tethered to its RNA target by
heterologous protein:RNA binding interactions (see 1.12): integrity of the activation domain
alone is crucial (McDonald et al., 1992; Venkatesan et al., 1992). This domain consists of critically
spaced leucine/isoleucine residues interspersed with generally hydrophilic residues of less
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primary significance (Malim et at., 1991). The carboxy-terminal portion of the domain displays
greatest conservation both amongst HIV-1 strains and between different retroviral Rev/Rex
proteins (Malim et at., 1991). Leucine periodicity is a feature of several proteins involved in
mediating protein:protein interactions; these include the U2 snRNP A' protein (Fresco etal.,
1991). This suggests that the activation domain contacts a cellular co-factor(s) essential for Rev
function, a hypothesis supported by analogy with other cellular and viral frans-activators.
Inactivating activation domain mutants display a dominant negative phenotype when co-
expressed with wild type protein (Malim et at., 1989b; Mermer et at., 1990; Venkatesh and
Chinnadurai, 1990). Such frans-dominant (TD) inhibition is dose-dependent and can be potent;
the mutant M10 (substitution of DL for LE at positions 78,79) reduces wild type function by 20-
fold when co-expressed at 10-fold molar excess (Malim etal., 1989b). It has been proposed that
these mutants interfere with the correct recruitment of the cellular co-factor by wild-type Rev.
Recent studies have purported to identify cellular proteins which interact with the
activation domain. Early evidence derived from study of the characteristics of the activation
domain made such identification possible. In particular, the activation domains of all studied
Rev/Rex proteins are believed to be functionally interchangeable: this is true for those proteins
with closely homologous activation domains, for example HIV-1 and SIVmac Rev (Berchtold etal.,
1995), and for those with less distinct domain structure with limited homology to HIV-1 Rev
(HTLV-I Rex) (Hope etal., 1991). The Rev proteins of FIV and EIAV have larger activation domains
which are characterised by polar residues rather than leucine periodicity (Mancuso etal., 1994):
these domains are also fully interchangeable with that of HIV-1 Rev (Fridell et at., 1993; Mancuso
et at, 1994). All Rev/Rex proteins must therefore share a cellular co-factor, or contact different
co-factors within the same cellular pathway. The conservation of the putative co-factor is
demonstrated by the fact that Rev function is supported by a range of cell types, from
human/primate to rodent (Olsen et at., 1990), Drosophila melanogaster (Ivey-Hoyle and
Rosenberg, 1990) and Saccharomyces cerevisiae (Stutz and Rosbash, 1994) cells. The co-
factor is likely to be an integral part of a fundamental cellular pathway.
The potent inhibitory effect of TD Rev mutants suggests a possible role in therapeutic
intervention against retroviral disease. 'Intracellular immunisation' (Baltimore, 1988) with
constructs expressing TD mutants might render the cell refractory to superinfection with wild type
virus: TD mutants of the regulatory protein VP16 are able to protect cells from challenge with
herpes simplex virus type 1 (HSV-1) (Friedman et a!., 1988). Hypothetically, there are three
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potential mechanisms of trans-dominance which may apply to Rev. These are; sequestration of a
limiting co-factor ('squelching'), formation of inactive mixed multimers, and competition for target
binding sites. Distinction between these possibilities is important: inhibition based on
sequestration of an essential cellular factor would induce toxicity, contra-indicating such therapy.
Initial experiments favoured the mixed multimer hypothesis: TD Rev can inhibit wild-type
Rev function in either the nucleus or cytoplasm (Hope et al., 1992). However, subsequent
demonstration that activation domain mutants were unable to support multimer formation in in
vivo assays (section 1.11.1.2) (Daly etal., 1993b; Madore etal., 1994) argued against this model.
Probable resolution of this question has been achieved by a series of experiments with Rev and
Rex. Both of these proteins can trans-activate through the RRE, although they have different
sites of binding (Solomin etal., 1990). They do not form mixed multimers (Bogerd and Greene,
1993), although their activation domains are functionally interchangeable. A Rev TD mutant is
able to inhibit Rex/RRE function (Benko et at., 1990), but only in the presence of the Rev core
binding site (Solomin etal., 1990). On a hybrid RNA with both the RRE and RxRE, Rev TD can
inhibit Rev but not Rex activity (Benko et a!., 1990). Inhibition cannot thus be due to formation of
an inactive complex, as Rev and Rex do not multimerise. The requirement for the Rev binding
domain strongly implies that Rev TD blocks Rex activity by sterically inhibiting binding to the RRE:
this cannot occur through the RxRE which is not bound by Rev. The mutant cannot 'squelch' the
cellular co-factor, as in this case it would inhibit both proteins on the hybrid RNA. The inability of
TD mutants to support In vivo multimerisation further supports the inactive monomer hypothesis:
TD mutants can compete efficiently for binding to the RRE, but are deficient in subsequent
critical protein assembly events mediated by the co-factor.
T-Cell lines stably expressing various Rev TD mutants remain susceptible to infection but
fail to support productive replication (Bevec etal., 1992; Malim etal., 1992). The Rev M10 mutant
has been the subject of proposed somatic gene therapy against AIDS (Nabel etal., 1994).
1.11.3 Phosphorylation
Rev/Rex proteins are post-translationally modified by the activity of nuclear serine
kinases (Dillon etal., 1991; Oberste etal., 1993). HIV-1 Rev is thought to be phosphorylated at
two terminal sites (Hauber et a!., 1988), the precise locations of which are uncertain. Serine
substitution mutants, defective for phosphorylation, are active in vivo, demonstrating that this
modification is not essential (Cochrane et a!., 1989b; Malim et a!., 1989b). In contrast, the in vitro
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RNA target binding ability of the HTLV-II Rex protein is directly related to the degree of
phosphorylation (Green et a/., 1992). Treatment of HTLV-I infected cells with the kinase inhibitor
H-7 blocks the expression of unspliced viral mRNA, suggesting an in vivo role for
phosphorylation state (Adachi etal., 1990). Rex regulation by phosphorylation may allow the
virus to monitor the physiological status of the host cell. HTLV-1 Rex is also a phosphoprotein
(Kiyokawa etal., 1985).
1.12 The Rev Responsive Element
Sequences acting in cisto confer rev responsiveness on RNA were initially described by
deletion mutagenesis (Rosen etal., 1988; Hadzopoulou-Cladaras etal., 1989). Subsequently,
these were found to coincide with a predicted highly complex region of secondary structure
within the env RNA (Malim etal., 1989c). The rev responsive element (RRE: also CAR, c/'santi-
repressor) is located immediately downstream of the SU/TM encoded boundary within env, and
thus is within the intron spliced out of the 2kb class of rev-independent mRNAs. The RRE retains
activity when relocated to various positions within env, demonstrating its independent nature;
however, it must be present in the sense orientation (Malim etal., 1989c). Subsequently, several
groups reported direct interaction of recombinant Rev protein with RRE-containing transcripts in
in vitro gel mobility shift and filter binding assays (Daly et al., 1989; Zapp and Green, 1989;
Cochrane etal., 1990a; Daefler et al., 1990). Binding to the RRE is an absolute requirement for
Rev activity (Dayton etal., 1989; Cochrane etal., 1990a). The interaction of Rev with the RRE is
highly specific, with an estimated dissociation constant (Kd) of 0.8-5nM (Cook et al., 1991;
Heaphy et al., 1990; Holland etal., 1990).
Computer simulations predict that the 234nt HIV-1 RRE forms a highly stable secondary
structure (AGf ~450-500kJ/mol), consisting of a central stem and five stem/loops (SLiib,c-v)
(figure 1.6) (Malim etal., 1989c; Le etal., 1990).The central stem (domain ia) is formed by base
pairing between complimentary nucleotides at the 5' and 3' termini of the RRE. Deletion
mutagenesis and RNase protection assays were performed to both confirm the predicted RRE
secondary structure, and to delineate the specific elements required for Rev binding and
function. Recent evidence suggests that an extended stemi is required to mediate full activity;
this defines a 351 nt element (Kimura and Ohyama, 1994; Mann et al., 1994). An 88nt fragment
encompassing SLiib and stemi ia and a portion of StemiA is able to confer full
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Figure 1.6: The HIV-1 Rev Responsive Element (RRE)
A
Computer prediction of the secondary structure of the Rev responsive element from tf
HXB-3 strain of HIV-1 (based on Malim eta!., 1989c, Bartel etal., 1991). Nucleotide positions a
given in reference to the RRE, where position 1 is equivalent to genomic location 7348. Tf
experimentally elucidated core Rev binding element is highlighted in bold. SL: stem loop.
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responsiveness when present as a dimer in rev-dependent sub-genomic constructs (Huang et
al., 1991). Further dissection of this region led to the identification of the base of SLiib as the
specific, core Rev binding site (Dayton et al., 1989; Holland et at., 1990; Malim etal., 1990). This
high affinity Rev binding element (RBE) consists of -13 non-contiguous nucleotides (figure
1.6b) (Heaphy et al., 1991). Although the experimentally defined location of the RBE was
supported by all authors, there was initial disagreement concerning both the contribution to Rev
recognition of sequence-specific versus structure specific-information, and of the base pairing
arrangements within the RBE. The interdependence of nucleotides with respect to overall
secondary structure and the limited knowledge of protein:RNA interactions in general may have
contributed to this. Bartel and colleagues (1991) presented evidence favouring a structural
recognition motif. In this model, the RBE consists of an asymmetric internal loop surrounded by
helical duplex RNA. The internal loop, or bulge, is purine rich and is characterised by non
Watson-Crick base pairing between nucleotides G48 and G71, and between G47 and A73.
Significantly, although substitution of a single A nucleotide for either G48 or G71 abrogates in
vitro Rev binding, a double substitution with A results in full activity. Homopurine base pairing at
this position would be expected to distort the RNA sugar-phosphate backbone, resulting in
sufficient widening of the narrow major groove for protein access. Without this distortion, the
groove is likely to be too deep and narrow for protein entry (Weeks and Crothers, 1993).
Recent evidence has both supported and extended the latter model. Attempts to
synthesise high affinity, synthetic Rev ligands by iterative selection of a random pool of RNA
sequence variants have generated oligomers which resemble the Bartel model (Giver et al.,
1993; Jensen etal., 1994). In particular, these studies have confirmed the importance of isosteric
G:G or A:A base pairing at RRE positions 48 and 71. Ligands with homopurine pairs bind Rev
with up to 160x greater affinity than other pairings. Chemical protection (Tiley et al., 1992),
nucleotide analogue (Iwai et at., 1992) and NMR studies (Battiste et al., 1994; Peterson etal.,
1994) have also proved valuable in discerning features of the Rev-RNA interaction. Certain
nucleotides are invariable and are likely to make specific contacts with Rev. The affinity of Rev for
the minimal RBE is less than that for the entire RRE, suggesting that non-specific contacts with
flanking bases are important in vivo (Tiley et al., 1992). Other nucleotides make a structural
contribution to the recognition motif. Thus, for example the looped out residue U72 cannot be
deleted from the RBE; however, it can be replaced with any other residue with no loss of
function. This suggests that it acts as a spacer to accommodate distortions of the helix
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introduced by the flanking non-canonical base pairing. Rev binding may induce conformational
changes in the RRE, including stabilisation of the purine bulge (Kjems etal., 1991a; Battiste et
al., 1994).
The HIV-1 protein, Tev, which displays Rev activity, is competent to bind to the RRE.
However, it possesses a relaxed binding specificity (Solomin etal., 1990). This is probably a
result of the presence of the Tat basic motif within the amino-terminal region of Tev (Benko eta/.,
1990).
The minimal RBE is insufficient to provide full Rev responsiveness in vivo. Vectors
incorporating the entire SLu sub-domain support approximately 50% of wild-type response
(Holland etal., 1992). The presence of a portion of stemi duplex RNA can increase this to 80%,
probably by providing low affinity binding sites for full Rev multimerisation. Rev binds to the
minimal RBE with one to one stoichiometry (Cook eta/., 1991). The high affinity binding event
induces the recruitment of additional Rev molecules to the RNA by co-operative oligomerisation
along SLiib, Stem iia and Stem i. Scatchard analysis of Rev oligomers suggests that
secondary binding involves low affinity protein:RNA interactions (Heaphy etal., 1991), and is
primarily driven by proteimprotein contacts. Rev monomers will bind to a low affinity site on a
nucleated RNA in preference to a free, high affinity site (Mann et at., 1994). Co-operative binding
also results in stabilisation of the Rev:RNA interaction: the half life for RNA association of a Rev
molecule at the RBE increase from 7-9 minutes to 20-25 minutes on binding of a second
monomer (Daly et al., 1993a). Visualisation of oligomeric complexes by gel retardation
electrophoresis has demonstrated that up to eight monomers can bind to a single transcript (Daly
et al., 1989; Heaphy et al., 1991; Wingfield et al., 1991). At saturating Rev concentrations and
appropriate conditions, Rev will form a filamentous structure up to 1,5mm in length on both RRE
and heterologous duplex RNAs (Heaphy et al., 1990).
The question of whether Rev binding is the only role of the RRE has been addressed by
tethering Rev to target RNA via a heterologous protein-RNA interaction. Near wild type levels of
trans-activation can be achieved if SLu is exchanged for the bacteriophage MS2 operator
element or HIV-1 TAR if Rev is fused to the cognate binding protein (Luo et al., 1993; McDonald
et al., 1992; Venkatesan et al., 1992). However, exchange of the entire RRE reduced
responsiveness by 50-65%. These experiments highlight two points: firstly, that at least a
substantial proportion of the response does not depend on any unique features of the RRE
beyond its Rev binding characteristics, and, secondly, that RRE domains outside of the binding
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regions contribute a quantitative, facilitating role to Rev responsiveness. Cellular factors which
reportedly bind the RRE are therefore unlikely to have a significant role in the Rev response.
These factors include a 56kDa ubiquitous nuclear protein (Vaishnav etal., 1991) and two human
proteins, p62 and p120 (Shukla etal., 1994). Deletion of the additional, non binding domains
(SL nc, hi, iv and v) results in a small, though distinct, loss of responsiveness to Rev,
supporting the conclusions of the heterologous RNA-binding experiments. For example, a
ASLiv orv mutant retains -90% wild type function; however a double deletion mutant retains
only -35% function (Holland etal., 1990; Malim etal., 1990). A degree of functional redundancy
therefore exists within the RRE. These domains are not binding sites; they are susceptible to
nuclease digestion even in the presence of saturating Rev concentrations (Mann etal., 1994).
The primary sequence of domains outwith the binding elements is generally not critical (Dayton
et at, 1992). It is possible that they stabilise the overall structure of the RRE, and may ensure that
the binding elements are presented in an appropriate structural context for Rev binding.
The Rex response elements (RxRE) of HTLV-I is situated within the U3/R region of the
viral LTR. It forms a predicted complex secondary structure of 254nt composed of two stems and
four stem loops (SLA-D) (Hanly etal., 1989). High affinity and specificity binding of Rex to in vitro
synthesised RxRE has been demonstrated (Bogerd etal., 1991; Unge etal., 1991): binding
correlates with function in vivo(Ballaun etal., 1991). The high affinity minimal binding site for Rex
has been isolated. It forms a stem:bulge:stem structure of -12 nt within the central stem of SLD
(Bogerd etal., 1992; Grone etal.., 1994). Rex is also able to bind and function through the HIV-1
RRE (Bogerd etal., 1991), though with different specificity to Rev, requiring stem loops hi,
iv and v (Solomin etal., 1990). This is probably the result of the fortuitous presence of a suitable
binding element, and suggests that Rex makes less discriminatory contacts than Rev. The core
RxRE binding site is well conserved between HTLV-I and HTLV-II and STLV (Bogerd etal., 1992).
HTLV-II Rex binds to this site on the HTLV-II RxRE (Kim etal., 1991).
The RxRE is predominantly located within the R region of the LTR. Elements in U3 are
not absolutely required for activity (Kim et a!., 1991). Formation of the 3' RxRE juxtaposes the
widely spaced polyadenylation signal and cleavage site, the 3' RxRE is therefore present within
all transcripts (Ahmed et at., 1991). Thus unspliced, genomic RNA contains two copies of the
element. The major splice donor site is located within the 5' RxRE; utilisation of this site removes
the core binding region. Spliced transcripts thus contain a single 3' RxRE. The basis of the
selective action of Rex on the incompletely spliced structural mRNA in these viruses is not clear:
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negative regulatory elements may exist in the coding regions of these transcripts to differentiate
them from multiply spliced, Rex independent mRNA.
1.13 THE MECHANISM OF REV FUNCTION
1.13.1 Retroviral Regulatory Mechanisms
Once integrated, the retroviral provirus is effectively a cellular gene. Transcription by the
host cell RNA polymerase II generates a pre-mRNA primary transcript. The retrovirus primary
transcript serves a three-fold function: as genomic RNA, as mRNA for gag and pol, and as pre-
mRNA for further processing to produce mRNA for env and the auxiliary genes if these are
present. The retrovirus thus has to overcome two problems: functional splice sites are required
within the primary transcript but a proportion of unspliced transcript must be retained, and this
transcript must be exported to the cytoplasm for translation and/or virion assembly, despite
incomplete processing.
The so-called 'simple' retroviruses employ cis-acting regulatory elements within their
genomes to regulate viral RNA processing and overcome these problems. Gene expression in
these viruses is constitutive. The 'complex' retroviruses employ an additional regulatory strategy,
the Rev/RRE axis, which allows temporal control of viral RNA processing and the consequent
biphasic pattern of viral replication. In order to reach an understanding of the mechanisms of
retroviral regulation, it is necessary to review the current understanding of the fate of RNA from
transcription to translation in eukaryotic cells.
1.13.2 mRNA Processing
Extensive processing of eukaryotic pre-mRNAs is required to produce mature mRNAs
competent for translation. Transcripts undergo 5' cap formation, methylation, 3' end cleavage,
polyadenylation and splicing to remove intervening sequences (introns). Processing is thought
to follow a highly integrated pathway, culminating in RNA translocation to the cytoplasm. Nascent
pre-mRNAs are co-transcriptionally coated with heterogeneous nuclear ribonucleoproteins
(hnRNPs) (reviewed by Laskey and Dingwall, 1993). The composition of the RNP may determine
the fate of the nascent RNA.
Introns are present in the majority of cellular genes; for many splicing is a requirement for
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efficient processing and nucleocytoplasmic export. Incompletely spliced RNAs are generally
retained within the nucleus. Retention is followed by further splicing or degradation (Ryu and
Mertz, 1989). Splicing is catalysed by a multi-subunit RNP complex, the spliceosome. Assembly
of this complex occurs as a step-wise process, with rapid initiation on nascent transcripts
(reviewed in Lamond, 1993). A large number of small nuclear ribonucleoproteins (snRNPs),
RNAs (snRNAs) and other splicing factors are involved. Many of these make specific contacts
with the substrate pre-mRNA at various points, including the 5' and 3' splice sites. An early step in
spliceosome assembly is the formation of a 'commitment complex' which may mark the RNA for
splicing (Seraphin and Rosbash, 1989). It was thought that binding of U1 snRNP to the 5' splice
site was responsible for formation of the commitment complex (Legrain et al., 1988; Seraphin
and Rosbash, 1989). Recent research, however, points to the involvement of a class of non-
snRNP splicing factors, the SR (serine-arginine rich) proteins (Fu, 1993). Since splicing and
nucleocytoplasmic translocation of most cellular transcripts are tightly coordinated, it has been
proposed that the commitment complex acts to retain pre-mRNA within the nucleus. In yeast,
certain splice site mutations result in increased cytoplasmic expression of pre-mRNA (Legrain
and Rosbash, 1989) suggesting that transport of pre-mRNA can occur if spliceosome assembly
is blocked.
The nucleocytoplasmic transport of most RNAs is dependent on prior processing events
(reviewed in Izaurralde and Mattaj, 1995). Splicing is a general prerequisite for export, and
disruption of this leads to nuclear retention. Kinetic data suggests that RNA translocation is an
energy dependent, saturable process, indicating that it is signal mediated. Furthermore, different
classes of RNA follow distinct export pathways (Jarmolowski et al., 1994). This points to the
involvement of specific trans-acting factors possessing appropriate export signals which mediate
ligand translocation.
1.13.3 Viral C/'s-Regulation
Certain retrovirus splice sites do not conform to the cellular consensus sequences. This
results in inefficient association with the splicing machinery and creates a pool of unspliced viral
RNA (Katz and Skalka, 1990). Creation of consensus splice sites by mutation results in
attenuated replication in simple retroviruses, such as Rous sarcoma virus (RSV) and avian
sarcoma virus (ASV) (Katz et al., 1988; Zhang and Stoltzfus, 1995). The RSV genome also
contains a number of discrete as-regulatory elements which regulate splicing through binding of
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cellular splicing factors. For example, an intragenic src suppressor of splicing (SSS) site inhibits
utilisation of the downstream splice acceptor site by interaction with an avian nuclear factor
(McNally and Beemon, 1992; Amendt et at., 1995). HIV-1 also contains suboptimal splice sites
and c/s-regulatory elements which regulate the complex mRNA balance (Amendt eta/., 1994;
Staffa and Cochrane, 1995).
Thus a pool of incompletely spliced transcripts is generated by the action of c/s-
regulatory elements. Fusion of such elements to heterologous genes shows that unspliced RNA
is retained within the nucleus (Arrigo and Beemon, 1988). Nucleocytoplasmic transport of this
RNA occurs constitutively in cells infected with simple retroviruses. A recently discovered 2l9nt
element within the 3' untranslated region (UTR) of the type D retrovirus Mason-Pfizer monkey
virus (MPMV) appears to mediate translocation, and has been named the constitutive transport
element (CTE) (Bray et al., 1994). Intronless genes are unlikely to access the mRNA
splicing/export pathway, and have been hypothesised to contain c/'s-acting signals to specify
transport (Buchman and Berg, 1988). The intronless hepatitis B virus contains a post-
transcriptional regulatory element (PRE) which can activate the cytoplasmic accumulation of
heterologous unspliced RNA when present in cis (Huang and Liang, 1993; Huang and Yen,
1995). The 119nt pre-mRNA processing enhancer (PPE) element is located within the intronless
thymidine kinase gene of herpes simplex virus type-1. Binding of the PPE RNA to hnRNP L
correlates with cytoplasmic accumulation (Liu and Mertz, 1995). Although it is unclear by what
mechanism hnRNP L mediates this effect, it is likely that the MPMV and HBV elements contact
this or similar factors.
1.14 Viral Trans-Regulation
1.14.1 The Rev Phenotype
Although the role of Rev in facilitating the expression of incompletely spliced viral RNAs
is clear, the mechanism by which this is achieved is not. Some uncertainty concerning the
distribution of viral RNA species with respect to Rev function also remains. In part, the use of
diverse reporter constructs and cell types to assay Rev function may explain this. Much of the
work performed to evaluate the role of Rev has involved transient transfection of transformed cell
lines using sub-genomic viral fragments in a non-viral vector context. Data from the study of the
other auxiliary gene products suggests that the function of lentiviral proteins may vary in different
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cell types. Many studies have utilised sub-genomic HIV constructs transfected into COS cells. It
is well established that the Rev deficient phenotype is associated with a high ratio of multiply
spliced to incompletely spliced viral RNA in the cytoplasm. The increase in incompletely spliced
RNA in the cytoplasm on transfection with a Rev expression plasmid is coincident with a
reduction in the level of multiply spliced transcripts. Thus, in these cells, Rev exerts negative
feedback control over its own production (Felber etal., 1990). Nuclear events are less clear. It has
been reported that incompletely spliced transcripts are present regardless of Rev activity such
that Rev functions to equilibrate the cytoplasm with a pool of pre-existing unspliced RNA. As
these transcripts are the substrate for splicing, the level of multiply spliced RNAs will fall.
Alternatively, some reports suggest that the total cellular level of unspliced RNAs is very low in
the absence of Rev, due to splicing and/or instability. Felber and co-workers found that the half
life of incompletely spliced RNA increased from under one hour to greater than six on Rev co-
expression (1989).
A recent report by Malim and Cullen (1993) is significant: these authors used a Rev
attenuated provirus established by authentic retroviral infection of T lymphocytes. It was found
that in these cells, Rev has no quantitative effect on the multiply spliced RNAs. Instead, Rev
activity induced a six-fold increase in the total amount of unspliced, 9kb RNA, due to enhanced
stability and concomitant nucleocytoplasmic translocation. It was concluded that the nucleus
harbours two pools of primary viral transcript; one that is a substrate for splicing and one that is
retained and degraded, and that Rev acted on this latter pool only. The physical difference
between these pools is unexplained; however differences in RNA fate in heterologous cell types
may be a consequence of varied kinetics of RNA processing events. For example, degradation
of unspliced transcript may occur at a faster rate in T-lymphocytes compared to COS cells.
1.14.2 Determinants of Rev Dependence
As discussed above, RNA which is dependent on Rev for expression is defective in the
absence of Rev. This is a result of nuclear retention (Rosen etal., 1988) degradation (Felber et
at., 1989) or inefficient translation (Arrigo and Chen, 1991) in the absence of Rev. It is presumed
that c/'s-acting signals mediate these fates, and hence specify Rev dependence. It is unclear
whether splice sites are required to specify Rev dependence, or whether intragenic c/s-acting
repressive sequences (CRS) possess this property.
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1.14.2.1 Role of Splice Sites
Inefficiently utilised splice sites have been shown to be required for Rev dependence.
Replacement of authentic sites with efficient {3-globin splice sites in a Rev dependent construct
results in rapid splicing and Rev independent expression (Chang and Sharp, 1989). Inhibition of
splicing by mutation of either splice site led to nuclear retention of the intron-containing
transcript, presumably a result of formation of a commitment complex unable to progress to
functional assembly. This was overcome by Rev/RRE interaction. Mutation of both splice sites to
prevent commitment complex formation resulted in constitutive nucleocytoplasmic export
(Chang and Sharp, 1989). Thus it was proposed that Rev dependence required the presence of
sub-optimal splicing signals retaining the ability to interact with the spliceosome machinery and
specifying nuclear retention. Rev may function by resolution of such snRNP complexes, allowing
export by a default mechanism. Other researchers found that a residual 5' splice site was both
necessary and sufficient to determine Rev dependence: binding of this site to U1 snRNA was
implicated in nuclear retention (Lu et al., 1990). Hammarskjold et al. (1994) extended these
observations, finding that envmust be defined as an intron for Rev dependence. These results
are highly controversial. Many authors have proposed that Rev dependence is retained in the
absence of utilisable splice sites (for example Emerman et al., 1989; Malim et at., 1989c). It is
possible that these transcripts retain the ability to form commitment complexes, even if they are
unable to progress to splicing. Elimination, as opposed to mutation, of all splice sites has also
been shown to preserve Rev dependence (Nasioulas et at., 1994): however, deletion of known
splice sites can reveal cryptic ones (Wieringa et al., 1983). Recent work in yeast cells has
suggested that partial entry of target RNA into a splicing commitment complex is necessary to
potentiate Rev function (Stutz and Rosbash, 1994).
1.14.2.2 CRS Elements
Elements other than splice sites have been proposed as the determinants of Rev
dependence. Several intragenic inhibitory elements have been identified which repress
expression of viral genes independently of the presence of functional splice sites. Two groups
have identified such elements which function in constructs where all viral splicing information has
been deleted (Brighty and Rosenberg, 1994; Nasioulas etal., 1994). These elements are known
as c/'s-acting repressive sequences (CRS) (Rosen etal., 1988). The effect of the CRS elements
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is overcome by deployment of the Rev/RRE regulatory axis. Regions with CRS activity have
been identified within the gag, pot and env genes of HIV-1 and HIV-2, and within HIV-2 vif (see
table 1.2).TheLTR R/U5 region of HTLV-I and-ll contain similar activities (Seiki etal., 1990; Black
et at., 1991). There is no evident homology between these sequences, some of which probably
overlap. Several of these elements have been shown to reduce the expression of chimaeric
heterologous genes (Rosen etal., 1988; Dayton etal., 1988; Cochrane etal., 1991; Schwartz
etal., 1992a), suggesting that they can function as independent units. Multiple CRSs may have
an additive inhibitory effect (Maldarelli et at., 1991). It is particularly intriguing that a CRS within
env may overlap the RRE (Nasioulas etal., 1994; Brighty and Rosenberg, 1994). A reduction in
expression of heterologous reporter genes on insertion of the RRE has been reported by
several groups (Huang etal., 1991; Holland etal., 1992), although this has not been universally
observed (Chang and Sharp, 1989). Brighty and Rosenberg have suggested that this CRS may
suffice to ensure Rev-dependence of a transcript. A simplistic model of Rev function would have
Rev competing for a sterically limited binding site with factor(s) which mediate reduced
expression via the CRS.
CRS elements may introduce defects into viral RNA at the level of instability, nuclear
sequestration and/or inefficient utilisation, which prevent functional expression. Several groups
have demonstrated the nuclear retention of CRS-containing RNA (see table 1.2). In contrast, a
gag CRS identified by Schwartz and co-workers (1992a) acts as an instability element which
reduces the steady state level of RNA in all cellular compartments. This element (INS-1) is
characterised by a high AU content (61.5%). Similar AU-rich elements (AURE) are present in the
3' untranslated regions of several cellular genes which are subject to rapid up- and
downregulation, for example c-fosand interleukin 1 (reviewed in Ross, 1995). Insertion of gag
INS-1 into the HIV-1 fafmRNA reduces its half life from four hours to under one (Schwartz etal.,
1992a). AUREs are often characterised by the pentamer AUUUA, although this sequence does
not feature in INS-1. However, there are several copies of this sequence within the structural
genes of HIV-1 and other lentiviruses (Schwartz et a!., 1992b). INS-1 can be inactivated by site-
directed mutagenesis to lower the AU content: this results in Rev-independent expression of
gag (Schwartz etal., 1992b).
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Table 1.2: Cis-Acting Repressor Sequences
VIRUS GENE LOCATION MECHANISM REFERENCE 1
HIV-1 GAG 287-1 549 Not stability Had.-Clad. 89
GAG 414-631 Instability Schwartz 92
GAG 711-2006 Nuclear retention Maldarelli 91
POL 2619-4551 Nuclear retention Maldarelli 91
POL 3795-4055 Translational ? Cochrane 91
ENV 6004-7595 Nl Nasioulas 94
ENV 6376-6725 Nl Rosen 88
ENV 7382-7623 Nuclear retention B & R 94
ENV 7735-7989 Nuclear retention Emerman 89
HIV-2 VIF 5020-5160 Instability? Reddy 95
ENV 8570-8760 Nuclear retention Keller 93
HTLV-I LTR 450-700 Nl Seiki 90 !
HTLV-II LTR 520-630 Nuclear retention Black 91
Genomic location and proposed mechanism of inhibition of described c/s-acting repressive sequences
(CRS) elements within the genomes of HIV-1, HIV-2, HTLV-I and HTLV-II. It is likely that some of these
elements overlap. Nl: not investigated. Had.-Clad.: Hadzopoulou-Cladaras et al., 1989. B & R: Brighty and
Rosenberg, 1994.
In addition to the effect on stability, AUREs can inhibit translation (Kruys et al., 1989).
The precise mechanism of CRS inhibition may be context dependent. The pol CRS identified by
Cochrane etal. (1991) mediates nuclear retention in an HIV background, but reduces translation
efficiency of a CRS/CAT chimaera.
CRS inhibition is probably mediated by the binding of cellular proteins. Several AU-
binding proteins have been characterised (for a review see Decker and Parker, 1995, and
references therein). Two cellular factors which bind the HTLV-II LTR CRS have been isolated
(Black et al., 1994). These proteins have recently been identified as two members of the hnRNP
family, hnRNP A1 and polypyrimidine tract binding protein (or hnRNPI) (Black et al., 1995).
Binding of hnRNP A1 was found to be necessary for CRS mediated inhibition of gene
expression. Olsen and colleagues (1992) have identified a 42kDa nuclear factor, a putative
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member of the hnRNP C family, which binds to a CRS within pot. hnRNP C is a splicing factor
which binds to intronic sequences (Bandziulis etal., 1989). The CRS may elicit the formation of
ribonucleoprotein complexes refractory to nucleocytoplasmic export. It is possible that these
complexes also protect pre-mRNA from splicing, thus preserving a pool of incompletely spliced
transcripts available for the late stage of viral replication.
In summary, several, distinct CRS elements downregulate the expression of lentiviral
structural genes by a variety of mechanisms. The significance of these elements with respect to
the determination of Rev dependence is still to be conclusively established. The recent work of
Brighty and Rosenberg (1994) strongly supports the role of CRSs. These authors found that
env-derived constructs which lacked the RRE associated CRS but possessed known splice sites
were expressed independently of Rev; constructs with the opposite content were Rev
dependent. It is also possible that there is functional redundancy within the complex retroviral
genome, with both splice sites and CRS elements interacting with nuclear factors to retain a pool
of incompletely spliced viral RNA.
1.15 Rev Functional Mechanisms
The mechanism of Rev function has not been fully characterised. A direct effect of Rev
on splicing would superficially explain the observed Rev phenotype. Rev cannot be a general
inhibitor of splicing, however, as it promotes the expression of the singly-spliced 4kb class of
transcripts concurrently with the unspliced genomic transcripts. A second proposed model for
Rev function is that Rev chaperones target RNAs from the nucleus to the cytoplasm. Cytoplasmic
activities have also been proposed for Rev.
1.15.1 Direct Inhibition of Splicing
A nuclear factor detected in HIV-1 infected cells was found to inhibit the splicing of pre-
mRNAs in in vitro assays (Gutman and Goldenberg, 1988). Subsequent analysis by Kjems and
colleagues has suggested that the basic domain of Rev may mediate this phenomenon. Using
an in vitro assay based on splicing of a construct containing an RRE within the intron and splice
sites derived from the (3-globin pre-mRNA, this group identified a 3-4 fold reduction in splicing
due to the full length Rev protein (Kjems etal., 1991b). A more significant 30-fold inhibitory
effect was achieved by use of a synthetic peptide corresponding to Rev residues 34-50. Further
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study purported to identify the mechanism of Rev inhibition: prevention of entry of the U4/U6.U5
tri-snRNP complex into the maturing spliceosome (Kjems and Sharp, 1993). Since the basic
domain was entirely responsible for this effect, it was proposed that conformational changes in
the RNA induced by binding to the RRE resulted in spliceosome assembly arrest. A proposed
interaction between the basic domain and the murine protein YL2, a homologue of human p32,
which co-purifies with the splicing factor SF2/ASF (Krainer etal., 1991) lent support to this model
(Luo et a!., 1994). SF2/ASF has been implicated in formation of a specific spliceosome
commitment complex involving the HIV-1 tat pre-mRNA (Krainer et al., 1990): sequestration of
this factor by Rev could reduce splicing. The relevance of these observations is questioned by
the finding that HIV-1 Tat basic domain also binds p32 (Fridell et al., 1995). More significantly, the
role of the basic domain has been shown to be limited to discriminatory RNA binding by the
binding of Rev chimaeras to heterologous targets (McDonald etal., 1992; Venkatesan et al.,
1992). Indeed, other observations strongly suggest that Rev has no direct in vivo anti-splicing
activity. Rev has no quantitative or qualitative effect on the distribution of multiply spliced mRNAs
in a T lymphocyte cell line (Malim and Cullen, 1993), despite a dramatic effect on unspliced RNA:
Rev action in these natural viral host cells therefore cannot involve inhibition of splicing.
Furthermore, by using Xenopus oocytes, Rev activity has been shown to occur in cells
simultaneously with splicing of transcripts containing the RRE (Fischer etal., 1994): Rev function
is therefore independent of any inhibitory effect on splicing.
Thus, despite some circumstantial evidence to the contrary, HIV-1 Rev does not appear
to have a role in the direct inhibition of splicing. However, Rev/Rex proteins of other viruses may
have such an activity. In both the HTLVs and EIAV, Rev/Rex binding to the response element has
been speculated to inhibit splicing at neighbouring splice sites, possibly by steric hindrance. Rev
activity correlates with a reduction in the production of a four exon multiply spliced EIAV mRNA
due to alternative splicing to remove the third exon (Martarano et al., 1994). In the HTLVs, the
splice donor site utilised to produce env and tax/rex mRNA is situated within stem-loop D of the
5' RxREs, close to the core Rex binding element. In HTLV-II, Rex activity requires the presence of
this site (Black et al., 1991). Although suggestive of a role for Rex in steric inhibition of splicing,
there is no experimental evidence to support this hypothesis.
1.15.2 Nucleocytoplasmic Export
Early reports suggested that Rev could increase the efflux of RRE-RNA from isolated
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vesicles (Pfeifer etal., 1991). Investigation into this model for Rev activity has been hampered by
the rudimentary state of current knowledge of the mechanisms of RNA export. However, recent
reports suggest that Rev function may become a paradigm for specific export mechanisms.
As noted above (1.13.2) RNA may be escorted through the nuclear pore complex by
specific transport factors. Several proteins which 'shuttle' between the nuclear and cytoplasmic
distribution have been linked to the cytoplasmic accumulation of distinct classes of RNA. For
example,hnRNP A1 may mediate the export of poly(A)+ mRNA (Pinol-Roma and Dreyfuss,
1992), and TFIIIA has been linked to the export of 5S rRNA (Guddat etal., 1990). Mutations
which prevent 5S rRNA from binding to TFIIIA result in RNA nuclear retention.
The recent demonstration that HIV-1 Rev is a shuttle protein (Kalland etal., 1994; Meyer
and Malim, 1994; Richard eta/., 1994) strongly suggests that it is a viral equivalent of such
factors, directly involved in mediating export of its ligand RNA. The originally described
nuclear/nucleolar localisation of Rev masks a dynamic situation. Transfection of cells expressing
Rev with a reporter construct expressing RRE-RNA induces the rapid cytoplasmic localisation of
the Rev protein (Richard eta/., 1994; Luznik eta/., 1995). However, the presence of RRE-RNA is
not essential for shuttling. Inhibition of nuclear import of Rev by disruption of RNA polymerase
activity with actinomycin D or 5,6-dichlorobenzimidazole riboside (DRB) resulted in Rev
accumulation in the cytoplasm (Meyer and Malim, 1994; D'Agostino eta/., 1995; Szilvay eta/.,
1995), regardless of the presence or absence of RRE-RNA. However, Rev molecules with
mutations of the activation domain remained in the nucleus under these conditions. The
biological activity of a series of activation domain mutants was found to correlate exactly with the
ability to enter the cytoplasm (Meyer and Malim, 1994). This is compelling evidence that the
primary biological action of Rev is to directly facilitate the nucleocytoplasmic export of target
mRNAs.
The activation domain is thus a putative nuclear export signal sequence (NES).
Confirmation of this has come from an elegant series of experiments recently reported by Fischer
etal. (1995). Intranuclear injection of BSA conjugated to synthetic peptides resulted in rapid
cytoplasmic accumulation if the peptide corresponded to the wild-type activation domain (AD) of
Rev or Rex, but to nuclear entrapment if a non-functional mutant (M10) was used. Identical
results were achieved by Wen et at. (1995), who also identified a leucine-rich NES in the cellular
protein kinase inhibitor (PKI). BSA-AD competitively inhibited both Rev function and the nuclear
egress of 5S rRNA and of certain snRNAs, though not that of mRNA, tRNA or other ribosomal
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components (Fischer eta!., 1995). This suggests that this export signal is recognised by a single,
saturable cellular factor, responsible for translocation. TFIIIA, implicated in 5S rRNA export,
contains a homologous leucine-rich motif: this protein may be a cellular Rev/Rex homologue
(Fischer et al., 1995). These export signals are compared below: interspersed hydrophobic,
generally leucine, residues (bold) are the major defining characteristic.
HIV-1 Rev 75 LPPLERLTL 83
HTLV-I Rex 84 AQLYSSLSL 92
P KI 39 LK-LAGLDI 46
TFIIIA 58 LSTVAVLTL 66
A putative factor has recently been isolated from both human (Bogerd etal., 1995; Fritz
et al., 1995) and Saccharomyces cerevisiae (Stutz etal., 1995) cells. These proteins bind
specifically to wild type, though not to inactivating mutant, activation domains of Rev and Rex.
The human variant, RIP (rev interacting protein) (Fritz etal., 1995) or RAB (rev/rex activation
domain binding protein) (Bogerd etal., 1995), is a 58-59kDa protein with sequence features
characteristic of human nucleoporins, protein components of the nuclear pore complex. These
include a high serine/threonine content, and numerous phenylalanine/glycine repeats. Rip/Rab
appears to localise predominantly in the nucleoplasm of transfected cells, with some distribution
in both the nucleolus and cytoplasm. This is not the expected distribution of a nucleoporin,
suggesting that Rip/Rab may function to transfer Rev/Rex from the nucleolus/nucleoplasm to the
perinuclear region, where it may 'dock' with the pore complex. Both groups found that
overexpression of Rip/Rab significantly enhanced Rev function. Bogerd and co-workers
demonstrated that Rip/Rab possessed several genetically pre-determined characteristics of the
Rev co-factor. These included a perfect correlation between activation domain mutant binding
and function, distribution in a range of cell types able to support Rev function, binding to Rev as
part of a Rev/RRE-RNA complex, and the ability to bind heterologous activation domains, such as
that of EIAV Rev, which can functionally replace HIV-1 Rev activation domain (Fridell etal., 1993;
Bogerd etal., 1995). The yeast variant, Rev interacting protein-1 p (RIP1p) (Stutz etal., 1995)
has a similar composition. Yeast mutants not expressing RIP1p do not support Rev function, but
maintain viability. Riplp may thus be a member of a class of functionally redundant molecules.
Riplp differs from its human homologue in its distribution at nuclear pores. Moreover,
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overexpression of Riplp dampens Rev response in yeast. This discordant finding may be due to
different levels of each factor in yeast and human ceils, such that lower levels in human cells are
supplemented by overexpression, but higher background levels in yeast cells lead to
'squelching' of Rev on overexpression.
Thus, Rev may function as a 'molecular bridge' connecting RRE containing RNAs with a
specific section of the nucleocytoplasmic export machinery. Investigation of the effect on viral
replication in natural target cells of ablation of Rip/Rab expression is an obvious future
experiment. If Rip/Rab is not essential for cell viability in humans, then ablation of expression is a
possible strategy for anti-HIV therapeutic intervention.
1.15.3 Translational Regulation
A number of researchers have recorded a potential discrepancy in the upregulatory
effect of Rev on structural protein synthesis as opposed to the increase in cognate mRNA
(Sodroski et al., 1986; Hadzopoulou-Cladaras eta!., 1989; Benko eta!., 1990; Chanda etal.,
1990; D'Agostino etal., 1992). These findings have been taken as evidence for a role for Rev in
translational regulation (D'Agostino etal., 1992). However, these data often refer to Rev-induced
increases in total cellular mRNA, which may not reflect the differential increase in cytoplasmic
mRNA occasioned by Rev action. However, the universality of Rev-induced alterations in mRNA
distribution has been challenged by other authors. Arrigo and Chen (1991) identified singly
spliced vif, vpr and env/vpu 2 mRNAs in the cytoplasm of Rev deficient lymphoid cells (729 B
cells). Rev function had little effect on the distribution of these mRNAs. Conventional results
were recorded in COS cells. Gag mRNA has been observed in the cytoplasm of HeLa cells
expressing ARev proviruses (D'Agostino et al., 1992). In both these systems, mRNA found in
the cytoplasm in the absence of Rev was translated inefficiently. This defect was found to be due
to exclusion of RNA from polysomes. Instead, RNA was associated with a 40-80S
ribonucleoprotein complex (Arrigo and Chen, 1991), which may be an arrested pre-initiation
complex. Incompletely spliced mRNAs expressed in the cytoplasm of lymphoid cells in the
absence of Rev were found to lack association with poly(A) binding protein (PAB1) (Campbell et
al., 1994). PAB1 is necessary for the completion of polysome formation (Sachs and Davis, 1989);
thus the failure of mRNA to interact with PAB1 would be expected to prevent efficient translation.
Pavlakis and co-workers proposed that CRS-mediated defects in RNA conformation or RNP
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composition might prevent poly(A) association, and that Rev would function to correct this
(Campbell eta!., 1994). In situ hybridisation experiments have revealed that Rev remains bound
to RNA molecules within the cytoplasm of infected cells (Arrigo etal., 1992), where it may allow
functional association with the translational machinery. Support for the translational regulatory
role of Rev comes from the identification of eukaryotic translation initiation factor 5A (elF-5A) as a
putative Rev co-factor (Ruhl et al., 1993). EIF-5A is a 19kDa hypusine residue containing protein
with an unknown in vivo role (for a review of initiation factor biology, see Park et al., 1993). In
vitro, this protein catalyses the formation of the dipeptide analogue methionyl-puromycin,
mimicking the formation of the first peptide bond during translation (Benne and Flershey, 1978),
although this activity might be artefactual (Kang etal., 1993). Rev may recruit elF-5Ato improve
the efficiency of translation of bound RNAs, perhaps by mediating the correct association of
PAB1. Since elF-5A has both nuclear and cytoplasmic distribution (Ruhl etal., 1993) it may have
a further role in Rev activity.
EIF-5A was isolated as a Rev activation domain binding factor. Evidence for the functional
importance of elF-5A is three-fold. Firstly, inhibition of elF-5A expression with antisense
oligonucleotides blocked Rev function (Ruhl et al., 1993). Secondly, Rev activity was not
observed in Xenopus laevis oocytes: exogenous elF-5A supported Rev function. Finally,
exogenous elF-5A was found to reconstitute Rex function in a system where the Rev/Rex co-
factor was sequestered by a Tans-dominant inhibitory mutant (Katahira et al., 1995). Several
objections to this evidence may be raised. Fischer etal. (1994) found Rev to be fully functional in
X. laevis oocytes, directly contradicting Ruhl and colleagues. Although Ruhl etal. demonstrated
binding of an activation domain synthetic peptide to elF-5A, they did not characterise binding to
the full-length protein, nor demonstrate lack of binding to known activation domain mutants. It
should be noted that others have failed to repeat the results of Ruhl etal. (Bogerd etal., 1995).
Moreover, although it has been genetically determined that Rev and Rex have a common co-
factor (Flope et al., 1991), Katahira and co-workers were unable to significantly reconstitute Rev
function with elF-5A.
The significance of the data concerning an effect of Rev on translation, and its possible
interaction with elF-5A is uncertain. In particular, most investigators have not observed large
amounts of Rev dependent mRNA in cytoplasmic fractions in the absence of Rev. Although
there may be cell type specific effects, Malim and Cullen (1993) were unable to repeat the
findings of Arrigo and Chen in CEM lymphoid cells. The latter authors employed quantitative PCR
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analysis to assess the nature of cytoplasmic RNAs. This technique would be sensitive to any
leakage of material from nuclear extracts during cell fractionation, which may explain the
discordant results. However, it remains a possibility that a proportion of RNAs may escape nuclear
retention by an unproductive route or as nonfunctional RNP complexes in certain cell types. Rev
would be required to redirect RNA through productive translocation and on to efficient polysomal
association.
1.15.4 A Unified Theory for Rev Activity
A possible model of HIV-1 Rev function based on the data currently available follows, and
is illustrated by figure 1.7.
The integrated HIV-1 provirus remains quiescent until host cell activation or
differentiation induces transcription from the viral LTR. The early phase of transcription produces
the regulatory proteins Tat, Rev and Net. Tat initiates a positive feedback loop, trans-activating
viral expression. Competitive interaction of cellular nuclear factors with various viral as-acting
signals determines the fate of the viral primary transcript. The primary transcript is either spliced to
completion, or retained in the nucleus. Degradation may occur. Rev protein produced from
multiply spliced RNAs is localised to the nucleus via the nuclear localisation signal: this event may
be mediated by interaction with the shuttle protein B23. Once within the nucleus, Rev may be
retained within the nucleolus by binding to B23 or to ribosomal RNA. Rev monomers may bind to
their core RNA target within the RRE, present on viral primary transcripts. However, this
interaction is insufficient to affect the fate of these transcripts. Once a critical intranuclear
concentration of Rev has been reached, rapid multimerisation, driven by highly co-operative
binding events, along the duplex RNA within the RRE occurs. The reiterated Rev activation
domains mediate interaction with a co-factor, Rip/Rab. This event stabilises the Rev oligomer.
Nucleocytoplasmic transport of the Rev/RNA complex then ensues, probably mediated by
'docking' of the co-factor with the nuclear pore complex. The transcript is translated, although
interaction with a second co-factor, elF-5A, may be required for functional association with the
translational machinery. Rev protein released from the transcript may return to the nucleus to
initiate further RNA translocation. Expression of the structural gene products marks the late
phase of replication, with packaging of the RNA genome and virion assembly.
Thus the primary mode of action of Rev may be to mediate nucleocytoplasmic transport
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Figure 1.7: Possible Model for the Activity of HIV-1 Rev
A proposed unified hypothesis for the function of HIV-1 Rev. Early (A) and late >
phases of viral replication are discernible. For simplicity, the fate of singly spliced viral RNA t
been excluded. For discussion, see text.
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of RNA containing the RRE. By acting as a chaperone for RNA, Rev activity might by-pass
divergent RNA processing and regulatory mechanisms. The presence and kinetics of such
mechanisms might vary between cells, accounting for the reported variation in Rev attenuation
phenotypes. Thus, the Rev/RRE interaction is sufficient to overcome the inhibitory effect of
heterologous c/s-acting repressive elements. An AURE in the 3' untranslated region of the
structural gene mRNAs of human papillomavirus types 1 and 16 reduces both the half life and
translatability of these transcripts (Kennedy etal., 1991; Tan and Schwartz, 1995). This effect is
counter-acted by Rev and the RRE (Tan and Schwartz, 1995). Rev also increases the expression
of hybrid transferrin receptor/RRE mRNAs which are otherwise rapidly degraded (Zolotukhin et
a!., 1994). It must be concluded that the action of Rev in 'rescuing' defective RNA is a general
one.
Confirmation of the validity of the above model is awaited. In particular, it will be necessary
to demonstrate physical association of the putative co-factor with the Rev/RNA ribonucleoprotein
complex, and with the nuclear pore complex.
1.15.5 NS1, An Orthomyxovirus Rev Homologue?
Influenza A virus is an orthomyxovirus with a genome consisting of eight RNA segments.
Two of these, 7 and 8, express additional mRNAs via splicing events (Lamb and Lai, 1980; Inglis
and Brown, 1981). Segment seven encodes non-structural protein 1 (NS1) from the unspliced
RNA, and NS2 from a spliced derivative. Thus, a similar problem to that faced by retroviruses
exists. The balance of splice products is controlled by both c/s-acting signals, and by a trans-
acting factor, NS1 (Alonso-Caplen and Krug, 1991). NS1 consists of 237 amino acid residues
and has a modular construction strikingly similar to Rev/Rex. An amino-terminal domain, which
mediates binding to poly(A) RNA, a carboxy-terminal effector domain and two nuclear localisation
signals are discernible (Qian et at., 1994; Qiu and Krug, 1994). Although the effector domain
consists of -30 residues, it is characterised by the presence of critical periodically spaced leucine
residues. Moreover, multimerisation is required for activity (Nemeroff et at., 1995). It might
therefore be expected that NS1 is functionally analogous to Rev. However, NS1 mediates the
inhibition of nucleocytoplasmic export of target RNAs (Alonso-Caplen etal., 1992). It is possible
that NS1 contacts the same co-factor as Rev, and that the additional effector domain residues are
required to inhibit rather than facilitate transport. Alternatively, a distinct co-factor requirement
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exists. NS1 has been reported to possess a plethora of activities, including splicing inhibition and
stimulation of translation of viral transcripts (De La Luna etal., 1995). How these activities are co¬
ordinated to regulate viral replication is unknown.
1.16 Rev and the Molecular Basis of Latency
A A rev HIV-1 provirus constitutively expressed in cell culture can be rescued to
complete replication by transfection with a Rev expression vector. By titrating the Rev vector,
Pomerantz and co-workers demonstrated that the relationship between induced virus replication
and Rev expression was non-linear (1992). A critical threshold level of Rev expression was
required to substantially increase virus production. The threshold effect may be advantageous to
the virus: it acts as a 'dam' allowing high level expression of viral RNA in the absence of
corresponding levels of structural proteins sensitive to immune surveillance: once the critical
level has been reached, the accumulated RNA can initiate high level production of structural
proteins to optimise the production of progeny virions.
The molecular basis of the threshold effect is thought to be the requirement for Rev
multimerisation on target RNA for activity (Malim and Cullen, 1991;Heaphy etal., 1992). Below
the threshold concentration, Rev would bind as a monomer to the high affinity site on the RRE.
At the critical concentration, oligomerisation of Rev nucleated by the high affinity binding event
would be induced. This would occur rapidly, due to the highly co-operative nature of Rev
multimer assembly. Optimal Rev activity is associated with full multimerisation along the RRE
SLiiBand Stem iA(Mann etal., 1994). Indeed, Mann and co-workers have described the RRE
as a 'molecular rheostat', detecting and responding to the intracellular Rev concentration (1994).
As has been discussed, lentivirus persistence in the host is, at least partially, a result of
restricted viral expression. Theoretically, maintenance of a sub-threshold Rev concentration
would be one method to restrict virus expression. Certain chronically infected cell lines have
been proposed as models of in vivo HIV latency. Transcriptional suppression underlies the
restricted viral state in two of these cell lines, the T lymphocyte-derived ACH-2 and monocyte-
derived U1 (Folks et al., 1989). However, a sub-threshold Rev concentration acts as a proximal
block to expression, preventing structural protein synthesis from the low basal level of viral
transcripts which are maintained in an aberrant pattern ('blocked-early') similar to that seen in the
early phase of single cycle productive infection (Pomerantz et al., 1990). Transduction with a
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retroviral vector expressing Rev induces a small increase in structural protein synthesis (Duan et
a!., 1994). A blocked-early transcript pattern is also demonstrated by the astrocytoma cell line
TH4-7-5 (Kleinschmidt etal., 1994). However, the restricted state of virus expression cannot be
increased by mitogenic stimulation, or by co-expression of exogenous Rev (Neumann etal.,
1995). Moreover, a heterologous gag construct cannot be regulated by Rev in these cells,
strongly suggesting that a cellular block to Rev activity exists. Since fusion with rev-permissive
cells does not relieve this block, it is probable that astrocytes contain factors antagonistic to Rev
activity. Low Rev activity is directly responsible for restriction in these cells. Virus can be rescued
from these cells by co-cultivation with monocytes, suggesting that latently infected astrocytes
may be a reservoir for viral spread within the central nervous system.
Study of viral RNA patterns in chronically infected cell lines may have relevance for
natural infection. Qualitative and quantitative analysis has shown that viral RNA in PBMCs may be
a surrogate marker for disease progression. Deterioration in CD4+ cell count is associated with
increase in total viral RNA levels. Several groups have studied viral RNA patterns in longitudinal
surveys of HIV+ individuals using quantitative reverse transcriptase-initiated PCR. These have
found that a shift in the predominant expression of multiply spliced RNAs to that of unspliced
RNAs correlates with disease progression (Seshamma etal., 1992; Furtado etal., 1995; Michael
et at., 1995b). A stable ratio of unspliced to multiply spliced transcripts is associated with a more
benign clinical course. It should be noted that this pattern has not been universally observed
(Saksela et at., 1994). Thus, in asymptomatic individuals the predominant viral expression pattern
is similar to the blocked early stage latency seen in chronically infected cell lines, and associated
with a lack of rev activity. This may be the indirect result of reduced transcription, as in ACH-2 and
U1 cells. However, rev attenuation as the direct cause of restriction cannot be discounted.
Approximately 10% of HIV-1 infected individuals are classified as slow progressors, or long term
survivors (Sheppard et al., 1993). Iversen and co-workers have found that long term survivors
may host attenuated viral variants, the presence of which correlates with, and contributes to, the
failure of disease progression (1995). In particular, an inactivating leucine to isoleucine
substitution at position 78 within the Rev activation domain was found to persist for over 4.5
years in one individual. Reversal of this mutation partially restored replication competence in
cloned isolates. All long term survivors studied possessed a proportion of putative attenuating
mutations within the rev gene. It is possible that rev attenuation is selected for in order to maintain
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the restricted state. Eventual immune system collapse removes this selective pressure in most
individuals; however others may avoid this fate due either to characteristics of their immune
response or to the nature or degree of virus attenuation.
1.17 The Rev/RRE Axis of Heterologous Complex Retroviruses
A rev ORF is identifiable in all lentiviral genomes. A similar phenotype is universally
associated with lack of functional rev expression (Cheng etal., 1990; Kalinski et al.t 1991; Phillips
etal., 1992; Oberste etal., 1993; Martarano etal., 1994). However, a degree of divergence does
exist. The rev/RRE axes of non-primate lentiviruses have yet to be fully characterised. Non-
primate lentiviral rev genes share a characteristic exon location, with the first coding exon
coincident with, and in the same reading frame as, the amino-terminal portion of env(Mazarin et
a!., 1988; Saltarelli etal., 1990; Stephens etal., 1990; Kiyomasu etal., 1991; Oberste etal.,
1993). Consequently, the signal sequence of non-primate lentiviral Env proteins is located at a
more distal location within Env than is the case in other retroviruses (Sonigo et at., 1985). The
non-primate lentiviruses are also characterised by large size relative to the primate proteins,
encoding 120-186 residues compared to 86-116 residues within the primate lentiviral group.
These details support the possible classification of the primate and non-primate lentiviruses as
separate evolutionary clades (1.2), and may point to the presence of additional functional
capabilities within these proteins.
Limited overall sequence identity exists between the various Rev proteins (figure 1.8a);
the only significant homologies being amongst the primate viruses. However, the two functional
domains elucidated in HIV-1 Rev are generally conserved (figure 1.8b and c). The functional
reciprocity of the putative activation domains has been discussed (1.11.2). Hydrophobic
residues at positions 9 and 11 seem to have greatest significance. A basic motif can be observed
in all proteins. However, those of both BIV and EIAV Rev are less distinct, with a lower proportion
of basic residues. The overall modular organisation of EIAV, BIV and FIV Rev appears to be less
distinct that that of the other proteins. An experimental definition of the RNA binding domains of
these proteins is awaited with interest. Both HIV-2 and the various SIVs possess homologous
RREs to HIV-1 in similar genomic locations (Le etal., 1990). Specific binding of the Rev proteins
from these viruses to cognate RREs in vitro has been reported (Garrett and Cullen, 1992). Both
FIV and EIAV demonstrate considerable divergence with respect to RRE structure and location.
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Figure 1.8: Sequence Comparisons between Rev/Rex Proteins
A
Overall amino acid sequence identity between selected complex retrovirus Rev/F
proteins. Pairwise comparisons were made using the 'BESTFIT' program of the University
Wisconsin Genetics Computing Group package (version 8). Percentage identities were obtair
by division of the total number of identical aligned residues by the number of residues in
smaller protein. Shown in bold are those comparisons giving greater than 30% amino a
identity.
Sequences used for comparison (with reference for rev gene sequence) were
following: HTLV-lQg1/pl_(Rimsky etal., 1988), HIV-1HXB3 (Malim etal., 1988), HIV-2Rod (^ai
and Cullen, 1992), SIVmac239 (Regier and Desrosiers, 1990), SIVagmsA2i (Sakai etal., 19f
SIVmndMDl2 (Sakai etal., 1991), MVVev1 (Sargan etal., 1991), CAEVqq (Saltarelli etal., 19<
BIV-|o6(Oberste etal., 1993), FIVPet(Phillips etal., 1992) and EIAVWy0(Stephens etal., 199»
B
Comparison of the experimentally defined (HTLV-1, HIV-1, HIV-2, SIVs) or puta
(remainder) RNA binding domains of the Rev/Rex proteins of the viruses listed above (A), h
protein sequences from the Maedi Visna virus variants 1514 (Sonigo etal., 1985) and SA-Ofv
(Querat et a!., 1990) are also included for comparison. Alignments made using the UWG-
program, 'PILEUP'.
C
Comparison of the experimentally defined (HTLV-1, HIV-1, HIV-2, SIVs, EIAV, FIV
putative (remainder) activation domains of the Rev/Rex proteins of the viruses listed above
Hydrophobic residues are marked in italics. The numbers 1,3,6,9,11 refer to residue positi
within the domain, with respect to the leucine residue at HIV-1 Rev position 73. A pa-
alignment of the EIAV activation domain can be made, however the entire functional impor
domain is shown below.
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HIV1 HIV2 MAC AGM MND MVV CAEV BIV FIV EIAV
18 20 18.7 17.1 22.9 15.5 15 16.1 13.7 10.9
HIV-1 COCO 31.8 31.7 24 17.2 18.1 24.1 13.8 21.6
HIV-2 57 40.2 25 18 17 26 22 26
SIVmac 40.2 37.8 18.7 19.6 27.1 23.4 15.9
SIVagm 29.3 17.1 13.4 22 17.1 28
SIVmnd 26 16.7 27.1 18.8 24
MVVevI 24.2 18.2 17.6 17.6
CAEV 25 16.7 20
BIV 20.9 18.2
FIV 18.3
MVVevI 71 . . .KTRRRKG WFKWLRRLKA R COCO
SA-OMVV 74 ...KTKRRKG WFQWLRKLRA R 91
MVV1514 73 ...KTKKKRG WYKWLRKLRA R 90
HIV-2 33 ASQRRNRRRR WKQRWRQ... 49
SIVmac 33 ANQRRQRKRR WRRRWQQ... 49
HIV-1 35 RQARRNRRRR WRERQR.... 50
SIVagm 28 ....ARQRRR ARRRWRQQQD 43
SIVmnd 43 . . . .ARQRRR RKQQLRTRRA 58
HTLVrex 1 ...MPKTRRR PRRSQRKR.. 15
FIV 82 KMKKKRQRRR RKKKAFKK.. 99
BIV 93 QNRRK QERRLSGLDR R1 08
EIAV 71 ....QHTPSR RDRWIRGQ.. 84
1 3 6 9 11
HIV-1 73 L Q L P p L E R L T L D 84
HIV-2 71 Q T I Q H L Q G L T I Q 82
MVVevI 102 S N V A G L E K L T L E 113
MVV1514 104 S N M V G M E N L T L E 115
SA-OMVV 105 G N C A G L E N L T L G 116
CAEV 91 P C L G A L A E L T L E 92
SIVmac 71 L A I Q Q L Q N L A I E 82
SIVmnd 72 L D R G P D Q L C Q G V 83
SIVagm 62 R L A D E A Q H L A I Q 73
BIV 145 G H L P P R S Y F K L K 156
HTLV1REX 82 L S A Q L Y S S L S L D 93
EIAV 41 W C R V L R Q S L P E E 52
FIV 95 KAFKKMMTDLEDRFRKLFGSPSKDEYT 120
EIAV 32 PQGPLESDQWCRVLRQSLPEEKIP 55
In FIV, the RRE forms an extended single stem loop and is positioned at the 3' end of env
(Phillips etal., 1992). EIAV may encode multiple RREs. Interestingly, these elements are not
predicted to contain a high degree of secondary structure, implying that EIAV Rev utilises a novel
mechanism for RNA recognition (Martarano et al., 1994). This correlates with the diverse basic
motif of EIAV Rev.
Determination of the functional reciprocity of Rev/RRE interactions between the various
lentiviral systems has provided important insights into Rev activity and delineation of functional
domains. Moreover, it may provide an insight into the phylogenetic relationship between these
viruses. Restricted reciprocity is likely to be a factor of RNA binding specificity. The relatively
relaxed binding specificity of Tat may explain the complete interchangeability of all primate
lentiviral Tat proteins (Sakai etal., 1993). HTLV-1 Rex binds the HIV-1 RRE, but the reverse is not
true (Solomin et al., 1990), thus providing a molecular basis for the observed incomplete
functional interchangeability (Rimsky etal., 1988). However, the inability of HIV-2 and SIVmac Rev
proteins to function through the HIV-1 RRE (Lewis etal., 1990; Sakai etal., 1991) is a result of a
failure to multimerise on the heterologous target (Garrett and Cullen, 1992). This suggests that
the HIV-2/SIV proteins make more discriminatory contacts than the promiscuous HIV-1 Rev and
HTLV-1 Rex molecules.
The recent discovery of a rev-like ORF within the genome of an endogenous human
retrovirus, HTDV (human teratocarcinoma derived virus), is intriguing (Lower et al., 1995). This
virus is thought to have been extant for approximately 30 million years. The presence of this ORF
suggests strong selective pressure in favour of the Rev/RRE regulatory system, and that this
system may have arisen by selection on at least two occasions. Alternatively, the presence of
conserved binding and activation domains between HIV-1, HTLV-1 and HTDV may implicate a
more recent recombination event as the source of these genes.
1.18 Maedi Visna Virus Rev: Aims of Research Project
Data concerning the putative rev gene of MVV available at the onset of this research
project was limited and somewhat contradictory. A MVV homologue to the HIV-1 rev gene was
hypothesised by Vigne and co-workers (1987), who demonstrated early and late phase viral
expression patterns. They suggested that the 1.2kb multiply spliced mRNA, expressed in the
early phase, might encode this gene. The location and splicing pattern of this mRNA was also
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suggestive of HIV rev(Sargan and Bennet, 1989). Subsequently, this mRNAwas shown to give
rise to a 19-21.5 kDa protein in in vitro translation systems (Mazarin et at., 1988; Davis and
Clements, 1989). This product reacted with immune sera from MVV infected sheep (Davis and
Clements, 1989; Mazarin eta!., 1990), indicating expression in vivo. Initially termed VEP1 (viral
early protein 1), the protein was renamed Rev on the basis of limited sequence similarity with the
Rev proteins of HIV-1, HIV-2 and SIV (Gourdou etal., 1989).
The multiply spliced, 1.2-1.4kb mRNA containing rev specific sequences may include
three or four exons (see figure 1.3) (Mazarin etal., 1988; Gourdou et a!., 1989): these forms
differ in the presence or absence of the small, non-coding second exon. The first coding exon of
rev is derived from the amino terminal region of env: these genes share an initiation codon. The
predicted signal peptide of MVV Env is located between residues 78-100 (Sonigo etal., 1985);
hence cleavage of this peptide will result in the absence of common Rev/Env residues in the
mature Env glycoprotein. The second coding exon overlaps the 3' region of env but is translated
in a different reading frame. The 1514 MVV isolate encodes a protein of 167/168 residues,
depending on the viral variant (Mazarin etal., 1988; Davis and Clements, 1989). Although the
overall sequence identity with other Rev proteins is low, the highly basic and leucine-rich
domains are intact (figure 1.8).
Analysis of the putative Rev protein by indirect immunofluorescence and protein
labelling in virally infected cells identified a cytoplasmic distribution, with a degree of association
with the membranous component after cell fractionation (Mazarin et al, 1990). This is in direct
contrast to the nuclear localisation of other Rev/Rex proteins (Cullen et al., 1988; Siomi et al.,
1988). A peptide motif with homology to a domain of HIV/SIV Nef is present in the carboxy-
terminal region of the Rev protein of the 1514 MVV strain used for these studies. As Nef
demonstrates cytoplasmic/membrane localisation (see 1.8.2) this homology might have
significance. However, although the common motif was implicated as functionally important in Nef
(Guy et al., 1990), this conclusion has been challenged (Kaminchik etal., 1990).
A second unexpected finding was the ability of Rev to trans-activate transcription from
the viral LTR (Mazarin et al., 1988). A later study failed to confirm such activity (Davis and
Clements, 1989).
Thus, the function and activities of MVV Rev were uncertain at this point. Although the
possession of a domain structure similar to that of the more characterised Rev proteins is strongly
suggestive of a shared biology, sequences unique to MVV Rev could mediate novel regulatory
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mechanisms. The divergence of HIV and MVV Tat proteins demonstrate that proteins which
mediate similar effects may do so by different mechanisms.
It was decided to investigate the nature of the MVV Rev protein, in an attempt to
establish the mode of function. A rev gene was cloned from EV-1, a variant of MVV isolated from
the peripheral blood mononuclear cells of a British sheep displaying symptoms of maedi.
Computer prediction, based on the nucleotide sequence of EV-1, indicated the presence of a
highly structured RNA element within the env gene. In order to examine the possible interaction
between the Rev protein and this element, it was decided to perform a series of in vitro binding
assays. This would require quantities of recombinant Rev protein in a non-denatured state, and
in vitro transcribed RNA corresponding to the predicted response element. If interaction could
be established in vitro, the significance of this in a cellular context would be established by
assays based on transient transfection with reporter constructs. Finally, the effect of the
observed variation between the revgene sequences and predicted RREs of MVV isolates would





The materials used during research for this thesis were obtained from the following
sources, unless otherwise stated. Chemicals were supplied by Sigma Chemical Company,
Poole, Dorset. Tissue culture and bacteriological media were supplied by Gibco/BRL, Paisley,
Strathclyde. Radiochemicals were purchased from Amersham International, Amersham,
Buckinghamshire. DNA modifying enzymes, including restriction endonucleases, were
obtained from several sources: Boehringer Mannheim, Lewes, East Sussex; New England
Biolabs., Hitchin, Hertfordshire; Northumberland Biologicals Ltd., Cramlington,
Northumberland; Promega Ltd, Southampton, Hampshire. Organic solvents were obtained
from BDH Laboratory Supplies, Poole, Dorset. Methods are described as most commonly
used. Modifications to the basic methods are noted in the main text.
2.1 Bacterial Culture
2.1.1 Bacterial Strains
The genotypes of the strains of E. coli used are detailed in Table 2.1
TABLE 2.1
GENOTYPES OF E. COLI STRAINS
Strain Genotype Reference
JM101 [F\ fraD36, proAB+, /acl9ZAM15]
supE, thi, A(lac-proAB)
Yanisch-Perron etal, 1985
DH5a F-, O80d /acZAM15, recA1, enc/A1, gyrA96 Gibco/BRL
thi-1, hsdR17 (rk",mk+), supE44, re/A1, deoR,
A (lacZYA-arpF) U169
Y1090 F', A/acU169, proA+, A (Ion), araD139, strA, Huynh etai, 1985
supF [frpC22::Tn10(tetr)], /7SdR(rk',mk+)
(pMC9,ampr)
BL21 F", hsc/S(rb-,mb_), gal, ompT, A (Ion) Grodberg and Dunn, 1988
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Strain JM101 was used for transformation of plasmids tor routine subcloning. For
large scale purification of plasmid DNA strain DH5a was used. These strains were also used
for the expression of recombinant protein using the pGEX system (2.12). Two protease
deficient strains, BL21 and Y1090, were also used for this purpose. As the pGEX system
involves selection of transformed cells on the basis of ampicillin resistance, Y1090 cells which
had lost the pMC9 plasmid, which includes an ampicillin resistance gene, were required.
These were obtained by picking satellites to major colonies grown on agar plates containing
ampicillin.
2.1.2 Bacterial Media and Culture Conditions
The standard medium for bacterial growth was Luria Bertani (LB) broth. This consisted
of 1% w/v tryptone, 0.5% w/v yeast extract, 0.171M NaCI, pFt 7.5. All plasmid vectors used
contained the ampicillin resistance gene as a selective marker; hence, selective media was
prepared by supplementation of LB with 125pg/ml ampicillin (LB/amp). LB/amp plates were
made by the addition of 1.5% w/v bacteriological agar. Addition of 200mg/ml 5-bromo-4-
chloro-3-indolyl p-galactopyranoside (X-gal) to LB/amp plates allowed for blue/white colour
selection of cells transformed with the pCR™ll plasmid from the TA cloning kit (section 2.7.1).
Unless otherwise stated, incubation of bacterial cultures was performed at 37°C with vigorous
shaking.
2.1.3 Bacterial Transformation
2.1.3.1 Preparation of Competent Bacteria
A modification of the method of Hanahan (1983) was used to produce bacterial cells
competent for transformation.
A single colony of the appropriate strain of E. coli was inoculated into 5ml of LB. This
preculture was grown to saturation and 200pl diluted into 20ml of an enriched medium, psi
broth. After incubation to an OD550 of approximately 0.3, 5ml of this culture was diluted into
100ml psi broth and grown to an OD550 of 0.48. After brief cooling on ice, the cells were
recovered by centrifugation at 2500-3000g for 5 minutes at 4°C. Pellets were resuspended
in 33ml of ice cold transformation buffer I (TfB I) and left on ice for 15 minutes. After
repelleting, the cells were resuspended in 4ml of transformation buffer II (TfB II) and left on ice
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for 20 minutes. Aliquots (200jil) were snap frozen on dry ice/ethanol and stored until required
at -70°C.
psi broth: 2% w/v tryptone, 0.5% w/v yeast extract, 20mM Mg2S04,10mM NaCI, 5mM KCI
TfB I: 15% v/v glycerol, 200mM MnCI2, 100mM RbCI, 10mM CaCI2, 35mM NaOAc, pH 5.9
TfB 11:15% v/v glycerol, 10mM RbCI, 80mM CaCI2, 10mM MOPS, pH 6.8 with KOH
2.1.3.2 Transformation
An aliquot (200pl) of competent bacteria was thawed on ice and incubated for 30
minutes with 50-200ng DNA. The cells were then heat shocked at 42°C for 60-90 seconds,
followed by brief cooling on ice. LB (800gl) was added, and the cells incubated at 37°C for 60
minutes. During this period the selective marker, the ampicillin resistance gene, is expressed.
The cells were then pelleted by centrifugation at 12000g for 30 seconds, resuspended in
10Opil LB, and spread onto LB/amp plates. After overnight incubation, single colonies were
picked for subsequent analysis.
Transformation of the commercially prepared DH5a cells was carried out as above, but
with slight modifications. The amount of DNA added to the cells was less (1-20ng), reflecting
the greater efficiency for transformation of this strain. Heat shock was performed at 37°C for
20 seconds.
2.1.4 Bacterial Stocks
A single colony of transformed bacteria was inoculated into 5ml LB/amp, and
incubated for 16 hours. Aliquots of the saturated culture were made up to 20% v/v sterile




Ovine fibroblasts used as the host cells for viral infection were obtained from MVV
negative sheep, by the biopsy method of Rheinwald and Green (1977) and were a kind gift of
Dr. B.A. Blacklaws, Department of Veterinary Pathology, University of Edinburgh. Simian COS-
1 cells, used for Rev functional assays, were a kind gift of Dr. G. Entrican, Moredun Research
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Institute, Edinburgh.
2.2.1.2 Media and Culture Conditions
Cells were maintained as adherent monolayers in plastic flasks (Nunclon, Denmark)
and incubated at 37°C in an atmosphere ot 5% CO2, unless otherwise stated. The growth
medium used was DMEM, supplemented with 2mM L-glutamine, 100gg/ml streptomycin,
100U/ml benzylpenicillin, 2.5pg/ml fungizone. Foetal calf serum (FCS) was added as
required, typically to 10% v/v. As used here, 10%FCS/DMEM refers to fully supplemented
DMEM containing 10% FCS.
2.2.1.3 Cell Passage
Cells were grown to near confluence and washed twice with versene (0.5mM EDTA,
0.0013% w/v phenol red). Incubation for 2 minutes in trypsin-versene (0.05% w/v trypsin in
versene) led to removal of the cells from the flask surface. The cell suspension was diluted
with 1/10 volume FCS to inhibit further trypsin digestion, and centrifuged at 1500g for 2
minutes. The pelleted cells were washed in 10%FCS/DMEM, and then seeded into fresh
flasks at a dilution factor of 1:4 (fibroblasts) or 1:20 (COS-1).
2.2.1.4 Estimation of Cell Concentration
A small volume (1 Optl) of cell suspension was diluted 1:1 in Trypan Blue stain. This was
applied to a haemocytometer chamber. Viable cells (unstained) were counted in each of four
divisions (total = n). The cell concentration was 2n/4 x 104/ml.
2.2.2 Virus Infection
Ovine fibroblasts were grown to near confluence, and the media removed. Virus was
diluted in 20ml of DMEM, and added to the flasks at an approximate multiplicity of infection of
one. The flasks were incubated at 4°C for 60 minutes to allow adsorption of virus to cellular
receptors. Transfer to 37°C resulted in synchronous infection of the fibroblasts. The medium
was removed after 1 hour, replaced with 2%FCS/DMEM and incubation continued. Cells were
harvested when displaying significant syncytia formation (viral cytopathic effect).
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2.3 Common Reagents in Molecular Biology
(1) Sterile Phosphate Buttered Saline (SPBS): 137mM NaCI, 26.8mM KCI, 14.7mM
KH2P04, 81 mM Na2HP04.
(2) TAE: 40mM Trizmabase, 0.114% w/v glacial acetic acid, 1mM EDTA
(3) TBE: 90mM Trizma base, 90mM boric acid, 1mM EDTA
(4) TE: 10mM Tris.HCI pH 8, 1mM EDTA
(5) TEN: 10mM Tris.HCI pH 7.4, 2mM EDTA, 140mM NaCI
2.4 Polymerase Chain Reaction
2.4.1 Preparation of template DNA
DNA from virally infected cells was used as a template for PCR. Infected cells were
removed from flasks by agitation with sterile glass beads (4.5-5.5mm, BDH) and washed twice
in SPBS. Cells were pelleted by centrifugation at 1500g for 5 minutes, and resuspended in
500pl lysis buffer (0.5% w/v SDS, 1M NaCI, 1mM EDTA, 50mM Tris.HCI pH 8). Proteinase K
was added to a final concentration of 100gg/ml, and the reaction incubated at 68°C for 1 hour.
DNA was purified by hot phenol extraction (2.5.2), precipitated in ethanol, washed in 70%
ethanol, and resuspended in 500pl TE. RNA contaminants were removed by incubation with
RNase A at 50pg/ml for 30 minutes at 37°C. A further round of phenol extraction and ethanol
precipitation yielded the purified DNA, which was resuspended in 200pldH20. A single T175
flask (~107 fibroblasts) yielded ~100pg DNA.
2.4.2 Primers
Primers were synthesised by Oswel DNA Service, Department of Chemistry,
University of Edinburgh, or by the oligomer synthesis unit, Howard Hughes Medical Center,
Duke University, North Carolina. Primers were designed according to certain criteria. Typically,
primers were 18-30 nucleotides in length. Complementary sequences within a primer were
avoided, so as to reduce the possibility of primer-dimer formation. A 3' terminal G or C residue
was included. To harmonise annealing temperatures, a 50% GC content was maintained.
2.4.3 Reaction parameters
PCR reactions were carried out in 10Opil volumes using sterile 0.5ml eppendorf
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tubes. Reactions were performed in Ohara buffer (3mM DTT, 50mM KCI, 1,5mM MgCI2, 10mM
Tris.HCI pH 8.8; Ohara, 1989) with 10pg BSA, 200pM of each dNTP, DNA template (1 pi Cell
DNA, ~500ng), primers (10-50 pmoles) and 2 units Thermus aquaticus (Taq) DNA polymerase
enzyme. Mineral oil (100pl) was added as a covering layer to prevent evaporation. Thermal
cycling was performed over 35 cycles using a Techne Programmable Driblock PHC-1
machine. Each cycle had the following parameters: denaturation at 95°C/30 seconds,
annealing at 55°C/30 seconds, extension at 72°C/60 seconds. A final extension step at
72°C for 5 minutes was included to allow completion of partially extended strands. The
reaction outcome was investigated by agarose gel electrophoresis of 10pl of reaction mix.
When necessary, completed reactions were stored at -20°C before analysis.
2.5 Purification of Nucleic Acids
2.5.1 Phenol/Chloroform Extraction
DNA was routinely purified by phenol/chloroform extraction, followed by ethanol
precipitation. Phenol was prepared by equilibration of an aliquot of redistilled phenol with
0.1M Tris.HCI pH 8.0, and the addition of 0.05% w/v 8-Hydroxyquinoline. Equilibrated phenol
was stored in the dark at 4°C for periods of up to 4 weeks. To extract DNA, an equal volume of
phenol was added to the sample and mixed by vortexing. The solution was centrifuged at
12000g for 1 minute to separate the aqueous and non-aqueous components. The upper,
aqueous layer was removed to a fresh tube. This procedure was repeated with
phenol/chloroform (1/2 volume of each), and with chloroform. RNA was extracted similarly,
using phenol equilibrated to pH 5 with NaOAc. The term 'phenol extracted' will refer to this
entire procedure.
2.5.2 Hot Phenol Extraction
DNA isolated by electrophoresis in low gelling temperature agarose (Igt), was purified
by hot phenol extraction. Lgt containing the isolated DNA was melted at 65°C for 10 minutes.
An equal volume of dH20 was added to disrupt resetting of the gel. The sample was then
extracted with 1ml phenol, preheated to 65°C. Subsequent extraction was carried out as
above (2.5.1).
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2.5.3 Purification with silica
DNA was purified by absorption to a modified silica matrix using the Geneclean II™ kit
(Stratech). The manufacturer's instructions were followed throughout. Briefly, the protocol
involved the removal of contaminants by the selective binding of DNA to the silica matrix in
chaotropic conditions (4M Nal). The bound DNA is washed with NaCI/ethanol, and eluted in
dH20 or a low salt solution. DNA molecules shorter than ~500bp may possess sufficiently
high avidity to the silica to result in a low yield on elution. Thus, this method was only used for
molecules >500bp in size.
2.5.4 Ethanol Precipitation
Nucleic acids purified by the above methods were precipitated by addition of 3M
NaOAc pH 5.2, to 0.25M, and 2.5 volumes of nucleic acid grade ethanol, with incubation at
-20°C for 30-90 minutes. The precipitated material was collected by centrifugation at 12000g
for 10 minutes, washed with 70% v/v ethanol, and air dried. The pellet was resuspended in an
appropriate volume of dH20 or TE (for RNA, RNase free dH20), and stored at -20°C.
2.6 Restriction Digests
DNA samples for analysis or enzymatic manipulation were digested using the
appropriate restriction endonuclease. Typically, 1-5pg of DNA was digested with 10U of
enzyme in manufacturer's buffer for 1 hour at 37°C. A second aliquot of enzyme was then
added, and incubation continued for 2-3 hours. Where double digests were required, the
buffer used was chosen to give greatest activity for both enzymes, using published activity
tables (Promega).
2.7 DNA Cloning
2.7.1 Preparation of DNA for Cloning
Vector and insert were digested with the appropriate restriction endonuclease(s). The
vector was dephosphorylated, to reduce the incidence of self ligation, by the addition of 1U of
calf intestinal phosphatase (cip) and incubation at 37°C. After 30 minutes a second aliquot of
cip was added, and incubation continued for 30 minutes. The vector and insert were purified
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using a technique appropriate to the size ot the DNA (2.5) and finally resuspended in dH20.
PCR products were initially cloned into the pCR™11 vector, a component of the TA Cloning Kit
(InVitrogen, USA), by following the manufacturer's instructions.
2.7.2 Ligation
Ligation reactions were typically carried out using 100ng of vector DNA, and an
approximate three fold molar excess of insert DNA. Where this was unsuccessful, a range of
insert to vector ratios from 1:3 to 3:1 was used. Ligations were performed in small reaction
volumes (10-20pl), using 5U T4 DNA ligase and the manufacturer's buffer. Reactions were
incubated at 12°C for 16 hours. A vector only control was included to allow determination of
cip efficiency.
2.8 Agarose Gel Electrophoresis
DNA samples were analysed on 1-1.5% w/v agarose/TAE gels containing 0.6pg/ml
ethidium bromide. Prior to loading, samples were mixed with 1/6 volume 6x DNA loading
buffer (14% w/v Ficoll, 0.25% w/v bromophenol blue, 0.25% w/v xylene cyanol). All gels were
run in 1xTAE buffer, at 80-100V. An UV transilluminator was used to visualise DNA bands.
Preparative agarose gels were run as above, with several modifications. DNA samples were
run in 1.5% low gelling temperature agarose/TAE gels. Electrophoresis was carried out at 50-
60V at 4°C to prevent melting of the agarose. Each sample was run on a separate gel, to avoid
potential cross-contamination. The DNA to be purified was located by UV transillumination and
excised in a minimum of agarose, using a clean scalpel blade.
2.8.1 DNA Markers for Agarose Gel Electrophoresis
Hindlll and EcoRI digested X DNA (NBL), with fragments of sizes: 21226, 5146, 4973,
4268, 3530, 2027, 1904, 1709, 1375, 947, 831, 564 and 125 base pairs.
2.9 Small Scale Purification of Plasmid DNA
A single colony of transformed bacteria was inoculated into 5ml LB/amp, and
incubated for 16 hours. Plasmid DNA was purified by a modification of the alkaline lysis
technique of Birnboim and Doly (1979). The saturated culture was centrifuged at 12000g for
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30 seconds, and the pelleted bacterial cells resuspended in 1 volume (typically 200pil) of ice
cold lysis buffer (50mM glucose, 10mM EDTA, 25mM Tris.HCI pH8.0). After incubating at
room temperature for 5 minutes, 2 volumes (400pl) of freshly prepared alkaline SDS (0.2M
NaOH, 1% w/v SDS) were added with gentle mixing by inversion. Addition of the alkaline SDS
solution leads to cell lysis and denaturation of the nucleic acids and proteins. Following
incubation on ice for 5 minutes, 1.5 volumes (300pl) of potassium acetate pH4.8 was added,
and incubation on ice continued for a further 10 minutes. The neutralisation of the solution
brought about by the addition of the potassium acetate leads to selective renaturation of the
covalently closed, circular plasmid DNA: the chromosomal DNA, protein and high molecular
weight RNA remains denatured and is precipitated as a complex by the high salt
concentration. Centrifugation for 10 minutes at 12000g leads to pelleting of the precipitated
material. The supernatant was decanted to a fresh eppendorf tube. Plasmid DNA was
extracted with phenol and precipitated in ethanol. After pelleting, washing in 70% ethanol,
and resuspension in dH20, the remaining RNA was removed by the addition of DNase free
RNase A to a final concentration of 20pg/ml, with incubation at 37°C for 60 minutes. After a
second round of phenol extraction and ethanol precipitation, the purified plasmid DNA was
finally resuspended in a small volume of dH20. Typically, 2ml of bacterial culture yielded 3-5pg
of plasmid DNA.
2.10 Large Scale Purification of Plasmid DNA
A single colony of transformed cells was inoculated into 10ml LB/amp and incubated
for 16 hours. The preculture was then diluted 1:100 into 500ml LB/amp, and regrown to
saturation (12-16 hours). Chloramphenicol amplification was used for certain plasmids which
gave a poor yield with this growth regime. The preculture was diluted 1:250 into 25ml LB/amp
and incubated until late log phase (OD60o ~ 0.6) was reached. This culture was then diluted
1:20 into 500ml LB/amp and incubated for 2.5 hours, at which point the OD60o had reached
0.4. Chloramphenicol was added to 170pg/ml (2.5ml of a 34mg/ml stock solution in ethanol)
and incubation continued for a further 12-16 hours. Cells were pelleted by centrifugation in a
bench top centrifuge at 3000g for 10 minutes.
Plasmid DNA was purified using the Qiagen Plasmid Kit (Hybaid Ltd, London)
following the manufacturer's instructions. In outline, a supernatant containing plasmid DNA is
generated by an alkaline lysis method which is essentially a scaled up version of that detailed
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above (2.9). An ion exchange resin binds specifically to plasmid DNA, allowing contaminants
to be removed. The isolated DNA is eluted in high salt conditions. The DH5a strain of E. coli
was used as the host strain of choice for plasmids purified by this procedure, as suggested by
the manufacturer.
2.11 DNA Sequencing
The di-deoxy chain termination method (Sanger etal, 1977) was used as the basis for
DNA sequencing.
2.11.1 Sequencing Reactions
Double stranded sequencing was performed using an alkaline denaturation protocol
and the Sequenase Version 2.0 kit (USB Corporation). High template purity is required for
double stranded sequencing, thus template plasmid was prepared by Geneclean treatment of
plasmid minipreparations, or by Qiagen column chromatography. Plasmid DNA (2-5pg in 20pl
dH20) was denatured by addition of 2jj.I denaturation buffer (2M NaOH, 2mM EDTA) and
incubated at 25°C for 5 minutes. The denatured DNA was neutralised with 6.5ml 3M NaOAc,
and precipitated at -20°C by the addition of 7pi dH20 and 75pl ethanol. Pelleted DNA was
washed with 70% ethanol and resuspended in 7pldH20, 2pl 5X sequenase buffer and 1 pi
primer. An approximate 1:1 template:primer stoichiometry was used. To anneal primer and
template, the solution was incubated at 65°C for 2 minutes and either snapped cooled on ice,
or cooled to 35°C over a period of 25-30 minutes. Sequencing reactions were then
performed with the Sequenase kit using the manufacturer's instructions. Briefly, 1pl 0.1 M
DTT, 2pl 1:5 diluted labelling mix, and 0.5pl a35S dATP (specific activity 400Ci/mmol) were
added to the reactions along with 2pl 1:8 diluted Sequenase Version 2.0 (a modified T7 DNA
polymerase) and incubated at 25°C for 5 minutes. To terminate the reactions, 3.5pl of each
mix was added to each of four tubes containing 2.5pl termination mix (a,c,g,t) and incubated
for a further 10 minutes at 37°C. Finally 4pl of stop solution was added to each tube.
Reactions were resolved immediately, or stored at -20°C for short periods.
2.11.2 Sequencing gels
Sequencing reactions were resolved by denaturing polyacrylamide gel
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electrophoresis. Gel mix consisted of 6% w/v acrylamide (29:1 acrylamide:bisacrylamide), 8M
urea, 0.5X TBE. The Sequi-Gen apparatus (Biorad) was used. The sequencing plates were
sealed at the base with 50ml gel mix, 150pi TEMED, 210pl 25% APS. For the main gel, gel
mix (150ml) was filtered at 45pm and degassed under vacuum; 150pl 25% APS and 150pi
TEMED added and the solution poured. Gels were pre-run in 0.5X TBE until the gel
temperature reached 50-55°C. The reactions were heated to 75°C for 3-5 minutes and 2pl
loaded onto the gel. Gels were run at 2500-3000 volts for 2-6 hours. The gels were then laid
onto Whatman 3MM paper and dried at 80°C for 2.5 hours under vacuum on a Bio-Rad Model
583 gel drier. Autoradiography was carried out by exposure to Kodak X-OMAT R film for 1-8
days.
2.12 Production of Recombinant Proteins in Yeast
2.12.1 Yeast Growth Media and Conditions
(1) YEPD: 2% w/v peptone, 2% w/v glucose, 1% w/v yeast extract
(2) Synthetic complete-glucose medium (Sc-glc): 0.67% w/v yeast nitrogen base without
amino acids, 1% w/v glucose
(3) Sc-glc/gal: As (2) above, but with 0.3% w/v glucose, 1% w/v galactose
(4) Amino acids: leucine (leu), tryptophan (trp) and uracil (ura) added to media as required
at 20mg/ml
(5) Agar plates: Medium supplemented with 2% w/v nutrient agar
(6) TEN buffer with protease inhibitors (TEN/pi): 1pg/ml each antipain, chymostatin,
leupeptin, pepstatin A (stock solutions in dimethyl sulphoxide, DMSO) and aprotinin
(in dH20) and 0.5mM PMSF (in ethanol) in TEN buffer
(7) Acid washed glass beads: Beads (40 mesh, BDH) washed once in concentrated
sulphuric acid, rinsed 10 times in H20 and 10 times in dH20, air dried and baked at
150°C for 2 hours
(8) Dialysis tubing: prepared by boiling for 3x3 minutes (1 x in 1 mM EDTA, 2x in dH20)
Incubation of yeast cultures was performed at 30°C with vigorous shaking on a flat
bed rotator (New Brunswick Scientific) at ~260rpm. Culture densities were measured by
spectroscopy at OD60o- For strain BJ2168, an OD600of 1 is equivalent to -3x107 cells/ml.
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2.12.2 Yeast strains
The protease deficient strain BJ2168 (a, Ieu2, trp1, ura3, prbl, pep4, perl, gal2) was
used as the host cell for expression of native and recombinant Ty-vlps. A second strain, the
diploid MC5 (prbl, prcl, pep4, trp1, ura3, Ieu2) was used in an attempt to circumvent
problems with recombinant protein toxicity.
2.12.3 Transformation of Yeast
Yeast cells were transformed using the lithium acetate based protocol developed by
Ito et al. (1983).
2.12.3.1 Generation of Competent Cells
Untransformed yeast of the appropriate strain were inoculated into 100ml YEPD/leu
and grown to an ODg0o of -0.7. Cells were harvested by centrifugation at 3500g for 5 minutes
and washed once with 10ml yeast transformation buffer (YTB, 0.1 M LiOAc, 1xTE, pH 7.5).
After repelleting, the cells were incubated for 30 minutes at 30°C in 20ml YTB. The cells were
pelleted once again, and finally resuspended in 1ml YTB. Competent cells were divided into
100pl aliquots and used immediately, or adjusted to 20% v/v glycerol and stored at -70°C.
2.12.3.2 Transformation
DNA (2-5pg each plasmid, 20pg boiled salmon sperm DNA as carrier) was added to an
aliquot of competent yeast cells. After incubation at 30°C for 30 minutes, 0.5ml YTB
supplemented with 40% w/v polyethylene glycol (PEG40oo).was added and incubation
continued for a further 60 minutes. The cells were heat shocked at 42°C for 5 minutes, before
plating out onto Sc-glc/agar plates containing selective nutrients. The plates were incubated
until colonies became visible (4-14 days).
2.12.3.3 Storage of Yeast Transformants
To generate stocks of transformants, a single colony was inoculated into 50ml of Sc-
glc with appropriate amino acids, and incubated until a cell density of 2-4x107 had been
reached. Glycerol was added to a final concentration of 20% (v/v) and 1ml aliquots frozen at
-20°C for two hours before transferring to -70°C for long term storage (9-12 months).
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2.12.4 Analysis of transformants
2.12.4.1 Constitutive Expression
Sc-glc/trp/ura (50ml) was inoculated with a single colony of yeast transformed with a
pMA5620 derived plasmid (T.A), and the culture incubated until an OD600 of 0.8-1 was
reached (2-3 days). The cells were pelleted by centrifugation at 3500g for 5 minutes and
resuspended in 1m! TEN buffer. Breakage of the cells was achieved by 3x1 minute periods of
vortexing with 1g acid washed glass beads. Cell lysates were collected and analysed by SDS-
PAGE and Western blotting.
2.12.4.2 Inducible Expression
Yeast transformed with a pOGS40 derived plasmid were grown to an OD600of 0.8-1 in
Sc-glc/trp. After pelleting as above, the cells were resuspended in 50ml Sc-glc/gal/trp, and
incubation continued for a further 24 hours. Subsequent steps were carried out as above.
2.12.5 Large scale production
2.12.5.1 Constitutive Production of Native p1 Ty-vlps
Sc-glc/trp/ura (200ml) was inoculated with a single stock of T.A cells (transformed with
pMA5620). The culture was incubated to an OD600of 1-1.2. 50ml of this culture was diluted
into each of 4x1 L Sc-glc/trp/ura in 2L conical flasks, and incubation continued for 24 hours.
The cells were harvested by centrifugation in a J2-21 rotor (Beckman) at 5000g for 5 minutes
at 4°C. Pellets were washed twice with dH20 and once with TEN, and then were processed
immediately or stored at -20°C.
2.12.5.2 Inducible Production of Recombinant p1 :Rev Ty-vlps
2.12.5.2.1 Original Protocol
A preculture of TRev.U cells was generated, as above, in Sc-glc/trp. The preculture
(50ml) was inoculated into 1L of Sc-glc/trp in 2L conical flasks, and grown to an OD600of -1.5.
This culture was then split into 4x1 L Sc-glc/gal/trp, and incubation continued for 24 hours.
Cells were harvested as above.
2.12.5.2.2 Modified Protocol
A modified protocol was established in an attempt to reduce the effect of toxicity of
expression of p1:Rev. Four yeast stocks were used to inoculate 100ml of Sc-glc/trp. After
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growth to OD600of ~1, the preculture (50ml) was inoculated into each of 2x400ml Sc-glc/trp.
This culture was grown to an OD60o of ~1, and split into 8x500ml Sc-glc/trp +/- 0.2% yeast
extract. Cultures were incubated for 24 hours, and then expression was induced by pelleting
of cells by centrifugation at 5000g for 5 minutes, and resuspension in an equal volume of Sc-
glc/gal/trp. Induction was carried out for 7 hours, and cells harvested as above.
2.12.6 Preparation of Ty-vlps
Cell pellets were removed to 4x30ml Corex tubes, and resuspended in 4ml TEN/pi
buffer. Acid washed glass beads (5ml) were added, and the cells broken by vortexing for 10x
30 second periods, with one minute intervals of cooling on ice. The cell suspensions were
centrifuged at 2000g for 5 minutes, and the supernatants collected. Pellets were
resuspended in TEN/pi and the above procedure repeated until greater than 80% cell
breakage had been achieved (by microscopic examination). Supernatants were pooled and
centrifuged at 13000g for 20 minutes at 4°C, to remove cellular debris. Ty-vlps were
concentrated by pelleting onto a sucrose cushion. The supernatant was layered onto 2ml
60% w/v sucrose/TEN in 30ml Corex tubes and centrifuged af 100,000g for 1 hour at 4°C.
The cushion and interface layer containing the Ty-vlps, were collected and the sucrose
removed by overnight dialysis against fresh TEN buffer, or by sephadex chromatography
(2.12.8).
2.12.7 Purification of Ty-vlps
2.12.7.1 Purification by Density Gradient Centrifugation
A 15-45% linear sucrose gradient was formed by sequential layering of 8ml volumes
of 45%, 35%, 25%, and 15% w/v sucrose in TEN buffer, in a 40ml centrifuge tube, with
overnight equilibration. A 2ml 60% sucrose cushion was applied immediately before use. Ty-
vlp containing material (4ml) was added to the top of the gradient, and the tube centrifuged at
100,000g for 3 hours at 4°C. The gradient was harvested as 2ml fractions, and the fractions
were analysed for Ty-vlp content by SDS-PAGE and Western blotting. A second round of
centrifugation was performed where necessary.
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2.12.7.2 Purification by Affinity Gel Chromatography
2.12.7.2.1 Preparation of Affinity Gel Column
Required volume (2ml) of Affigel-10 (Biorad) was removed from an isopropanol
suspension and washed twice in ice-cold water. Protein coupling was performed by
incubating the purified y-globulin fraction of rabbit anti-p1 antiserum (ap1; 2.23.2) with affigel-
10 with gentle agitation at 4°C overnight. Free antibody was removed by decanting the
supernatant after centrifugation of the affigel-10 for 5 minutes at 1500g. Unoccupied protein
binding sites in the affigel-10/ocp1 were blocked by incubation with 0.2ml 1M ethanolamine
(pH 8)/ 1ml phosphate buffer/0.05% sodium azide for one hour at 25°C. The affigel-10
suspension was washed three times with PBS/0.05% sodium azide by centrifugation,
resuspension and mixing. Washed affigel-10/ap 1 was loaded into a 10x1cm Econo-
chromatography column (Biorad), and stored until use in PBS/0.05% sodium azide.
2.12.7.2.2 Purification
Immediately prior to adsorption of antigen, the affigel-10/apl column was washed
with 15mM triethanolamine/0.5% sodium deoxycholate (TEA/DOC; pH 8) for 30 minutes,
followed by TEA/DOC/0.5M NaCI pH 11.3 for a maximum of 30 minutes. The column was then
washed once in PBS/0.05% sodium azide and once in TNT (20mM Tris, 140mM NaCI, 0.5%
Triton X-100, pH 8). The p1:Rev gradient fractions to be purified were adsorped onto the
column over 24 hours by recirculation using chromatography tubing. The column was washed
once with TNT and once with TEA/DOC, before elution of specifically bound material in
TEA/DOC/NaCI pH 11.3. The eluate was collected as 1ml fractions, with each fraction
neutralised by the addition of 0.3ml 0.5M TEA pFI7.9. The fractions were analysed for p1 :Rev
content by SDS-PAGE and western blotting.
2.12.8 Removal of Sucrose by Sephadex Chromatography
Sephadex G-25 (Sigma) was swollen in TEN/pi and ~5ml applied to a chromatography
column. After washing with 2x20ml TEN/pi, sucrose-containing material was added. After the
bed volume of liquid had run through the column, samples were collected as 2ml aliquots.
These were analysed for protein content by SDS-PAGE and protein concentration assay, and
for sucrose content by use of a refractometer (Mackay and Lyn, Edinburgh), using 5%
sucrose as standard.
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2.13 Production of Recombinant Proteins in Bacteria
2.13.1 Small Scale Production and Purification of GST Fusion Proteins
Small scale purification of GST fusion protein for analysis was achieved by following
the protocol of Smith and Johnson (1988). A single colony of bacteria transformed with the
recombinant plasmid was inoculated into 2ml LB/amp and incubated until visibly turbid (3-5
hours). Fusion protein expression was induced by the addition of IPTG to 0.1 mM, with further
incubation for 2-3 hours. The cells were pelleted by centrifugation at 12000g for 30 seconds,
and the pellet resuspended in 500|il ice cold SPBS. The cells were lysed by sonication using
a Dawe 2mm probe sonicator in a single 10-15 second burst of sonication with immersion of
the probe tip well within the solution to prevent frothing. Centrifugation at 12000g for 5
minutes at 4°C removed the cellular debris and intact cells. The supernatant was removed to a
fresh eppendorf tube. The fusion protein was purified by addition of 50gl of a pre-swollen
50% slurry of glutathione-agarose beads (Sigma) which selectively bind to the GST moiety.
The tubes were mixed on an orbital shaker for 5 minutes at room temperature. The beads
were collected by centrifugation at 1500g for 1 minute, and washed three times with SPBS.
Finally, the beads were resuspended in an equal volume (50pil) of SDS-PAGE sample buffer,
and analysed on a 10% SDS polyacrylamide gel.
2.13.2 Large Scale Production and Purification of GST Fusion Protein
Large scale purification of fusion protein for use in functional assays was performed in
an essentially similar manner to the protocol outlined above, but by using scaled up volumes.
A single colony of pGEX transformant was inoculated into 100ml LB/amp and incubated for
12-16 hours. This culture (50ml) was then diluted 1:10 into 500ml LB/amp and incubation
continued for 1 hour. IPTG was added to 0.1 mM and incubation continued for 3-4 hours. After
induction, the culture was centrifuged at 5000g for 10 minutes in a Beckman JA-10 rotor at
4°C. Cells were resuspended in 10ml ice cold SPBS. 2 x30 second bursts of sonication were
separated by a 1 minute interval of cooling on ice. Triton X-100 was added to 1% v/v in order
to discourage interactions between the fusion protein and contaminating bacterial proteins.
The samples were centrifuged at 10000g for 5 minutes in a Beckman JA-20 rotor at 4°C. The
supernatant was removed to a 15ml plastic tube, and 500|J of a 50% slurry of glutathione
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agarose beads added. Following gentle mixing at room temperature for 5-10 minutes, the
beads were collected by centrifugation at I500g in a bench top centrifuge and washed three
times with 15ml SPBS. The beads were finally resuspended in 1.5ml of SPBS and transferred
to an eppendorf tube.
2.13.3 Elution of Fusion Protein from Agarose Beads
The beads were resuspended in 500pil elution buffer (10mM reduced glutathione,
50mM Tris.HCI, pH 8.0). Tubes were mixed gently for 5 minutes at room temperature,
centrifuged at 1500g for 1 minute and the supernatant collected. Elution was repeated twice.
Protein eluates for use in functional assays were made up to 10% v/v glycerol, 50mM NaCI,
10mM KCI, 2mM DTT, 0.25mM PMSF, and stored in 100ml aliquots at -70°C for up to 6 weeks
before use.
2.14 Protease Cleavage of Fusion Proteins
Fusion protein samples for cleavage were adjusted to the appropriate conditions for
protease activity. Ty-vlps were dialysed into factor Xa buffer (100mM Tris.HCI pH 7.6, 10mM
CaCI2) and 0.05% w/v sodium deoxycholate, 0.05% w/v CHAPS (3-(3-cholamidopropyl)
dimethylammonio-1-propanesulphonate). GST fusion protein eluates were adjusted to imM
CaCI2 for factor Xa buffer, 2.5mM for thrombin buffer. Thrombin or activated factor X was added
at a range of concentrations (0.1-5% w/w) and the reactions incubated at 25°C for 2 hours.
Reaction outcomes were analysed by SDS-PAGE and Western blotting.
2.15 Analysis of Proteins
2.15.1 Gel Electrophoresis
Proteins were analysed by discontinuous sodium dodecyl sulphate-polyacrylamide
gel electrophoresis (SDS-PAGE) under denaturing conditions, using a modification of the
method of Laemmli (1970). A stock solution of 30% w/v acrylamide:0.8% w/v bisacrylamide
was prepared, degassed under vacuum, and stored at 4°C for up to 6 weeks. To prepare
separating gels, the stock solution was diluted to the required concentration (typically 10%).
The gel mix additionally contained 0.1% SDS, 1.3mM EDTA, 0.26M Tris.HCI pH 8.7. Gels
were polymerised with 0.5% w/v APS and 0.05% v/v TEMED, and cast into the gel mould.
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Gradient gels were made by the mixing of two different percentage acrylamide solutions using
a Watson Marlow peristaltic pump. A volume of water was overlaid in order to ensure formation
of a smooth gel interface. When the separating gel had set, a layer of stacking gel was applied.
This consisted of 3.48% acrylamide, 0.12% SDS, 0.145M Tris.HCI pH 6.8, 0.05% APS, 0.1%
TEMED. Wells for sample loading were made by indentation of the stacking gel with a
multitooth comb. Protein samples for SDS-PAGE analysis were prepared by mixing with an
equal volume of SDS-PAGE sample buffer (15% v/v glycerol, 0.05% SDS, 0.005% w/v
bromophenol blue, 150mM (3-mercaptoethanol, 50mM Tris.HCI pH 6.8) and boiling for 3
minutes. The samples were loaded onto the gel using a thin gauge Hamilton pipette, and
electrophoresis performed at 200V 25mA for 60-90 minutes in running buffer (0.156M
glycine, 0.1% SDS, 25mM Trizma base).
2.15.2 Concentration of Proteins by Acetone Precipitation
Where necessary, protein samples to be analysed by SDS-PAGE were concentrated
by acetone precipitation. Protein sample was incubated at -20°C for one hour with five
volumes acetone. The precipitate was pelleted by centrifugation at 13000g for one minute,
and resuspended in an appropriate volume of SDS-PAGE sample buffer.
2.15.3 Visualisation of Proteins Resolved by SDS PAGE
Once electrophoresed, gels were rinsed with dH20 and either stained for
visualisation, or electroblotted for Western blot analysis. The expected protein concentrations
determined which stain was used. Coomassie blue stain has an approximate detection limit of
50ng per protein band, staining with silver nitrate a limit of 5ng. After staining the gels were
rinsed, and dried onto 3MM paper under vacuum for 2 hours at 80°C.
2.15.3.1 Staining of Gels with Coomassie Blue
Gels were routinely stained with Coomassie brilliant blue G-250 or Coomassie blue R
(0.25% w/v Coomassie blue, 20% v/v methanol, 5% v/v glacial acetic acid) for 30 minutes at
room temperature, followed by thorough destaining in 20% methanol, 5% glacial acetic acid,
to remove dye not bound to protein.
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2.15.3.2 Staining of Gels with Silver Nitrate
Gels were fixed by sequential immersion and gentle agitation in (i) 50% methanol,
10% glacial acetic acid for 15 minutes, (ii) 5% methanol, 7% glacial acetic acid for 20-30
minutes, (iii) 10% v/v gluteraldehyde for 20-30 minutes. The gels were then washed in several
changes of dH20 over 16 hours. A modification of the method of Merril ef a/( 1981) was used
to stain the gels. Gels were stained with 0.1% w/v silver nitrate for 15 minutes, rinsed briefly in
dH20 and the stain developed by addition of 0.05% v/v formaldehyde in 2.6% w/v sodium
carbonate solution. To stop the reaction, 2-3 g of solid citric acid was added, followed by
thorough rinsing in dH20. The stained gels were fixed in 10% v/v llfofix (llford Lab.) for 1
minute and rinsed in dH20.
Gels which had previously been stained in Coomassie blue could be restained in
silver nitrate. In this case, the gel was thoroughly rinsed in dH20 after destaining, and the
above protocol followed, beginning with immersion in 10% gluteraldehyde.
2.15.4 Western Blotting
2.15.4.1 Electrophoretic Transfer
After separation by SDS-PAGE, proteins were transferred onto a nitrocellulose
membrane using a modification of the technique of Towbin et al. (1979). Transfer was
performed by placing the gel and nitrocellulose membrane (Hybond C, 0.45pm, Amersham)
between sheets of Whatman 3MM paper, soaking with blotting buffer (25mM Tris, 20%
methanol) on a Semi Dry Electroblotter (Ancos, Denmark) and electroblotting for 1 hour at
120mA. After transfer, the portion of the membrane containing the molecular weight markers
was cut off, stained in 5% w/v amido black and destained in 50% methanol, 5% glacial acetic
acid. To prevent non specific binding of probe to empty binding sites on the filter, the
nitrocellulose membranes were blocked with 5% w/v skimmed milk/SPBS for a minimum of 12
hours at 4°C.
2.15.4.2 Immunodetection
Blots were probed with primary rabbit antibody diluted in 1% skimmed milk/SPBS for 1
hour at room temperature, with subsequent washing over a 30 minute period with several
changes in 1% milk/SPBS. The blots were then incubated with an anti-rabbit IgG alkaline
phosphatase linked second antibody, for a further hour, and again washed in 1% milk/SPBS.
After equilibration in 0.1 M Tris.HCI pH 9.5, the blots were developed by addition of 10ml
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development solution (0.2mg/ml NBT (Nitroblue tetrazolium), 0.1mg/ml BCIP (5-bromo-4-
chloro-3-indolyl phosphate, diluted in DMF), 200pM MgCI2, 0.1M Tris.HCI pH 9.5).
Development was stopped by washing in dH20, before the background staining became too
pronounced. The blots were air dried.
2.16 Determination of Protein Concentration
Protein concentrations were determined by use of an assay adapted from the
Bradford dye binding procedure (Bradford, 1976), supplied by BioRad Lab.Inc. (Hemel
Hempstead, Hertfordshire). This is a colorimetric assay based on binding of protein to
Coomassie brilliant blue G-250 dye. The assay was performed according to manufacturer's
instructions. BSA was used as a protein standard.
2.17 Electron Microscopy
2.17.1 Negative Staining of VLPs
The structure of Ty-vlps was investigated by transmission electron microscopy. A drop
of solution containing Ty-vlps was placed on a plastic coated grid. After 15 seconds the grid
was washed 3 times with a single drop of dH20 and allowed to air dry. The sample was fixed in
2% w/v uranyl nitrate and examined.
2.17.2 Preparation of Yeast Cells
Yeast cells were prepared for visualisation by electron microscopy by an adaptation of
the method of Byers and Goetsch (1975). Pelleted cells were resuspended in 5ml cacodylate
buffer (3% v/v gluteraldehyde, 0.1M cacodylate, 5mM CaCI2, pH 6.8) and incubated at room
temperature for 30 minutes. Cells were pelleted, resuspended in 10ml cacodylate buffer, and
incubated for 16 hours at 4°C, with rotation. Cells were washed twice with 10ml pre-treatment
buffer (0.1M mercaptoethanol, 20mM EDTA, 0.2M Tris.HCI, pH 8.1) and resuspended in 5ml
citrate-phosphate buffer (40mM citric acid, 60mM Na2HP04, pH 5.8) containing 250pl
glusulase (DuPont Co., USA) to create spheroplasts. The cells were incubated for one hour at
30°C, followed by two washes in 10ml citrate-phosphate buffer, and resuspended in 5ml of
the same buffer. The cells were fixed by incubation at 0°C for one hour in 2% w/v osmium
tetroxide, rinsed with dH20, and incubated for a further hour in 2% (v/v) aqueous uranyl
acetate. The cells were then dehydrated and embedded in araldite resin. Blocks were
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sectioned using a microtome, and viewed by transmission electron microscopy.
2.18 Synthesis of RNA for Functional Assays
2.18.1 Precautions against RNase Contamination
Where possible, all solutions used for experiments involving RNA were made up in
RNase free water. This was obtained by treatment of dH20 with 0.05% v/v DEPC, with
incubation for 1 hour at 65°C and for 16 hours at 37°C. The solution was then autoclaved to
remove all traces of DEPC. Plasticware for use with RNA was kept solely for this purpose.
Manipulation of RNA was performed, where possible, in a laminar flow hood. Gloves were
worn throughout, and changed frequently.
2.18.2 Preparation of Template for Transcription
In order to produce transcripts derived only from the insert sequence, template
plasmids were linearised by digestion with a restriction endonuclease with specificity for a site
at the 3' end of the insert/vector junction. The products of digestion were resolved on a 1%
agarose gel, and digested plasmid purified by hot phenol extraction, precipitated in ethanol,
and resuspended in RNase free dH20 at 200-800ng/pl. It was important to purify digested
template away from undigested plasmid as this latter can give rise to very long transcripts
which can sequester a large proportion of the labelled nucleotide, thus reducing the
efficiency of the transcription reaction.
2.18.3 In Vitro Transcription
In vitro transcription was performed using a Maxiscript™ in vitro transcription kit (AMS
Biotechnology Ltd, Witney, Oxfordshire). The reaction components were assembled in the
following order; 1/5x transcription buffer, 10mM DTT, 1pg template DNA, 0.5mM
ATP.CTP.GTP, 10 U RNase inhibitor (RNasin) , 50pCi a-32P UTP (400 Ci/mmol) and 10U T7 or
SP6 RNA polymerase, made up to 20pil in RNase free dH20. Incorporation of cold UTP into
the reaction is discussed in the main text. The reaction was incubated at 4°C for 30 minutes,
at which point a second 10U of polymerase was added, and incubation continued for a further
30 minutes. To stop the reaction, RNase free DNase (2U) was added to remove the template,
with incubation at 37°C for 15 minutes. RNase free dH20 was added to 200pl, and the RNA
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purified by extraction with phenol (pH5). After precipitation in ethanol, and washing with 70%
ethanol, the RNA was resuspended in 200pi RNase free dH20. Aliquots (50pi) were stored at
-70°C for up to 2 weeks before use.
2.18.4 Analysis of the Transcription Reaction
2.18.4.1 Reaction Efficiency
The efficiency of the reaction was determined by TCA (trichloroacetate) precipitation.
2pl of the purified RNA was diluted into 198pl TE containing 100mg RNase free salmon sperm
DNA. After mixing by vortexing, 5pl of this solution was spotted onto a Whatman GF/C glass
fibre filter and air dried. This represents the total radioactivity present. Ice cold 10% w/v TCA
(1ml) was added to the remainder of the solution, and the RNA precipitated by incubation on
ice for 10 minutes. The salmon sperm DNA acts as a carrier for precipitation, due to the small
mass of RNA present. The precipitated RNA was collected by filtration under vacuum through
a GF/C filter, with washing in 5ml ethanol, and 5ml 10% TCA. The filters were air dried. This
represents the radioactivity incorporated into the RNA. Both filters were immersed in
scintillation fluid in a scintillation vial, and the radioactivity counted. The proportion of
radioactive label incorporated into RNA could thus be determined.
2.18.4.2 Reaction Products
Products of the transcription reaction were analysed by denaturing polyacrylamide gel
electrophoresis. An aliquot (2pl) of the purified products was diluted with 3gl of RNase free
dH20 and 5pl of gel loading buffer (80% w/v formamide, 0.1% w/v xylene cyanol, 0.1% w/v
bromophenol blue, 2mM EDTA) added. The tube was heated at 85°C for 3-5 minutes to
denature the RNA. The sample was then loaded onto a 6% acrylamide/ 8M urea /TBE gel, and
electrophoresis carried out for 45 minutes at 200V. The results were visualised by
autoradiography of the dried gel.
2.18.4.3 RNA Markers for PAGE
RNA markers were obtained from Gibco/BRL. Fragment sizes were: 1770, 1520,
1280, 780, 530, 400, 280 and 155 bases.
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2.19 In Vitro Rev Binding Assays
2.19.1 Binding Conditions
Variable amounts of GSTRev protein were incubated with 20,000 precipitable cpm
32P RNA in a sterile 0.5ml eppendorf tube. The reaction also contained RNA binding buffer
(20mM Tris.HCI pH 7.5, 50mM KCI), 1mM DTT, 20pg BSA, 15U RNasin, 2pg yeast tRNA,
RNase free dH20 to a total reaction volume of 20pi. The binding reaction was incubated at
25°C for 10 minutes before the addition of 32P RNA, in order to allow non-specific binding of
protein to ytRNA. After addition of 32P RNA, incubation was continued for 15 minutes. Where
cold competitor RNA was used, this was added to the reaction before the labelled RNA, and
incubated for 10 minutes. The outcome of the binding reaction was determined by two
methods. The gel retardation assay involved electrophoretic resolution of complexes formed
between protein and RNA. A second method was the filter binding assay, where complexes
were trapped by filtration through a nitrocellulose membrane, and quantitated by scintillation
counting.
2.19.2 Gel Retardation Assay
Protein-RNA complexes were resolved by electrophoresis through 6%
nondenaturing polyacrylamide (crosslinked 29:1 with bisacrylamide) gels, using the Biorad
Protean II minigel apparatus. Reactions were diluted with an equal volume of loading buffer
(15% glycerol, 0.25% bromophenol blue, 0.25% xylene cyanol) and 10pl loaded onto the
gel. Gels were run at 100V for 4 hours at 4°C. Gels were dried onto 3MM paper, and the
results visualised by autoradiography.
2.19.3 Filter Binding Assay
Filter binding assays were based on the method of Carey et al, (1983). Complexes
were filtered through a nitrocellulose membrane (Hybond C, 0.45gM, Amersham) using a
Biorad Slot Blot apparatus. The membrane was soaked in RNA binding buffer, placed onto 3
sheets of Whatman 3MM filter paper, and the apparatus secured under vacuum. The filter was
prewetted with 500pl RNA binding buffer. Slots were filled with 200pl RNA binding buffer, and
the rev binding reactions added. After filtration, the slots were washed twice with 500pl RNA
binding buffer, and the membrane air dried. The membrane was divided into sections
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following the slot outlines, and the bound activity determined by scintillation counting.
2.20 Transfection
Transfection of COS cells for assaying transient expression of introduced genes was
performed using two methods. DEAE Dextran mediated transfection was based on the
method of McCutchan and Pagano (1968). Transfection by calcium phosphate precipitation
was based on the original observation of Graham and Van der Eb (1973).
2.20.1 Preparation of Cells for Transfection
Six well plates ( 35mm diameter, Nunclon) were pretreated with 0.1% w/v gelatin for 1
hour at room temperature. After washing with 10%FCS/DMEM, each well was seeded with
2x105 COS cells. The cells were incubated for 16 hours in 10%FCS/DMEM, at which point
the cell monolayers had reached 60-80% confluence.
2.20.2 Preparation of DNA for Transfection
High plasmid purity is required for efficient transfection. All plasmids were prepared by
Qiagen column chromatography (2.10) and resuspended in dH20 at 0.2 to 1 pg/ml. The
purity and concentration of plasmid DNA was determined by spectrophotometry, and checked
by agarose gel electrophoresis (2.8).
2.20.3 Transfection with DEAE Dextran
Immediately before transfection, media was aspirated, and the cells washed with 2ml
prewarmed SPBS. Transfection solutions (1-2pg total DNA, 100pg DEAE Dextran made up to
200pl with SPBS) were added to each well and distributed evenly by gentle tilting of the
plate. The plates were incubated for 30 minutes before addition of 10%FCS/DMEM (2ml)
supplemented with 2.5p.g/ml fungizone (total 5pg/ml) and 100mM chloroquine to each well,
and continued incubation for 2.5 hours. Chloroquine is thought to enhance transfection
efficiency by inhibiting microsomal vacuole formation resulting in reduced degradation of
incoming DNA (Luthman and Magnusson, 1983). Media was removed by aspiration and the
cells shocked by addition of fresh 10%FCS/DMEM supplemented with 10% DMSO for 2.5
minutes at room temperature. DMSO may aid transfection by increasing cell membrane
permeability. Following aspiration of the shock solution, the cells were incubated for 48 hours
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in 2-3ml 10%FCS/DMEM.
2.20.4 Transfection by Calcium Phosphate Precipitation
Cell media was aspirated and replaced with fresh 10%FCS/DMEM 2-4 hours prior to
transfection. Each well was treated with 250jal DNA/calcium phosphate precipitate, composed
of 125p.l 2x DNA precipitation buffer (280mM NaCI, 10mM KCI, 12mM glucose, 1.5mM
Na2HP04, 50mM HEPES, pH 7.05), 125mM CaCI2, 4-6pg total DNA, diluted in dH20. The
precipitate was formed by the stepwise addition of the dH20, DNA, CaCI2 and buffer to a
sterile eppendorf tube with gentle mixing, followed by incubation at room temperature for 20
minutes. The treated cells were incubated for 4 hours. In order to increase transfection
efficiency, the cells were then shocked by incubation for 1 minute in 15% v/v glycerol ( in 1 x
precipitation buffer). The cells were washed twice in DMEM and incubated for 48 hours in
10%FCS/DMEM.
2.21 Radioimmunoprecipitation
After 48 hours incubation, media was aspirated and cells washed three times with
cysteine/methionine free DMEM (cys/met- DMEM). The cells were starved of cysteine and
methionine by incubation in 1ml cys/met- DMEM for one hour. Media was again aspirated, and
replaced with 500pl cys/met- DMEM supplemented with 50mCi tran35S label (ICN Flow). After
2 hours incubation, the cells were harvested by gentle agitation in 1ml
radioimmunoprecipitation assay buffer (RIPA; 0.1% SDS, 1% Triton X-100, 1% w/v sodium
deoxycholate, 0.15M NaCI, 1mM EDTA, 0,25mM PMSF, 10mM Tris.HCI pH 7.4). The
suspension was transferred to a 1.5ml eppendorf tube, and cell debris removed by
centrifugation at 12000g for 20 minutes at 4°C. The cleared cell lysate was frozen at -70°C at
this stage before immunoprecipitation.
The lysate was transferred to a fresh tube, and specific antibody added at the
required dilution (typically 1:200) for 16 hours at 4°C. The antibody complexes were
precipitated by the addition of 50pl protein A Agarose beads (Sigma). The beads were
pelleted by centrifugation, washed three times in RIPA buffer, and an equal volume (50|j.l) of
SDS-PAGE sample buffer added. The agarose/ antibody/ antigen complexes were resolved
by electrophoresis through 15% denaturing polyacrylamide gels. The results were visualised
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by autoradiography of the dried gels.
2.22 CAT Assay
2.22.1 Harvesting of Transfected Cells
After 48 hours incubation, cells were washed once in SPBS. Glass beads (4.5-
5.5mm, BDH) were added to each well, and the cells removed from the plates by agitation in
1ml 250mM Tris.HCI pH 8.0. The suspension was collected in a sterile 1.5ml eppendorf tube,
and centrifuged at 12000g for 1 minute. The cell pellet was resuspended in 50pl 250mM
Tris.HCI pH8.0. Cells were lysed by three rounds of freeze/thawing (freezing in dry
ice/ethanol 15 minutes: thawing in a 37°C water bath 5 minutes). Cellular debris and intact
cells were removed by centrifugation at 12000g for 5 minutes, and the supernatant collected
for analysis.
2.22.2 Assay for CAT activity
CAT activity in cell lysates was determined by liquid scintillation counting, based on
the method of Seed and Sheen (1988). Briefly, a sample of lysate (5pi) was mixed with 5pl n-
butyryl CoA (5mg/ml), 2pl 14C-chloramphenicol (0.025mCi/ml) and 118p.l 250mM Tris.HCI pH
8.0. After incubating at 37°C for 1 hour, the reaction products were extracted by the addition
of 250pl mixed xylenes (Aldrich Chemical Co., Gillingham, Dorset), with vigorous mixing. After
centrifugation at 12000g for 3 minutes, the upper organic phase containing the acetylated
chlramphenicol was removed to a fresh tube, 250pl dH20 added, and extraction repeated.
Finally, 125pil of the organic phase was mixed with scintillant, and counted in a scintillation
counter.
2.22.3 p Galactosidase Assay
The reporter plasmid, pSV-p-Gal (Promega), which expresses the enzyme p-
galactosidase, was used as an internal control for transfection and cell harvesting efficiency.
Enzyme activity in cell lysates was determined using a colorimetric assay. Cell lysate (10pJ) was
made up to 50|il with dH20, added to an equal volume of 2x assay buffer (120mM Na2HP04,
80mM NaH2P04, 2mM MgCI2, 100mM p-mercaptoethanol, 1.33mg/ml ONPG) and incubated
at 37°C for 30-60 minutes. The reaction was terminated by the addition of 150pl 1M NaCC>3,
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and the OD420 determined by spectrophotometry.
2.23 Antibody Generation
2.23.1 Immunisation Protocol
An equal volume (0.5ml) of antigen diluted in SPBS was added to Freund's Complete
Antigen (Sigma) and the immunogen emulsified by sonication. Dutch albino rabbits were
immunised sub-cutaneously with 0.5ml emulsion. Subsequent immunisations, using
Freund's Incomplete Antigen, were performed at 10 and 24 days after priming.
Blood samples were taken immediately prior to initial immunisation and at intervals
from 24 days subsequently. Samples were obtained by bleeding from the ear vein, and were
allowed to clot by incubation at 4°C for 18 hours. Serum was removed from the clot and stored
in 500pl aliquots at -20°C.
2.23.2 Purification of Antiserum by Caprylic Acid Precipitation
Serum (10ml) was diluted in the ratio 1:2 with acetate buffer (0.2M acetate, pFi4).
Caprylic (octanoic) acid (37.5pl/ml serum) was added dropwise, with vigorous mixing. The
mixture was incubated at room temperature for 30 minutes, before centrifugation at 15600g
for 30 minutes to precipitate impurities. The supernatant was removed, and dialysed against
0.1 M phosphate buffer pH7.2 overnight.
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CHAPTER THREE
EXPRESSION OF EV1 REV IN THE
YEAST TY-VLP SYSTEM
3.1 Introduction
The recent advances in biotechnology which have allowed the expression of
heterologous genes in environments which are easily amenable to manipulation, such as
bacterial or yeast cells, have had an immeasurable impact on virological research. Systems for
the expression of genes often involve inserting the gene into an expression cassette which
contains the c/'s-acting signals, such as those for transcription initiation and termination,
required for high level expression in the host cell. In addition, where the expression system
involves the formation of fusion proteins, the carrier protein possesses certain characteristics
which allow for ease of purification. One such fusion protein expression system is the yeast
Ty-VLP system. Developed by British Biotechnology Limited (BBL), Oxford, this system was
chosen as the means of expression of MVV EV1 Rev protein. Several reported attributes of
this system are of benefit when expressing recombinant protein for functional studies. These
include high yield and purity of product, a relatively simple purification system involving non-
denaturing conditions, and the option of regulatable expression. The nature of the
purification process also allows for versatility with respect to the size of the encoded protein.
The Ty-VLP expression system is based on the Ty1 retrotransposon element of the
yeast Saccharomyces cerevisiae. The majority of the 30-35 Ty elements distributed at variable
chromosomal locations within the yeast haploid genome are 5.9kb in length. Each element
consists of an unique region containing two open reading frames, TYA and 7TB, surrounded
by long terminal repeats (LTRs or'5' sequences) of 335bp. Transcription, initiated from inside
the 5' 5 sequence, produces a 5.7kb transcript which functions both as the major message,
and as an intermediate in transposition (Boeke etal., 1985). Translation of this message gives
rise predominantly to the product of TYA, a 50kDa phosphoprotein, p1. 7TBis expressed by a
low frequency (-3%) frameshift event, induced by a ribosomal stalling/slippage mechanism at
the 3' boundary of TYA, which results in translation continuing in the +1 reading trame register
(Mellor etal., 1986). The resulting product, p3, is a 190kDa fusion protein containing both p1
and 7TB encoded residues. The 7TB specific residues contain reverse transcriptase,
protease and integrase activity. These proteins assemble into pre-virus-like particles (VLPs).
Particles undergo a process of maturation which involves proteolytic degradation of p1 into
four smaller derivatives (p2,4,5,6; Adams etal., 1987b). The mature VLPs, which also contain
Ty RNA and atRNAmet primer, are located in the cytoplasm and have an approximate diameter
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of 60nm. Transposition is completed when a cDNA copy of the Ty RNA is reverse transcribed,
and integrates into the yeast genome, often upstream of tRNA genes.
The Ty-VLP expression system is based on the observation that protein p1 alone can
self-assemble to form particles without the presence of p3 and subsequent maturation events
mediated by p3 protease activity (Adams etal., 1987a). The expression cassette common to
the Ty-VLP vectors contains a modified form of 7YA (dTYA), truncated by the formation of a
BamHI linker at codon 381. Hence in frame insertion of a foreign gene at the linker region
results in the production of a fusion protein which subsequently assembles into hybrid Ty-
VLPs, each containing approximately 300 monomers. Morphologically, the hybrid particles are
thought to contain a p1 core with spikes of foreign protein protruding from the surface (Adams
etal., 1988).
The expression cassettes are contained within two vector species. Both are derived
from bacteria/yeast shuttle vectors, allowing genetic manipulation in bacteria followed by
expression in yeast cells. Vector pMA5620 (illustrated by figure 3.1a; Adams et at., 1987a)
directs constitutive expression of protein from the yeast phosphoglycerate kinase (PGK)
promoter (Dobson etal., 1982). Expression from this strong promoter can generate up to 5%
of total cellular protein (Mellor etal., 1985). The expression cassette is followed by termination
codons in all three reading frames, and by a transcription terminator. The plasmid also contains
origins of replication for both hosts. The yeast origin is based on the 2p plasmid, maintaining
the plasmid at 100-200 copies per cell. Transformed cells are selected in bacteria on the basis
of an ampicillin resistance gene and in yeast by the presence of the gene LEU2, which
renders strains auxotrophic for leucine independent of this amino acid.
The vector pOGS40 (figure 3.1b; Gilmour et al., 1989) is a derivative of pMA5620,
containing a modified PGK promoter (PAL), generated by the replacement of the upstream
activating sequence (UAS) of the PGK promoter with that of the GAL 1/10 promoter
(Kingsman etal., 1990). The hybrid directs high level transcription only in the presence of
galactose. Regulatable transcription allows the cell growth and gene expression phases to be
uncoupled. Thus the physiological load on the host cell of high level production of a protein
without cellular benefit is lessened. This is of particular importance where expression of the
gene exerts a toxic effect on the host cell.
The PAL promoter is regulated by two, host encoded, proteins, the activator pGAL4
and its antagonist pGAL80. In glucose based media, the GAL80 protein binds to the
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Figure 3.1: Ty-VLP Expression Vectors and the Helper Plasmid pUG4lS
The diagram illustrates the two Ty-VLP expression vectors, pMA5620 and pOGS40
Expression from pMA5620 (A) is driven by the constitutive PGK promoter. The pOGS4
vector (B) is regulatable, due to the presence of the hybrid PGK/GAL promoter, PAL
Expression is induced on addition of galactose.
The helper plasmid pUG4lS (C) provides high levels of the regulatory protein pGAL4 to th>
PAL promoter in a galactose inducible manner.
pPGK: the phosphoglycerate kinase promoter.
pPAL: the hybrid PGK/GAL promoter.
pGAL 1/10: the promoter of the genes GAL 1 and GAL10. Contains elements to caus
repression in glucose and induction in galactose.
UAS-PGK: the upstream activating sequence of the PGK promoter.
UAS-GAL: the upstream activating sequence of the GAL 1/10 promoter.
TYA(d): truncated form of the gene TyA.
PGKt: translational termination codons in three reading frames from the PGK gene.
BamHI: cloning site for insertion of heterologous gene.
GAL4: gene encoding the galactose positive regulatory factor pGAL4
2 micron: replication module for yeast, maintaining plasmid at 100-200 copies per ce-
ARS1/CEN4: autonomous replicating sequence for yeast.
ampR: ampicillin resistance gene.
LEU2: gene for leucine biosynthesis.




























activation domain of pGAL4, preventing its interaction with the UAS-GAL within the PAL
promoter (reviewed in Schultz etal., 1987). Only in the absence of glucose and the presence
of galactose is the inhibitory effect reversed. Binding of pGAL4 to the UAS-GAL in the
context of the GAL 1/10 promoter leads to an approximate 1000-fold increase in expression
(St John and Davis, 1979). Thus, the inducibility of this promoter is critically dependent on the
relative concentrations of pGAL4 and pGAL80. As the level of pGAL4 within cells may be too
low to maximally induce transcription (Johnston and Hopper, 1982), this protein can be
supplied by means of a helper plasmid, pUG41S (figure 3.1c). This low copy number plasmid
expresses GAL4 under the control of the GAL1/10 promoter, which is itself galactose
inducible. Co-transformation of cells with pOGS40 and pUG41S therefore should give rise to
greater expression than with pOGS40 alone (Schultz etal., 1987). Cells transformed with
pUG41S are selected on the basis of uracil independent growth.
The S. cerevisiae strain, BJ2168, has a phenotype with several characteristics
required for Ty-VLP expression. It is partially protease deficient. This should reduce possible
host-mediated degradation of the expressed protein. It is auxotrophic for three amino acids,
leucine, tryptophan and uracil, which is the basis for selection of cells transformed with the Ty-
VLP vectors. It should be noted that BJ2168 cells contain a mutation within the GAL2
galactose permease gene, which results in the inability to uptake galactose by an inducible
mechanism. However, galactose can enter the cell via a less-efficient constitutive pathway,
thus ensuring the inducibility of plasmid pOGS40.
Purification of fusion proteins is described briefly. Cells which have expressed hybrid
Ty-VLPs are harvested and lysates prepared. Purification of the Ty-VLPs is based on
centrifugation of crude extracts through sucrose density gradients (Burns etal., 1991). The
particulate nature of the Ty-VLPs results in relatively tight banding within the gradient. Within a
range of approximately 3-40kDa, fusion of a foreign protein to p1 does not significantly alter
the sedimentation properties of the Ty-VLPs (Burns etal., 1992). This fact adds to the
versatility of the system. Two rounds of sedimentation may be required for enhanced purity. If
the foreign protein is required in its native state, it can be removed from the VLPs by the
incorporation of a specific protease cleavage site at the boundary between (d)7YA and the
inserted gene (Braddock etal., 1989).
Proteins which have been successfully expressed in the yeast Ty-VLP system
include HIV-1 Tat (Braddock etat., 1989), Nef (Gilmour etal., 1990) and p249a9 (Gilmour etal.,
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1989), MVV p259a9 (Reyburn etal., 1992), ovine tumour necrosis factor a (TNF-a) (Green
etal., 1993) and ovine interleukin-1 (IL-1) (Fiskerstrand etal., 1993). Typical yields of fusion
protein achieved are in the range 2-5mg/L yeast culture. Exceptionally, yields as high as 50-
60mg/L have been reported (Reyburn etal., 1992). Several of the recombinant proteins have
been shown to possess biological activity, including HIV-1 Tat (Braddock et al., 1989) and
ovine TNF-a (Green et al., 1993). It should be noted that when this system was being
developed for Rev expression it was being successfully used in the laboratory for the
production of various MVV and ovine proteins.
3.2.1 Generation of Recombinant Ty:Rev Plasmids
A rev gene was derived by PCR from cDNA prepared from ovine choroid plexus cells
infected with the British isolate of MVV, EV1 (Sargan et al., 1991). The product was cloned
into pTZ19R, to produce the plasmid pRev5, and sequenced. pRev5 was used as a template
for further PCR using primers incorporating BamHI sites and a sequence corresponding to the
recognition site for the protease Factor Xa was also incorporated into the 5' primer. The
sequence of these two primers was as follows:
BamHI Factor Xa rev
CGGATCCATAGAAGGTAGAATGGCAAGCACAAAG






The PCR product was subcloned into the expression vectors pMA5620 and pOGS40
by digestion with BamHI (to yield a 520bp fragment) and subsequent ligation. The products
were named pRev.A and pRev.O with reterence to the parental vectors, pMA5620 and
pOGS40 respectively. This work was carried out by Drs D. Roy and D. Sargan and Mr. I.
Bennet.
To validate sub-cloning, the vectors were sequenced across the tyaJrev boundary.
The primer 098G (sequence CAG GAG AAA TCC GAG TG: obtained from C. Cousens),
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complementary to a region ~50bp upstream of the cloning site within tya was used for double
stranded sequencing. Results confirmed the correct subcloning of rev.
3.2.2 Sequence Characteristics of the Cloned EV1 Rev Protein
The nucleotide and predicted amino acid sequences of the revinsert are illustrated
by figure 3.2a. It should be noted that a stop codon at position 148 prevents the translation of
15 carboxy-terminal residues present in the Rev protein of the 1514 strain (Mazarin eta!.,
1988). The predicted molecular weight of EV1 Rev is 19.5kDa. There are two differences
from the EV1 genomic sequence published by Sargan et al. (1991). These are T to C at
position 32, and A to G at position 117. Only the former substitution results in an amino acid
change, replacing a valine residue with an alanine. This does not affect either of the regions
with significant homology to the functional domains of the HIV/SIV Rev proteins. These
regions are shown in detail in figure 3.2b. The putative basic domain of EV1 Rev (residues 69-
90) contains 12/22 arginine and lysine residues and has a central region consisting of 3/4
hydrophobic residues (WFKW). The putative activation domain (residues 104-113) has a
significant degree of amino acid identity with HIV-1 Rev, with the presence and distribution of
three leucine residues conserved. Overall, the sequence identity between these two
proteins is low however (18.1%). The protein has a highly basic character, 27/147 residues
are arginine or lysine (18.4%). The predicted isoelectric point (using the UWGCG programme
'Isoelectric') is 10.46. A computer prediction of the secondary structure of Rev is shown in
Figure 3.3. The main structural features include predicted a helix between residues 78-90
and 104-119, which includes part or all of both putative functional motifs; and ares of ppleated
sheet within the amino terminal regions, at residues 24-33 and 43-57. There are no significant
regions of hydrophobicity.
3.3 Transformation of Yeast with Recombinant Plasmids
Ceils of the Saccharomyces cerevisiae strain BJ2168 were transformed by the lithium
acetate based protocol (section 2.12.3) with the plasmids pMA5620 and pOGS40 and with
the two recombinant vectors containing the rev gene insert (pRev.A and pRev.O). Several
DNA concentrations were used, the most successful outcomes were associated with the use
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Figure 3.2: Nucleotide and Predicted Amino Acid Sequence of pRev5 Inser
A The nucleotide sequence of the pRev5 insert. The 500bp insert does not show th»
terminal regions incorporated by PCR, which contain restriction endonuclease and proteast
cleavage sites (see text 3.2). The two base variations from the published nucleotid
sequence of EV1 (Sargan etal., 1991) are highlighted in italics. The predicted amino aci
sequence obtained by translation of this insert is shown using the three letter code. Th>
boundary between residues encoded by the first and second exons of the rev mRNA i
shown (EB).
B Sequence comparison between the amino acid sequence of the EV1 and HIV-1 Re
proteins. Comparison made using the UWGCG (ver. 8) programme 'Bestfit'. Identical amin
acids are marked by a dash, dots indicate similarity of residue. Regions of homology are limite
to the two known functional domains of HIV-1 Rev: the basic (RNA binding and nucler
localisation) and activation domains. These HIV-1 basic domain and the EV1 Rev homolgou













































BASIC DOMAIN ACTIVATION DOMAIN
33 GTROARRNRRRRWREROROIHSISERILSTYLGRSAEPVP P/Of.PPPF'RFTLD 84
66 SGPRGKTRRRKGWFKWLRRLKAREKNIPAHFYPDMESNV . . . . AGT,F.KLTLF.KKJ,KF.KP I 121
85 CNEDCGTSGTQGVGSPQILVESPTILESGAKE 116 HIV-1:HXB3
122 YESTTSTGGTSVAGR DWMDWRESAQK 147 MVV: EV1
Figure 3.3: Predicted Higher Order Structure of the EV1 Rev Protein
The secondary structure of EV1 Rev was predicted using the UWGCG programmes
'Ppetide structure' and 'Plotstructure'. Alpha helices are shown as sine waves, beta-pleatei
sheets are shown in narrow zig-zag from. Blue denotes regions ot significant hydrophilicity




of ~5|ig vector and 20jag salmon sperm DNA as carrier. Transformants were selected by
leucine independent growth, ie by growth in regeneration agar containing tryptophan and
uracil, but not leucine. The various combinations of transfecting plasmids and the outcome of
transformation are summarised in table 3.1. Five colonies from each transformation were
selected, and re-streaked onto fresh plates. The TRev.A and TRev.O plates were
photographed after 2 and 3 days incubation, and are illustrated by figure 3.4. It is clear from
both table 3.1 and figure 3.4 that cells transformed with pRev.A display a lag in growth
compared to those transformed with pRev.O. The nature of the promoter directing fusion
protein expression is the only difference between these transformants: hence, it must be
responsible for the observed difference in growth. Therefore, constitutive expression of the









T.A pMA5620 200 2-3 days 8f
T.O pOGS40 200 2-3 days 6b j
TRev.A pRev.A 10-15 12-14 days 2a




5-6 days 5c. 1
fusion protein in the pRev.A transformants must be detrimental to cell growth. Although it is
possible that high level expression of the fusion protein acts as a physiological restraint on cell
growth, the lack of such an effect on cells constitutively expressing p1 alone strongly
suggests that p1 :Rev exerts a toxic effect on the host cell. The slightly reduced growth of
cells transformed with pRev.O compared to those transformed with pMA5620 further
supports this hypothesis; furthermore, this suggests that the PAL promoter is not
transcriptionally silent in the absence of the inducing agent. Transformations were carried out
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Figure 3.4: Growth of Ty:Rev Transformants in Solid Medium
Five colonies transformed with the Ty-VLP vectors containing the rev gene insert wer
chosen, and re-streaked onto Sc-glc agar plates. The growth of two of these transformants
2e (TRev.A) and 5e (TRev.O) is shown after 48 (A) and 72 (B) hours incubation.
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with the help of Dr. D. Roy.
3.3.1 Transformation of TRev.O with the Helper Plasmid pUG4lS
Co-transformation of cells with both a pOGS40-derived plasmid and pUG41S should
lead to enhanced expression from the PAL promoter where the regulatory protein pGAL4 is
limiting. TRev.O cells were transformed with 5-1 Opg of pUG41S according to the above
parameters. Transformants were selected on the basis of leucine and uracil independent
growth on plates containing Sc-glc agar and tryptophan. As the presence of pUG4lS should
correlate with increased expression of fusion protein, even in the absence of IPTG, the delay
in visible colony formation (5/6 days compared to 4/5 days for pRev.O alone, table 3.1) is
further evidence to suggest a toxic effect of p1:Rev expression. Doubly transformed cells
were denoted TRev.U. One colony, TRev.U.5c.1, was chosen for future experiments.
3.4 Validation of Fusion Protein Expression by Transformants
Selected transformants were screened for expression of fusion protein by generation
of small scale (50ml) cultures, with induction with galactose where appropriate. Cells were
harvested after 48 hours growth, and crude extracts prepared by lysing cells with glass beads.
Protein production was analysed by SDS-PAGE. Gels were stained with Coomassie blue, or
electroblotted onto nitrocellulose and probed with a polyclonal anti-pi antiserum (a kind gift of
British Biotechnology Ltd.). A blot positive band with apparent molecular weight in the range
55-58kDa is present in the p1 extracts (figure 3.5a,b). Although this is considerably larger
than the expected weight of 42kDa, reduced mobility of p1 in this gel system has previously
been observed (Adams et at, 1987a). By comparison with the p1 extract, the tracks
corresponding to the Ty:Rev transformants demonstrate loss of the p1 band and its
replacement with a band with size in the range 74-76kDa. The expected molecular weight of
p1:Rev fusion protein is 61.5kDa (42kDa p1 + 19.5kDa Rev), the altered mobility of the p1
moiety is presumably responsible for the observed discrepancy. There may also be an
anomaly due to the high basic content of Rev, a feature which is associated with reduced
mobility in SDS-PAGE (Gabriel and Wong, 1969). This band was therefore assigned to the
expressed fusion protein, p1 :Rev. A sample of purified p1 :p259a9 included as a control, has
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Figure 3.5: Validation of Fusion Protein Production by Ty Transformants.
Cell extracts were analysed by electrophoresis through 10% polyacrylamide gels. Tot;
protein content of extracts was equalised by use of the Biorad assay. Gels were stained wit-
Coomassie blue (C,D) or Western blotted and probed with anti-pi antiserum (1/1000 dilutior
(A,B).
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j I I %■ ■■■.
ma1 •SEi #H£§S

















slightly reduced mobility when compared to p1:Rev. No blot positive material was present in
extracts from untransformed BJ2168 cells, suggesting that endogenous Ty elements were
not expressed under these conditions.
There is little observed difference in terms of pi :Rev band intensity between TRev.A
(A) and TRev.U (B) cells, nor between TRev.U and TRev.O (data not shown). It should be
noted that in order to equate the amount of protein in each gel track, approximately 4p.l of
p1 :Rev extract was loaded, compared with 1pl of p1 extract. This suggests that the p1 :Rev
expressing transformants might be low yielding. Examination of Coomassie stained gels
(figure 3.5c,d) failed to identify a band corresponding to p1 :Rev in the whole cell extracts. By
contrast, a band of enhanced intensity (arrowed), running at ~55kDa and thus corresponding
to p1, is clearly visible in the T.A and T.U tracks.This indicates that the yield of p1 :Rev is less
than that of native p1. The toxic effect of the rev insert identified during transformation (3.3
above) is a likely mechanism for reduced yield. It was decided that the TRev.U colonies would
be used for further study, in the belief that the inducible nature of p1 :Rev expression would
potentially allow improved growth and yield compared to the constitutively expressing TRev.A
cells.
3.5 Large Scale Production and Purification of pl:Rev
Large scale protein purification was performed on extracts from four-litre cultures of
induced TRev.U cells. Culture conditions and purification protocol were based on the
methods of Adams et al. (1991), and are as described in section 2.12.4.2. As a control, native
p1 protein was purified from T.A cells (transformed with the constitutive expression vector
pMA5620). Sucrose gradient fractions were analysed by resolution of protein by SDS-PAGE.
The Coomassie stained profiles of both p1 :Rev (Figure 3.6a) and p1 (3.6b) gradients are
presented. Much of the contaminating yeast protein accumulates in the upper section of the
gradients, with the particulate VLPs sedimenting in lower sections. p1 protein concentrates in
fractions 5-10 (where fraction 1 is the top of the gradient and fraction 19 is the bottom), where
it is the predominant protein. These fractions were pooled, dialysed against TEN buffer, and
subjected to a further separation on a 15-45% sucrose gradient. By Coomassie staining, this
results in an essentially homogeneous preparation (figure 3.6d) with a total yield of
approximately 5mg/L yeast culture. By contrast, there is no discernible band due to p1 :Rev
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Figure 3.6: Purification of Ty-VLPs by Density Centrifugation
A A 41 culture of TRev.U cells were induced to express fusion protein by incubation i
Sc-glc-gal medium for 24 hours as described (2.12.5). Cell extracts were prepared, an-
cellular debris removed (2.12.6). Purification of recombinant VLPs was achieved by densit
centrifugation through a 15-45% sucrose gradient (2.12.7). Fractions (2ml) were collecte
from the gradient, and samples (10pJ) resolved by SDS-PAGE through a 10% polyacrylamid
gel. Visualisation is by staining with Coomassie blue. Gradient fractions are numbered from
(top) to 19 (bottom). Fraction 20 contains material derived from a 2ml 60% sucrose cushio
underlaying the gradient.
B A 41 culture of T.A cells was incubated for 24hrs in Sc-glc medium, and treated &
above (A). A sample of pre-purified p1 is included as an internal marker.
C A similar gel to (A) above was blotted onto nitrocellulose and probed with anti-p
antiserum (1/1000 dilution).
D Fractions from the T.A sucrose gradient containing peak concentrations of p1 (5-1F
were pooled and subjected to a second round of density centrifugation. Fractions wet
collected and analysed as above (A). Figure shows two fractions containing purified p1.
E Fractions from the TFtev.U sucrose gradient containing peak concentrations >
p1 :Rev (12-16: identified by Western blotting) were pooled and subjected to a second rour
of density centrifugation. Fractions were collected and analysed as above (A). Figure shov
two fractions containing putative purified p1 :Rev. The candidate band corresponding












































visible by Coomassie staining. Although two possible candidates (figure 3.6a: arrows) are
present in the expected location, a western blot of the p1:Rev gradient (Figure 3.6c)
demonstrates accumulation of the protein in fractions 12-16, a distribution which does not
correlate with that of these bands. A proportion of p1 :Rev falls into the 60% cushion. The fact
that this concentration of p1 :Rev occurs without a parallel increase in visibility by Coomassie
staining leads to the conclusion that p1 :Rev is produced at a much lower level than native p1
protein. The peak fractions for p1:Rev content were pooled, sucrose removed by sephadex
chromatography (section 3.9.3.1) or by dialysis, and subjected to a second round of
centrifugation through a 15-45% sucrose gradient. The VLPs were found to behave in a
similar manner to the first sedimentation. Blot positive fractions (14 and 15) were analysed by
Coomassie staining (Figure 3.6e). These samples appear to demonstrate concentration of a
band of approximately 72-75kDa which is not present in blot negative fractions (figure 3.6e
arrow). This band is the faster migrating of two bands found in a similar position to those seen
after the first sedimentation (3.6a) and may represent resolution of these proteins. This was
therefore assigned as a candidate band for pl:Rev. Flowever, further purification would be
required for an unequivocal demonstration of the identity of this band. The purity of this
protein as estimated from the Coomassie staining profile was -10%. The overall protein
concentration in fractions 14 and 15 was 1.2mg/ml, giving an approximate total yield of pi :Rev
of 480pg (120p.g/L yeast culture). The second gradient fraction 14 (F14) material was used as
the main source of p1 :Rev for further studies.
Purification of VLPs relies on a relative rather than absolute separation of yeast
proteins, such that a high yield of recombinant protein is essential to generate a highly pure
preparation. One possible explanation for the low yield of p1:Rev is instability of the fusion
protein. Many yeast proteases are located within the vacuole, and can attack the expressed
protein on release by cell lysis. However, the strain used here is deficient in several known
proteases, and is associated with stability of several other heterologous proteins. Particle
formation is thought to promote fusion protein stability (Gilmour et at., 1989). Moreover, there
is no evidence for the production of intermediates by proteolysis by western blotting
detection. Although instability cannot be ruled out, the previously observed inhibitory effect
of p1 :Rev expression on the growth of yeast cultures suggests that a toxic mechanism for low
yield is more likely. To investigate this possibility, a time course study of expression was
performed, and the effects of p1 :Rev on yeast morphology examined by microscopy.
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3.6 Time Course of Fusion Protein Expression
The growth characteristics of both induced and uninduced pRev.O transformants
were investigated in order to analyse the observed retardation of growth of cells containing
the rev insert. Transformants were grown in Sc-glc/trp until an OD600nm of 0.2-0.3 had been
reached. The cells were then pelleted and resuspended in pre-warmed Sc-glc/trp or Sc-glc-
gal/trp where appropriate, followed by continued incubation. Culture turbidity was recorded at
four hour intervals for 20 hours, and subsequently at eight hour intervals until 44 hours.
Protein expression was monitored at regular intervals by removal of 50ml aliquots of culture for
the preparation of crude cellular extracts. This work was performed in conjunction with Mr. J.
Warden.
Figure 3.7a demonstrates the growth profiles obtained in this experiment.
Untransformed cells grew rapidly, although growth rate was not optimal due to the poor uptake
of galactose by these GAL2 mutants. It is clear that the growth of cultures expressing p1 :Rev
is dramatically inhibited. Reduction in growth is evident from as early as eight hours, and
growth effectively has ceased when the cultures attained a density of -2x107 cells/ml.
Dilution of an aliquot of stationary cells in fresh, non-galactose containing media did not lead
to an increase in culture growth, suggesting that inhibition of growth is irreversible. Growth of
cells doubly transformed with pRev.O and pUG41S (TRev.U) would appear to lag slightly
behind that of singly transformed cells, although as only a single experiment was performed
for each transformant it is impossible to determine the significance of this observation. The
growth of TRev.O and TRev.U cultures in non-inducing conditions would appear to be
retarded in comparison with untransformed cells, correlating with previous observations of
colony formation in solid phase media in the absence of galactose. Cells expressing p1 alone
(T.O) demonstrate some reduction in growth in late log phase.
Light microscopic examination of cells at various time points further confirmed the
toxic nature of p1:Rev. At 24 hours post-galactose shift, the appearance of untransformed
cells was essentially normal (Figure 3.7b.i), with budding cells forming chains characteristic of
rapid growth in good conditions. However, at the same time point, TRev.U cells formed large,
dense aggregates (Figure 3.7b.ii). This is strongly suggestive of cell death rather than of a
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the untransformed cell culture. Aggregates were clearly visible by microscopic examination as
early as eight hours post induction. Clumping ot cells also occurred to a lesser extent in
uninduced TRev.O and TRev.U cultures at later time points. Cells expressing p1 did not
demonstrate clumping and appeared healthy. This suggests that the observed reduction in
culture growth was due to the physiological effects of high level expression of p1, rather than
to a toxic mechanism.
Protein production at various time points was examined by SDS-PAGE analysis of
crude extracts of harvested TRev.U cells. Recombinant protein was detected by probing
Western blots with anti-p1 antiserum (Figure 3.7c). p1 :Rev was clearly detectable, though at
low levels, prior to induction, thus confirming the previous suggestion that the pOGS40 PAL
promoter is incompletely repressed in the absence of galactose. After induction it is evident
that the amount of fusion protein detected does not alter greatly with time. This might be
expected given the observed growth characteristics of induced TRev.U cells. One can
hypothesise that cellular expression of p1 :Rev is accompanied rapidly by toxic effect, leading
to cell death.
In conclusion, the toxic nature of pi :Rev expression has been confirmed. It is not
known whether this effect is mediated at the mRNA or protein level. The best strategy for the
large scale production of pl:Rev would therefore appear to be the attainment of a high
density culture before induction, with the induction period itself kept to a minimum.
3.7 Examination of VLPs and Expressing Cells by Electron Microscopy
Transmission electron microscopic examination of sucrose gradient fractions
containing p1:Rev confirmed the production and isolation of VLPs. Recombinant VLPs
(Figure 3.8b) possess an electron-light 'shell' surrounding an electron-dense core region.
Particles have a largely spherical morphology, although there is a degree of heterogeneity in
shape not observed in native VLPs. With particle diameters in the range 30-1 OOnm, p1:Rev
VLPs are also larger than native VLPs (20-40nm). Aggregations of recombinant particles were
observed throughout the microscope field. Unidentified electron-light material is associated
with such aggregates. Although possibly an artefact of the staining process, this
phenomenon has not been observed to occur with purified native or other recombinant
particles.
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Figure 3.8: Electron Microscopic Examination of Ty-VLP Expression.
Ai-iv Transmission electron micrographic examination of TRev.U yeast cells at varioi
points post-shift into Sc-glc-gal/trp. Cells were fixed in osmium tetroxide (2.17.2
Representative cross-sections are presented. Arrows denote features discussed in the text
Magnification x 3550
B Isolated Ty-Rev VLPs. 1 OjllI sample of second gradient fractionl 4 (F14) material fro
p1 :Rev purification applied to a grid and the sample was negatively stained by fixing in uran
nitrate (2.17.1).
Magnification x 11 0000
C Ty-VLPs within yeast cell. TRev.U cell from 12hrs post-induction. Cell ultrastructur





Analysis of cells expressing p1:Rev VLPs at various points of the time course
experiment (section 3.6) demonstrated the severe toxic effect of expression of this protein.
Prior to induction, the majority of TRev.U cells displayed normal morphology, with evidence of
budding forms (Figure 3.8b i, arrows). A small proportion, however, possess enlarged, poorly
defined central vacuoles, characteristic of unhealthy cells. The percentage of such cells
increases with induction time (3.8b ii-iv). Many cells assume an irregular shape, and display
increased diameter: this may be a result of arrested cell division. Vacuolation in severely
affected cells proceeds to the stage where the normal cellular ultrastructure has been
completely destroyed, with tight packing of cellular components between the vacuole and
outer membrane (3.8b iii, arrow). These cells are obviously dead. It is not known whether
autolysis of dead cells occurs, although some cells at the 24 hour time point have a
condensed appearance suggestive of a post-lysis stage (3.8b iv, arrows). At 24 hours post
induction essentially normal cells are rare. In contrast, T.U cells expressing native VLPs
retained normal morphology throughout the induction period (data not shown). By
examination at a higher magnification, candidate recombinant VLPs were observed at a low
frequency as aggregates within the cytoplasm, though not the nucleus, of cells retaining a
degree of normal structure (3.8c). There is no equivalent, however, of the densely packed
arrays of VLPs found in cells expressing native p1 VLPs (Mellor et al., 1986).
The toxic effect of p1 :Rev expression on host yeast cells has therefore been shown
to involve dramatic alterations in cell morphology. Such changes are almost certainly
irreversible in nature, leading to cell death. p1:Rev induced cell enlargement may explain the
slight increase in culture turbidity at 8-20 hours post induction, at a point where viable cell
numbers are probably decreasing, rather than increasing.
3.8 Production of Polyclonal Antisera Against Ty-VLPs
The particulate nature of VLPs suggests that they are likely to act as good
immunogens. Production of an anti-Rev antiserum would be potentially useful in the further
purification of Rev protein, in addition to investigation of other aspects of Rev biology. A fresh
anti-pi antiserum was also prepared. Rabbits were immunised with either 100pg p1 (rabbit
R194) or ~200pg of p1:Rev preparation (of which 20-40pg was estimated to be fusion
protein) (rabbit R190) derived from second gradient fraction 14, according to the protocol
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3.9: Characterisation of Polyclonal Rabbit Antisera Raised Against Ty-VLPs
Polyclonal antisera were obtained by immunisation of rabbits with p1 (R194) (
p1 :Rev (R190) containing material as described in the main text. Pre-immune and immur
sera were tested for reactivity with both p1 and recombinant proteins by probing western bio
derived from 10% polyacrylamide gels. Antigens present in each blot are indicated.
A R194 anti-p1 (1/1000 dilution)
B R190 anti-p1:Rev (1/100 dilution)
C R190 antiserum was further characterised by probing extracts of ovine fibroblas
from several time points post-infection with the EV1 strain of MVV (a kind gift from Dr. D Roy
Extracts resolved by electrophoresis through a 10-20% polyacrylamide gradient ge
Antiserum used at 1/100 dilution.
D R190 reactivity with EV1 Rev protein expressed as a fusion to the protein glutathior
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outlined in section 2.23.1. Serum obtained 24 days after primary injection was tested for
specificity by western blotting. Antiserum from R194 was found to react with p1 and the p1-
derived proteins p1:p259a9 and p1:Rev (Figure 3.9a); serum from the pre-immune animal
gave no such reactivity. R194 therefore demonstrates the same specificity as the anti-p1
antiserum obtained from BBL. Blots of the p1:Rev fraction 14 material used to immunise
R190, and p1 and p1 :p259a9 were probed with both pre-immune and the resulting antiserum
(Figure 3.9b). p1:Rev was detected by the immune serum only. Although a number of other
proteins were recognised by this serum, the strongest reactivity was with p1 :Rev, as might be
expected given the particulate nature of the VLPs. Strong reactivity with p1 was also
recorded. Further experiments were performed in order to resolve the reactivity of R190 with
p1 :Rev into anti-p1 and anti-Rev components. To identify anti-Rev reactivity, R190 was used
to probe extracts from fibroblasts infected with EV1 (a kind gift of Dr. D. Roy, Department of
Veterinary Pathology, University of Edinburgh). No reactivity was demonstrated (Figure 3.9c),
despite the presence of Rev-specific mRNA in these cells (D. Roy, personal communication).
R190 antiserum also failed to identify a Rev-specific band on protease cleavage of the fusion
protein (see section 3.11). Reactivity with a bacterial Rev fusion protein, GSTRev (chapter 4)
was characteristic of both the pre-immune and immune sera (3.9d), suggesting that reactivity
may be anti-GST in nature. The reactivity of R190 with p1:Rev would thus appear to be
entirely due to recognition of the p1 moiety of the fusion protein, with no evidence for anti-
Rev activity. This was surprising, given the proposed advantages of antigen presentation in
the form of polyvalent particles (Adams eta!., 1987).
3.9 Attempts to Improve Yield and Purity of p1:Rev
Three approaches were taken in an attempt to increase the yield and purity of p1 :Rev
fusion protein. These were; modifying the growth and expression protocol to moderate the
effects of Rev-mediated toxicity; minimising the loss of Ty-Rev VLPs during steps in the
purification protocol, and finally, the use of alternative methods of purification.
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3.9.1 Culture Conditions and Expression
In order to increase yield of expressed protein by altering culture conditions it would
be necessary to boost the number of expressing cells before and/or during induction, or to
increase the effectiveness of induction, for example by altering the delivery of the inducing
agent. Expression of p1:Rev is accompanied rapidly by cell death, placing a limit to the
amount of protein expressed by each cell. Thus, only by increasing the number of cells can
the overall yield be increased. Growth of cells transformed with pRev.O in glucose is
hampered by the observed 'leakiness' of the PAL promoter, resulting in cell death in the
absence of the inducing agent. It was found that the conditions used above resulted in a high
proportion of clumped, dead cells, before induction. Several modifications to this protocol
were assayed. The most successful of these is described in section 2.12.7.2.2. This involved
a gradual increase in culture volume, with dead cells being eliminated at each step. At later
stages, 0.2% yeast extract was added. Although this had the result of promoting growth, it
may have been at the expense of a degree of loss of the transformed state, due to the
presence in yeast extract of the selective agents leucine and uracil. Immediately prior to
induction the culture contained an estimated 20% clumped yeast, as determined by light
microscopy. This figure was lower than that seen with other protocols. The induction period
was set at seven hours, at which point a proportion of viable cells remained.
However, significant increases in the final yield of p1:rev were not apparent despite
the improved growth. This suggests that increases in the number of VLPs were insufficient to
overcome limiting parameters within the purification process.
3.9.2 Minimising Loss of p1:Rev During Purification
Significant loss of fusion protein was likely to occur at three main stages of the
purification protocol. Incomplete lysis of cells would reduce the volume of protein available for
purification. Cell lysis was monitored by microscopic examination. Greater than 80% lysis was
achieved on each occasion, thus reducing the potential variation between preparations. The
proportion of protein lost due to sequestration within intact cells was therefore kept to the
minimum possible level.
Pelleting of p1 :Rev within cellular and macromolecular debris during pre-sucrose
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Figure 3.10: VLP Loss During Purification
A SDS-PAGE and western blot analysis of the distribution of p1 :Rev between pellet and
supernatant fractions after post-lysis centrifugation. TRev.U yeast cells were incubated in Sc-
glc-gal/trp for 24 hours and harvested. Lysates were prepared in TEN/pi (protease inhibitors)
or TEN/pi supplemented with Triton X-100 (TX-100) or additional NaCI as indicated. An
identical sample (0.25%) of each fraction was analysed. Samples were analysed by
electrophoresis through a 10% polyacrylamide gel and blots probed with anti-p1 antiserum
(1/1000 dilution).
B Recombinant Ty-Rev VLPs were prepared from supernatants derived from (A) above
by centrifugation over 60% sucrose cushions. Centrifugation fractions (2ml) were collected
and analysed by electrophoresis through 10% polyacrylamide gels. Gels were western
blotted and probed with anti-p1 antiserum (1/1000 dilution). Numbers refer to fraction position
after collection: 20 corresponds to the sucrose cushion. A sample of purified p1:p259a9 is
included as an internal marker.
i Cells lysed in TEN/pi




SN Pt SN Pt SN Pt
TEN + 0.2% TX-1 00 + 50mM NaCI
Bi
p1:Rev —►





13 14 15 16 17 18 19 20 p1:p25
TOP GRADIENT BOTTOM
FRACTIONS
cushion centrifugation was the second area of significant loss of protein. Western blot
analysis of the distribution of pi :Rev after this 13000g centrifugation step demonstrates that
most of the p1:Rev accumulates in the supernatant rather than in the pellet as expected
(Figure 3.10a). Addition of the detergent Triton X-100 to 0.2% (v/v) of the cell extracts prior to
centrifugation resulted in a reduction in the amount of residual p1 :Rev within the pellet. This
was not seen on the addition of 50mM NaCI. The value of this observation was reduced when
it was observed that the presence of Triton X-100 within the sample pelleted onto the 60%
sucrose cushion led to considerably less concentration of p1:Rev at the cushion interface
than was otherwise the case, leading to a further loss of protein at this stage (figure 3.10b).
Detergent was therefore not incorporated into the general purification protocol.
Sucrose cushion and sucrose gradient centrifugation also led to loss of p1:Rev.
Selection of particular fractions enriched for VLPs meant that those particles which were
distributed in less concentrated fractions were lost. This was an inevitable consequence of
the purification procedure.
3.9.3 Alternative Purification Methods
3.9.3.1 Size Exclusion Chromatography
Chromatography was considered as a further purification step after gradient
centrifugation of VLPs. The use of a Sephacryl S-1000 (Sigma) size exclusion column has
been reported to enhance the purity of recombinant VLPs (Gilmour etal., 1989). Preliminary
investigations into the feasibility of such an approach using p1 :Rev found that the volume of
matrix required for purification was such that the relatively small number of VLPs would be
massively diluted, and that adjustments to optimise chromatographic separation would be too
time consuming to be justified.
Chromatography through sephadex G-25 was initially used to remove sucrose from
selected cushion and gradient fractions as an alternative to dialysis, which was both time
consuming and resulted in formation of a precipitate of yeast proteins which had to be
removed by filtration. Pooled fractions from the sucrose gradient (13-16, volume 8ml) were
applied to the column, and the flow through material collected in 2ml aliquots and analysed for
sucrose content by refractometry, and for protein content by a dye-binding assay (Biorad).
Figure 3.11a plots the concentration of sucrose and protein in each fraction. The distribution
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3.11: Sephadex Chromatography
Fractions obtained from first round density centrifugation with peak p1:Rev
concentrations were pooled and sucrose removed by column chromatography through
Sephadex G-25. Run through fractions were collected in 2ml aliqouts and analysed for
sucrose and protein content.
A Total sucrose and protein content of G-25 fractions. Sucrose content is plotted as a
percentage for each sample: values obtained by refractometry. Pre-column material had a
22% sucrose content. Total protein content was calculated by Biorad protein concentration
assay and is plotted in mg/ml.
B Western blot analysis of the distribution of p1:Rev between Sephadex column
fractions. Samples from each fraction (10pl) were resolved by electrophoresis through a 10%
polyacrylamide gel and western blotted. Blots were probed with anti-pi antiserum (1/1000
dilution). A sample of purified p1 was included as an internal marker. pre-M: Pre-column
material.
C Coomassie stained PAGE profile of pre- and post-column fractions. pre-M: pre-
column material. F7: fraction 7 from column run-through. A sample of p1 :p259a9 was included
as an internal marker.
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of p1 :Rev within the column fractions is illustrated by western blotting (Figure 3.11b). It was
found that this procedure resulted in both a degree of concentration of the VLPs, and of
purification. The peak fractions for VLP content (6-8, volume 6ml) are essentially free of
sucrose (pooled sucrose content 1.5%). Furthermore, approximately 50% of total protein has
been eliminated from these fractions, implying an increase in VLP purity. Examination of these
fractions by Coomassie staining (figure 3.11c) however, demonstrates that this effect is not as
marked as these figures would suggest. Fractions 6-8 were pooled and used for further study.
Partial proteolysis of the fusion protein to release the carrier p1 molecule may have
occurred during chromatography, as evidenced by the appearance of blot-positive bands in
the p1 :Rev fractions migrating with the characteristics of p1. Possible contamination of the
Sephadex with proteases may have caused this, and highlights the importance of maintaining
conditions appropriate to protein stability during the purification process.
3.9.3.2 Immunoaffinity Chromatography
The methods of purification of p1 :Rev outlined above are all based on the physical
properties of the VLP. As has been demonstrated, the success of these methods is
dependent on the yield of protein at the commencement of purification. To achieve high
purity from a low yield preparation, a more specific selection process is required. The rabbit
antiserum generated against p1 (section 3.8) was considered a suitable probe for the isolation
of Ty:Rev VLPs. Coupling of antibody to an agarose based matrix allows for the isolation of
antigen by antibody-affinity chromatography. This method has been shown to result in
purification of protein essentially to homogeneity (Maze and Gray, 1980).
The y-globulin fraction of R194 anti-p1 (a-p1) antiserum was purified by caprylic acid
precipitation (2.24.2). After dialysis into a suitable buffer, the serum was coupled to Affi-gel 10
(Biorad). This form of crosslinked agarose contains an ester group which reacts specifically
with ligands containing primary amino groups to form a covalent bond. Immunoglobulin G (IgG)
molecules are thus immobilised by attachment to the affigel matrix. By monitoring the protein
concentration of the serum before and after binding, the coupling efficiency was found to be
61%. This figure is relatively low compared to values quoted by the manufacturer (for
example: 90% efficiency for human globulin). The affigel 10-apl was poured into a support
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Figure 3.12: Purification of p1:Rev by Immunoaffinity Chromatography
An anti-p1 Affi-gel column was prepared as described (2.12.7.2.1). Fraction 14 (2ml)
from the first sucrose gradient centrifugation step was applied and purification carried out as
described (2.12.7.2.2). Eluted fractions (1ml) were collected and analysed by SDS-PAGE
through 10% polyacrylamide gels and western blotting.
A Coomassie stained profile of SDS-PAGE analysis of chromatography fractions.
Numbers refer to eluted fractions. Pre-M: pre-column material. A sample of p1 :p259a9 was
included as an internal marker. Arrows indicate protein bands discussed in the main text.
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column, and p1:Rev containing material (primary sucrose gradient F14) adsorbed. Eluted
tractions were tested for p1 :Rev content by SDS-PAGE analysis. Fractions 5-11 contain
protein as visualised by staining with Coomassie blue (Figure 3.12a). Three protein species
are apparent, with molecular weights in the range 75-78, 50-55 and 25-30kDa. The largest of
these migrates close to p1 :p259a9, and is a candidate for p1 :Rev. This band is detected by
immunoblotting with anti-p1 antiserum (Figure 3.12b) in fractions 7-9 only. This suggests that
the band at 75-78kDa contains multiple species, although the one present in F7-9 may be
predominant. Assuming this to be the case, the purity of p1:Rev as estimated from the
Coomassie stained profile is -40%. Although an obvious improvement on previous
preparations, this result was disappointing. The nature of the contaminants is unknown. The
lack of reactivity with anti-p1 antiserum rules out the possibility that degradation of the full
length fusion protein is the source of these impurities: furthermore, as the probing antiserum
is the same as that used in purification the contaminants cannot have been specifically
recognised by the affigel I0-ocp1. Non-specific antibody binding activity might account for the
presence of contaminants, alternatively incomplete blocking of the affigel 10-pl column might
have led to binding of yeast extract proteins, although these would not be expected to then
undergo elution. Alternatively, protein which is bound to p1:Rev may be retained on the
column, and co-elute with p1 :Rev. The presence of 140mM NaCI within wash solution might
not be sufficient to dislodge specifically bound ligands. The efficiency of immunopurification
of p1 :Rev is impossible to gauge, given the lack of a reliable figure for the purity of p1 :Rev in
the pre-column material. The estimated total yield of p1 :Rev eluted from the column was 20-
25pg, leading to a final yield of ~5-6pg/L yeast culture. Although improvement in purity and
yield of product might have been achieved by altering the conditions used, this figure was
considered too low to justify further experimentation with this system. Use of the second
gradient fraction 14 material as antigen might have increased purity of product, although the
lower concentration of p1:Rev within this material might have reduced the yield of column
product even further.
3.10 Expression of p1 :Rev in an Alternative Host Strain
MC5 is a homozygous diploid strain (genotype: prbl, prcl, pep4, trpl, Ieu2, ura3) of
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S. cerevisiae. (M. Cunningham, BBL, personal communication). Cells of this strain have a
larger volume than haploid cells. It was hoped that this fact would allow these cells to withstand
the toxic effect of expression of p1 :Rev to a greater extent than the haploid BJ2168 cells, in
turn leading to improved yield of protein.
MC5 cells were co-transformed by lithium acetate treatment with 5pg pRev.O and 5pg
pUG41 S. Double transformants (MRev.U) were visible after 4 days, although only 2-3 colonies
per plate were obtained. Growth of MC5 transformants thus compared favourably to that of
BJ2168 transformants (section 3.3). Selected transformants were used to seed small scale
(100ml) cultures. Galactose induced cultures were monitored by light microscopy. There was
some indication that MC5 transformants maintained higher viability during p1 :Rev expression:
however the proportion of dead cells was still high. Cell lysates were prepared and protein
production analysed by SDS-PAGE. Immunoblotting with anti-p 1 antiserum revealed the
successful production of p1:Rev by the MC5 transformants. A similar level of protein is
detected in each extract. No band due to pl:Rev is detectable when resolved extracts are
stained with Coomassie blue (Figure 3.13a), however. By contrast, p1 :p259a9 is clearly visible
in a crude lysate. A time course study of the growth characteristics of MRev.U transformants,
compared to TRev.U cells, was carried out as described in 3.6. The result is illustrated in figure
3.13b. It is clear that there is no significant difference between these yeast strains with
respect to viability during p1 :Rev expression.
Thus, although there may be a limited increase in p1 :Rev tolerance associated with
the diploid MC5 strain, this did not lead to an appreciable increase in protein yield. No further
investigation into the effect of p1 :Rev expression on MC5 growth was carried out.
3.11 Protease Cleavage of pl:Rev Fusion Protein
Although little data is available concerning the possible requirement for cleavage of
fusion protein to generate biologically active recombinant proteins, cleavage of hybrid VLPs
has been shown to be crucial for the activity of recombinant ovine interleukin-a and p (C.
Fiskerstrand, PhD thesis, 1994). Sucrose-gradient purified p1:Rev protein was tested for
reactivity with Factor Xa in the hope of generating a Rev polypeptide which might then be
purified away from contaminating yeast material. The results of cleavage were analysed by
probing western blots with anti-p1 antiserum, and with the anti-p1 :Rev antiserum R194 (3.8)
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Figure 3.13: Expression of p1:Rev in an Alternative Yeast Host Strain
The vectors pRev.O and pUG4lS were transformed into Saccharomyces cerevisiae
strain MC5. Transformants (MRev.U) were used to seed small scale (100ml) cultures. Cultures
of BJ2168 cells co-transformed with pUG41S and pRev.O and pGag.O (expressing
p1 :p259a9) (TRev.U and TGag.U respectively) were also grown. Cultures were split, and half
used to induce fusion protein expression by incubation in Sc-glc/gal/trp. Cells were harvested
after 24 hours, and extracts prepared by lysis.
A Cell extracts (5pl) were analysed for protein content by SDS-PAGE through a 10%
polyacrylamide gel. Proteins were visualised by staining in Coomassie blue. U: uninduced
cultures, I: induced cultures. The band corresponding to p1 :p259a9 is arrowed.
B Time course study of culture growth. The optical density at 600nm (OD600nm) of the















in an attempt to identify cleaved product. The extent of cleavage was monitored by the loss of
the p1 :Rev band at 75kDa, and its replacement with a p1 band at 55kDa (Figure 3.14a). It can
be seen that the reaction proceeds efficiently, with cleavage to completion after two hours
incubation at an enzyme concentration of 1% of that of the substrate. The reactivity of the
anti-p1:Rev antiserum R206 with contaminating yeast proteins makes interpretation of this
blot (3.14b) difficult. The pattern of smaller, blot-positive proteins alters between the cleaved
and uncleaved samples, perhaps reflecting protease activity on the contaminants. No Rev-
specific band can be allocated. Silver staining a replica of this gel gave a similarly confusing
result, with no evidence of a potential Rev polypeptide. The failure to detect a blot-positive
Rev band may not be surprising, given the incomplete characterisation of R190 antiserum
with respect to anti-Rev activity (3.8), however the lack of a silver stained product suggests
that the cleaved polypeptide may be unstable, leading to complete proteolysis.
3.12 Discussion
This chapter has reported the generation of plasmids to direct the expression of
recombinant MVV EV1 Rev protein as a fusion to the p1 component of yeast Ty-VLPs.
Although expression was achieved, the yield and purity of product were found to be low in
comparison both to native p1 and to several other hybrid VLPs. The purification process is
dependent on the particulate nature of the hybrid VLPs, and thus involves non-specific
enrichment of VLP containing material, rather than protein-specific procedures. This has the
advantages of rapidity and versatility, but is relatively inefficient and is dependent on a high
initial yield of product. The low yield of p1 :Rev achieved meant that low purity was inevitable,
such that even two rounds of sucrose gradient enrichment resulted in only 10% purity at best.
3.12.1 Toxicity of p1:Rev
The growth of cell cultures was quickly curtailed on induction of p1 :Rev expression.
Microscopic examination of cells showed that this was due to cell death rather than cytostasis.
No such effect was observed in cells expressing native p1 protein, implicating the Rev-
specific region of the fusion protein in p1 :Rev toxicity. There are several indications that the
toxic mechanism is specific, resulting in cytocidal effect at low concentrations. These include
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3.14: Factor Xa Digestion of the pl:Rev Fusion Protein
Aliquots (25ml) of p1 :Rev containing samples from second sucrose gradient fraction
14 were incubated with the protease Factor Xa for two or eight hours as indicated, at a range
of concentration ratios (approximately 1-5% w/w enzyme to substrate). Reaction conditions
as described in 2.14. After incubation, samples were boiled in SDS-PAGE loading buffer to
stop reactions, and resolved by electrophoresis through 10-20% gradient polyacrylamide
gels. The gels were western blotted and probed with rabbit anti-pi Rev antiserum.
The relative positions of p1 and p1 :Rev are marked by arrows.
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the rapid reduction in growth on induction of p1:Rev expression and the low yield of protein
obtained. Cells doubly transformed with a pOGS40-based vector and the helper plasmid
PUG41S have been shown to yield six-fold more fusion protein than single transformants
(Reyburn et at., 1992). The lack of a significant difference in terms of growth and yield
between such transformants observed here suggests that toxic effect is manifest at an early
stage of expression and at low fusion protein concentrations.
The actual mechanism of Rev toxicity is open to speculation. Although toxicity at the
mRNA level cannot be dismissed, it seems probable that toxic effect is mediated by the
protein. Direct effects of Rev itself are the probable cause of toxicity, although the role of Rev-
induced modifications to the structure of p1 within the context of VLPs cannot be ruled out.
The failure of attempts to express the HIV-1 Rev protein in the Ty-VLP system due to toxic
effect (S. Adams, BBL, personal communication) suggests that regions of homology
between HIV-1 and EV1 Rev proteins may be responsible for toxicity. Such regions are the
two conserved functional domains, containing putative RNA and protein binding motifs (3.2).
Thus, toxicity may be the result of non-specific, large scale binding of Rev to yeast RNA,
resulting in reduced expression of cellular genes and/or disruption of ribosomal structure.
Alternatively, or in concert, binding of the leucine-rich motif to cellular proteins may be
important. Specific binding of HIV-1 Rev leucine-rich domain to the human protein eukaryotic
translation initiation factor 5A (elF-5A) has recently been demonstrated (Ruhl et at., 1993).
This factor is highly conserved amongst eukaryotes, such that human elF-5A can functionally
substitute for the homologous yeast gene HYP2(Koettnitz etal., 1995). Cellular depletion of
this factor has been shown to result in immediate inhibition of the growth of cultures of S.
cerevisiae (Kang and Hershey, 1994), although these authors did not record whether this was
a consequence of cell death. It is therefore possible the Rev-mediated sequestration of
pHYP2/elF-5A is at least partially responsible for cytotoxicity. Other cellular factors could also
be sequestered in this manner.
The conformation of Rev may be significant. One possibility is that toxicity is apparent
before assembly of p1 :Rev monomers into VLPs; this would explain the low density of VLPs
evident in expressing cells by electron microscopy. However, western blot data demonstrates
that most of the fusion protein extracted from cells behaves as particles during density
centrifugation. It is also possible that the reverse is true, ie that particle formation is a
prerequisite for toxicity. Expression of native HIV-1 Rev protein in S. cerevisiae cells has not
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been associated with toxicity (Stutz and Rosbash, 1994), whereas Ty:HIV-1 Rev
demonstrates toxicity (S. Adams, BBL, personal communication). Regardless of their nature,
the formation of VLPs consisting of -300 pi :Rev monomers would result in extensive cross-
linking of possible Rev ligands within the cell. If the ligands were components of cellular
structures such as the ribosomes or nuclear membrane, then cross-linking might cause the
observed disruption in yeast morphology. Vacuolation of host cells could occur as a
consequence of disruption. Recently, a putative component of the yeast nuclear pore
complex, Rip-1 p, has been shown to specifically interact with the HIV-1 Rev activation domain
(Stutz etal., 1995). Although these authors demonstrate that depletion of this factor does not
significantly reduce cell viability, Rev cross-linking of this molecule might cause damage to the
cell ultrastructure. Evidence for the interaction of p1:Rev with cellular macromolecules is
available in the behaviour of pl:Rev during density centrifugation, and possibly, in the co-
purification of contaminating molecules during affinity chromatography. Addition of the
detergent Triton X-100 altered the pattern of p1 :Rev distribution, reducing the concentration
in the lower half of the gradient. As one effect of detergents is to reduce binding between
proteins, this would argue that hybrid VLPs were found in the form of complexes under
normal conditions. Furthermore, the gradient fractions containing the highest purity of p1 :Rev
after two rounds of centrifugation include more contaminants than are present in a similarly
obtained preparation of native p1. p1:Rev induced aggregates are the likely source of these
co-sedimenting proteins.
HIV-1 Rev is functional in yeast cells (Stutz and Rosbash, 1994). This implies that the
known characteristics of HIV-1 Rev, such as nuclear import and multimerisation, can occur in
yeast cells. Although there was no evidence by electron microscopy for Ty:Rev VLP entry into
yeast nuclei, disruption of cellular morphology meant that definite conclusions as to
subcellular particle distribution could not be drawn. Specific entry of the large, polymeric VLP
into the nuclear pore may not occur; however, entry of p1 :Rev monomers might occur. This
would allow the expression of possible nuclear toxicity. Blocking of nuclear pores by
recombinant VLPs may also be a significant factor in the toxic effect.
Further study would be required to confirm the role of Rev in toxicity. Indeed, the
tractability of the yeast system could allow more detailed investigation into the nature of Rev
binding. Determination of the involvement of conserved domains of Rev in toxicity by
engineering mutations into the expression plasmid could lead onto identification of cellular
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proteins bound by Rev. Subcellular localisation of Ty:Rev VLPs within yeast cells by
immunofluorescence would determine whether cellular aggregates are associated with these
particles.
Diploid MC5 cells were used in an attempt to circumvent problems of toxicity. That
these larger cells appeared to survive slightly better than the haploid hosts lends credence to
the toxic hypothesis outlined above. However, toxicity was sufficiently high to ensure that
protein yield was not significantly increased by expression in this strain.
One problem associated with the regulatable pOGS-based vector was the level of
pre-induction expression directed by the PAL promoter. This caused reduced growth of pre-
induced cells, leading to problems in increasing culture biomass before fusion protein
expression. Neither the background level nor the galactose induced percentage increase in
PAL transcription have been documented. However, transcription from the PGK promoter is
reduced, but not abolished, by removal of the UAS-PGK (Ogden eta!., 1986). A recently
developed promoter, pJC78, contains the upstream repression sequence from the GAL 1/10
promoter, and should therefore be tightly repressed in the presence of glucose (M.
Cunningham, BBL, personal communication). Use of this promoter might allow improved Rev
expression by increasing the number of healthy cells prior to induction; however, any such
improvement is likely to be slight given the extremely toxic nature of p1 :Rev expression.
It was noted that, even after 24 hours incubation in galactose, a small proportion of
yeast cells retained normal morphology. It is possible that these cells were incompletely
induced and had not expressed sufficient fusion protein to experience toxic effect. An
alternative explanation is that the severe nature of toxicity created a strong selective pressure
for reduction in copy number, total loss or mutation of the expression plasmid, such that
growth in the absence or reduced concentration of the selected nutrients was favoured over
growth in the presence of p1 :Rev. The consequences in terms of yield of fusion protein of
reduced copy number are likely to be masked by the toxicity of expression.
3.12.2 Particle Formation
Early investigation into the nature of hybrid Ty-VLPs supported the hypothesis that
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the foreign polypeptide was expressed at the surface of the particle (Adams eta!., 1988).
This, in turn, led to the assumption that hybrid Ty-VLPs were ideal immunogens, presenting
multiple copies of the foreign protein in an accessible, particulate form. The Ty:HIV-1 p249a9
VLP was shown to elicit a strong anti-p24 immune response (Gilmour etal., 1989) and, by
immunogold analysis, to present p24 on the surface of particles (Adams etal., 1994). Particles
composed solely of p1 demonstrate diversity in size but retain symmetry, suggesting that
assembly occurs by an ordered, but flexible, procedure (Burns etal., 1992). However, many
hybrid particles possess the irregular morphology demonstrated by Ty-Rev VLPs, for example
Ty:MVVgp46 (C. Cousens, PhD thesis, 1994) and Ty:MVV gp135 (residues 1-311)(Carey et
a!., 1993). In addition, immunisation with these and other hybrid particles has been found to
mimic the response to Ty:Rev, by the development of strong anti-pi responses, but little or
no response to the foreign antigen (Reyburn etal., 1992; Fiskerstrand etal., 1993). A
possible explanation for these findings is forthcoming from the recent study of the detailed
structure of native VLPs by Brookman and co-workers (1995). Using monoclonal antibodies
directed against known p1 epitopes, these authors determined that the carboxy-terminal
region of p1 is buried within the VLP, and that the amino-terminal region projects from the
surface. As the Ty-VLP expression system is based on carboxy-terminal fusions, then the
proposed model of hybrid particles is unlikely to be accurate. Although the mechanism of
particle formation is unknown, the presence of significant additions to the carboxy-terminus is
likely to cause extensive disruption, explaining the heterogeneity of hybrid VLPs. The
location of the foreign protein within hybrid VLPs may be an important factor in determining
both immunogenicity and biological activity. An internal location for the foreign polypeptide is
the likely reason for poor immunogenicity. It should be noted that amongst those hybrid
particles which do function well as immunogens, several, including Ty:HIV-1p249a9 (Gilmour
etal., 1989) and Ty:SIVp279a9 (Lehner et at., 1994) contain added proteins with intrinsic
assembly determinants, which might compete with those of p1 to alter the structure of the
particle. Thus, the arrangement of proteins within the particle may be the result of higher order
structural interactions between the carrier and added protein, and may be different for each
hybrid. If multimerisation is a property shared by MVV and HIV-1 Rev proteins, then
intramolecular interactions between the Rev moieties might interfere with particle assembly.
The heterogeneity in particle size observed suggests that there may be variation in particle
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structure between hybrid Ty-Rev VLPs, which might support this hypothesis.
There is conflicting evidence concerning the location of Rev within the Ty:Rev
particles. Efficient cleavage and the specific toxic effect of expression suggest that Rev is
largely or completely superficial in character (although the detergent utilised in proteolysis
might disrupt native structure). However, the lack of an apparent anti-Rev immune response
argues for masking of Rev by p1. It may be that the structure is complex, with certain residues
of Rev exposed and others hidden within the particle. A similar analysis to that of Brookman
etal( 1995) would be required to determine the actual structure of Ty:Rev VLPs.
3.12.3 Improved Expression of Rev in Yeast
The precise structure of the Ty:Rev VLP is of importance to the success of affinity-gel
purification. The antiserum used for purification must recognise the hybrid particles in their
native form. Use of the anti-p1:Rev antiserum (R190) for purification was counter-intuitive,
since this serum was developed against the same sucrose gradient material to be purified.
The anti-p1 antiserum (R194) was therefore used. Immunisation with the p1:Rev material
induced a strong anti-pi response, implying that p1 has at least a degree of surface
localisation. Thus, purification of Ty:Rev VLPs with anti-pi antiserum should be feasible.
However, a relatively poor result was achieved using this approach. It is possible that the p1
epitopes recognised by R194 are mostly hidden within the Ty:Rev particle, reducing the
effectiveness of purification. Purification would be improved by use of an antiserum directed
specifically against Ty-Rev VLP surface epitopes.
Other aspects of affinity gel purification were subject to improvement. The coupling
efficiency of antibody was relatively low. The binding of affigel is dependent on the buffering
of the ligand. Affigel 10 has a slight negative charge, and binds to neutral and basic proteins. If
components of the polyclonal antiserum possessed isoelectric points below the pH of the
buffer used (7.2), then they would assume a negative charge and bind poorly to the affigel,
thus resulting in a low overall efficiency of coupling. Changing the buffer system might boost
coupling. Altering the elution conditions might also be beneficial; Ikeda and Steiner (1976)
achieved purification of platelet-derived tubulin from antibody linked to affigel 10, to 96% by
eluting in 0.05% Triton X-100/0.1 M phosphate buffer, pH 7.0. Use of a monoclonal antibody
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would allow more precise optimisation of conditions.
Other strategies to improve expression would involve combating the problem of
fusion protein toxicity. Replacing the PAL promoter with one more tightly repressed in the
absence of galactose has already been discussed. Use of an alternative yeast strain has been
attempted here with little success. Other, more genetically diverse, strains might prove useful.
Another approach would be to substitute the Ty-VLP system for one based on the secretion
of heterologous proteins from host cells, in the hope that toxicity could thus be by-passed.
Many of these systems are based on fusion to the leader sequence of the yeast mating
hormone a-factor (reviewed by Brake, 1990).
3.13 Summary
A rev gene derived from EV1, a British isolate of the ovine Maedi Visna Virus, was
cloned and sequenced. Regions of homology to the partially characterised HIV-1 Rev protein
were identified. Vectors to direct the expression of the Rev protein as a carboxy-terminal
fusion to a modified form of the p1 protein of the S. cerevisiae retrotransposon Ty, were
constructed. Transformed cells produced p1 :Rev in the form of hybrid particles, detected by
western blotting and electron microscopy. Both the yield and purity of p1 :Rev were found to
be lower than expected. Examination of the growth profiles of expressing yeast
demonstrated that p1:Rev production was associated with inhibition of culture growth.
Dramatic deleterious effects of p1 :Rev on yeast morphology were observed. Conventional
purification of hybrid VLPs was largely unsuccessful, due to the requirement for high yield for
high purity. Some improvement in culture condition was obtained by altering growth
conditions. Product purity was enhanced by immunopurification with an anti-p1 antiserum;
however overall yield was further reduced. Immunisation of a rabbit with p1 :Rev preparation
elicited a strong anti-p1 response, but no detectable response against Rev. It was decided
that this system was not appropriate for the production of Rev protein for functional studies.
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CHAPTER FOUR
EXPRESSION OF EV1 REV IN THE
BACTERIAL pGEX SYSTEM
4.1 Introduction
Chapter 3 outlined the production of recombinant Rev protein in the yeast Ty-VLP
V
system. It was shown that Re-induced cytotoxicity resulted in low yields of Ty:Rev fusion
A
protein. Fusion protein purity was also found to be low, due to the nature of the purification
process. An alternative expression strategy was therefore sought. It was hoped that the use
of a prokaryotic expression system would circumvent problems of toxicity present in yeast.
The pGEX system was chosen as several requirements for the production of biologically
active proteins are reported features of this system. These typically include high yield, good
solubility and a rapid and efficient purification protocol based on affinity binding without the
need for denaturing conditions, thus preserving the antigenicity and functionality of the
recombinant protein.
Foreign polypeptides are expressed in the pGEX system as carboxy-terminal fusions
to a modified form of Sj26, the glutathione-S-transferase (GST) enzyme of the parasitic
helminth Schistosoma japonicum (Smith et al., 1986). The original expression vector pGEX1
has been modified to incorporate additional features to aid cloning and expression: the
derivative vector pGEX2T is illustrated by figure 4.1. The foreign gene is inserted at the 3' end
of gst. Expression is under the control of the facpromoter (Ptac), a hybrid derived from the
trp and lac promoters (Amann et al., 1983; De Boer, et al., 1983). Ptac is constitutively
repressed by the product of the laclh gene, but directs high level transcription on induction
with the de-repressor, IPTG. Constitutive repression and inducible expression is an important
feature when dealing with a potentially toxic protein (Brosius, 1984). The presence of the
lacfi gene within the vector means that expression is independent of host genotype.
The polylinker region at the cloning site varies in reading frame between the plasmids.
In the derivative vectors pGEX2T and pGEX3X the polylinker region also encodes several
extra amino acids which form protease cleavage sites. These allow removal of the protein of
interest from the carrier. The polylinker is followed by translational termination codons in all
three reading frames.
After induction of expression for a suitable period, transformed cells are harvested
and a cell lysate prepared by sonication. The fusion protein is isolated by specific binding of
the GST carrier to glutathione immobilised by covalent attachment to agarose beads. After
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Figure 4.1: The Expression Vector pGEX2T
The diagram shows the map of the vector pGEX2T. The cloning site of the vector is depicted
below. The restriction enzyme recognition sequences, encoded amino acid sequence and
the position of thrombin cleavage site are marked.
Ptac- the hybrid facpromoter. Directs inducible, high level transcription
GST: modified form of the glutathione-S-transferase gene (Sj26) of Schistosoma japonicum
PL: polylinker region
AmpR: ampicillin resistance gene
ori: origin of replication
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washing, the fusion protein is collected by elution from the beads through competition with
free, reduced glutathione.
Successful protein expression in the pGEX system has been widely reported. Fusion
proteins have been used for immunological (Frosch eta!., 1991), vaccine (Fikrig etal., 1990)
and functional studies (Kaelin et al., 1991). Indeed, in many cases the full fusion protein
demonstrates correct activity, obviating the need for proteolysis to remove the carrier (Plutzky
etal., 1992). However, in some cases cleavage of the recombinant protein is required to
release activity (Gearing et al., 1989). Fusion proteins with total molecular weights from 32kDa
to 84kDa have been expressed (Smith and Johnson, 1988). Typical yields of recombinant
protein are within the range 1-5mg/L bacterial culture (Smith and Corcoran, 1990), though
exceptionally yields as high as 20-80mg/L have been obtained (Frorath etal., 1991).
The main problems encountered using this system, as with other bacterial expression
systems, have involved fusion protein solubility and stability. High level expression of
proteins in E. colioften leads to sequestration in insoluble inclusion bodies. This is not the
case with native GST, which remains in a soluble state even when expressed at levels up to
15pg/ml bacterial culture. It was initially suggested that the majority of proteins expressed in
pGEX would be soluble (35/47 expressed proteins, Smith and Johnson, 1988). More
widespread recent use of this system has demonstrated that insolubility is actually
commonplace (Frangioni and Neel, 1993). However, it has also been shown that detergent-
mediated solubilisation of fusion protein inclusion bodies can work efficiently to produce
pure, functional protein. Fusion protein instability can also be problematic. Factors governing
stability are poorly understood, though it has been suggested that host bacterial genotype
can play a role in determining stability (Smith and Corcoran, 1990).
4.2 Generation of a Polyclonal Anti-Rev Antiserum
In order to aid purification of the recombinant Rev protein, it was decided to raise an
anti-Rev antiserum by utilising a synthetic peptide corresponding to a sequence motif within
the EV1 revgene. It was hoped that this would generate a more reliable reagent than the anti-
pi :Rev serum, R190.
The central, highly basic region of the EV1 Rev molecule is the most antigenic,
according to computer prediction. However, technical difficulties were encountered in the
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4.2: Characterisation of an Anti-Rev Peptide Antiserum
A Extracts of ovine macrophages prepared at several time points post-infection with
MVV strain EV1, were obtained from Dr. D. Roy, Department of Veterinary Pathology,
University of Edinburgh. These were resolved by SDS-PAGE and Western blotted. Blots
were probed with rabbit (R206) serum obtained prior to or 24 days after immunisation with a
peptide derived from the EV1 Rev sequence (1/100 dilution). Un: uninfected cell extract,
numbers refer to hours post-infection.
B Western blot analysis of yeast samples containing p1 :Rev and p1 :p259a9 (chapter 3).
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synthesis of this arginine-rich peptide. A sequence overlapping the carboxy-terminal region
of EV1 revwith homology to the activation domain of the HIV/SIV Rev proteins was chosen as
an alternative antigen. The sequence, amino acid residues 101-119, is as follows:
101 ESNVAGLEKLTLEEKLEEKC 119
The carboxy-terminal cysteine residue does not appear within the protein sequence,
and was added to allow peptide conjugation to ovalbumin, to generate a more immunogenic
reagent. Conjugation was mediated by the bifunctional cross-linking reagent, 3-(2-
pyridyldithiojpropionic acid N-hydroxysuccinimide (SPDP) which forms disulphide bonds with
cysteine residues. The peptide was synthesised by Mr. D Thomson, Department of Veterinary
Pathology, University of Edinburgh. A polyclonal antiserum was raised as described in section
2.24.1. To test for anti-Rev reactivity, both pre-immune and immune sera were used to probe
Western blots (figure 4.2). The immune serum is reactive with a protein of apparent molecular
weight 22-23kDa present in EV1-infected ovine macrophages (4.2a): this reactivity does not
extend to uninfected cells. This band is assumed to represent Rev, which may migrate more
slowly than its calculated molecular weight of 19.5kDa suggests (see section 3.3). Moreover,
the immune serum specifically recognises a band corresponding to p1 :Rev in a TRev.U yeast
cell extract (figure 4.2b). Thus the anti-Rev activity of this serum was confirmed.
4.3 Construction of Recombinant pGEX:Rev Expression Plasmids
The recombinant pOGS-derived plasmids used for expression in the yeast Ty system
were a convenient source of rev gene insert. Both pOGS and pGEX contain a BamHI site
within the polylinker region, enabling the rei/insert to be transferred directly. Vector pGEX2T
was chosen to maintain the correct reading frame. An additional benefit of using the pOGS-
based insert was the presence of a protease Factor Xa site within the gene fragment. This led
to the presence of two different enzyme sites within the GST/Rev adapter region.
The revgene fragment (520bp) was excised from plasmid pRev.O (3.3) by digestion
with BamHI, isolated by agarose gel electrophoresis and purified by hot phenol extraction.
Ligation into the BamHI, CIP treated vector pGEX2T (a kind gift of Dr. Donald Smith) was
carried out at approximate molar ratios of 1:2, 1:1, 2:1. Ligation products were transformed
135
Figure 4.3: Restriction Digest Analysis of pGEX2TRev Transformants
Plasmid DNA was prepared from several pGEX2T/rev insert transformants. Restriction digest
analysis of one of these (811) is shown. Analysis of the original pGEX2T vector is shown for
comparison.
Restriction enzymes used:
A: Aval B: BamHI X: Xhol
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into competent E. coli JM101 cells, and transformants selected on the basis of ampicillin
resistance.
A small number (10) of transformants was obtained. The colonies were screened for
the presence of an insert of the correct molecular size by BamHI restriction digest of plasmid
minipreparations. Analysis of one of the colonies, 811, is shown in Figure 4.3. Insert identity
was confirmed by the susceptibility of the plasmid to digestion with Xhol, a recognition site for
which is present in the rev gene but not in pGEX2T. Insert orientation was determined by the
presence of Aval sites within the insert (position 218) and immediately 3' to the BamHI
insertion site in the vector. Double digest with BamHI and Aval produced an additional smaller
fragment (218bp) compared to digest with Aval alone, when the insert was present in the
correct orientation.
4.4 Validation of Transformants for Expression of Fusion Protein
Four transformants were selected on the basis of restriction digest analysis and were
used to prepare small scale cultures (2ml). Bacteria transformed with pGEX2T alone were
used as controls. Cultures were induced with IPTG for three hours, the cells harvested and
fusion proteins purified by incubation of cellular lysates with glutathione-agarose beads.
Purified proteins were resolved by SDS-PAGE and visualised by silver staining (Figure 4.4a).
A band migrating with an apparent molecular weight of 45-48kDa was found to be present in
the purified extracts from all four potential pGEX2TRev transformants. This size is broadly
consistent with the predicted molecular weight of GSTFtev (47kDa: GST 27.5 + Rev 19.5).
Although evidence from figure 4.2 suggests that free Rev migrates with an apparent
molecular weight of 22-23kDa, the presence of the GST carrier may alter mobility. A group of
proteins with molecular weights in the range 28-34kDa are also present in the purified
material. Cells transformed with pGEX2T produce native GST which was found to migrate with
a molecular weight similar to its predicted value of 27.5kDa. It should be noted that there is a
considerable reduction in yield of GSTRev compared to GST.
To confirm the identity of the 45-48kDa protein as GSTRev, a Western blot of the
above gel was probed with the anti-Rev peptide antiserum. The result of this blot is illustrated
by figure 4.4b. Only the 45-48kDa protein is recognised by the antiserum. Neither native GST
nor the cluster of contaminating proteins are blot positive.The 45-48kDa protein is thus a
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Figure 4.4: Analysis of Protein Expressed by pGEX Transformants
A Protein was purified on glutathione-agarose beads from lysates of cultures of each of
the bacterial clones shown. Proteins bound to the beads were resolved on a 10% SDS-PAGE
gel, and visualised by silver staining. The putative GSTRev protein is indicated by an arrow.
Clones: pGEX2TRev transformants: (32 (34 811 522
pGEX2T transformants: a6 a9
B A replica of the above gel was Western blotted and probed with anti-Rev antiserum
(1/200 dilution).
C Crude lysates of induced or uninduced (+ or - IPTG) cultures of the clones shown
below were prepared by sonication. Proteins were resolved by SDS-PAGE on a 10%
polyacrylamide gel. The gel was Western blotted and the fusion proteins detected by probing
with anti-Rev antiserum (1/200 dilution).
D As above, except only one pGEX2TRev transformant (511) was analysed. Blot was
probed with pre-immune or immune serum (1/200 dilution) from rabbit immunised with
synthetic Rev peptide (figure 4.2).
E Induced cultures of the pGEX2TRev transformant 511, and of cells transformed with
the pGEM 11 plasmid, were harvested. Samples of crude extract (CE) and of glutathione-
agarose bead purified eluate (PE) were resolved on a 10% SDS-PAGE gel. Proteins were
visualised by staining with Coomassie blue.
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strong candidate for the fusion protein GSTRev.
To confirm that GSTRev is only produced by induced cells, duplicate cultures of two
of the transformed clones, and one of the pGEX2T transformed clones, were generated.
IPTG was added to one of each of the cultures, and the cells harvested after three hours. Anti-
Rev antiserum was used to probe crude extracts of these cells after SDS-PAGE and Western
blotting (Figure 4.4c and d). One positive band, with apparent molecular weight of 35-37kDa,
is present in all extracts tested, and is believed to be due to non-specific recognition of a
ubiquitous bacterial antigen. This is confirmed by figure 4.3d, which demonstrates that the
pre-immune serum is also reactive with this protein. This band disappears on purification.
However, it can be seen that a band with an approximate molecular weight of 46kDa appears
only on induction of pGEX2TRev cultures (4.4c). The complete absence of this band from
uninduced cultures suggests that the tac promoter is strongly repressed in the absence of
IPTG, with little or no 'leaky' expression.
Finally, it was necessary to demonstrate that the candidate fusion protein was not
expressed in bacterial cells as a general reaction to the presence of IPTG. Crude extracts and
glutathione-purified samples of cells transformed with pGEX2TRev or with the unrelated
plasmid pGEM11 and induced with IPTG for 4.5 hours were analysed by SDS-PAGE, and the
proteins visualised by staining with Coomassie blue. From figure 4.4e it can be seen that no
detectable protein is purified from the pGEM11 transformed bacteria by the addition of
glutathione-agarose beads. This suggests that the 45-48kDa protein is specific to cells
transformed with the plasmid pGEX2TRev. It is also apparent that native GST is not present in
bacterial cells. This is supported by other authors (Frangioni and Neel, 1993).
Scanning densitometric analysis of Coomassie stained gels of purified GSTRev
revealed that the 45-48kDa protein comprised between 10-18% of the total sample. The
contaminating bands seen in figure 4.4a represent the largest fraction of purified protein.
These impurities have been found consistently in purified samples, and are clearly positively
selected for by the purification process. Similar contaminants have been noted in other GST
fusion protein preparations (Tetzlaff etal., 1992). Although it is possible that the contaminants
are Rev binding proteins, co-purified with GSTRev, precedent suggests that instability of the
fusion protein, resulting in proteolytic degradation, is the source of these contaminants (an
alternative hypothesis is discussed in 4.8.3). The GST moiety is itself stable, hence
degradation products would be selected for by the purification protocol. Removal of the
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carboxyl terminal regions of the fusion protein containing the peptide antigen would render
the degradation product invisible to the anti-Rev antiserum. The fastest migrating
contaminating bands (27-28kDa) coincide with native GST and probably represent the
complete removal of the Rev moiety from the recombinant protein. To demonstrate that the
contaminating proteins were indeed GST-based, a replica of the gel shown in figure 4.4e was
Western blotted and probed with a polyclonal anti-GST antiserum (a kind gift from Miss P.
Carter, Department of Veterinary Pathology, University of Edinburgh). The resulting blot is
illustrated in figure 4.3f. This antiserum recognises an approximately 36-38kDa antigen in
whole cell extracts, in common with the anti-Rev antiserum. Pre-immune serum from this rabbit
was also reactive with this band (P. Carter, personal communication): this strengthens the
putative identification of this protein as a common bacterial antigen. In the lane corresponding
to purified GSTRev, it is evident that all the proteins visible by Coomassie staining are also
recognised by the anti-GST antiserum. No such blot positive material is detected in the
pGEM11 cell extract, indicating that the pGEX2TRev plasmid must be the ultimate source of
the contaminating proteins.
Fusion protein was therefore shown to be successfully produced by the transformed
clones. One clone (511) was chosen for further study. Large scale preparations of fusion
protein were produced by induction of 500ml cultures. Glutathione-agarose bound material
was eluted with excess free glutathione.The efficiency of purification was difficult to assess,
and it must be assumed that a proportion of the recombinant protein was lost during the
purification process. It was therefore impossible to arrive at a figure for overall protein yields.
However, typical yields of eluted protein were 12.5mg/L culture of native GST, and 3-4mg/L
culture of GSTRev. There is therefore a 75-80% loss in yield of GSTRev compared to GST.
Scanning densitometric analysis of Coomassie stained gels demonstrated that full-length
GSTRev comprised between 10-18% of the total sample (0.3-0.75mg/L). This is probably a
slight overestimate, due to the likely presence of contaminating proteins at levels below that
required for detection by Coomassie staining. It was hoped that variation of growth and
purification conditions might lead to both an explanation for, and an improvement in, the
observed lower yield and stability of GSTRev in comparison with native GST.
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4.5 Yield of GSTRev Fusion Protein
Although the yield of eluted fusion protein was relatively high, it was less than half that
obtained with native GST. Reduction in yield could be a product of expression and/or
purification. To attempt a distinction between these possibilities, crude extracts and purified
eluates of induced pGEX2T and pGEX2TRev cultures were analysed by SDS-PAGE and
Western blotting. Comparison of the Coomassie staining pattern of the crude extracts (Figure
4.5a) demonstrates that the band due to native GST is clearly visible as a higher proportion of
total cellular protein than that due to GSTRev. Indeed, the band allocated to GSTRev within
the crude extract may actually resolve into a doublet, with one of the bands representing a
common bacterial protein also present in the GST crude extract. To examine the relative
efficiencies of purification, a Western blot of this gel was probed with anti-GST antiserum
(figure 4.5b). The relative signals of both GST and GSTRev are enhanced to an approximately
similar extent within the purified eluate as compared to the crude extract. It seems unlikely,
therefore, that gross differences in purification efficiency are responsible for the loss of yield
of GSTRev.
Thus, although interpretation of the data was hazardous due to the difficulty in
correctly determining the identity of the band corresponding to full length GSTRev in crude
material, and by the fact that much of the purified GSTRev sample consists of degradation
products of the fusion profein, it does appear that reduced protein expression is, at least in
part, responsible for lower GSTRev yield. The growth characteristics of cultures expressing
the fusion protein were studied in order to determine whether toxicity was a factor in this
system.
4.5.1 Growth Characteristics of pGEX Transformants
A time course study of the growth of both native and recombinant pGEX2T
transformants was performed. Overnight cultures of both pGEX2T and pGEX2TRev were
diluted into 200ml media and induced after one hour. The growth of cultures was monitored
by ODgoonm readings for 5 hours. Uninduced cultures were also included in the time course
study. Protein expression was confirmed by SDS-PAGE analysis of representative culture
aliquots (data not shown). The results of a representative time course study are shown in
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Figure 4.5: Analysis of Crude Extracts of Cells Expressing GSTRev
Medium scale (200ml) cultures of the clones a6 (expressing GST) and 811 (expressing
GSTRev) were induced with IPTG and cells harvested after 3 hours. Both crude extract (CE)
and glutathione-agarose bead purified (PE) samples were analysed by resolution on a 10%
SDS-PAGE gel, with protein visualisation by staining with Coomassie blue (A). A replica of this






Figure 4.6a. Although it is clear that the dramatic toxic etfect of Rev expression observed in
transformed yeast cell cultures is absent in bacteria, there is a reduction in growth for both
cultures on induction. The growth of pGEX2TRev transformants is affected more severely
than that of the pGEX2T transformants. Although it is possible that this is a result of the
greater physiological cellular stress due to the production of the larger fusion protein, the
overall yield of GSTRev is less than that of native GST. It therefore seems possible that a
degree of toxicity is present in this system. The lower yield of fusion protein might therefore
be a result of the observed reduction in culture growth occasioned by GSTRev synthesis.
However, it should be noted that after three hours (typical induction period for large scale
preparations) there is an approximate 25% reduction in cell numbers between GSTRev and
GST expressing cultures. This, by itself, is insufficient to explain the approximate 80% fall in
yield of GSTRev compared to GST.
It would be expected that increasing the density of cell culture before induction would
increase the yield of recombinant proteins with consequent toxic effects on the expressing
cell. Conversely, if the toxic effect was minimal or absent, greatest yield would be promoted by
induction at a lower density, allowing the cells to grow and divide vigorously in early log phase,
while expressing protein. To investigate the effect of altering culture density before induction
of GSTRev expression, cultures were grown to an OD60onm of 0 3 or 0 55 before addition of
IPTG. Growth was continued for three hours. Cells were harvested and the purified protein
obtained from each culture analysed. From figure 4.6b, it can be seen that the yield of protein
falls slightly on induction at the higher density (total yield ~1.4mg for lower density induction,
~1.2mg for higher density). This suggests that any toxic effect of Rev on bacterial cells is
minimal in scope, and that the best yields of protein can be obtained by induction of
expression at a lower cell density.
4.5.2 Fusion Protein Purification
Although the observed reduction in growth in cultures expressing GSTRev protein
may account for reduced protein yield, it was possible that aspects of the purification
procedure may also be a factor. In particular, partial insolubility of the fusion protein would
reduce purification efficiency by sequestration of the insoluble fraction. To determine whether
a significant proportion of GSTRev was insoluble, samples of supernatant and pellet obtained
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Figure 4.6: Growth Characteristics of pGEX Transformants
A: Growth of Colonies Transformed with pGEX2T and pGEX2TRev
Cultures derived from the selected 511 pGEX2TRev clone were grown overnight and diluted
1/10 in fresh medium. After further growth to an ODg0Onmof ~0.2, protein expression in one
culture was induced with IPTG. Incubation was continued for 5 hours, with the culture
ODgoonm recorded at regular intervals. Cultures derived from pGEX2T transformed cells were
used as controls.
B: Effect of Cell Density on Expression of GSTRev
Medium scale cultures (200ml) of 511 cells were grown and induced at the ODgQ0nm va'ues
shown on the diagram. Induction was continued for three hours, and the cells harvested.
Recombinant proteins were purified and analysed on a 10% SDS-PAGE gel. Proteins were
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after the centrifugation stage of protein preparation, immediately prior to affinity purification,
were analysed for GSTRev content by SDS-PAGE and Western Blotting. On probing with anti-
Rev antiserum it can be seen that a significant amount of the fusion protein is trapped within
the pelleted debris after centrifugation (Figure 4.7:compare lanes 1 and 2). This may be due
to one, or more probably a combination of several factors: incomplete solubility, incomplete
cell lysis or interactions with cellular macromolecules. To determine whether the proportion of
fusion protein within the soluble fraction and thus available for purification could be increased,
the concentration of Triton X-100 was varied and the resulting supernatants compared (Figure
4.7 lanes 2-4). Triton X-100 is a non-ionic detergent included in the protocol to reduce
interactions between proteins. It would appear that increasing the concentration of detergent
from 1% to 1.5% (v/v) does increase the proportion of GSTRev within the supernatant. It
should also be noted that the level of the ~36kDa protein additionally recognised by the Rev
antiserum in crude extracts (section 4.4) increases concomitantly with GSTRev. As it had
previously been shown that the ~36kDa protein is excluded by affinity purification, it was
decided to use Triton X-100 at 1.5% in future preparations. This concentration of detergent
should not alter the binding of fusion protein to glutathione-agarose beads (Frangioni and
Neel, 1993).
4.6 Attempts to Increase the Purity of GSTRev Fusion Protein
It was previously shown that the contaminating proteins which comprise -80% of
GSTRev preparations were reactive with an anti-GST antiserum. It was concluded that product
impurity was the result of fusion protein instability rather than contamination with
heterogeneous bacterial proteins. Two approaches were taken in an attempt to increase
fusion protein purity. Firstly, increasing stability would be expected to lower the concentration
of contaminants. Secondly, varying purification conditions might allow separation of the full-
length fusion protein from the contaminants.
4.6.1.1 Fusion Protein Stability: Purification
Instability of the full-length fusion protein may result in cleavage by proteases. This
may occur within the bacterial cell during expression, and/or externally during purification.
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Figure 4.7: Analysis of the Distribution of GSTRev between Soluble and
Insoluble Fractions after Post-Lysis Centrifugation
Cells induced to express GSTRev were harvested and lysed by sonication. After
centrifugation at 10000g for five minutes, the supernatant and pellet were separated and a
sample (0.25% of total volume) of each analysed for GSTRev content by SDS-PAGE and
Western blotting. The blot was probed with anti-Rev peptide antiserum. Subsequently, the
concentration of Triton X-100 added to the lysed cells prior to centrifugation was increased,
and the GSTRev content of the resulting supernatants compared as above.
Lane 1: 1% Triton PELLET
Lane 2: 1% Triton SUPERNATANT
Lane 3: 1.25% Triton SUPERNATANT
Lane 4: 1.5% Triton SUPERNATANT
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Comparison of the profiles of GSTRev crude extract and purified eluate probed with anti-GST
antiserum (figure 4.4f) demonstrates that all the final contaminants are present prior to
purification. This suggests that degradation of the Rev polypeptide can occur within the cell,
or during cell lysis. However, there is some suggestion of an increase in fragments with
molecular weights between those of native GST and full length GSTRev in the purified eluate.
Limited degradation of the remaining full length protein may occur during the purification
process. The affect on stability of several alterations in the purification protocol was analysed.
Addition of 0.25mM PMSF, a serine protease inhibitor, to cell lysates was routine. However,
exclusion of PMSF did not alter the protein profile of GSTRev preparations. Similarly, inclusion
of 50mM EDTA, an inhibitor of divalent cation dependent metalloproteases, in the lysis buffer,
was without effect. Purification at 4°C had no visible effect, compared with routine preparation
at room temperature. Similarly, altering the period of sonication from a minimum of 20 seconds
to a maximum of 90 seconds, did not reduce the level of contaminants, suggesting that this
procedure did not induce protein degradation. Thus, it was concluded that degradation
occurs predominantly within the cell, or occurs rapidly on cell lysis, with the major enzymes
involved not sensitive to the inhibitors used here, or to the effect of reduced temperature.
4.6.1.2 Fusion Protein Stability: Expression
It has been demonstrated that the host cell genotype can have a marked, and
unpredictable effect on the expression of foreign genes in bacteria (Smith and Corcoran,
1990; Frorath etal., 1991). In particular, the use of protease deficient strains may be beneficial
(Buell etal., 1985). To investigate the effect of bacterial genotype on expression of GSTRev,
the plasmid pGEX2TRev was transformed into each of three different strains: DH5a, Y1090
{Ion protease deficient), and BL21 {Ion and omp Tprotease deficient). Protein expression
was induced from small scale cultures of each strain, and purified protein analysed by SDS-
PAGE (Figure 4.8a-d). Densitometric analysis was used to estimate the proportion of full-
length protein obtained. It can be seen from figure 4.8 that contaminants of the same size
range are present in all strains used. However, the proportion of full-length fusion protein
does vary to some extent. In particular, the double protease deficient strain BL21 would
appear to promote greatest protein stability. Approximately 20% of the protein eluate
obtained from this strain is composed of full-length molecules, compared to 16% (JM101),
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Figure 4.8: The Stability of GSTRev Fusion Protein
A-D: The Effect of Host Cell Genotype on Expression of GSTRev
The plasmid pGEX2TRev was transformed into cells of each of the strains of E. coli shown
below. Small scale cultures (10ml) of each strain were induced with IPTG and cells harvested
after 3 hours. Purified protein was analysed on 10% SDS-PAGE gels. Proteins were
visualised by staining with Coomassie blue.
Figure A: JM101 clone: 811 Figure B: DH5a clone: DH1
Figure C: Y1090 clone: Y7 Figure D: BL21 clone: B1
E: The Effect of Induction Period on the Expression of GSTRev
Medium scale cultures (200ml) of BL21 cells transformed with pGEX2TRev (clone B1) were
induced with IPTG for 0-4.5 hours. Cells were harvested and purified protein analysed on a
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11% (Y1090) and 9% (DH5oc). Although insufficient samples were analysed to provide
statistically relevant data, the BL21 strain was chosen as the host for all subsequent protein
production.
Reducing the induction period might be expected to lessen the effect of bacterial
proteases (Ghosh et al., 1995). Medium scale cultures (200ml) of BL21 transformants were
induced for 1.5, 3 or 4.5 hours, and normal purification procedures carried out. Eluted
proteins were resolved by SDS-PAGE and visualised with Coomassie blue (Figure 4.8e) and
the proportion of full-length protein estimated by densitometry. There is no observed
correlation between induction period and fusion protein stability. Indeed, reducing induction
time from 3 to 1.5 hours is accompanied by a fall in the proportion of full-length protein from
20% to 16%. Variation in expression conditions was therefore not effective in increasing
fusion protein stability.
4.6.2 Enhanced Fusion Protein Purity
During routine preparation of fusion protein, three sequential elution steps were
undertaken. It was noted that there often appeared to be a decrease in the relative
concentration of contaminating proteins with increasing elution number. SDS-PAGE analysis
of sequential eluates of GSTRev and native GST from a typical preparation are illustrated by
figure 4.9. The percentage of full-length fusion protein increases from 14% (first eluate) to
17% (second eluate) and 26% (final eluate). This phenomenon was observed in all studied
preparations (although variation in the proportions of full length protein was recorded) and has
been reported with other GST fusion proteins (N. Carey, PhD thesis, 1992). There is an
accompanying decrease in the concentration of protein with sequential elution step, such
that an average of -75% of total protein is present in the first eluate. This affect of elution
number on purity might be expected to be a function of the relative molecular weight of the
full-length and contaminating proteins. Reduced glutathione might compete more efficiently
with the smaller contaminants, therefore removing them from the agarose beads more rapidly
than the larger, intact protein. The typical increase in full length protein purity with increasing
elution number was not considered sufficient to outweigh the fall in concentration of product,
and thus the first eluate alone was collected.
149
Figure 4.9: Analysis of Sequential Eluates of Purified GSTRev
Large scale cultures (500ml) of JM101 cells transformed with pGEX2TRev (511) and
pGEX2T(a6) were induced with IPTG for three hours and the cells harvested. Expressed
proteins were purified by the binding of glutathione-agarose beads to cell lysates. Bound
material was recovered by elution from the beads in 50mM Tris.HCI pH8/ 10mM reduced
glutathione for 5 minutes. Three sequential eluates (e1 e2 e3) were collected. Protein
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4.7 Proteolytic Cleavage of GSTRev
One reason for choosing the pGEX2T vector for the bacterial expression of Rev
protein was the presence of a thrombin cleavage site in the adapter region between the Rev
protein and the GST carrier. Moreover, a Factor Xa site was also included due to the use of the
pOGS-based vectors as the source of the rev gene insert. It was hoped that cleavage of the
Rev protein from the carrier could be followed by removal of the carrier by re-adsorption with
glutathione-agarose beads, resulting in a pure Rev product. Fusion protein eluates were
incubated with either protease at concentration ratios of 0.2%, 1% and 4% (w/w). After six
hours, the reactions were boiled to terminate cleavage, and the products analysed by SDS-
PAGE and Western blotting (Figure 4.10). Visualisation by Coomassie staining (4.10a),
reveals the removal of the 48kD band corresponding to the full-length fusion protein and its
replacement with a band of enhanced intensity at ~28kD, corresponding to native GST, in the
protease treated samples. This demonstrates that cleavage with both enzymes proceeds
efficiently, with digestion to completion at protease concentrations of 0.2% for Factor Xa and
1% for thrombin. It is also observed that the contaminating, intermediate bands are removed
by proteolysis. These proteins must therefore contain both thrombin and Factor Xa
recognition sites, further confirming the status of these contaminants as degradation
products of the fusion protein.
There are no obvious candidate bands for released Rev protein revealed by
Coomassie staining. However, blotting with anti-Rev antiserum (4.10b) reveals the presence
of two bands, migrating closely together at ~20kDa, in all the cleaved fractions. These are
thought to represent the full-length Rev protein. The more rapidly migrating of the two bands
is present predominantly in the Factor Xa cleaved samples, with the more slowly migrating
band predominant in the thrombin cleaved samples. Cleavage with thrombin is expected to
give rise to a polypeptide six amino acid residues (sequence: GSIEGR) larger than that
released by Factor Xa cleavage, due to the positioning of the respective proteolysis sites.
One explanation for the existence of the double band is therefore that the minor band is the
product of non-specific protease activity at the heterologous recognition site. It is also
possible that contamination of each enzyme source with small concentrations of the other
enzyme not removed during purification from plasma might account for these results.
With increasing protease concentration, it is seen that the bands allocated to full-
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Figure 4.10: Protease Digestion of GSTRev
GSTRev (~800p.g) was incubated with either thrombin or factor Xa at the concentrations
shown, for six hours at 25°C. Samples were analysed by SDS-PAGE on a 10-20%
polyacrylamide gradient gel. Proteins were visualised by staining with Coomassie Blue (A), or
by Western blotting and probing with an anti-rev antiserum (B).
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length Rev decrease in intensity. This suggests that secondary cleavage sites for both
enzymes are present within the Rev moiety of the fusion protein. An antiserum positive
smear is present at ~16kDa when thrombin was used at high concentrations (4.10b); this is
not present on cleavage with Factor Xa. The proteases thus appear to act at different
secondary sites. The number and position of such sites is difficult to determine. Factor Xa
cleavage does not produce additional blot positive bands. Thus, cleavage at a single site may
remove the carboxy-terminal ~50 residues containing the peptide recognised by the
antiserum, rendering the major fragment invisible to blot detection, with the blot positive
fragment too small for SDS-PAGE detection, or cleavage at multiple sites may result in near
complete proteolytic degradation. Thrombin cleavage may remove 3-4 kDa at either terminus
to preserve the blot positive status of the major 16kDa fragment. The broad smear obtained
suggests limited exolytic activity uncharacteristic of a site-specific protease, and may be due
to the high concentration of enzyme or enhanced activity of contaminating proteases on the
partially cleaved protein. The proliferation of Rev fragments produced by the promiscuous
action of the proteases on both the full-length and partially degraded fusion proteins would
result in small numbers of each fragment size. This would explain the failure to allocate a single
Coomassie-stained band to the Rev polypeptide. Reduction of incubation time from six hours
to one hour did not prevent secondary cleavage events (data not shown).
In summary, cleavage ot the Rev protein from the GST carrier proceeded efficiently.
Flowever, the presence of different substrate molecules and the non-specific activity of the
proteases led to a plethora of cleaved fragments and an inability to isolate a full-length Rev
polypeptide. It was therefore decided that cleavage of the fusion protein would not be used
to produce Rev protein for functional studies.
4.8 Discussion
This chapter describes the construction of a vector to direct high level expression of
recombinant EV1 Rev protein as a fusion to the glutathione-S-transferase enzyme of
Schistosoma japonicum. Analysis of expressed and purified protein demonstrated that
successful expression had been achieved. Several strategies to improve the yield and purity
of the recombinant protein have been attempted, with at least some success.
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4.8.1 Protein Yield
The yield of eluted GSTRev was typically 3-4 mg/L culture. Although this figure is in
the middle of the range of yields recorded by the authors of this system (Smith and Johnson,
1988), it is nevertheless less than that obtained for native GST (12.5mg/L). Lew and co¬
workers (1991) have produced purified GST/Protein A at ~50mg/L. One rationale for the use
of a fusion system is the presence of both cis- and trans- acting factors known to give rise to a
good yield and quality of product. Variation in yield on insertion of a foreign gene must
therefore be due to the effect of that gene and its products on the carrier system. Induction of
GSTRev protein synthesis has been shown to retard the growth of host cells. However, it
would appear that the reduction in growth is not sufficient to explain fully the reduced yield of
GSTRev. The extent and form of possible Rev-mediated toxicity in bacterial cells must remain
speculation. Increasing culture density before induction of expression did not increase the
yield of fusion protein as might be expected. The product of the envgene of MVV has been
shown to exert a severe toxic effect in bacteria (N. Carey, PhD Thesis 1992). This might
implicate the amino-terminal region of Rev, which is shared with the Env glycoprotein, in
potential toxicity. However, the stretches of hydrophobicity thought to be responsible for the
toxic effect of viral glycoproteins expressed in bacteria (Sisk et at., 1992) are not present
within the Env/Rev common region.
The alteration of growth conditions in ways other than attempted in this chapter might
also influence protein expression. Authors reporting successful production of GST fusion
proteins have used a hundred-fold variation in the concentration of the inducing agent, IPTG,
from 0.1 mM (Smith and Johnson, 1988; this thesis) to 10mM (Frosch et at., 1991). Higher
concentrations of IPTG within the culture may ensure maximal induction of the tac promoter,
by 'mopping up' the product of the /ac/f gene. Although this might be expected to increase
expression by boosting transcription, it could have the opposite effect if mRNA or protein
toxicity was a factor. Pressure of time did not allow investigation into this aspect of expression.
Reduced expression of GSTRev might also be due to factors other than protein
toxicity. Transcriptional or translational efficiency and mRNA stability might also influence the
level of GSTRev. Translational efficiency, in the form of codon usage, will be discussed below.
It seems probable that a combination of factors is responsible for differences in recombinant
protein yields, with each protein possessing unique characteristics.
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Although experimental data suggested that purification was not a limiting step with
respect to GSTRev yield, small, incremental increase in yield might have been possible to
obtain by alterations to the purification protocol. Affinity purification requires a soluble
substrate. A degree of insolubility promoted by the foreign protein would reduce the pool of
molecules available for binding to the glutathione-agarose beads. Although insolubility is
often associated with a high hydrophobic content and large molecular size, it has been found
to be a common problem with the pGEX system (Frangioni and Neel, 1993). A proportion of
the recombinant GSTRev is present in the discarded pellet after post-sonication
centrifugation (4.5.2). This could be the result of partial insolubility of the fusion protein, but it
is also likely that much of the pelleted material is trapped inside intact cells or sequestered
within macromolecular complexes, perhaps bound to cellular RNA. The increase in the level of
GSTRev within the supernatant correlating with increased concentration of the detergent
Triton X-100, supports the latter explanation. There is therefore no evidence to suggest that
GSTRev is not readily soluble. Increasing the concentration of Triton X-100 did not give rise to
a consistent increase in final protein yield.
The protein binding capacity of the glutathione-agarose beads is estimated at
>8mg/ml (Sigma). Frangioni and Neel (1993), have suggested that the capacity of the beads
decreases sharply with increasing substrate size, by a factor larger than would be expected for
constant binding on a molar basis. Thus, the 47kDa GSTRev protein would saturate the beads
at a significantly lower concentration than the 27.5kDa native GST. Increasing the number of
beads used in the purification process might lead to increased yield. The elution of protein
from the beads may also be a limiting factor. As described above (4.6.2) smaller proteins may
elute more readily from the beads than larger ones. An increase in the period of elution might
therefore increase the yield of GSTRev with respect to GST. Other measures which might aid
elution include altering the concentration of free glutathione and the use of nonionic
detergent in the elution buffer (Frangioni and Neel, 1993). The concentration of glutathione
in the eluting buffer has been reported as high as 25mM (Tetzlaff eta/., 1992). Increasing
elution efficiency might be expected to improve yield. However, approximately 75% of all
eluted GSTRev was recovered in the first of three eluates, suggesting that the protocol used
was relatively efficient, and that elution was not a limiting step.
It has therefore proved impossible to determine exactly which aspect of expression
and/or purification is responsible for variation in yield between native GST and GSTRev. It is
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probable that several factors are involved. The instability of the full length fusion protein is
undoubtedly linked to reduced yield; cleaved residues are lost from the final purified material.
For further elucidation, a more complete examination of the various stages of protein
production would be required; this was not considered an appropriate subject for further
study.
4.8.2 Protein Purity
Scanning densitometric analysis of electrophoresed samples of purified GSTRev
demonstrated that the eluted material consisted of 10-20% full length product. Contaminating
protein bands were identified consistently at the same positions, and were found to be
reactive with an anti-GST antiserum. This suggested that these contaminants were stable
intermediate products of proteolysis of the full length fusion protein. Proteolysis of proteins
expressed in bacteria has been widely reported (Goldberg and St. John, 1976; Nakano etal.,
1994). The product of the fusion between GST and the Babesia bovis merozoite protein Bb-
1, for example, is cleaved almost to completion (Tetzlaff etal., 1992). Both primary and higher
order protein structural features are likely to determine susceptibility to proteolytic
degradation. In the present study, the GST moiety is not cleaved, which suggests that it and
the Rev polypeptide form independent folding domains. This may conversely be beneficial,
as it may promote functionality of the fusion protein. The major contaminating proteins have
apparent molecular weights in the range 28-34kDa, which represents the carrier molecule in
addition to approximately 0-6.5kDa of Rev. This would suggest that the largest of the
contaminants contains the 60 amino-terminal residues of Rev (based on an average amino
acid residue molecular weight of 110Da). Degradation of the fusion protein was shown not to
occur significantly during purification. Degradation might therefore occur within the cell or
during cell lysis. Two strategies were employed in an attempt to reduce the proportion of
fusion protein affected by proteolysis. Firstly, the period of induction of expression was
reduced. This was not found to lead to reduced degradation. It may be that a shorter period of
induction than the 1.5 hours used in this study might be beneficial. Secondly, the effect of
bacterial host genotype on expression was investigated. Studies using a p-galactosidase
somatomedin-C (a human serum protein) chimaera, have shown that a higher yield and longer
protein half life are obtained in the protease deficient E. coli strain SG936 compared to other
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strains (Buell etal., 1985). Variation in GSTRev fusion protein stability between host cells was
noted, although the differences were not large. The strain BL21 was found to promote the
greatest stability. Two protease genes, Ion and ompT, are absent in this strain. The Y1090
strain is also Ion deficient, which would appear to implicate the ompT product in the
proteolysis of GSTRev. Bonds between successive basic residues are especially susceptible
to OmpT cleavage (Sugimura and Higashi, 1988); such bonds are common within the Rev
polypeptide. Proteolysis by a membrane associated enzyme occurs predominantly during cell
lysis (Sugimura and Higashi, 1988). Uncharacterised differences between bacterial strains
with respect to protease activity cannot, however, be discounted. It may be possible to further
increase stability and yield of GSTRev by use of other bacterial strains. A second ompT
deficient strain, AD202, is also associated with enhanced stability of certain GST fusion
proteins (Nakano etal., 1994). Cells with a mutation of a heat shock regulatory gene htpR
have been shown to promote stability of expressed proteins (Baker et at., 1984). The effect of
bacterial proteases may also be countered by reducing the incubation temperature for
expression. Growth of cells expressing a GST/MVV Env fusion protein at 25°C has been
shown to reduce the level of contaminants (P. Carter, Department of Veterinary Pathology,
University of Edinburgh, personal communication). The relative abundance of full length
forms of heterologous GST fusions has been reported to be increased by incubation at a
lower temperature and for a shorter period. Such conditions do not universally bring success,
however (Ghosh etal., 1995).
A different approach would be to employ the recently described vector pETGEXCT
(Sharrocks, 1994). This vector, a hybrid containing elements of both the pET and pGEX
systems, allows foreign polypeptides to be expressed as fusions at either terminus of GST.
Fusion of the fungal transcriptional activator protein QUTA to the amino terminus of GST has
been shown to reduce protein proteolysis associated with fusion to the carboxyl terminus
(Sharrocks, 1994).
4.8.3 Codon Utilisation
Although instability of the fusion protein was initially assumed to be the reason for the
presence of contaminating proteins in purified preparations, experimentation did not provide
conclusive support for this hypothesis. In particular, reduction in induction period did not
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reduce the level of contamination. An alternative explanation was possible. The rate of
utilisation of synonymous codons is non-random, and varies between different organisms. E.
coli exhibits a strong bias against several codons; for example, four of the six codons
specifying arginine are rarely used. Two of these, AGA and AGG, are the least frequently
observed codons in the E. coli genome (Zhang etal., 1991). Thus, the presence of rare
bacterial codons in genes of non-bacterial origin might affect translational efficiency: difficulty
in translation of foreign genes containing such codons has been predicted by Konigsberg
and Godson (1983). Experimentally, reduced expression of full length eukaryotic protein in
transformed E. coli has been associated with increasing the percentage content of AGA and
AGG codons (Brinkmann et at., 1989). However, Varenne and co-workers recorded that
consecutiveness, rather than total content, of rare codons was critical (1989). The number of
consecutive rare codons may be directly proportional to the repressive effect on correct
translation (Rosenberg etal., 1993): this may vary between individual genes and according to
the intramolecular position of the rare codons within each gene.
The explanation for the inhibitory effects of rare codons on translation lies in the fact
that the frequency of codon occurrence reflects the cellular abundance of cognate tRNA
species (Ikemura, 1981). Thus, although isolated rare codons can be decoded efficiently, the
presence of consecutive codons causes a pause in translation with the first codon bound in
the ribosomal peptidyl-tRNA site due to a shortage of tRNA required for the downstream
codon bound at the amino acyl-tRNA site. This could lead to uncoupling of the mRNA from
the ribosomal complex resulting in premature translational termination. Alternatively, ribosomal
slippage may recruit a more abundant tRNA species, resulting in a frameshift event. Two
consecutive AGG codons induce 50% frameshifting into the +1 frame in the rat interferon a1
gene (Spanjaard and van Duin, 1988). A high error rate was also recorded in the presence of
tandem AGA codons. Such events would be manifest by reduced yield of full-length protein
and the presence of aberrant or truncated polypeptide molecules. If the truncated molecules
adopted a stable secondary structure, they might be expected to avoid proteolytic cleavage
which is the usual fate of abnormal proteins (Goldberg and St. John, 1979).
The E. coli frequency profile of codons present in pGEX2TRev is illustrated in Figure
4.11. The eight most rare codons (as defined in Zhang etal., 1991) comprise 19 of the 153
rev (plus linker region) codons (12.3%), but only 14/224 (6.2%) of the GST codons. There is a
particular bias toward the arginine codons AGA and AGG in the rev gene; these comprise
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Figure 4.11: Distribution of Rare Bacterial Codons in pGEX2TRev
The genes gst and rev are illustrated. The position of the eight codons most rarely used by
Eschericia coli bacteria is marked by a vertical line. Rare codons are defined as follows









Numbers indicate codon position within each gene. The highlighted region (rev codons 55-
88) has a high density of rare codons. The DNA sequence from this region is shown. Rare
codons are indicated as follows:
The amino acid sequence encoded by this region is shown in bold. The boxed region








7.8% of the total (12/153) compared to 0.9% in gst(2/224). The region between residues 69-
81 within rev is particularly rich in rare codons (6/13), largely due to the preponderance of
arginine residues. No such region is present within GST. Thus the distribution of rare codons
within pGEX2TRev correlates with the high level expression of intact GST and the presence
of shortened Rev molecules. The tandem AGA codons at revcodon positions 63/64 and at
74/75 may induce ribosomal frameshifting or disengagement. Frameshift into the -1 register
would halt translation at one of several termination codons: there are no such codons in the
+1 register. A full-length protein could thus be generated by +1 frameshifting; however, this
would not be recognised by the anti-Rev peptide antiserum. Although electrophoretic
analysis of GSTRev suggested that the largest of the contaminating proteins would contain
approximately 60 residues of Rev, and the other contaminants considerably fewer, it is
possible that anomalous migration of products truncated at positions 63/64 or 74/75 could
account for this difference. Limited degradation of the truncated protein could also occur,
reducing molecular weight.
Translation of consecutive rare codons is also linked to reduced bacterial growth and
viability (Brinkmann et at., 1989). The minor tRNAs specific for arginine are required for
chromosomal replication: sequestration of these molecules in polysomal complexes would
inhibit cell division. Expression of those bacterial genes specifying rare codons might also be
repressed. This provides a possible explanation for the reduced growth of pGEX2TRev
transformed cells on IPTG induction.
Removal of the rare codons by mutagenesis to synonymous codons found more
frequently in bacteria would determine whether this hypothesis was valid. The number of
such codons found in rev would, however, make this a difficult task. An alternative approach
would be to co-transform host cells with a vector directing high level expression of the
appropriate tRNAar9 species. Co-expression of the argU gene, encoding the bacterial
tRNAAQA/AQQ, resulted in high level expression of the full length 28kDa protein of barley
yellow mosaic virus RNA2 (Shenk et a!., 1995): a minor truncated product was observed in the
absence of argU.
The effect of rare codons could also explain the reduced yields of GSTRev compared
to native GST. Bogerd and co-workers (1991) have reported an approximately two-fold
increase in yield of a GST/HTLV-1 Rex fusion protein on substitution of two rare arginine
codons for ones more efficiently utilised by bacteria.
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A different approach to improving the purity of GSTRev would be to isolate the full-
length molecules from the contaminants by size exclusion chromatography. The relatively
small differences in size involved meant that such an approach would require considerable
manipulation of matrix size and conditions for success. Time did not allow for an investigation
into the practicalities of such a strategy.
4.8.4 Cleavage of the Fusion Protein
Thrombin and restriction factor Xa are serine proteases with highly specific target
sequences. Although both cleave arginyl and/or lysyl bonds, the environment required for
efficient cleavage has been incompletely elucidated: hence, prediction of cleavage activity is
imprecise. Thrombin cleaves selectively at only two of 181 R/K-X bonds in fibrinogen
(Blomback et at., 1967). However, low efficiency cleavage may occur at a large number of such
bonds (Chang, 1985). This phenomenon has also been observed to occur with factor Xa
digestion (Nagai and Thogersen, 1987). An internal site (63-YLGRSAE-69) within the HIV-1
Rev molecule is susceptible to partial secondary digestion (Jensen et at., 1995). Cleavage at
secondary sites has been reported to coincide with protein instability (Riggs, 1992). Thus the
suggested instability of the GSTRev protein may contribute towards the observed multiple
cleavage events on treatment with both proteases. As a result of the inability to allocate actual
bands on Coomassie stained gels to the products of such cleavage events, it is impossible to
determine the number and identity of secondary sites. Examination of the amino acid
sequence of Rev enables some conclusions to be drawn about possible secondary sites,
however. The basic cleavage sites for the two enzymes are (from Chang, 1985; Nagai and
Thogersen, 1987):
Thrombin : X--R--Y, with X preferred P or G, and Y is often G, V, D, I, C, or R.
Factor Xa : X-R-Y, where X is usually G, and Y is often I or T, never P.
In both cases, lysine may replace the central arginine at certain sites. Other surrounding
residues may also be influential. The closest matching potential protease site throughout
GSTRev is at position 135-137 of Rev, with the sequence G-R-D. Cleavage at this position
would release an eleven residue fragment, removing 1.63kDa from the Rev molecule, and
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leaving the antiserum positive peptide intact. Minor reactivity at this site might explain the
double band of ~20kDa observed on protease digestion. Following initial digest the
susceptibility of the protein to further cleavage may increase, possibly due to alteration of the
higher order structure. The data concerning thrombin digestion implies cleavage 3-4kDa from
either terminal region: a thrombin secondary cleavage at the G--R-D sequence might initiate
less specific events resulting in removal of this residue mass. Positions 68-70, P-R-G, of Rev
provide a second close match to the thrombin consensus sequence. Cleavage at this
position would effectively halve the Rev molecule, producing two fragments of approximately
9.5kDa. This does not fit the data obtained for thrombin cleavage.
It must be emphasised that prediction of cleavage sites is inexact. As an example,
internal thrombin cleavage within the Maltose Binding Protein/Poliovirus 2C fusion occurs in
the absence of a predictably susceptible arginine bond (Rodriguez and Carrasco, 1995).
More data concerning the sizes of the products of cleavage would be required before a more
accurate analysis of potential sites would be possible.
4.8.5 GSTRev for Functional Assays
The aim of the work of this chapter was to produce Rev protein for in vitro functional
studies. Unfortunately, pure Rev protein could not be obtained, due to the instability of the
protein and its susceptibility to secondary cleavage by proteases. However, it is possible that
the intact fusion protein, GSTRev, could be functionally equivalent to native Rev. Several
groups have reported successful functional studies using proteins attached to an expression
carrier. A GST/Influenza A virus NS1 protein fusion has been shown to bind NS1 target RNA in
in vitro binding assays (Qian et at., 1994). Similarly, in the period since the work of this chapter
was begun, several groups have reported successful expression and functional
characterisation of HTLV-1 Rex, HIV-1 Rev and MVV strain 1514 Rev proteins. Binding activity
of a GST/HIV-1 Rev fusion has been shown to be indistinguishable from that of wild type Rev
(Jensen et at., 1995) (Discussed in more detail in chapter 6). However, it should be noted that
correct activity of the expressed protein is not always observed. Gearing and co-workers
(1989) demonstrated that a GST/leukaemia inhibitory factor (LIF) fusion was non functional,
due to conformational restraint. Correct activity was released on protease cleavage of the
fusion protein. Thus, the major factor determining fusion protein functionality is likely to be the
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higher order structure. The possible susceptibility of the Rev but not the GST portion of the
fusion protein to proteolytic degradation suggests that the two polypeptides form
independent folding domains. This would be likely to promote Rev functionality. This
suggestion, along with the evidence of other groups for the activity of intact fusion proteins,
led to the decision to use GSTRev as the source of Rev activity for functional assays. The
main potential problem with this approach would be the presence of the contaminating,
truncated GSTRev molecules. Whereas those contaminants which consisted of the GST
polypeptide alone, or with a small Rev content, would not be expected to interfere with the
functional assays, the larger contaminants might be problematic. Data from SDS-PAGE gel
analysis of the fusion protein suggests that the largest of the contaminants should contain up
to 60 residues of Rev; thus the predicted RNA binding domain of Rev (section 3.2) would not
be present in any of the contaminants. However, the actual size of the contaminants could be
significantly different, due to anomalous migration in the SDS-PAGE system. The potential
binding or interfering activity of truncated products of GSTRev would have to be taken into
consideration when interpreting results from such binding assays.
4.9 Summary
A vector to direct the inducible expression of MVV Rev as a fusion to the enzyme
GST was constructed. A protein of the predicted molecular weight, and reactive with an
antiserum raised against a synthetic Rev-derived peptide, was shown to be specifically
produced by bacterial cells transformed with this vector. The total yield of protein, although
less than that of native GST, was found to be within expected limits. Fusion protein stability
was found to be problematic. Approximately 80-90% of purified protein consisted of
truncated fragments of the fusion protein. Several different approaches were taken in order to
improve yield and purity of product, with some success, in particular, the use of host cells with
protease deficient phenotype, was found have some benefit. Protease cleavage of the
fusion protein, to release the Rev moiety, resulted in secondary cleavage events within the
Rev polypeptide. It was decided that the fusion protein would be used for Rev functional
studies in its uncleaved form.
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CHAPTER FIVE
IN VITRO STUDIES OF GSTREV
RNA BINDING
5.1 Introduction
RNA molecules in biological systems are rarely, if ever, present in naked form, but
instead are complexed with a range of RNA-binding proteins. Many RNA-binding proteins
mediate specific, discriminatory interactions. These interactions are of significance for the fate
of intracellular RNA. The processing, nucleocytoplasmic export and translation of pre-mRNAs,
for example, are dependent on events mediated by specific RNA binding proteins. The
structural determinants of RNA/protein interactions are poorly understood. In part, this is a
consequence of the structural versatility of RNA molecules. RNA molecules can adopt a range
of higher order structures, which are likely to form elements recognised by proteins. 'Stem'
structures formed by base pairing between regions of sequence complementarity are
commonly recognised elements, as are internal deformations in such regions caused by non-
base paired nucleotides.
The protein motifs involved in RNA binding are also poorly characterised. However,
three distinct classes are presently recognised. The conservation of these motifs suggests
that common protein structural elements may be used for target recognition. The RNA
recognition motif (RRM, also RNP, ribonucleoprotein motif) is the most commonly occurring of
these classes, and is recognised in over 200 distinct proteins (Bandziulis etal., 1989). Many
of these are involved in RNA processing, and include 5' cap-binding proteins and
spliceosome components (for a review of the RRM, see Nagai et al., 1995 and references
therein). Two conserved domains of 6-8 residues within a less conserved -80 residue region
constitute this motif. Certain nucleolar and hnRNP proteins contain a second RNA recognition
motif, characterised by arginine/glycine/glycine repeats (Kiledjian and Dreyfuss, 1992). A
diverse group of molecules constitute the third class of RNA-binding proteins, those with a
distinct basic residue binding motif containing a preponderance of arginines. Bacteriophage
anti-terminator N proteins, ribosomal proteins and RNA viral capsid proteins are included
within this group (Lazinski et al., 1989). The arginine-rich binding domain is characterised on
the basis of a high arginine/lysine content over a stretch of 10-15 amino acid residues, with
little additional sequence similarities. Electrostatic interactions between the positively charged
arginine residues and the negatively charged phospho-diester RNA backbone are probably
involved in initiating contact between molecules. It seems likely that non-arginine residues are
important in making discriminatory contacts with RNA targets to give these proteins their
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individual specificities (Lazinski etal., 1989). Proteins containing an arginine-rich binding motif
are able to make specific contacts with a variety of RNA secondary structures.
RNA/protein interactions play a critical role in the life cycle of those viruses, such as
the retroviruses, which possess an RNA genome. HIV-1 encodes three proteins with RNA-
binding activities, Gag, Tat and Rev. The RNA binding of both Tat and Rev is dependent on
arginine-rich motifs (Dingwall et at., 1989; Malim eta/., 1989b). Isolated peptides containing
these motifs are competent to mediate target binding with similar characteristics to the full
length protein (Weeks etal., 1990; Kjems etal., 1992). However, recent evidence suggests
that, despite the similarities in the binding domains, Tat and Rev RNA binding is mediated by
different structural features (Calnan etal., 1991; Tan etal., 1993; Tan and Frankel, 1995).
Both of these regulatory proteins recognise their specific target sequences in the
context of complex RNA secondary structure (Muesing etal., 1987; Malim etal., 1989c; Malim
et al., 1990). This recognition is critical for virus viability. The Tat recognition element, TAR,
consists of a single stem-loop, with recognition mediated by a trinucleotide bulge at the stem-
loop intersection (Dingwall et al., 1990).The RNA target for HIV-1 Rev, the RRE, is more
complex, consisting of a long stem of duplex RNA and five stem-loops. It has been predicted
to contain 234nt (Malim etal., 1989c), although more recent analysis has suggested that
351nt are required for full function (Kimura and Ohyama, 1994; Mann et al., 1994). A core
high affinity binding site within the RRE consists of -13 non-contiguous nucleotides (Heaphy
et al., 1991) with a helix-internal loop-helix structure (Bartel et al., 1991).
The experimental determination of Rev and Tat RNA interactions was achieved by the
use of In vitro binding assays. The substrates for these assays were recombinant proteins and
in vitro transcribed RNA. Sequences corresponding to the predicted RNA targets were
cloned into vectors containing promoters for bacteriophage DNA dependent RNA
polymerases, and transcribed in the presence of radioactively labelled ribonucleotide
triphosphates. Protein/RNA interactions can be observed by electrophoresis through non-
denaturing polyacrylamide gels with subsequent autoradiographic visualisation. Complex
formation is indicated by a 'shift' in the position of the band due to the labelled substrate as a
consequence of reduced electrophoretic mobility; hence the term 'gel retardation assay'. This
assay may be quantified by densitometric analysis of the distribution of free and retarded
probe signals. Alternatively, protein/RNA complexes may be detected by filtration through a
nitrocellulose filter in conditions which favour the retention of complexes but the filtration of
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non-complexed substrate. Filter binding assays are scored by the counting of radioactive
substrate bound to the nitrocellulose after filtration.
The presence of a highly basic region with 7/22 arginine residues (3.2.2) within the
MVV EV1 Rev protein was suggestive of an RNA binding capability similar to that of HIV-1 Rev.
Computer predictions of secondary structure were used to define an RNA region within the
EV1 envelope gene, close to the encoded surface glycoprotein/transmembrane protein
(SU/TM) cleavage site, which may adopt a stable secondary structure with similarities to the
HIV RRE. In order to investigate possible interactions between EV1 Rev and this putative
RNA element, this region was cloned into vector plasmids and used to generate radioactively
labelled RNA by run-off transcription. Binding reactions were carried out using partially purified
GSTRev fusion protein (chapter 4). Potential complex formation between protein and RNA
was monitored by both gel retardation and filter binding assays.
5.2 A Potential Rev Responsive Element within the EV1 Envelope Gene
The Rev responsive elements of the primate lentiviruses are positioned immediately
downstream of the boundary between the coding region for the SU and TM glycoproteins
(Malim et at., 1989c; Le etal., 1990). Computer simulation of the secondary structure of RNA
from this region of the Maedi Visna virus EV1 was used in an attempt to locate a similar
element. Figure 5.1 illustrates a 176 nucleotide RNA secondary structure from this region with
a predicted free energy of formation of -70.5kcal/mol (prediction programme based on Zuker,
1989). Minor variations in formation energy were recorded by the use of slightly different
sequence elements; however, the basic structure observed in figure 5.1 was conserved. The
secondary structure begins at nucleotide 7995 and terminates at 8170. The element is
therefore located nine bases downstream of the predicted SU/TM boundary (Sargan et al.,
1991): this is remarkably consistent with the location of the HIV-1 RRE (Malim et al., 1989c).
Although there is no primary sequence homology with the RREs of any of the primate
lentiviruses, the secondary structures contain conserved elements. In particular, these
regions are characterised by a main helix of double stranded RNA enclosing several stem-
loop structures. The EV1 element contains three stem loops, two of which are linked by a
duplex region within the 5' section of the structure: this arrangement is similar to that of the
HIV-1 RRE (see figure 1.6). The high affinity Rev binding element of the HIV-1 RRE is situated
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Figure 5.1: The Predicted Rev Responsive Element of MVV EV1
Computer prediction of the RNA secondary structure within the transmembrane
glycoprotein coding sequence of EV1 env. Position 1 corresponds to nucleotide 7986 of the
published EV1 genomic sequence (Sargan etal., 1991). The secondary structural element
begins at position 9 (7995) and terminates at position 186 (8170). The AGf for this structure is
-70.5kcal/mol. Computer prediction made using the UWGCG (version 8) programme
'FOLDRNA' and represented by the programme 'SQUIGGLES'.
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within the base of one of these stem-loops. Thus, by analogy a possible site for EV1 Rev may
be found within these structures. The presence of only one additional stem-loop within the
EV1 element in contrast to the three found in the HIV-1 RRE is intriguing, given the functional
redundancy of these domains within HIV-1 (Holland et al., 1990). This further suggests that
the Rev binding site may be located within the two linked stem-loops.
A report on secondary structure elements within the envgene of the Cork strain of
CAEV appeared to confirm the above prediction for the ovine/caprine lentivirus RRE (Saltarelli
et al., 1990). This report also predicted the structure of the putative RRE for the 1514 MVV
strain. All three putative RREs are situated in identical genomic locations and are 176nt in
length. The relationship between these elements will be investigated in more detail in chapter
6.
5.3 Generation of an RNA Substrate for Functional Assays
In order to determine whether EV1 Rev was an RNA binding protein with specificity
for the putative response element within the envgene, a series of functional assays were
carried out. These involved detection of ribonucleoprotein complexes formed by
protein:RNA interactions. The protein substrate for these assays was the fusion protein
GSTRev. Transcripts generated by in vitro transcription of the putative RRE by insertion into
appropriate plasmid vectors were to serve as the RNA substrates.
5.3.1 In Vitro Transcription
RNA transcripts can be generated from cloned DNA sequences by the use of DNA
dependent RNA polymerases derived from certain bacteriophages. The Eschericia coli
bacteriophages T3 and T7, and the Salmonella typhimurium SP6 encode polymerases with
several characteristics suitable for in vitro transcription. These include the ability to transcribe
any sequence placed downstream of the 23bp consensus promoters; the requirement for a
simple reaction buffer with no additional transcription factors (Melton et al., 1984), and high
specificity for transcription from the cognate promoter (Butler and Chamberlin, 1982).
Moreover, these polymerases demonstrate high specificity with respect to the DNA strand
transcribed: this latter property is of particular importance in the current context. T7 or SP6
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polymerase transcription from a linearised template with a 5' protruding or blunt terminus gives
rise to less than 0.2% transcripts derived from the non-coding strand (Cox et at., 1984;
Schenborn and Mierendorf, 1985). Several commonly used vectors encode RNA polymerase
promoters adjoining the multiple cloning site. Thus, RNA can be obtained by run-off
transcription from a plasmid linearised with an appropriate restriction enzyme. The amount of
extraneous sequence derived from the vector can thus be kept to a minimum. With all four
ribonucleotide triphosphates (rNTPs) present in the reaction mixture at saturating
concentrations (>50pM) a yield of 10-20 copies of RNA per template can be obtained (Melton
et at., 1984). For product detection, a radioactively labelled rNTP is included in the reaction.
The concentration of this substrate will therefore be lower than that of the other rNTPs, and
this may result in a lower yield of product. Moreover, disengagement of the polymerase from
the template at sites where the limiting nucleotide is required may give rise to a proportion of
incompletely synthesised molecules (Melton eta!., 1984).
5.3.2 Transcription from a pTZ18R-Based Vector
A template for the synthesis of the putative EV1 RRE was available in the form of a
vector derived from pTZ18R and containing the 5' region of the env gene, encoding the
amino-terminal portion of the transmembrane glycoprotein, gp46 (a kind gift from C.
Cousens). This plasmid (pCCR6) contained an insert consisting of the gp46 bases 1-462
(EV1 bases 7986-8449), which was cloned into pTZ18R via a digestion site for the restriction
enzyme EcoRI. The vector pTZ18R is depicted in figure 5.2a. A single T7 promoter is located
at the junction of the multiple cloning site within three base pairs of the EcoRI site, and thus
can be used to direct transcription from the insert containing only three bases of vector-
derived sequence. This plasmid was available in two forms, with the insert present in both
possible orientations, allowing synthesis of both the plus strand (template pCCR6(+): sense
RRE) and negative strand (pCCR6(-): antisense RRE) which would serve as a control. The
vectors were linearised with the restriction enzyme BamHI for the synthesis of sense RRE,
and with Hindlll for the synthesis of antisense RRE. Different restriction sites were used to
avoid confusion: but were not functionally necessary, as the insert was cloned in a different
orientation in each plasmid. Vectors were obtained from large scale preparations using the
'Qiagen' system (2.10). RNase was excluded from the protocol, in an effort to avoid possible
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Figure 5.2: Transcription from the pTZ18R Vector, pCCR6
A The parental vector pTZ18R. This plasmid contains a multiple cloning site (MCS). The
position ot restriction sites used here are shown. The MCS is situated within the lacZ coding
sequence, which allows production ot p-galactosidase fusion proteins from inserted
sequence. A T7 RNA polymerase promoter directed toward the MCS, allows the production
of RNA from a sequence insert. The plasmid contains two origins of DNA replication (ORI) and
ap-lactamase ampicillin resistance gene tor selection.
B In vitro transcription from linearised, full insert length pCCR6 plasmids. Transcription
was carried out according to standard procedures with 5pl (50pCi) a-32P UTP in the presence
or absence of 25pM unlabelled UTP as indicated. After incubation for one hour, an aliquot was
used to determine the percentage of label incorporated. Approximately lOOOOcpm of product
were analysed by electrophoresis through a 6% denaturing (8M urea) polyacrylamide gel, and
products visualised by autoradiography.
C In vitro transcription of Aval linearised pCCR6(+). Transcription carried out as above,
using 25pM unlabelled UTP. Arrow indicates potential full length transcript (~200nt).
170
AmpR
0 25jiM 0 25|iM + unlabelled UTP
pCCR6(+) pCCR6(-)
contamination at later stages. Plasmid was digested with the appropriate restriction enzyme,
and digested plasmid isolated by excision from a 1% low gelling temperature agarose gel
(2.8). The digested plasmid was purified with silica (2.5.3) and phenol extracted, before
resuspension in TE at a concentration of ~1mg/ml. This procedure was deemed necessary in
order to prevent contamination with undigested plasmid, which could direct the transcription
of vector-length RNA molecules and greatly reduce the efficiency of insert transcription
(Melton eta/., 1984). Transcription was carried out using a commercial kit obtained from AMS
Biotechnology (2.18.3). Ten units of the RNase inhibitor RNasin (Promega) were included in
each reaction. The radiolabeled rNTP chosen was a32P-UTP, which had a specific activity of
400|iCi/mmol and was present in the reaction mixture at a concentration of 6.25pM. The
reaction products were visualised by electrophoresis through a 6% denaturing polyacrylamide
gel with subsequent autoradiography (2.18.4.2) and the efficiency of the reaction gauged by
precipitation of RNA with trichloroacetate (2.18.4.1). The transcripts obtained by this
procedure are illustrated in figure 5.2b. It is clear that the proportion of full-length transcript
(465nt) produced is low: a number of bands with reduced molecular size are present.
Additionally, the indistinct radioactive signal is suggestive of a problem with degradation,
especially with the antisense RRE (lane 3). There is essentially no full-length antisense RNA.
The efficiency of the transcription reaction was also low, and somewhat variable: the
percentage of a32P UTP incorporated into RNA was on average 24.2 +/- 14.2% for sense
RNA, and 19.7 +/- 4.2% for the antisense RNA (mean +/- standard deviation, for three
independent reactions). In an attempt to increase the proportion of full-length molecules,
unlabelled UTP was included in the initial reaction at a concentration of 25pM. Although this
would result in a considerable reduction in the specific activity of the RNA probe, the benefit
in terms of yield might make this acceptable. From figure 5.2b it can be seen that although
there is some decrease in the proportion of smaller sized truncated fragments associated with
the presence of cold UTP, the yield of full-length product remains low.
Ling and co-workers (1989) have reported that the yield of radiolabeled full-length
product may be considerably reduced due to abortive initiation of transcription, if the limiting
nucleotide is present within the first 8-12 bases from the transcriptional start point. The first
twenty bases transcribed from pCCR6(+) and pCCR6(-) are as follows:
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pCCR6(+): CUUAU GUGGG CAUAG GGU UG
pCCR6(-): CUUAAUUCUU UGUGCAUCCC
where the initial trinucleotide CUU is derived from the pTZ18R vector, and positions 4-
7 (AUGU) in the sense transcript are derived from the primer used to clone this region
(C.Cousens, PhD thesis, 1993). The preponderance of uridines within the antisense
transcript (9/20) may explain the low incorporation achieved, due to a high rate of abortive
initiation. The alternative use of cytidine triphosphate as the label was contra-indicated by the
presence of this base in the first position after transcription initiation. Moreover, it was clear
that even when initiation proceeded normally, there was a high level of subsequent
termination. The vector context and insert sequence have been reported to affect the
success of in vitro transcription with bacteriophage polymerases (Melton et at., 1984). In
particular, the coincidental presence of a region with homology to the poorly defined
polymerase terminating sequences within the insert may induce transcript truncation. The
length of the full-length transcripts (466b: 463 derived from insert and 3 from the vector) was
in excess of that required for transcription of the predicted RRE, so it was decided to utilise a
unique Aval restriction site within the insert (position 219) to reduce the transcript size. It was
hoped that this would encourage the production of full-length transcripts, by removing
regions which may induce truncation. An Aval site within the multiple cloning site of pTZ18R
(position 197) is located downstream of the T7 promoter/insert, such that digestion resulted
in removal of the 3' section of the insert with no affect on the template. pCCR6(+) was
digested with Aval and used as template for transcription of the sense strand. Unlabelled UTP
(25pM) was included in this reaction. The result of this experiment is depicted in figure 5.2c.
The putative full-length product (222 bases, arrow) comprises approximately 60% of the total,
a considerable improvement on the previous results. The efficiency of transcription, as
judged by TCA precipitation, remained low, however. A major contaminating fragment, of
approximately 200 bases, is present. Intact HIV-1 RRE transcripts have been reported to
migrate as two bands under native gel conditions (Benko etal., 1990), presumably due to the
ability to form distinct conformations. However, it was also possible that this species was a
degradation or truncation product. Possible competition for Rev binding between these two
fragments meant that this was not a suitable reagent for functional assays. Isolation of the full-
length fragment by denaturing gel electrophoresis with subsequent elution of the RNA was
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found to be an inefficient method of purification. The percentage of label incorporated into
RNA remained low with this template, as would be expected if there was significant abortive
termination.
It was thus decided to proceed by utilising an alternative vector for RRE transcription,
and to alter the composition of the insert by including different flanking sequences. It was
hoped that in this way the problems of truncation might be avoided.
5.3.3 Transcription from a pGEM-based Vector
A region including the putative RRE was obtained by Polymerase Chain Reaction
(PCR) using EV1 DNA extracted from infected ovine choroid plexus cells as template, in order
to study Rev function in transient transfection assays (see chapter 6). It was decided that this
fragment would be a suitable template for in vitro transcription. The primers used for PCR
incorporated selected restriction sites to allow sub-cloning of the product into the transient
transfection assay vector, pOXlOO (chapter 6). However, these sites could also be utilised to
ligate the insert into the plasmid, pGEM11Zf(+) (obtained from Promega). This vector contains
dual, opposing bacteriophage polymerase promoters, for the T7 and SP6 enzymes, flanking
the multiple cloning site (figure 5.3a). The primers used for amplification were as follows








The 5' primer (14949) is predicted to hybridise with EV1 genomic positions 7920-
7943, and the 3' primer (G0242) with 8207-8228. The amplified DNA fragment should thus
have a size of 309 bp. PCR was carried out under standard conditions (2.4.3) and the result is
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Figure 5.3: Cloning of Putative RRE into the pGEM11Zf(+) Vector
A The parental vector pGEM11Zf(+). This plasmid contains similar elements to pTZ18R
(figure 5.2). The multiple cloning site (or polylinker region) is larger, and several restriction
sites are indicated. Flanking the polylinker are two, opposing RNA polymerase promoters, for
the T7 and SP6 enzymes.
B PCR amplification of DNA fragments containing the putative EV1 RRE. PCR was
performed using viral genomic DNA as template, and oligonucleotide primers as described in
the main text. A: primers 14949 and 14948 (see chapter 6) B: primers 14949 and G0242. The
product of reaction B was termed RRE.9/2
C Nucleotide sequence of the insert RRE.9/2. The fragment obtained by PCR (B) was
purified and ligated into the pGEM11 vector. Sequence was obtained using double stranded
sequencing reactions and the standard M13 reverse sequencing primer, which hybridises to
pGEM11. Sequence flanked by the unique restriction sites used for subcloning is shown.
The position of the start of the sequencing region for the transmembrane glycoprotein, gp46
(TM) is indicated. The region predicted to form secondary structure is marked (RRE start and
end). Base changes from the published EV1 sequence (Sargan eta!., 1991) are highlighted
in bold.
D Map of the plasmid pGEM11/RRE. The arrow indicates insert orientation. The region
of secondary structure within the insert is stippled. The linearised templates for RNA
synthesis are also shown. Each template shows the utilised RNA polymerase promoter,



























AAA TAG AAG AAA TGC TTT TAA GAA
|TM start IRRE start
GAG GpG CAT AGG GfT GGT TAT AGT
GGC AAT AAT AGC TGC TGC AGG AGC
TGC AAA TGC CGT GCA GCA GTC CTA
TGT CCA GTC TCC TGC TAA CGC AAC
TGT GTT AGA AGC AAC TTA TGC CAT
| RRE endCAAI AGG AGT AAG AAT ATT AGA GGC




tT7 - sense RNA
Xbal
47 bases





illustrated by figure 5.3b. The fragment generated (RRE.9/2) was of the expected size, and
was cloned in the first instance into the pCR™ll vector using the TA cloning kit (In Vitrogen;
2.7.1). A small scale DNA preparation of this plasmid was produced, and ~2pg used for
restriction digest with Bglll and Xbal. The excised fragment was located by agarose gel
electrophoresis, and purified by hot phenol extraction (2.5.2). An aliquot of the vector
pGEM11Zf(+) was digested with the enzymes BamHI and Xbal, and dephosphorylated with
CIP (2.7.1). The enzymes BamHI and Bglll produce compatible protruding ends, which can
religate to produce a sequence susceptible to digestion with neither enzyme. This feature
was used to subclone the RRE fragment directly into pGEM11Zf(+), which does not contain a
Bglll recognition site. Vector and insert were ligated and transformed into DH5a bacteria.
Transformants containing a plasmid with the expected restriction digest characteristics were
used to generate a large scale plasmid preparation. The recombinant plasmid, designated
pGEM11/RRE, contains EV1 sequences 7935-8216, and was sequenced using the M13
reverse primer, which hybridises to the parental vector at positions 128-144. The sequence
obtained is shown in figure 5.3c. There are four base changes between the cloned insert and
the corresponding published sequence (which forms the insert in pCCR6). These all occur
within the putative RRE. Prediction of secondary structure based on these changes suggests
a more stable structure (AGf -78.9kcal/mol) than that found in the original sequence. This
perhaps suggests that the changes are authentic sequence variants and not artefacts of the
amplification and cloning process.
To generate templates for in vitro transcription, the plasmid pGEM11/RRE was
digested with appropriate restriction enzymes (figure 5.3d). Xbal was used to generate
template for sense RNA, using the T7 promoter (linearised template referred to as tT7). A
unique Xhol site situated 6bp upstream of the 5' end of the insert was used to generate
antisense RNA by utilising the SP6 promoter (template tSP6). A possible problem with the
use of pGEM11 as host vector for transcription is the relatively large amount of extraneous
sequence separating the promoter sites from the insert (47 bases for the T7 promoter and 40
for the SP6 promoter). These regions might participate in the formation of secondary
structure and interfere with the native RNA form of the insert. To investigate this possibility,
computer predictions of the structure of the entire transcript generated by transcription from
both promoters was performed. From figure 5.4 it can be seen that additional elements of
secondary structure are present in the sense pGEM11/RRE transcript. However, the putative
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Figure 5.4: Predicted Secondary Structure of RNA Transcribed from the
pGEM11 /RRE Vectors
Computer predictions as for figure 5.1.
A Sense RNA, derived from tT7




RRE is intact and is identical to that predicted for this region alone. The presence of
extraneous stem-loop structures gives the whole element a stability of -101,5kcal/mol., and
may thus conversely be beneficial by stabilising the putative RRE. The possibility of non¬
specific binding to Rev mediated by the extraneous sequences must be considered when
interpreting results of experiments using this RNA. The structure of the antisense transcript
contains a region with some similarity to the sense element; in particular the presence of a
central helix surrounding three stem-loops, two of which are linked. However, there are
important differences in terms of the size and positioning of substructures, and the primary
sequence is divergent. Certain regions of double stranded RNA stems within the antisense
probe form mirror images of the sense probe, although these are not extensive. The high
degree of secondary structure demonstrated by the antisense transcript suggests that it is a
suitable control to study the specificity of EV1 Rev binding.
Radiolabeled RNA was obtained by transcription from linearised templates as
described above. Varying concentrations of unlabelled UTP were incorporated into each of
five separate reactions using the sense template tT7. In addition, the reaction was carried out
at 20°C, as lower temperature has been shown to promote the synthesis of full length
product (Krieg, 1991). The results of this experiment are depicted in figure 5.5. It is
immediately obvious that this template gives rise to a considerably higher yield of product than
was previously obtained with pCCR6. The average percentage incorporation of labelled UTP
achieved in the absence of unlabelled UTP was 82.4 +/- 5.6% (mean +/- standard deviation
for three independent reactions). This figure is within the expected range quoted by the
transcription kit manufacturer. The first fifteen nucleotides transcribed by T7 polymerase from
the tT7 template are as follows:
GGG CGA AUU GGC CAA
The presence of only two positions requiring the limiting uridine nucleotide may explain the
high rate of incorporation achieved by this vector, in contrast to transcription from pTZ18R.
Moreover, even with no unlabelled UTP, the proportion of truncated transcripts obtained is
low, with a major contaminating species of approximately 300 bases. This species is virtually
eliminated in the presence of 25pM cold UTP. Although the presence of this volume of
unlabelled nucleotide reduced the percentage incorporation of the label to 25.8% (figure
5.5a), it was found that increasing the reaction time to two hours, and adding a second aliquot
of enzyme after one hour increased the average incorporation to 65.8 +/- 3.6%. The
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Figure 5.5: Transcription from the pGEMH/RRE Vector
RNA was synthesised from the tT7 template in the presence of a range of
concentrations of unlabelled UTP, as described in the text. Reaction products were analysed
for the efficiency of label incorporation and for the presence of full length transcripts.
A The efficiency of reactions was analysed by TCA precipitation of synthesised RNA,
and scintillation counting of the amount of incorporated label. The percentage of incorporated
label is plotted against the concentration of unlabelled UTP used in the transcription reaction.
B Reaction products (~5000cpm) were analysed by electrophoresis through a 6%
denaturing polyacrylamide gel. The result was visualised by autoradiography. Labelled
transcripts migrating with the expected full length size (329nt) are denoted by an arrow. An
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importance of the purity of the transcript for use in functional assays meant that it was decided
to continue with transcription reactions containing 25pM cold UTP (figure 5.5b). The molarity
of labelled UTP present in the reaction was 6.25gM; the molar ratio of unlabelled to labelled
nucleotide in the reaction was therefore 4:1. Assuming that there was no bias in
incorporation, each transcript would contain 20% radiolabeled uridine nucleotides. Typically,
250-300ng of RNA were produced per reaction, with the specific activity of labelled transcript
in the range 2.5-3 x 107 cpm/pg (counting efficiency assumed to be 100%, hence dpm are
equivalent to cpm). Antisense RNA, produced from the tSP6 template, was similarly pure, and
contained an average 65.5 +/- 4.6% incorporated label (two independent reactions). A
template included with the transcription kit was utilised as a second control source. This
plasmid was based on the pTRIPLEscript vector, containing a 250bp insert derived from the
murine p actin gene. Transcription from this vector with T3 polymerase generates a 325b RNA
product. This is almost identical in size to the sense and antisense RRE RNA, and was used
as an internal marker control for gel electrophoretic examination of the products of
transcription.
The DNA template was digested by incubation with RNase free DNase to terminate
transcription, and unincorporated nucleotides were separated from the probes by two rounds
of phenol (pH5) extraction and ethanol precipitation. This procedure resulted in the
percentage of incorporated label rising to over 80%.
5.4 Rev Binding Assays
5.4.1 Conditions for Binding
The basis of RNA binding assays for analysis of EV1 Rev function was the creation of
conditions to allow an equilibrium of protein:RNA interactions to occur, with subsequent
examination of the equilibrium by detection of complexed RNA by its reduced mobility during
gel electrophoresis, or by its retention on nitrocellulose filters. The reaction conditions
chosen were based on the results of published analysis of the in vitro RNA binding activity of
HIV-1 Rev (Heaphy eta!., 1990; Holland etal., 1990; Cook eta!., 1991). Partially purified
GSTRev was incubated at a range of concentrations (25nM-1,275pM) in binding buffer in
moderate ionic conditions (20mM Tris.HCI pH8; 50mM KCI) with yeast tRNA (2pg) to reduce
non-specific binding. Labelled RNA probe (~20,000cpm, typically 7.5fmol of 320-330nt
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transcript) was subsequently added. The binding reaction was set up in a small volume (20pJ)
to encourage the formation of equilibrium conditions, and incubated at 25°C for ten minutes
prior to analysis.
5.4.2 Gel Mobility Retardation Assays
Analysis of protein:RNA complex formation by the direct electrophoretic separation of
complexed and free labelled RNA on non-denaturing, low percentage polyacrylamide gels
was developed by Konarska and Sharp (1986) for the study of spliceosome formation. These
experiments involved the use of whole cytoplasmic extracts as the protein component.
Modifications to the original procedures have been made for the identification of complexes
formed by purified protein preparations, including the influenza A virus NS1 protein (Qiu and
Krug, 1994), HTLV-1 Rex (Bogerd etal., 1991) and HIV-1 Tat (Dingwall etal., 1990) and Rev
(Daly et at., 1989; Cochrane etal., 1990a; Daefler etal., 1990; Holland et at., 1990; Malim et
a!., 1990; Cook etal., 1991; Kjems etal., 1991a).
GSTRev/RNA binding reactions were diluted in running buffer, containing 15%
glycerol for stability, and electrophoresed through 6% native polyacrylamide gels. The results
of binding of GSTRev to sense RRE RNA and the (3-actin control RNA are illustrated by figure
5.6a,b. A retarded complex appears to be formed by sense RRE RNA in the presence of
210ng GSTRev (~220nM). The mobility of this complex is further reduced by the presence of
higher concentrations of GSTRev. A different pattern is apparent with control RNA. Although
the mobility of the major portion of RNA is unaffected by the concentration of GSTRev, a small
retarded signal is apparent at all protein concentrations (arrow). The uniformity of the retarded
signal with respect to protein concentration, and the degree of retardation, suggests that this
is may be a non-specific phenomenon. This experiment therefore provides preliminary
evidence for specific interactions between GSTRev and RNA corresponding to the predicted
RRE. However, the degree of degradation of RNA probe observed on binding and
electrophoresis makes interpretation difficult. It is clear from the sense RRE reaction that
intermediates of degradation are present regardless of the presence of protein. To determine
whether RNases were active during the binding/incubation and/or electrophoresis phase of
this assay, a time course of degradation was performed by incubating aliquots (lOOOOcpm) of
sense RRE probe with ~630ng of GSTRev and boiling the reaction to terminate possible
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Figure 5.6: Analysis of GSTRev Function by Gel Mobility Retardation
Approximately 20,000 TCA-precipitable cpm of 32P labelled RNA probe
(~7.5fmol/0.37nM) was incubated in binding buffer (20mM Tris.HCI, pH 7.5. 50mM KCI, 1mM
DTT, 2mM MgCI2, 2pg yeast tRNA, 15U RNasin) with a variable volume of eluted, partially
purified GSTRev fusion protein in a total volume of 20pl. After ten minutes incubation at 25°C
complex formation was analysed by addition of loading buffer and electrophoresis of a "lOgl
aliquot through a native, 4% acrylamide gel. The result was visualised by autoradiography.
A Sense RNA probe
B Control ((3-actin) RNA probe
The input probe and retarded signals are indicated, as are degradation products due
to RNase activity.
C Analysis of the effect of the addition of the GSTRev fusion protein to RNA stability.
Sense RNA (10,000 cpm) was incubated at 25°C in binding buffer containing ~630ng of
GSTRev (total ~3.2mg protein), for 5-60 minutes. Reactions were terminated by the addition
of denaturing loading buffer (includes formamide) and boiling. Electrophoresis through a 6%
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degradation. The results were visualised by electrophoresis through a denaturing (8M urea)
6% polyacrylamide gel, with subsequent autoradiography, and quantified by TCA precipitation
of incorporated label. It was assumed that denaturing conditions would inhibit further RNase
activity. From figure 5.6c it can be seen that little degradation occurred. The level of
incorporated label was found not to fall significantly. Thus, it would appear that native gel
conditions may have been responsible for probe degradation. Although strict precautions
were taken against RNase contamination, ie all buffers were made up with
diethylpyrocarbonate (DEPC) treated water, and glassware treated similarly, the large buffer
volumes and the degree of manipulation and time involved in PAGE analysis meant that
complete inhibition of RNase activity was difficult. Experiments with antisense RRE RNA were
unsuccessful, due to the almost complete degradation of the probe during electrophoresis.
The presence of degradation products meant that quantification of the results of retardation
assays by densitometric analysis was not feasible. Moreover, this assay proved to be poorly
reproducible. Ribonucleoprotein complex dissociation may have been responsible for this,
despite the use of the binding buffer as electrophoresis buffer. Unavoidable delays in loading
reactions onto gels, and subtle differences in local buffer conditions might have resulted in
differences in the stability of complexes, leading to dissociation prior to, or during
electrophoresis. Attempts to increase stability by the addition of glycerol to 4% v/v within the
gel (Nalin et at., 1990; Bogerd et at., 1991) were unsuccessful. Given the problems
associated with the gel mobility retardation assay, it was decided that the filter binding assay
would be employed as an alternative.
5.4.3.1 Nitrocellulose Filter Binding Assays
Filtration of small radiolabeled RNA transcripts through a 0.45pM nitrocellulose
membrane will result in significant retention on the filter only if the RNA is complexed with
protein. Scintillation counting of the retained probe allows complex formation between
protein and RNA to be quantified. Filter binding assays were developed in an attempt to
identify the DNA binding specificity of the E. coli lac repressor (Riggs et at., 1968).
Subsequently, this method was adapted for use with RNA systems by Carey and co-workers
(1983), during investigation of the characteristics of binding between the bacteriophage R17
coat protein and the RNA genome. Filter binding has the advantages of ease and rapidity,
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Figure 5.7: Preliminary Nitrocellulose Filter Binding Assay
Variable amounts of GSTRev were incubated with 20,000 cpm of two RNA probes,
sense and antisense RRE RNA (from pGEM11/RRE) as described in figure 5.6. The whole
reaction volume was filtered through pre-wetted 0.45pM nitrocellulose filter using a
Schleicher and Schuell 'slot blot' apparatus. Filters were washed twice with binding buffer
(20mM Tris.HCI pH 7.5, 50mM KCI) and air-dried. Trapped ribonucleoprotein complexes were
quantified by scintillation counting of individual sections of filter. The results are plotted as the
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which should reduce contaminating RNase activity. Furthermore, a number of reactions can
be carried out simultaneously, which should reduce inter-experimental variation.
Preliminary experiments to determine the validity of this assay were performed.
Varying concentrations of GSTRev were incubated with labelled sense and antisense RRE
RNA (~20,000cpm) obtained from pGEMH/RRE, in the presence of nonspecific competitor
RNA (yeast tRNA, 2p,g/20p.l reaction). The results are illustrated in crude form in figure 5.7. A
proportion of the probe is clearly retained even in the absence of protein. The sense RRE
probe is retained on the filter at low GSTRev concentrations. This is suggestive of specific
ribonucleoprotein complex formation. In contrast, the antisense probe requires higher
concentrations for significant retention. Retention of the antisense probe does not reach a
plateau, suggestive of non-specific interactions. Further experiments were carried out in
order to define assay parameters.
5.4.3.2 Assay Parameters
The accuracy and hence the utility of the filter binding assay depends on the amount
of retained label accurately reflecting the equilibrium binding between protein and RNA
achieved prior to filtration. The mechanics of the assay may distort this equilibrium in two main
ways. Firstly, leaching of RNA from complexes retained on the nitrocellulose membrane would
lead to an underestimation of binding. The number of washes after filtration might be
expected to affect leaching. Moreover, if the complex half life did not greatly exceed the time
taken for filtration, then dissociation would occur. Secondly, inappropriate, non-specific
binding of RNA by membrane bound protein would lead to an overestimation of binding. If a
sufficiently large protein concentration was added, blocking of the filter might result in large
scale retention of labelled probe. The relative impurity of the GSTRev preparation meant that
the total mass of protein added was high: hence this latter point might be significant in the
current context.
The parameters for the reliability of the assay were therefore investigated. To test for
leaching of bound probe, an experiment was carried out using standard procedures, in
GSTRev excess (500nM), but varying the number of post-filtration washes from none to five.
The time spent on the membrane was directly proportional to the number of washes, so that
complex dissociation due to all factors could be studied. The results are shown in figure 5.8a.
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Figure 5.8: Filter Binding Assay Parameters
A Standard filter binding assay, using 500nM GSTRev and 20,000 precipitable cpm
sense and antisense RNA probes (~8fmol sense/7.5fmol antisense). The number of post-
filtration washes was varied from none to five, and the retained RNA analysed by scintillation
counting. The results are plotted as retained RNA (cpm) against the number of wash steps.
B Standard binding reactions with variable protein concentrations but without labelled
RNA were set up, and filtered. Subsequently, 20,000 cpm of sense RNA in a total volume of
20pl was added to each well, and filtration repeated. Bound RNA was counted after a single
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The first two washes appear to have no effect on the level of bound RNA. Subsequently,
there is a shallow decline in binding, which is, perhaps surprisingly, more evident with sense
RRE RNA than with the antisense RRE RNA. It is impossible to determine whether the
reduced binding is due to leaching caused by repeated washing and filtration, or a
consequence of dissociation kinetics. However, this experiment suggests that loss of bound
RNA is not significant up to two washes. Thus, two wash steps were retained within the
experimental procedure.
To test for the effect of pre-bound protein on filtration of free probe, binding reactions
with varying protein concentrations were set up and filtered without the addition of labelled
RNA. An aliquot of labelled, sense RRE RNA (~20,000cpm) was then added to wash buffer
within each chamber, and filtration repeated. The amount of bound RNA was counted, and is
illustrated by figure 5.8b. It is clear that the presence of <8pg total protein does not reduce
the filtration of RNA under these conditions. However, pre-binding of 12pg of protein resulted
in -50% retention. This suggests that blocking of the filter can occur at very high protein
concentrations. These concentrations were avoided during further analysis of GSTRev
binding.
5.4.3.3 GSTRev RNA Binding Affinity
A series of filter binding experiments were carried out in order to investigate the
binding of GSTRev to RNA targets. Three different RNA probes were used; the sense and
antisense RRE probes derived from tT7 and tSP6 respectively, and the p-actin probe derived
from the control template. Initial experiments were performed in the presence of 2pg/20pl
reaction of yeast tRNA. For data analysis, the concentration of GSTRev was determined by
Biorad assay, and the percentage of full-length product by densitometric analysis. The
molarity of GSTRev was thence calculated on the basis of a predicted molecular weight of
47kDa. Typically, 1pl of GSTRev preparation contained 1.2mg/ml protein, of which 20% was
full length fusion protein (240ng). Addition of ipl to a 20pl binding reaction resulted in a final
GSTRev molarity of approximately 250nM. A standard probe input of ~20000cpm was
maintained. The specific activity of each probe was determined, and the mass of input RNA
calculated. The results of these studies are depicted by figure 5.9. Figure 5.9a demonstrates
the affinity of GSTRev for each labelled probe. This graph was computed on the basis of an
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Figure 5.9: The Affinity of GSTRev for Radiolabeled RNA Probes
Standard binding reactions were set up, with varying concentrations of GSTRev (25-
1275nM). Three input labelled RNAs were used, the sense and antisense RRE RNAs and the
(5-actin RNA. RNA input was standardised to 7.5fmol (18000-20000cpm).
A Results are plotted as the percentage of total input RNA retained at each
concentration (fractional binding) against the GSTRev concentration. Figures represent the
mean +/- standard deviation from three independent reactions.
B Variation in results obtained from the filter binding assay. Three separate reactions
were performed at each protein concentration using the same substrate sources, to
represent the intra-assay variation. The results presented in A are used to represent inter-
assay variation. Figures refer to the mean +/- standard deviation.
C Standard binding assay, using non-fusion GST as the protein substrate. Results are
derived from a single experiment.
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average of three independent functional assays, involving distinct protein and RNA probe
preparations. The mean and standard deviation of these results are shown. The results are
plotted in the form ot fractional binding, that is the percentage of input probe bound at each
distinct protein concentration. GSTRev has a relatively high affinity for the sense RNA (S-
RRE) probe. Probe retention occurs on input of low protein concentrations, and rises rapidly.
A plateau is reached at approximately 500nM GSTRev. A proportion of the S-RRE probe
remains unbound, even in the presence of saturating GSTRev concentrations. This
proportion is variable between different preparations. GSTRev also demonstrates binding to
the antisense probe, A-RRE. However,binding characteristics are different, with binding
slowly increasing with protein concentration. Only -20% of this probe is bound at a GSTRev
concentration of 1.25pM. GSTRev effectively fails to bind to the control probe, p-actin RNA.
Variation between experiments was examined to investigate the reproducibility of this
assay. Figure 5.9b tabulates the mean and standard deviation of three data sets derived from
independent reactions (inter-assay variation) or three different assays from the same reaction
(intra-assay variation). Variation is clearly significant between different reactions, but appears
to be minimal with respect to assays performed using the same reactions. The assay itself is
therefore reproducible. Systematic errors introduced by the requirement for estimation of
both the protein concentration and purity, and in the addition of probe may in part explain
such inter-assay variation.
To investigate which component of the GSTRev fusion chimaera was responsible for
RNA binding, a separate experiment was performed using purified GST as the input protein.
GST fails to bind to the sense RRE or p-actin control probes, although the antisense probe
was retained to a slight degree (figure 5.9c). As only a single experiment was performed, the
relevance of this was difficult to gauge.
The background level of probe retention was low throughout these assays. The
average retention in the absence of protein was 4 +/- 1.6% for p-actin RNA; 6.5 +/- 0.4% for S-
RRE, and 6.3 +/- 0.4% for A-RRE (from three independent reactions). To calculate the degree
of affinity for RNA, background levels were subtracted from the totals. The dissociation
constant (Kd) is a measure of affinity, and is here defined as the protein concentration at half
maximal binding. This figure is only valid if the concentration of one binding substrate is in
excess over that of the other. For the sense RRE probe, the saturation level was 60% of input
probe. Hence, the Kd for GSTRev binding to S-RRE under these conditions was estimated at
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120nM. At this concentration, GSTRev is present in an approximate 325 molar excess over
the sense RNA probe (120nM compared to 370pM).
5.4.3.4 GSTRev RNA Binding Specificity
To investigate the specificity ot GSTRev RNA binding, a series of preliminary
experiments were performed in which components of the binding reaction were varied. The
arginine-rich putative basic domain of EV1 Rev might be expected to mediate non-specific,
electrostatic interactions with RNA. This is the likely basis for affinity to the antisense RRE
probe. Altering the ionic conditions within the binding buffer would affect such non-specific
interactions, but have little influence on specific binding. To determine the effect of ionic
strength on binding by GSTRev, binding was carried out in 50mM potassium chloride as
standard, and in phosphate buffered saline (PBS), which contains 137mM sodium chloride,
and 26.8mM potassium chloride. The result is presented in figure 5.10. Whilst the change in
buffer conditions did not alter the binding curve of GSTRev to sense RRE RNA, there is a
slight decrease in binding to the antisense probe in higher ionic conditions, most noticeably
at higher protein concentrations. It must be emphasised that, due to pressure of time, only a
single experiment was performed. Further investigation would be required to attempt a
statistical analysis of this data. Furthermore, a study of binding activity by titration of ionic
conditions would be required for full analysis.
The level of unlabelled RNA required to compete out the binding of GSTRev to
labelled probe is a measure of the specificity of binding. Reduction in binding at low
concentrations of competitor indicates a low specificity binding, whereas highly specific
binding requires a high concentration of competitor for inhibition. Competitor RNA was added
prior to the addition of probe RNA in all experiments. Two competitor species were available.
Yeast tRNA, included in the standard reactions to act as a 'sink' for non-specific interactions,
was added at a range of concentrations. The effect of titrating yeast tRNA on binding is
illustrated by figure 5.11a. The concentration of protein used in these experiments was
constant, and set at 480-500nM. The molarity of yeast tRNA was determined by assuming that
the average molecule contains 80 nucleotides. The membrane retention of sense probe is
relatively unaffected by the concentration of tRNA, within the range used here. Flowever,
binding to antisense RRE is strongly dependent on the level of tRNA competitor. In the
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Figure 5.10: The Effect of Buffer Conditionson RNA Binding by GSTRev
Binding reactions between GSTRev and the sense and antisense RNA probes were
performed using standard buffer conditions, or by replacing the Tris/KCI with sterile







absence of competitor, a high proportion (-60%) of antisense RNA is retained. Retention is
dramatically reduced above 0.4pM tRNA. The concentration of tRNA required for 50%
binding inhibition can be estimated from this result to be -1,05pM; however, more data points
would be required for an accurate determination of this value, as there is a steep reduction in
binding between 0.36pM and 3.6pM yeast tRNA. The mass of specific probe used in these
experiments was ~0.8ng. This equates to a molarity of 0.37nM for each probe (which differ by
7/329 nucleotides: assume average nucleotide mass of 330Da). Hence, 50% reduction in
binding to the antisense probe is achieved in the presence of a -2800 molar excess of yeast
tRNA.
A second competitor species was available in the form of unlabelled sense and
antisense RNAs. Theoretically, binding to labelled sense probe should be reduced by a
simple molar excess of specific unlabelled competitor. It is assumed that the binding protein
does not discriminate between labelled and unlabelled forms. In practice, the concentration of
protein will affect the level of competition. Unlabelled ('cold') RNA was prepared by increasing
the concentration of unlabelled UTP in the transcription reaction to 500pM; thus all four
ribonucleotides were present at saturating concentrations. Transcripts were purified by
phenol extraction and ethanol precipitation, and the concentration estimated by
spectrophotometry. An aliquot of each transcript was visualised by denaturing gel
electrophoresis (figure 5.11b). RNA of the expected size was clearly present. Cold sense
RRE RNA was used as a competitor in reactions between 480-500nM GSTRev and 0.35-
0.4nM labelled probe. Non-specific competitor (yeast tRNA) was excluded from these
reactions. The result of this experiment is illustrated by figure 5.11c. Unexpectedly, the
fractional binding of GSTRev to both the sense and antisense RRE RNA probes is almost
totally unaffected by the titre of cold sense RRE RNA. Although there may be a slight fall in
antisense RRE binding, it is clearly not a significant reduction. The highest cold RNA
concentration used, lOOnM, corresponds to an approximate 250-275 molar excess of cold
over 'hot' RNA. An identical experiment with antisense competitor gave similar results (data
not shown). Further experiments, to analyse the effect of reducing the protein concentration
and of increasing the titre of competitor RNA, were indicated: unfortunately, pressure of time
did not allow for completion of this work.
191
Figure 5.11: The Specificity of GSTRev Binding: Competition Experiments
A The effect of the level of heterologous RNA on GSTRev binding was investigated by
standard binding reactions, with the pre-incubation step containing varying concentrations of
yeast tRNA (0-36|iM - 0-20pg). The concentration of GSTRev was 500nM, and 20,000cpm of
labelled probe were subsequently added. Results are plotted as the fractional binding of
input labelled probe against the concentration of yeast tRNA.
B Transcription of unlabelled ('cold') sense and antisense RRE RNA. Transcription
reactions were assembled with all four ribonucleotides present at saturating concentration
(500pM). Products of transcription were analysed by electrophoresis through a 8%
denaturing acrylamide minigel, with visualisation by staining in ethidium bromide.
C Competition experiment performed as described in A above, except that unlabelled
competitor was sense RRE RNA. The fractional binding of labelled probe is plotted against
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This chapter has reported the generation of RNA probes for the attempted
characterisation of the EV1 Rev responsive element. Binding of GSTRev fusion protein to
these probes was analysed by assaying for the presence of ribonucleoprotein complexes.
Although a gel mobility shift assay proved technically unworkable, results were generated by
the use of a nitrocellulose filter binding assay. Evidence was obtained to suggest that data
derived from this assay accurately reflected the degree of solution binding of protein and
RNA. Conclusions drawn from the results presented in this chapter are subject to several
caveats, and further study to confirm the specificity of the Rev/RRE reaction in the absence of
contaminating proteins and RNA substructures will be required.
5.5.1 GSTRev Binding Affinity
Saturation binding experiments were performed in order to investigate the affinity of
GSTRev for RNA probes derived from the EV1 viral genome. Addition of GSTRev resulted in
membrane retention of the RNA probe containing the putative RRE in the sense orientation
during filtration. The estimated dissociation constant (Kd), a measure of binding affinity, was
120nM. This figure, and other conclusions drawn from this work, must serve as a preliminary
estimation of binding affinity, given the following important points concerning experimental
design and conditions. The protein substrate was only -20% pure, and contained truncated
fusion fragments which may be capable of binding; this would lead to an underestimate of the
concentration of functionally competent protein molecules within the reaction. The RNA
probe contained extraneous sequences, including an additional stem-loop structure which
may have interfered, positively or negatively, with binding. The Kd should be largely
unaffected by the concentration of input probe: however, these experiments were performed
at a single input probe concentration. At the Kd point GSTRev was present in an approximate
325 molar excess over the sense RRE probe (GSTRev 120nm: RNA ~0.37nM). The effect of
altering this concentration on the Kd should be examined to validate the estimated figure. To
eliminate the possibility that differential degradation of probes occurs during filtration, such
that the antisense RNA has lower stability, the filtration run-through could be collected and
analysed for RNA stability be gel electrophoresis. To confirm the protein specificity of the
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binding reaction, an anti-Rev antiserum could be used to block binding: the anti-peptide
antiserum described in chapter tour has specificity for the carboxy-terminal protein region and
would not be suitable for this purpose.
GSTRev was also able to mediate partial retention of antisense RRE RNA at high
concentrations. In the absence of non-specific competitor, high levels of antisense probe
were retained at saturating GSTRev concentrations. This RNA is predicted to form extensive
secondary structure. The failure to similarly interact with the mouse (3-actin probe suggests
that GSTRev has a general affinity for regions of secondary structure. The superficial similarity
between the antisense and sense probes with respect to the presence and organisation of
stem-loop structures suggests that the primary Rev recognition element is dependent on
primary structure or on distinct substructures not shared by the two probes. A low level of
transcription may occur from the incorrect strand during RNA synthesis (Schenborn and
Meirendorf, 1985): thus there may be contamination of the antisense RNA preparation with
sense structures, which may mediate the observed low level binding. If a template error level
of 0.2% is assumed for the polymerases, then the concentration of heterologous probe
would be in the region of 0.75pM per binding aliquot. Reactions using this concentration of
specific sense probe might indicate whether contamination of the antisense preparation is
sufficient to mediate the partial binding observed, or whether GSTRev possesses affinity for
the antisense probe in its own right.
Thus, given the structural and genomic locational similarity of the EV1 RNA element
to the HIV/SIV RREs, and the high affinity of GSTRev for a probe containing this element, it
can be tentatively concluded that the EV1 env sequences 7935-8216 contain a GSTRev
binding element effective only in the sense orientation. Further delineation of this element,
and in particular the definition of possible binding sites of different affinities, would require
analysis using truncated RNA fragments. The pGEM11/RRE construct might be suitable for
such a study, by utilising unique restriction endonuclease sites within the EV1 insert to
linearise the plasmid as a transcriptional template. Excision of the extraneous, vector-derived
sequences from the RNA probe would remove the uncertainty surrounding the precise role
of the virus-derived sequences in protein binding. Incorporation of a polymerase promoter
within a primer used to amplify the putative RRE by PCR would result in the production of RNA
containing viral sequence only. This 'promoter tagging' technique has been utilised by other
authors working on the HIV-1 Rev/RRE interaction (Holland etat., 1990; Cook eta/., 1991). It
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should be noted that the relatively large region of extraneous sequence derived from the
pGEM vector may have improved transcription efficiency compared to the pTZ18R vector, by
providing an initiating sequence with few uridine nucleotides. Alternatively, synthetic
oligonucleotides could be employed as the RNA substrate. For this approach to be
technically feasible, further localisation of a EV1 Rev high affinity binding element would be
required. Synthetic peptides corresponding to the HIV-1 Rev arginine-rich domain are able to
bind the RRE with similar affinity and specificity as the intact molecules (Kjems etal., 1992).
Peptides corresponding to the EV1 Rev basic domain, and several variants, were designed
for a similar study. However, technical problems, due to the high arginine content, were
encountered by several commercial chemical companies in the manufacture of these
peptides.
The estimated Kd for HIV-1 Rev binding is 0.8-5nM (Heaphy etal., 1990; Holland et
a!., 1990; Cook etal., 1991). A high Kd may be necessary for functional discrimination of viral,
target RNA from an excess of competing cellular RNA within the infected cell nucleus.
However, specific discrimination of target from background molecules can be achieved with a
relatively low Kd; the ribosomal S4 protein has a Kd of 14mM for 16S ribosomal RNA, its
molecular target (Vartikarand Draper, 1989). The estimated binding constant for EV1 GSTRev
of 120nM, is in the region of two orders of magnitude lower than that of HIV-1 Rev. Although
this might suggest a reduced affinity for target RNA exhibited by the EV1 molecule, the
aforementioned points concerning the validity of this data mean that over interpretation
should be avoided. Possible modulation of binding affinity by the GST fusion partner could
explain the lower binding constant reported. Cullen and co-workers found that 27ng of free
HIV-1 Rev protein were functionally equivalent to 330ng of GSTRev (~130ng Rev) in a RNA
binding gel retardation assay (Malim and Cullen, 1991). Thus the efficiency of binding of
fused Rev was in the order of one fifth of that obtained with the free protein. The validity of
GST fusion protein functional studies is discussed in more detail in chapter seven. A source
of pure, free EV1 Rev protein would be required to determine how the relevance of the
fusion protein data.
5.5.2 GSTRev Binding Specificity
Competition experiments were performed in order to investigate the specificity of
195
GSTRev binding to RNA ligands. The concentration of competitor ligand required for a 50%
reduction in binding is a standard measure of binding specificity. A non-specific competitor,
yeast transfer RNA, was shown to inhibit the binding of GSTRev to the antisense RRE ligand.
A concentration of ~1.05pM tRNA was required to reduce the fractional binding of antisense
RNA by one half. This value is within the range reported for a similar inhibition of HIV-1 anti-
RRE Rev binding (0.7-20pM) (Daly etal., 1989; Cook etal., 1991). These figures are not
directly comparable, however, as the configuration of the antisense molecules will differ, and
mediate different binding affinities. Binding to sense RRE RNA was not significantly reduced
in the presence of 36p,M tRNA, an approximate 28,000 fold molar excess. Cook and
colleagues have reported that a 105 fold excess of tRNA is required for a 50% reduction in the
binding of HIV-1 Rev to sense RRE RNA (1991). Altering the ionic strength of the binding
buffer was performed to further investigate binding specificity. Farrington and colleagues
(1991) have shown that the HIV-1 Rev protein can bind both sense and antisense RRE RNA
with similar affinities in low ionic strength buffers, but that raising the ionic strength results in a
progressive loss of binding to the non-specific probe. Although the different conditions used
in this report did not result in significantly altered binding, the difference in ionic strength was
relatively minor. The use of greater variations in buffer strength is indicated.
The failure to achieve an inhibition of the binding of GSTRev to labelled probe in the
presence of an excess of unlabelled specific competitor was an unexpected finding.
However, the use of a saturating protein excess in these experiments probably provides an
explanation. If both specific and non-specific RNA binding sites are present within the protein
molecules, then the total number of binding sites present in saturating concentrations of
protein will be very high. Binding of specific competitor to the high affinity sites of a proportion
of these molecules will not disrupt the subsequent binding of either specific or non-specific
labelled RNA. Repetition of these experiments with reduction the protein input concentration
to the estimated Kd value is indicated.
5.5.3 Fractional Binding
Although a high percentage, 60-70%, of the input sense RRE probe was retained on
the filter at saturating GSTRev concentrations, the fractional saturation did not reach 100%.
This phenomenon has been widely reported, both during Rev/RRE investigation (Heaphy et
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a/., 1990; Holland etal., 1990), and in other systems (Carey eta/., 1983; Qiu and Krug, 1994).
Furthermore, the plateau level of fractional binding was found to be the most variable figure
within the filter binding assay data set. This latter point suggests that a property of the reaction
substrates may affect fractional saturation. A proportion of the protein or RNA input molecules
may therefore have not been competent for binding, due perhaps to incorrect folding leading
to masking or inactivity of functional domains. Variation in this proportion between
preparations would account for the observed variation. It should be noted that to estimate the
binding Kd, it was assumed that all molecules within the reaction were competent for binding.
A second explanation is that the kinetics of the binding reaction prevent saturation of the
RNA. The relative half lives for complex assembly and disassembly would determine the
proportion of ligand bound at equilibrium; this will not approach 100% unless the half life for
binding greatly exceeds that for disassembly.
5.5.4 The Gel Retardation Assay
Gel mobility retardation assays have been widely employed in the study of HIV-1 Rev.
These assays have the benefit of visualisation of the stoichiometry of the binding reaction, as
multiple retarded complexes have been observed at varying protein concentrations (Iwai et
al., 1992; Daly etal., 1993a). The difficulties here encountered in high resolution of stable
ribonucleoprotein complexes by electrophoresis meant that the binding stoichiometry could
not be so examined. Reducing the level of gel cross-linking by lowering the bis-acrylamide to
acrylamide ratio from 40:1 to 80:1 has been associated with high resolution of complexed
RNA (Konarska and Sharp, 1986). The apparent RNase susceptibility of probe under native
gel conditions may be countered by more extensive DEPC treatment of glassware and
buffers, although the precautions used in this project were already stringent. Attempts to
increase complex stability by altering gel conditions, and by running gels at 4°C, were
unsuccessful.
5.6 Summary
A 176nt RNA element from within the EV1 envgene, immediately downstream of the
SU/TM boundary, is predicted to form a stable secondary structure with superficial
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resemblance to the HIV/SIV RRE. Generation of this RNA sequence by run-off transcription
was found to be dependent on vector context. Highly pure RNA was obtained by transcription
from a pGEM11Zf(+) vector containing a PCR derived env gene insert. Binding between
radiolabeled RNA and partially purified GSTRev fusion protein was monitored by assays
designed to detect ribonucleoprotein complexes. Problems with RNase degradation and
complex stability negated the use of a gel mobility retardation assay, although preliminary
experiments were suggestive of GSTRev binding to a probe corresponding to the putative
RRE element. Nitrocellulose filter binding assays were more successful. GSTRev was found
to bind with high affinity to sense RRE RNA, and with less affinity to antisense RRE RNA. The
dissociation constant for GSTRev binding to sense RNA was estimated to be 120nM. Binding
to antisense RNA was dependent on the level of a non-specific RNA competitor, and there
were indications that buffer conditions were also significant. This was suggestive of low
specificity interactions between GSTRev and antisense RNA. Finally, specific competitor RNA
was found to be unable to competitively inhibit probe binding at the concentrations used in
this study. The use of a saturating GSTRev concentration may have meant that the insufficient




THE REV/RRE AXIS OF
OVINE/CAPRINE LENTIVIRUSES
6.1 Introduction
Chapter 5 reported the characterisation of a region within the EV1 genome (7928-
8212) which could be transcribed to generate an RNA sequence able to mediate specific and
high affinity binding in an in vitro assay to a GSTRev protein extract. A subsection of this
region with co-ordinates 7995-8170 was predicted to form a highly ordered secondary
structure. The coincidence of these facts suggests that the MVV EV1 Rev protein functions
in a analogous manner to the more fully characterised HIV-1 Rev and HTLV-1 Rex proteins.
RNA binding, however, is insufficient for full HIV Rev activity (Malim et al., 1989b). The
conservation of a second HIV/HTLV functional motif, the leucine-rich activation domain, and
the temporal control exerted over viral gene expression by MVV (Vigne et al., 1987) suggests
that further aspects of Rev biology may be shared. HIV-1 Rev function has been assayed by
the ability to rescue Rev-deficient, and hence replication incompetent, mutant proviruses
(Pomerantz et al., 1992). The effect of HIV Rev function on gene expression within the
cellular environment has also been extensively investigated by the use of transient
transfection experiments. Generally, expression of subgenomic constructs containing
authentic viral splice sites and/or putative c/s-acting repressive sequences (CRS) from viral
structural genes is dependent on Rev function. To assay for Rev activity, expression of viral
structural proteins from such constructs can be analysed. This is a more amenable procedure
than viral rescue. Immune detection of Env or Gag proteins has been frequently utilised
(Knight et al., 1987; Hammarskjold et al., 1989; Chanda et al., 1990). Alternatively, reporter
genes with identifiable products can be inserted within an intronic location such that the
functional expression of pre-mRNA is required for detection of gene products. Defects in
nucleocytoplasmic transport, stability or translation in eukaryotic cells prevent efficient
expression of pre-mRNA. These may be overcome by co-expression of the Rev/RRE
regulatory axis. Commonly utilised reporter genes include chloramphenicol acetyltransferase,
luciferase and p-galactosidase. An alternative to assaying for protein products is to directly
analyse RNA expression patterns (Chang and Sharp, 1989; Felber etal., 1989; Lawrence et
al., 1991).
Elements which act to repress the expression of structural genes during the early
phase of MVV infection have yet to be characterised. Thus, the use of reporter constructs
based on HIV regions with known Rev-dependent characteristics may allow MVV Rev function
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to be analysed. Insertion of the putative EV1 RRE into such vectors may place expression
under EV1 Rev control, although the effect of the heterologous background would have to
be considered.
Two HIV-based reporter constructs were obtained (kind gifts of Dr. B. Cullen and Dr. R.
Fridell, Duke University, North Carolina). The presence or absence of Rev activity determines
expression of different forms of the Tat protein from pgTAT (Malim et al., 1988). This vector is
responsive to the HTLV-1 Rex protein (Bohnlein, S. etat., 1991), demonstrating that the HIV-
derivation of this construct does not prevent the function of heterologous Rev/Rex proteins.
The derivative vector pOXlOO was created by substitution of the tat exons for the more
quantifiable CAT reporter gene (Fridell et at., 1993). Thus, the aim of this chapter was to
investigate EV1 Rev function by cloning of the rev gene and the RRE element into
appropriate eukaryotic vectors and the use of these vectors for transient transfection based
assays. The Rev responsive properties of the putative RRE would also be revealed by these
experiments.
All lentiviruses demonstrate considerable intraspecific sequence divergence,
indeed, these viruses may exist in many variant forms within a single infected host organism;
the term 'quasispecies' has been used to describe such variants (Holland et al., 1992).
Sequence variation is a consequence of the poor fidelity of the retroviral reverse
transcriptase. Variation within the MVV genome has been estimated to occur at a rate of
between 0.8-1.7 x10"3 substitutions per nucleotide per year (Braun etal., 1987;Querat etal.,
1990). The small ruminant lentiviruses (MVV and CAEV) exhibit a particularly divergent strain
range (Yaniv etal., 1985): the nucleotide sequences of three MVV strains contain -20%
divergence (Sargan et al., 1991). This divergence is concentrated in particular genomic
locations: the rev coding region of these three strains displays the greatest variation, with
-35% divergence at the amino acid level (Sargan et al., 1991). Thus, it was of interest to
discover the degree of conservation of Rev function between different ruminant lentiviruses.
Detailed analysis of such conservation may aid the functional characterisation of Rev/RRE
sequences important for function. Transfection assays utilised to establish the functionality of
the EV1 Rev/RRE interaction could easily be adapted for such reciprocal studies by
interchanging both revgenes and putative RRE sequences from a range of viral strains.
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6.2 Rev/RRE Cloning
Although the EV1 rev gene and putative response element were already available in
cloned form, it was decide to re-clone these regions from viral DNA so that possible variation in
their origins could be minimised. Moreover, cloning from EV1 DNA would serve as a control for
the attempted cloning of the homologous regions from a number of other ruminant lentiviral
strains. Viral genomic DNA was obtained by extraction of DNA from virally infected ovine
fibroblasts (2.4.1). The viral strains used were the MVV isolates EV1, the Dutch isoalte
ZZ1050 and the Icelandic isoalte K184, and the CAEV isolate G63 (Knowles etal., 1991). The
CAEV Co strain molecular clone (Saltarelli etal., 1990) became available at a later date. Of
these strains, the genomic sequences of only EV1 and Co were known. Thus, primers for
polymerase chain reaction (PCR) amplification were designed with respect to these
sequences, and used in conjunction with the heterologous strains in the hope that sequence
conservation would be sufficient to allow correct cloning. However, it was realised that low
hybridisation efficiency due to mismatches might result in failure to isolate sequences by this
approach.
6.2.1 MVV Rev Genes
The revgene consists of two coding exons, separated by the length of the envgene.
In order to isolate the rev gene from viral DNA, it was necessary to perform a two stage
polymerase chain reaction. The primers and experimental strategy used are illustrated by
figure 6.1a,b. The exons are amplified independently by the use of primers which flank each
exon. The products of these reactions are then used as template for the second stage
reaction. The internal primers are designed to overlap one another, such that the products of
the first stage contain complementary ends. This will allow a proportion of these strands to
anneal to one another during the second reaction. Priming off the 3' ends of these annealed
partial duplexes results in the synthesis of a full length gene. This can then act as a template
for conventional PCR amplification, primed off the external primers. This process is termed
PCR mediated ligation.
Primers were designed based on the published EV1 sequence (Sargan etal., 1991).
The external primers, the 5' first exon and 3' second exon primers, were designed to
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Figure 6.1: Cloning of MVV Rev Gene into the Expression Vector
pBC12CMV by PCR Driven Ligation
A Oligonucleotide primers for amplification of the two coding exons of the rev gene.
The two external primers (15156 and 15157) contain mismatches with the EV1 sequence in
order to incorporate specific restriction endonuclease sites into the cloned fragment. These
mismatches are highlighted in bold. The position of the restriction sites are also shown.
Numbers refer to the EV1 genomic position from which these primers were derived and to
which they will hybridise. The internal primers (14941 and 14942) contain complementary
sequence to allow hybridisation of the products during the second PCR reaction. These
sequences are denoted C1 and C2. Thus only the 3' portion of each primer will hybridise with
the location required for the first reaction, which may reduce efficiency. The EV1 rev splice
donor (SD) and acceptor (SA) sites are marked.
B PCR driven ligation. During the second PCR reaction the 5' strand of the first exon
and the 3' strand of the second exon may anneal due to the introduced complementary
sequences (C1 and C2). Polymerase activity can thus be primed off the 3' end of each of
these strands, to form two full length, complementary strands. Subsequent rounds of the
reaction will proceed due to priming from the external oligonucleotide primers (15156 and
15157).
C Agarose gel electrophoresis of the first and second stage PCR products for cloning
of the rev gene. The results of the first stage reaction for the first (1) and second (2) exon
amplifications, from two templates, EV1 and ZZ1050 viral DNA are shown. Subsequently, the
EV1 products were used as templates for the second reaction. The predicted full length gene
product is marked by an arrow. Numbers refer to marker sizes in base pairs.
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D The eukaryotic expression vector pBCl2CMV/Rev. Expression of the inserted rev
gene is driven by the strong, human cytomegalovirus major immediate early gene promoter
(pCMV IE). The unique restriction sites Ncol and Xhol are used to insert the rev gene (but see
text for EV1 insertion). The major portion of the plasmid is derived from pBR322, and contains
an ampicillin resistance gene, and SV40 and bacterial origins of replication.
E Predicted amino acid sequence of the EV1 revgene obtained by the above method.
Comparison with the MVV strain 1514 Rev sequence is made. Identical amino acid residues
are denoted by a dash. The exonic boundary is shown as a vertical line. Horizontal lines
indicate the positions of the putative basic (EV1 residues 69-90) and activation (104-113)
domains, by sequence homology with the experimentally defined HIV/SIV/HTLV domains.
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Derived from pBCI 2CMVIL2
EV1 1 MASTKSKPSRATWTDMEPPQKEKWGQWQELVTRQQNEER 40
1514 1 KE T—R LR-T-N--L K Q—E 40
41 QGLVTCJLQADSTDQIYTGNSGDRRTSGPRGKTRRRKGWFK 80
41 EQ S-| SKA T-G-IG KKKR—Y- 82
81WLRRLKAREKNIPAHFYPDMESNVAGLEKLTLEEKLEEKP 120
83 K-R SQ MV-M-N TQ--DNA 122
121 IYESTTSTGGTSVAGRDWMDWRESAQK*. .KRKGGLSGQR 147
123 L-NPA-HI-DMAMD—E--E QKE 162
TDAHD*
163 -N-YPGK* 169
incorporate restriction sites tor the enzymes Ncol and Sail respectively. The internal primers
contained sequence derived from either side of the revsplice donor and acceptor sites. Both
EV1 and ZZ1050 viral DNA were used as templates for the first reaction. The expected sizes
of the first stage products using EV1 DNA as template were 153nt for exon 1, and 395nt for
exon two. From figure 6.1c it can be seen that products of the expected size are present in
the EV1 reaction, but are absent when ZZ1050 DNA was used as the template. This was not
surprising, given the high variability of the rev gene between sequenced MVV isolates. As
discussed above, primer hybridisation to the appropriate ZZ1050 sequence was therefore
likely to be weak. A similar failure to generate appropriate products was observed by PCR with
the remaining viral templates. The EV1 PCR products were isolated by agarose gel
electrophoresis, purified by hot phenol extraction, and used as template for the second stage
reaction, using the external primers. The result of this can be seen in figure 6.1c. A product of
similar size to the expected 529nt is present. This fragment was isolated as above, and
digested with the restriction enzymes Ncol and Sail, to allow cloning into an expression vector.
The vector pBC12CMV was chosen to express the rev gene product in eukaryotic
cells. This vector contains the human cytomegalovirus major immediate early gene promoter,
which directs high level expression due to an active enhancer element (Cullen, 1986). It is
derived from a vector designed to express interleukin 2 as an indicator of transcriptional
regulation, and contains both a eukaryotic (SV40) and prokaryotic (pBR322) origin of
replication, and the p-lactamase ampicillin resistance marker. The vector pcL, which contains
the rev gene from the MVV 1514 strain (Braun etal., 1987; Tiley et al., 1990) as an Ncol/Xhol
insert in pBC12CMV positions 67-663, was obtained (figure 6.1d: a kind gift of Dr. B. Cullen,
Duke University), and for clarity, will here be here referred to as pRevI 514. To obtain a vector
for expression of EV1 rev, the 1514 fragment was removed by digestion with Xhol and Ncol.
The parental vector was isolated by gel electrophoresis, excised, purified with silica and CIP
digested. Ligation of the vector and the PCR-derived EV1 rev gene fragment to form the
plasmid pRevEVI, was possible due to the compatibility of the restriction products of the
enzymes Xhol and Sail (incorporation of a Xhol site into the rev gene fragment by PCR was
contraindicated by the presence of such a site at position 8658 in the EV1 genome, within
the rev second exon). Ligated DNA was transformed into DH5a bacterial cells, and
approximately twenty colonies were obtained. These were screened for possession of the
insert by restriction digest analysis. Colonies containing the expected insert were used to
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generate large scale DNA preparations, and the correct insertion of the gene fragment
validated by double stranded sequencing. Primers for sequencing were designed to
hybridise with vector sequence approximately 50bp distant from the site of cloning. The
sequence of these primers (5'-3') and the positions within pBC12CMV from which they were
derived, were as follows:
5'sequencing primer G6711: CGTGTA CGG TGG GAG GTC TA: pBC12CMV 3885-3904
3'sequencing primer G6712: GCA GCA CTG ATC CAC GAT G: pBC12CMV 714-732
A single base change from the published EV1 genomic sequence, at rev gene
position 32 (genomic position 6025) was identified. Interestingly, this change, a cytidine for
thymidine substitution, was also demonstrated by pRev5, the fragment used to construct the
Ty and pGEX expression vectors (3.2.2). This substitution results in an alanine for valine
change in the amino acid sequence.
An amino acid sequence comparison between the predicted Rev proteins encoded
by the vectors pRev1514 and pRevEVI is presented in Figure 6.1e. The overall sequence
identity between these proteins is 65.3%. Many of the non-identical residues represent
conservative changes. This is especially true within the two putative functional domains. The
1514 protein has a bias towards lysines within the basic domain, compared to the arginine bias
demonstrated by EV1. This suggests that basic nature, rather than specific amino acid identity
may be important in mediating RNA binding. Within the leucine-rich domain, there are
conserved hydrophobic residues in identical positions in each protein.The EV1 protein is
truncated with respect to the 1514 protein (147 residues compared to 169 residues). This is a
consequence of the presence of a translation termination codon at the 3' terminus of the rev
gene. The conservation of the predicted sequence downstream of this codon with that
expressed by 1514 suggests a recent, secondary mutation event has ablated expression of
this region in EV1.
6.2.2 Rev Responsive Elements
Data obtained from the in vitro RNA binding studies presented in chapter 5, and from
reports of the Rev activity of the MVV 1514 strain and of a potential RRE within the CAEV CO
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strain env gene (Tiley et at., 1990; Saltarelli eta!., 1990) suggested that the ovine/caprine
lentiviruses possess a Rev responsive element in a conserved genomic location. To isolate
the RRE trom genomic DNA, primers were designed to flank the putative element, and were
centred on sequence which allowed the incorporation of restriction sites with the minimum of
nucleotide substitution. A 5' primer, 14949, included a recognition site for Bglll, and allowed
ligation into both reporter constructs. However, differences in the cloning regions of these
vectors meant that distinct 3' primers were required, and that two independent cloning
reactions were necessary. Isolation by PCR and subsequent cloning of the EV1 RRE
fragment by the 14949 and G0242 primers has been discussed (5.3.3). This fragment was
used for cloning into the vector pOXIOOpL (see below). To amplify fragments for insertion into
the reporter vector pgTAT, a primer incorporating a Hindi 11 restriction site was synthesised
(14948: figure 6.2a). Amplification with 14949 and 14948 predicts a 337nt product,
encompassing EV1 genomic sequences 7920-8256. The results of PCR using these primers
and the various virally-infected cell derived DNA is presented in figure 6.2c. All four templates
give rise to a product of the expected size, although in the ZZ1050 reaction this is not the
major product, and only in the EV1 reaction is this the only visible product. These fragments
were excised from an agarose gel, purified and cloned directly into pgTAT by digestion with
Hindi 11 and Bglll, with subsequent ligation into a similarly restricted pgTAT plasmid.
Sequencing of plasmids derived from transformants was used to confirm the nature of the
insert. Primers for double stranded sequencing were designed to hybridise with regions of
the pgTAT plasmid approximately 30 base pairs distant from either cloning site. The sequence
and hybridisation positions of these primers was as follows (5'-3'):
5'primer G0192: GGC CAG TAG TAT CAA CTC pgTAT 1949-1966.
3' primer G0191: CTT TTC TTG CTG GTT TTG CG pgTAT 3160-3141.
The sequence obtained confirmed the correct cloning of the EV1 sequence, which
was identical to the published sequence except for the inclusion of four nucleotide changes
identical to those described in 5.3.3. This was expected, due to the use of the same template
DNA for cloning of these two fragments. However, the inserts cloned from the remaining
viruses did not appear to contain viral-derived sequence. Despite the amplification of a
fragment of the expected size by PCR this was not entirely unexpected, given the probable
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Figure 6.2: Cloning of the Putative Rev Responsive Elements from
Ungulate Lentiviruses.
A Oligonucleotide primers for PCR amplification of the RRE from various ungulate
lentivirus strains. Primers were designed from the known EV1 sequence. Numbers refer to
the predicted genomic hybridisation positions with respect to the EV1 sequence. The
positions of incorporated restriction sites are shown, as are the base mismatches introduced
to accommodate these sites (bold).
B Oligonucleotide primers for PCR amplification of the CAEV CO strain RRE. Primers
were designed from the known CO sequence. Other information as above (A).
C Agarose gel electrophoresis of products of the PCR using primers 14949 and 14948
(A) for amplification of the RRE. The arrow indicates the predicted correct product. The
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Figure 6.3: Primary and Secondary Structure of the Cloned Ungulate
Lentiviral Putative RREs
A Nucleotide sequence comparison of the region with predicted higher order structure
from the cloned RREs. Identical nucleotides to the 1514 sequence are denoted thus (.).
Positions 1-200 correspond to genomic positions 7923-8122 (1514: Braun etal., 1987),
7985-8184 (EV1: Sargan etal., 1991) and 7907-8106 (CAEV CO: Saltarelli etal., 1990). The
SU/TM Env boundary occurs from the G at position 2 in all these viruses.
B Percentage primary sequence divergence between the above regions of EV1, 1514
and CO.
C Representation of the predicted secondary structure of an RNA element derived from
the above sequences. The structure was predicted using the EV1 sequence; those bases
which are conserved between all three viruses are highlighted in bold. Substructures are
named by analogy with the HIV-1 RRE. Position 1 corresponds to position 10 in the above








AGGGATAGGC TTGGTTATTG TGCTAGCCAT CATGGCAATA ATCGCTGCTG
G..C G ...A C..T A
. . .CG.T C. . .A TT G . A C.
51
CAGGAGCTGG TCTCGGTGTC GCAAACGCCG TGCAGCAATC CTATACCAGG
T T G A. . .
. ... G .. . TC ...G..A GA . T G.. T..C..T.A.
101
ACGGCTGTCC AGTCTCTTGC TAACGCAACT GCTGCCCAGC AGGAAGTGTT
C T A . T
G . A A . C T A T
151
GGAAGCATCG TATGCCATGG TACAGCATAT AGCCAAAGGA ATAAGAATCC
A A . T G G G AT
A. .G. . . A . C G. G. .T C G. .C T
B Percentage Sequence Divergence of Putative RREs
CO EV1











































































































degree of variation between the sequences of these viruses. The plasmids containing these
viruses were discarded, and unfortunately time did not allow for a further attempt to clone the
RREs by more stringent PCR or by other methods. However, subsequent to the completion
of the pgTAT assay section of this report, a molecular clone and the entire genomic sequence
of the CAEV Co strain (Saltarelli etal., 1990) became available. Primers for amplification of the
putative RRE were designed (figure 6.2b), and a fragment of the expected size (258bp)
obtained. This fragment was subcloned into the pCRII vector of the TA cloning kit, and
subsequently ligated into pOX100/pL after restriction with Bglll and Xbal.
The sequence of the 200 bases encompassing the putative RREs of the viruses
used in this study, MVV EV1, 1514 and CAEV Co are compared in figure 6.3. The nucleotide
primary sequence is illustrated by figure 6.3a, the percentage dissimilarity of this region by
figure 6.3b, and the predicted secondary structure by figure 6.3c. The two Maedi Visna viral
isolates demonstrate a greater degree of similarity to one another than to the CAEV isolate
from which they are equally diverged. Conserved bases are distributed throughout the
predicted secondary structure element. However, several regions, such as the length of steml
display particularly strong conservation. This is presumably due to the requirement to maintain
base pairing within this region. Primary sequence variation is generally structurally
conservative, so that essentially the same structure is predicted for all three sequences.
Some variation in the content and position of substructures such as bulges is seen. Minor
variations in predicted formation energies are also recorded.
6.3 Vectors for Functional Assays
6.3.1 p g TAT
The assay vector pgTAT contains a section of the genome of the HIV-1 HXB-3 proviral
clone within the pBC12CMV background (Malim etal., 1988). Both exons of the tat gene are
present within the HIV-1 insert. These are separated by an intron which comprises the 5' and
central regions of the envgene, and includes the RRE (figure 6.4a). The intron is delineated
by authentic HIV-1 splice sites, and may contain c/'s-acting repressor sequences within the
env coding region. Thus, expression of pgTAT is dependent on Rev activity. In the absence
of Rev activity, this vector predominantly expresses a fully spliced cytoplasmic tat mRNA,
which gives rise to the two-exon, 86 amino acid form of Tat. However, if Rev activity is present,
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then splicing can be avoided, and a substantial proportion of the RNA is present in the
cytoplasm in an unspliced form. This is translated to produce the single exon (72 amino acid)
form of Tat. The pattern of Tat expression can be assessed by immunoprecipitation of cell
extracts with an anti-Tat antiserum and subsequent electrophoretic separation. No other HIV
proteins are expressed by this vector (Malim etal., 1988). The HIV-1 RRE in pgTAT is flanked
by unique restriction sites, for Bglll and Hindlll. Excision of the RRE by digestion at these sites
allows the insertion of heterologous sequence. These can therefore be assayed for RRE-
activity. The vector pgTAT/RRE-V contains the MVV 1514 putative RRE sequence (genomic
positions 7923-8124) (Tiley and Cullen, 1992). This vector is responsive to the Rev
expression plasmid, pRev1514.
6.3.2 pOX100/pL
A second reporter construct was available. This vector is a hybrid constructed by
replacement of the first fat coding exon of pgTAT with an insert derived from the vector
pDM128 (figure 6.5) (Hope etal., 1991b). The pDM128 plasmid contains a 780 base pair
chloramphenicol acetyltransferase gene within the env coding region of the HIV-1 Sp2 proviral
clone. Definition of the CAT/env region as an intron by the presence of flanking HIV-1 splice
sites and the presence of the RRE means that CAT gene expression is under Rev mediated
control. The hybrid pOX100/pL was constructed by excision of the splice donor/CAT region
from pDM128 and its insertion into Sall/Bglll restricted pgTAT. The intronic location of the CAT
gene is maintained by the presence of the splice acceptor site within pgTAT. A polylinker
sequence has been engineered in place of the HIV-1 RRE, and aiiows insertion of
heterologous response elements. A pOXIOOpL derivative vector, pOX100/1514, was also
obtained (a kind gift of Dr. R Fridell, Duke University). This construct contains the 1514 RRE
(genomic positions 7901-8127) ligated into the Bglll/Xbal site of pOX100/pL. The EV1
fragment generated by PCR with the primers 14949 and G0242 (5.3.3) and cloned into the
pCRII vector was released by digestion with Bglll and Xbal and ligated into a similarly restricted
pOX100/pL vector. Subcloning was confirmed by restriction digest analysis.
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6.4 Rev Functional Assays
6.4.1 Transient Transfection
COS cells (Gluzman etal., 1982) are SV40 transformed African green monkey kidney
cells which constitutively express the large T antigen. Transfection of these cells by chemical
treatment of cells which results in DNA interaction with cell membranes, and possible DNA
entry by endocytosis proceeds relatively efficiently. Although only a proportion (10-20%) of
the cells are competent for transfection, copy number per cell may be high (Cullen, 1987).
Transfected plasmids are expressed at peak levels for 48-72 hours post-transfection. COS
cells were initially transfected by DEAE-dextran treatment, the reported optimal method for
this cell line (Cullen, 1987). Subsequent analysis of transfection efficiency, important to
reduce inter-assay variation with the quantifiable CAT assay, suggested that the calcium
phosphate precipitation method was more efficient for this particular cell line. Throughout this
work, Qiagen column chromatography was used for the purification of plasmids, as the quality
of DNA preparation may adversely affect transfection efficiency. Standard amounts of plasmid
were transfected (5pg per 35mm dish for calcium phosphate transfection), using the parental
vector pBCl2CMV to maintain this amount where necessary.
6.4.2 Radioimmunoprecipitation: pgTAT
COS cells were grown to near confluence in 35mm six-well plates, and transfected by
the DEAE-dextran method (2.20.3). Each plasmid, the indicator construct pgTAT and
derivatives, and the expression construct pBCl2CMV and derivatives, was added in a 500ng
aliquot, with the total DNA content standardised at 1 pig. An initial assay to test the protocol
was performed using 500ng each of pRev1514 and pgTAT/vRRE, which are both derived
from the MVV 1514 strain, and have been shown to provide a positive result in this assay
(Tiley et at., 1991). Transfected cells were labelled with tran35S label after 48 hours
incubation, and subsequently harvested. Immunoprecipitation with an anti-Tat antibody (a
kind gift of Dr. B Cullen, Duke University) was followed by electrophoretic resolution through a
15% SDS-PAGE gel. The result was visualised by autoradiography, and is illustrated by figure
6.4b. In the presence of the parental vector pBCl2CMV alone, pgTAT/vRRE gives rise to a
single form of Tat of ~16kDa apparent molecular weight. Co-transfection with pRev1514
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Figure 6.4: The pgTAT Radioimmunoprecipitation Assay
A The reporter construct pgTAT. Regions derived from the HIV-1 HXB3 (genomic
sequence 5367-8055) proviral clone, and the pBC12CMV parental vector are indicated. Tat
exons are shown by dark stipling. SD: splice donor site, SA: splice acceptor site. Restriction
sites: SI - Sail, B2 - Bglll, H3 - Hindlll. A schematic outline of the assay procedure is shown.
B Results of preliminary pgTAT assay. COS cells were co-transfected with
pgTAT/1514RRE and pRev1514 or the parental vector pBCl2CMV. Cells were labelled with
35S amino acids after 48 hours and harvested. Tat protein was immunoprecipitated with anti-
Tat antiserum and resolved by electrophoresis through a 15% polyacrylamide gel. Gels were
dried and the results visualised by autoradiography.
C pRev1514 was co-transformed with the original pgTAT plasmid (+HIV-1 RRE) and the
MVV derived pgTAT/EV1RRE and pgTAT/1514RRE. Assays were performed as above (B).
Arrows indicate the position of the two forms of Tat, the 86 amino acid two-exon and the 72
amino acid one exon form.
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induces the expression of a second form of Tat, with an apparent molecular weight of 14-
15kDa. Thus, the outcome of expression of pgTAT/vRRE is dependent on the presence of
functional Rev activity. A second experiment was performed in order to investigate the
functional compatibility of pRev1514 with the RRE of other viruses. This result is illustrated by
figure 6.4c. The original pgTAT vector, containing the HIV-1 RRE, is unaffected by pRev1514
expression, generating only a single Tat protein form. Both the 1514 and EV1-RRE
containing pgTAT vectors appear to be responsive to pRev1514 expression. However, it is
clear that the relatively poor resolution of this autoradiograph makes a definite conclusion
difficult. Further experiments produced essentially similar results, with poor resolution of the
bands due to Tat protein. Electrophoresis through a 10-20% gradient gel did not result in
more effective resolution, nor did immunoprecipitation with protein A sepharose in place of
agarose. Replacing the tran35S label with pure 35S labelled methionine also proved
ineffective. Thus, interpretation of the results achieved with this assay was considered to be
unreliable, and further analysis was not carried out.
6.5 CAT Assays
6.5.1 Introduction
The bacterial drug resistance gene, chloramphenicol acetyltransferase (CAT), is the
most widely used reporter gene for transient transfection assays (Gorman etal., 1982; Cullen,
1987). Although commonly used as an indicator of promoter strength, the CAT assay can be
adapted to investigate other aspects of gene regulation. The level of expression of a
construct containing the CAT gene can be directly related to the resulting CAT enzymatic
activity. Measurement of CAT activity is a rapid and sensitive technique, with the added
advantage of low background readings due to the restriction of this gene to prokaryotes. CAT
catalyses the inactivation of chloramphenicol by acetylation of hydroxyl groups (Shaw, 1975).
Methods to detect CAT activity take advantage of the differential solubility of substrate and
product. Thus, chloramphenicol is soluble in aqueous solution. However, acetylation
increases hydrophobicity, resulting in ready substrate solubility in organic solvent. This
divergence between substrate and product is increased if the acyl group is derived from the
co-factor, n-butyryl Co-enzyme A. Thus, discrimination between product and substrate is
more efficient, and the two can be separated by a phase extraction technique (Seed and
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Figure 6.5: The Reporter Construct pOXlOO/pL
The important functional regions of pOX100/pL are shown. Sequence originating
from the pgTAT parental vector, and the pDM128 insert are indicated. The nucleotide
sequence of the polylinker region is shown in detail, this region replaces the HIV-1 RRE. The
positions of the two restriction sites used in this report for subcloning are highlighted. The
CAT gene is inserted into a background derived from HIV-1 clones, and is defined as an intron








Sheen, 1988). The use of back-extractions meant that only -0.035% of the substrate
chloramphenicol was detected in the organic phase during the development of this
technique (Seed and Sheen, 1988). The phase extraction technique has a further advantage
over other techniques in that it generates linear results over a two to three order of magnitude
enzyme concentration. The use of 14C labelled chloramphenicol allows the assay to be
scored by scintillation counting. As the presence of certain detergents may inhibit CAT
activity, cell extracts were prepared by three rounds of freeze/thawing. In this chapter, results
are presented as the percentage of input 14C-chloramphenicol converted to butyrylated
product in each extract.
6.5.2 Assay Parameters
6.5.2.1 Transfection Efficiency
The quantifiable nature of the CAT assay meant that experiments were required to be
controlled for variability in transfection efficiency and cell extract preparation. The plasmid
pSV-ff-galactosidase (Promega) was used as a control. This expresses the enzyme p-
galactosidase under the control of the SV40 promoter. It must be assumed that the control
and experimental plasmids are transfected and expressed identically. A standard amount
(1pg) of this plasmid was co-transfected with assay vectors. After harvesting, the cell lysate
(10pl) was tested for p-galactosidase activity by a colorimetric assay (2.22.3) and the
absorbance at 420nm measured by spectrophotometry. To obtain standard values, the (3-gal
activity was translated into units of enzyme by reference to a standard curve derived from
known concentrations of purified enzyme. Individual cell extracts were then standardised for
transfection/extraction efficiency by use of a correction factor to convert to a standard p-Gal
activity.
Transfection with the pSV-p-Gal control plasmid was used to judge the relative
efficiencies of transfection using the DEAE-dextran and calcium phosphate precipitation
techniques. It was noted during preliminary investigation that the COS cell line used appeared
sensitive to DEAE-dextran treatment, and that cell death resulted in variability in the volume of
cell extract obtained. Thus, the pSV-p-Gal plasmid (1pg) was transfected into COS cells in four
35mm dishes by both techniques, and the resulting p-gal activity compared. From figure 6.6a
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Figure 6.6: CAT Assay Parameters
A The relative efficiency of transfection techniques. COS cells were transfected with
the control plasmid pSV-(3-Gal by DEAE-dextran or calcium phosphate precipitation. Cells
were harvested after incubation for 48 hours, and a cell lysate prepared by three rounds of
freeze-thawing. B-gal activity was assayed by standard techniques and is presented as
absorbance at 420nm after one hour incubation. The results are shown as the mean +/-
standard deviation from four transfections. The results differ from one another significantly
(p<0.05). Statistical analysis using two sample t test for independent variables.
B/C Variation of parameters during a standard CAT assay. Assay was performed using an
extract prepared from cells co-transfected with the plasmids pRevEVI and pOX/EV1RRE.
CAT assay was carried out with variation in either the volume of extract used (B) or the
incubation time before reaction termination (C). Results are presented as the amount of



















it can be seen that calcium phosphate precipitation gives rise to a higher enzyme activity; this
proved to be a significant difference (P<0.05). Thus, calcium phosphate precipitation was
used for transfection of both expression and reporter constructs for further analysis.
6.5.2.2 CAT Assay Parameters
The linearity of the results of the CAT assay with respect to enzyme concentration and
activity, and hence to the degree of gene expression, was investigated by analysis of extracts
prepared from cells co-transfected with pRevEVI and pOX/EV1, which results in substantial
CAT activity (see below). The phase extraction assay was performed using a range of cell
extract volumes (figure 6.6b) or by using a single volume (5gl) and varying the reaction time
before extraction (figure 6.6c). As can be seen from these results, the recorded CAT activity is
effectively linear over the ranges used. Thus the phase extraction assay was deemed an
appropriate technique for these studies, and could be used without extract dilution. CAT
activity from cells transfected with heterologous vectors, such as pRev1514, was found to be
very low (% acetylation <0.01% of input chloramphenicol) which suggested that the phase
extraction procedure was an effective discriminatory method between substrate and product.
For further analysis, the background level of CAT activity was assumed to be zero. Statistical
analysis was carried out using a standard two sample t-test for independent variables.
6.5.3 Basal CAT Activity
It has been reported that the removal of the HIV-1 RRE from vector constructs may
lead to an increase in the basal level of expression (Huang eta/., 1991). This observation has
been suggested to be the consequence of the presence of a c/s-acting repressor sequence
(CRS) overlapping the RRE (Brighty and Rosenberg, 1994; Nasioulas etal., 1994). Partial or
complete removal of this element would thus relieve the block to gene expression, as has
been demonstrated by inactivation of a gag gene CRS (Schwartz eta/., 1992). In order to
investigate the possible presence of a similar repressive element within the RRE-containing
gene sequences of the ungulate lentiviruses, the basal level of activity of each of the pOXlOO
derivatives was analysed. Data was obtained from three independent transfections, and is
presented by figure 6.7a. A low level of CAT enzyme activity (-1% acetylation with these
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Figure 6.7: Basal Expression from pOXlOO/pL and Derivative Vectors
A COS cells were transformed with pOX100/pL (2pg) or derivative vectors as indicated
by calcium phosphate precipitation, and extracts prepared after 48 hours. An aliquot of extract
(5pJ) was assayed for CAT activity, and the results presented as the percentage of input 14C
chloramphenicol converted to the butyrylated form, after correction for transfection/extraction
efficiency by p—Gal activity. Results shown are the average of three independent transfections
(mean +/- standard deviation). * indicates result significantly different (p<0.01) from the
parental vector pOX100/pL.
B The effect of co-transfection of pOX100/pL with pBCl2CMV and derivative Rev












































assay parameters) was detected by transfection with the pOXlOO plasmid alone. This level
presumably reflects inefficient nucleocytoplasmic transport and translation of CAT pre-mRNA
in the absence of Rev. Insertion of the EV1 and 1514 RREs did not alter the basal level of CAT
activity. However, insertion of the CAEV CO RRE resulted in an approximate 4 fold increase in
basal activity. The increase in acetylated product over that generated by pOX100/pL proved
to be significant (P<0.01). Thus, the CO RRE has the opposite effect to that subscribed by
some researchers to the HIV-1 RRE. This is a surprising finding, especially given the degree
of sequence and structural identity between the CO and 1514/EV1 RREs. Hypothetically, this
could be due to the possession of a positive enhancing effect on expression by the inserted
sequence, or to a negative effect on surrounding repressor sequences. This latter option
appears to be more likely. It is possible that the conformation of the CO RRE may interfere with
regions of the pOXlOO pre-mRNA which mediate reduced expression, perhaps through
nuclear retention (see 1.14.2). The lack of a similar effect due to the isosteric MVV RREs may
contradict this; however, the inserted regions are not identical in size or genomic location and
include RRE flanking sequences.
The effect of co-transfection of the pBC12CMV-based expression vectors pRev1514
and pRevEVI on CAT expression from the parental vector pOX100/pL was investigated.
From figure 6.7b it can be seen that the level of CAT activity is unaffected by co-transfection
with pBCl2CMV or its Rev-expressing derivatives. Thus, MVV Rev is unable to activate the
expression of this construct in the absence of putative responsive elements.
6.5.4 The Effect of Rev Co-Expression on CAT Activity
To study the effect of Rev expression on indicator constructs containing putative
RRE inserts, COS cells were co-transfected with pOXlOO- and pBC12CMV- based plasmids.
In order to elucidate the reciprocal nature of Rev/RRE interactions both intra- and inter- strain
combinations were essayed. The average results of three independent transfections (mean
+/- standard deviation) are illustrated in graphic form in figure 6.8a-c. It is apparent that both
the 1514 and EV1 Rev expression vectors significantly increase expression from all three
reporter constructs. Thus Rev activity is able to increase expression of the CAT pre-mRNA if
an appropriate c/s-acting responsive element is present. The level of induced activity,
however, varies with respect to the viral strain of origin of both the protein and RRE. Thus,
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pRev1514 induces significantly higher CAT activity from the cognate pOX100/1514RRE
plasmid than does pRevEVI (p<0.01) (6.8a). Although the reverse is also true for induction
from pOX100/EV1 RRE (6.8b), the difference was found not to be statistically significant
(p>0.2). Co-transfection with the heterologous pOX/CORRE resulted in higher CAT activity
with both MVV strain Rev proteins. Again, although the 1514 protein induced higher
enzymatic activity, the difference between the two proteins was not found to be significant.
These results are translated into levels of induction of CAT activity (+Rev) over the
background (-Rev) for each reporter construct in table 6.1. The highest fold increase in
expression is recorded by the 1514 Rev/RRE pair (27.8x background). The 1514 Rev protein
is also a better inducer of the conspecific EV1 RRE than of the CO RRE (p<0.l). The
induction achieved by the EV1 protein is similar with both the MVV RRE constructs, and is
less with the CAEV construct.This difference is significant with p<0.01 for the 1514RRE and
p<0.1 for the EV1 RRE: the difference in certainty being a result of the variation observed
with the assays with the EV1RRE construct. It should be noted that high backgrounds meant
that the fold induction of expression from the pOX1 OO/CORRE plasmid were lower than crude
CAT activity would suggest.






1514 27.8 +/- 5.1 10.4 +/- 1.6
EV1 7.6 +/- 1.6 10.9 +/- 4.9
CO 4.8 +/- 1.5 3.9 +/- 1.3
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Figure 6.8: Effect of pRev Co-Transfection on CAT Expression from
pOX100/RRE Vectors
All assays and presented results are as described in figure 6.7a. Significant differences from
transfection with pBC12CMV alone are denoted thus: * p< 0.01 ** p< 0.001. + denotes
difference from co-expression with pRevEVl p<0.02.
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6.6 Discussion
The use of eukaryotic transfeclion techniques to assay for the intracellular activity of
the MVV Rev protein has been reported in this chapter. Proteins derived from both the
Icelandic 1514 and the British EV1 strain were competent to mediate a significant increase in
in CAT activity from reporter constructs. It is assumed that this reflects functional expression of
pre-mRNA containing a CAT reporter gene linked to a viral sequence with structural similarities
to the characterised HIV RRE. Such activity was not observed in the absence of this element.
Although these experiments do not indicate the mechanism of trans-activation, by analogy
with HIV-1 it may be assumed that MVV Rev acts to correct defects in the expression pathway
of pre-mRNA. Confirmation of this hypothesis would be obtained by analysis of the presence
and distribution of both unspliced and spliced reporter construct RNA in the presence and
absence of Rev co-expression. In conjunction with the in vitro binding results discussed in
chapter 5, this data is sufficient to define an RNA Rev responsive element located between
nucleotides 7935-8244 of EV1. The coincidence of this region with an area of predicted
secondary structure strongly supports this conclusion. Insertion of the RRE regions into the
assay vector in the antisense orientation could be used to confirm the functional significance
of these results. It may also be necessary to repeat these experiments in ovine cells to
demonstrate the relevance to naturally occurring situations. Preliminary studies in ovine
fibroblasts appeared to indicate poor transfection efficiencies. A similar failure to demonstrate
Rev activity by transient transfection in caprine primary cells has been reported (Schoborg et
a!., 1994); it was suggested that this may be a consequence of poor plasmid replication and
stability in these cells.
6.6.1 Reciprocity of the Rev/RRE Interaction
Although both viral proteins tested were able to mediate functional interactions with
all three vector constructs containing the putative ungulate lentiviral RREs, the level of up-
regulation of expression was found to vary. It was found that both proteins demonstrated
greatest activity through the cognate RRE sequence, although further experiments would be
required to draw statistically relevant conclusions as to the significance of some of the results.
This suggests that the rev gene and its responsive element have evolved as a unit, such that
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divergence in either sequence is matched by divergence in the other. Given the expected
essential nature of the Rev/RRE interaction for viral viability, such co-evolution is not
surprising, as the selective pressure to maintain functional interactions will be strong. It might
be expected that co-evolving genomic units would vary at a lower rate than other regions, due
to such selective pressure. However, the Rev proteins of three sequenced MVV strains,
1514, EV1 and SA-OMVV, demonstrate the greatest degree of dissimilarity of any viral
proteins. Examination of the amino acid sequence of the Rev proteins used in this study
(figure 6.1 e) shows that variation occurs throughout the proteins, and also affects the
proposed functional domains. However, it is apparent that amino acid changes within these
domains are in most cases of a conservative nature. Thus, there are lysine/arginine
substitutions in the basic domain and hydrophobic (valine/methionine/leucine) substitutions
in the activation domain. The possible importance of a central hydrophobic core within the
basic domain is suggested by the conservative substitution of the 1514 tyrosine residue
(position 81) for phenylalanine in EV1. The RREs of 1514 and EV1 are approximately 11.5%
divergent at the nucleotide level (figure 6.2b). The overall dissimilarity of the transmembrane
glycoprotein (TM) coding region for these viruses is 18.4% (Sargan etal., 1991). It would
therefore appear that selection has favoured a relative conservation of the RRE sequence.
However, the protein sequence encoded by the RRE region is also more conserved than the
overall TM (7.7% against 20.4%) which can be interpreted as the result of evolution to
maintain either the RNA or the protein sequence, or both. The CAEV Co strain has an RRE
which is equidistant from the MVV sequences, and mediates a similar activation level for both
proteins. The unexpected finding that insertion of the CAEV RRE led to an increase in basal
CAT activity may be interpreted as interference with repressive sequences present in the
surrounding HIV sequence. Interestingly, a report of CAEV Co Rev/RRE function published
since the completion of this work has shown that insertion of certain Co sequences into a HIV-
1 Gag subgenomic construct also resulted in higher basal activity compared to insertion of the
HIV-1 or HTLV-1 response elements (Saitarelli etal., 1994). This finding was not commented
on and does not have supporting statistical analysis.
The functional reciprocity of the tested Rev proteins and RREs was therefore
complete with respect to presence of function, but incomplete with respect to degree of
function. Observed results appeared to correlate with the degree of overall divergence. Thus
the close phylogenetic relationship of these viruses is supported by these data. However, it
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should be remembered that the complete reciprocity demonstrated by the HTLV-1 Rex
protein and the HIV-1 RRE (Rimsky et at., 1988) is the probable result of the fortuitous
presence of a high affinity binding site and not a consequence of phylogenetic relatedness.
Although the Icelandic neurovirulent K1514 MVV strain (Sonigo etat., 1985) and the CAEV
Cork (Co) strain (Narayan etal., 1980; Saltarelli etat., 1990) are recognised as prototypic
members of two ruminant lentiviral groups with distinct biological and genetic properties
(reviewed in Narayan and Clements, 1989) there is a considerable overlap in the properties of
other virus isolates; hence complete classification of ovine/caprine lentiviruses has proven
controversial. Thus, partially sequenced isolates from naturally infected sheep in France
displayed 4-7% divergence from CAEV Co, but 12-15% divergence from MVV K1514
(Leroux et at., 1995). American ovine lentiviruses cause disease with pulmonary and synovial
pathology similar to that of classical CAEV disease (Lairmore et at., 1986). The failure to
amplify regions from the other viral strains used in this report is also suggestive of sequence
divergence of these viruses. Extension of the Rev functional assays reported here may help
elucidate the relationships of these viruses by demonstrating the degree of cross-strain
reciprocity.
It has been suggested that gene therapy with frans-dominant inhibitory Rev mutants
may be a suitable approach to combating lentiviral disease (Malim et at., 1989b). If the
mechanism of frans-dominant inhibition involves binding competition for high affinity sites,
and subsequent lack of multimerisation by mutant molecules (see 1.11.2) then the ability to
bind to the RRE of numerous possible strains of infecting virus is essential. If the incomplete
reciprocity reported here reflects binding events, which seems possible, then an animal
expressing TD Rev mutants of the EV1 strain may not protect against challenge with the 1514
strain. Although, as has been discussed, the degree of ungulate lentiviral divergence is
especially high, this may have important implications for human anti-AIDS gene therapy. It
should be noted that incomplete reciprocity between HIV strains has not been documented,
and that a highly divergent HIV-2 isolate has been shown to be responsive to Rev function of
the prototypic HIV-2ROD strain (Kawamura et at., 1992). However, it is also possible that
incomplete reciprocity reflects poor multimerisation on heterologous RREs, which may not
interfere with gene therapy. Failure to multimerise on the HIV-1 RRE is the mechanism behind
the lack of functional activity on this element demonstrated by the SIV/HIV-2 Rev proteins
(Garrett and Cullen, 1992; Berchtold et at., 1994). Further research to distinguish these
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possibilities is indicated.
The higher activity demonstrated by the 1514 protein may suggest a greater trans-
activating ability. However, to confirm this studies of the level of expression of each protein in
transfected cells would be required. Higher level of expression or greater stability of the 1514
protein may underlie the higher induced activation levels. Experiments designed to identify
the effect of titrating the level of co-transfecting pRev plasmid on CAT activity may also be of
benefit.
It is impossible from these results to draw any conclusions as to the site of Rev
interaction with the RRE. However, progressive truncation of the RRE insert may allow the site
of interaction to be pinpointed more exactly. Preliminary results from such experiments might
allow the construction of oligonucleotide probes for in vitro binding studies.
6.6.2 The pgTAT Assay
The poor signals and resolution of the immunoprecipitated, radiolabeled Tat proteins
meant that interpretation of this assay was difficult and contra-indicated its use for analysis of
Rev/RRE functional interactions. These difficulties have been encountered by other
researchers (R. Fridell, personal communication) using the MVV 1514 Rev/RRE combination.
The source of the problem was not identified by attempts to increase resolution. Two
possibilities are that trans-activation of pre-mRNA expression by MVV Rev in this system is
poor, or that technical problems are encountered. The latter possibility would allow possible
improvements in this assay. A modified form of pgTAT, pB94, has been constructed: this
expresses forms of Tat with greater differences in molecular weight, and may aid discrimination
and resolution of the assay (R. Fridell, personal communication). Alternatively, poor
transfection efficiencies may have been responsible for the low signal from labelled Tat by
reducing the level of expressed protein. Limited proteolytic degradation of the Tat protein
may have been responsible for low and indistinct signals. However, it is possible that the
fundamental problem with this assay is an inefficient interaction of MVV Rev with cognate
RRE in the context of the HIV-1 hxB3 subgenomic sequence. This may be due to inhibition of
the correct formation of the RRE. Replacement of the HIV-1 sequences with a similar
subgenomic region of MVV would test this hypothesis, and provide a more appropriate test
for MVV Rev function. A molecular clone of the EV1 sequence is not presently available,
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however. Discrimination between the possible causes of the poor results demonstrated by
this assay may be achieved by analysis of the RNA expression pattern in transfected cells.
High level cytoplasmic expression of full length, pre-mRNA in co-transfected cells would
indicate that the major problem was of a technical nature. Functional studies of Rev using
pgTAT have been scored by RNA analysis (Malim etal., 1988; Lawrence etai, 1991).
6.7 Summary
The rev gene and putative responsive element of the MVV EV1 strain were cloned
from viral genomic DNA. A RRE was also isolated from a molecular clone of the CAEV Co
strain. An attempt to clone these regions from heterologous viral strains proved unsuccessful,
a probable consequence of sequence variation. The rev gene was cloned into a eukaryotic
cell expression vector, and the RREs into the HIV-1 based reporter constructs pgTAT and
pOX100/pL. Vectors containing the MVV 1514 strain rev gene and RRE were also available.
Functional studies of Rev function with the pgTAT assay provided preliminary evidence for
1514 protein interaction with vectors containing the cognate RRE and the EV-1 element.
However, poor resolution of results meant that this system was of limited usefulness. In
contrast, the CAT assay based on the pOXlOO vector proved to be relatively reproducible.
Preliminary results indicated that Rev co-expression was sufficient to rescue the expression
of the CAT gene if a putative RRE element was present within the CAT intron. A series of
reciprocal experiments suggested that although both EV1 and 1514 Rev proteins were able
to function through all three tested RREs, the degree of function was greatest with the
cognate RRE. Co-evolution of the rev gene and Rev responsive element of each strain is
suggested by these results. Possible implications for anti-lentiviral gene therapy with trans-






The expression and partial functional characterisation of the Rev protein from the
British EV1 isolate of the ovine Maedi Visna lentivirus has been reported. Expression of this
protein in a yeast system was found to induce a significant degree of cytotoxicity which
resulted in a low yield and purity of product. Expression in bacterial cells as a GST fusion gave
rise to a reasonable yield and partial product purity. This fusion protein was used in in vitro
RNA binding studies to delineate a region of the EV1 envgene which mediates high affinity
binding to GSTRev. Transient transfection of eukaryotic cells with a Rev expression vector
and reporter constructs containing the binding element demonstrated that this interaction
could mediate the functional expression of genes constitutively expressed at a low level.
Reciprocal studies of the functional interaction of Rev proteins and response elements from
different viral strains suggested that co-divergence of this axis had occurred.
An extensive discussion has accompanied each chapter throughout this thesis.
Thus, this final discussion chapter will concentrate on the possible significance of the
observed results, on the relevant literature published since the outset of the research project,
and on possible future directions for MVV regulatory gene research.
7.2 Expression of Recombinant EV1 Rev Protein
A source of MVV EV1 Rev protein was required for the attempted functional
characterisation of this potentially important regulatory protein. Extraction and purification from
virally infected cells was clearly impracticable. Thus, an approach based on the generation of
recombinant protein was taken. The choice of which of the multiple expression systems
available to use was made on the basis of the biochemical requirements for the expressed
protein. Thus, solubility, high purity and maintenance of native conformation were considered
important. Systems based on fusion to a carrier molecule were chosen in the hope that the
known, beneficial characteristics of the carrier would aid expression and purification (for a
review of recombinant expression systems, see Marston, 1986).
The isolated rei/gene was cloned into expression constructs based on the yeast Ty-
VLP and the bacterial pGEX systems. Although correct expression was confirmed in both
cases, the yield and purity of product varied considerably. A rapid and devastating toxic effect
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was associated with Rev expression in yeast cells. As the Ty-VLP purification protocol
involves selection through physical rather than biochemical protein characteristics, it is
critically dependent on high protein yield for success. Thus, the purity of p1 :Rev protein was
low. Attempts to increase yield and purity by altering aspects of the expression and
purification protocol met with limited success but did not allow the production of workable
protein levels. Expression in the bacterial system was more successful. A moderately high
yield and purity of product were achieved. Contaminating molecules were found to
correspond to truncated fragments of the full length recombinant protein, and were
hypothesised to be the products of proteolysis or mis-translation. By comparison with other
reports of the biological activity of GST fusion proteins, the chimaeric protein GSTRev was
considered a suitable substrate for functional assays.
7.2.1 Expression of Recombinant Rev/Rex Molecules
At the outset of this project there were few reports of the in vitro expression of
recombinant lentiviral Rev protein. Subsequently, the production of HIV-1 Rev by a variety of
mechanisms and in different cell types has been widely reported. Comparison of these
reports with the expression of EV1 Rev achieved in this project may produce suggestions for
a future improvement in the purity and yield of recombinant EV1 Rev.
Both direct and fusion-based expression protocols have been utilised. Purification to
near homogeneity has been associated primarily with direct expression protocols (Nalin etal.,
1990; Wingfield etal., 1991; Zapp etal., 1991). HIV-1 Rev was expressed as a soluble
cytoplasmic protein in these systems, and was purified using denaturing techniques, with
subsequent refolding. Yields of up to 5% of total cellular protein were achieved (Zapp etal.,
1991). Significantly, there are no reports of protein instability using these systems. As direct
expression might be more likely to promote instability than fusion to a known stable product,
the lack of apparent instability of nonfusion HIV-1 Rev in a soluble form suggests that stability
in bacterial cells is an intrinsic property of this protein. Recombinant protein derived from direct
expression systems has been shown to retain function, despite the requirement for
denaturation. Fusion systems have also been used to produce recombinant Rev. Heaphy and
colleagues generated functional protein by fusion to ff-galactosidase (1990). This produces
inclusion bodies within host cells, which can be isolated by their distinct sedimentation
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properties and purified in denaturing conditions. MVV Rev from the 1514 strain has been
produced as a p-galactosidase fusion: however the chimaeric protein was purified by excision
form a SDS-PAGE gel and used only as an immunogen (Mazarin et al., 1990). Successful
fusion to the enzyme (3-glucuronidase has also been reported (Daly et al., 1993; Auer eta!.,
1994). However, the pGEX system has been most widely used as the source of recombinant
Rev/Rex protein. HIV-1, HIV-2 Rev and HTLV-1 Rex proteins have been successfully
expressed (Bogerd et al., 1991; Malim and Cullen, 1991; Garrett and Cullen, 1992;
Hammerschmid et al., 1994; Jensen et al., 1995). However, none of these authors claim
purification to homogeneity using the pGEX system. Indeed, in many cases the final purity
achieved is not recorded, although Jensen et al. (1995) have claimed a figure of 70%. Tiley
and Cullen (1992) have published results of expression and binding studies on the Rev
protein from the MVV 1514 strain. The fusion protein was reported to be between 25-50%
pure, although a SDS-PAGE profile of the protein was not presented. This result is relatively
similar to that achieved in this report for the protein of the EV1 strain, and suggests that these
proteins have similar characteristics in this system. It is also noticeable that these authors do
not report removal of the carrier in either the HIV-1 or MVV fusions by proteolytic cleavage,
implying that problems similar to those reported here may have been encountered. It is clear
that the problems associated with EV1 Rev expression are by no means unique.
Other findings presented in this study are consistent with reports in the literature.
Several authors use BL21 as the host strain for expression (Bogerd etal., 1991; Malim and
Cullen, 1991; Hammerschmid et al., 1994). A three-fold difference in HIV-1 Rev yield
depending on host strain was reported by Wingfield and colleagues (1991), illustrating the
potential importance of the host genotype with respect to encoded proteases (reviewed in
Gottesman, 1989). Several groups used synthetic fragments of the rev/rex genes, or altered
certain codons by site-directed mutagenesis, in order to conform to the parameters set by
bacterial codon frequency rates (Nalin etal., 1990; Heaphy etal., 1990; Bogerd etal., 1991).
7.2.2 Alternative Expression Strategies for EV1 Rev
The results obtained here, and by other groups, support the proposition that each
protein has unique characteristics, and that estimates as to the outcome of expression
studies are not to be relied upon. Properties such as the toxicity of EV1 Rev in S. cerevisiae
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cells cannot easily be predicted. Direct experimentation is thus an absolute necessity.
Suggestions as to an alternative approach to the synthesis of recombinant Rev may
be made based on the experience of other groups and on that gained in this project,
although with the above proviso. The functionality of HIV-1 Rev protein derived from
denaturing purification systems suggests that these may be useful. In particular, expression of
EV1 Rev as an insoluble fusion to a carrier such as p-galactosidase, might be expected to
stabilise the protein by the formation of biologically inert inclusion bodies. Substitution of rare
bacterial codons in the rev sequence for more common synonymous codons may be helpful
(see 4.8.3). Elucidation of the mechanism responsible for the presence of truncated
molecules in the GSTRev preparations would indicate which of these two strategies would be
most beneficial. Purification by inclusion body isolation, protein precipitation, size exclusion
chromatography and renaturation by dialysis may be successful. An alternative strategy would
be to utilise the system recently described by Orsini and colleagues (1995). HIV-1 Rev was
over-expressed in E. coli using the bacteriophage X P|_ promoter. Purification was based on
the addition of polyethyleneimine, which precipitates nucleic acids and nucleic acid binding
proteins, such as Rev. Further purification by chromatography does not require denaturation,
which means that the expressed protein retains its authentic structure. Rev was purified to
homogeneity by this protocol.
7.2.3 GSTRev as a Reagent for Functional Assays
The decision to use the chimaeric GSTRev protein as a substrate in in vitro RNA
binding assays was a forced one due to the inability to specifically remove the GST carrier
without secondary protease activity. An identical problem was encountered by other authors
using a HIV-1 GSTRev fusion (Jensen etal., 1995). However, there are numerous reports of
wild type functional activity residing within GST fusions, which would vindicate the approach
taken in this project. GST chimaeras have been used as traps to isolate factors which interact
with the GST fusion partner. Success has been achieved with fusions to the retinoblastoma
gene product and herpes simplex virus type 1 VP16 (Kaelin etal., 1991; Lin and Green,
1991). Essentially normal enzymatic activity is associated with a GST-phosphatase fusion
protein (Plutzky et at., 1992). More significantly, several reports on the functionality of distinct
RNA binding protein fusions have been published. The polypyrimidine tract binding protein
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(hnRNP A) binds correctly to an RNA target within the 5' untranslated region of the hepatitis C
virus as a GST fusion (Ali and Siddiqui, 1995). A GST influenza virus NS1 (see 1.18) protein
fusion binds with identical characteristics as free protein to the poly(A) containing RNA which
is its functional target at low concentrations (Qiu and Krug, 1994). At high concentrations,
however, the nonfusion NS1 protein binds target RNA with slightly higher efficiency than the
GST-NS1 fusion. There is some reported variation in the relative RNA binding activity of
Rev/Rex proteins when expressed as GST fusions. This may reflect differing purification
protocols, bacterial host strains or RNA binding assay conditions, and highlights potential
problems encountered when comparing data obtained by different research groups. Zapp
and co-workers were unable to record significant binding of HIV-1 GSTRev to RRE-RNA, and
suggested that the fusion protein was severely defective in functional activity (1991).
However, in most cases the differences in activity observed are quantitative rather than
qualitative. Steric or conformational restraints imposed by the GST carrier may be responsible
for altering the activity of the Rev polypeptide. However, essentially identical RNA binding
characteristics using free or GST fusion Rev protein have been reported by other groups
(Hammerschmid etal., 1994; Jensen etai, 1995). Minor variations in the primary sequence of
the Rev proteins used might result in different higher order structural interactions between
the Rev and GST moieties, which in turn could influence Rev function. Alternatively,
differences in the presence and concentration of contaminating molecules between
preparations might be significant. The fact that reports suggest that only partially pure
GSTRev preparations were successfully used in functional studies vindicates the approach
adopted in this study, and supports the validity of the reported results.
7.2.4 Toxicity
Expression of p1 :Rev within yeast cells was associated with rapid inhibition of culture
growth. Preliminary investigation by electron microscopic examination of host cells
demonstrated dramatic disruption to the cellular ultrastructure. Although the toxic mechanism
and resulting sequence of events are unknown, it is clear that cell death is the endpoint.
There was no indication that cytotoxicity was reversible, implying fundamental damage to the
cell. Extensive vacuolation within cells may be a cellular defence response to the presence of
toxin: the presence of putative recombinant VLPs within vacuoles may support this
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hypothesis. However, the irregular vacuolar morphology is perhaps more likely the result of
formation by physical upheaval due to the 'imploding' of cellular components. Cross-linking of
Rev ligands by the multimeric VLPs could induce such a phenomenon. Alternatively, or in
concert, direct disruption of subcellular components by, for example, Rev-mediated VLP
blockage of the nuclear pore complex, may be significant.
Although sequestration of Rev binding substrates by recombinant VLPs would
certainly be expected to have deleterious consequences for cell viability, the rapidity of
toxicity, coupled with the ultrastructural consequences lend support to the hypothetical cross-
linking mechanism.The low yield of recombinant VLPs also suggests that ligand
sequestration does not sufficiently explain toxicity.
The reduced growth of GSTRev-expressing bacterial cell cultures with respect to
uninduced cultures may point to a toxic effect in this system. However, the yield of protein
obtained was within the expected range, and the reduction in growth considerably less
marked. The possible significance of rare bacterial codons appearing in tandem within the
rev mRNA have been discussed. In particular, it should be noted that reduced viability of
bacterial cells has been associated with the expression of foreign genes possessing
consecutive rare codons (Brinkmann etal., 1989). Thus, there is no evidence to link GSTRev
to the dramatic toxicity observed in the yeast system, although further study of the
consequences for bacterial viability of EV1 rev gene expression would be required to draw a
firm conclusion. Differences in the consequence of Rev expression must be a product of cell-
and/or expression system-specific properties. The functional activity of HIV-1 Rev in yeast
cells (Stutz and Rosbash, 1994) implies the presence of appropriate Rev interacting
structures and factors. Homologues of the three putative Rev cellular co-factors, elF-5A, B23
and the putative nucleoporin Rip/Rab (see chapter 1) are not present in prokaryotes. Thus
there is an obvious correlation between the presence of Rev ligands and cellular toxicity.
However, since monomeric, native HIV-1 Rev does not demonstrate high toxic activity in yeast
(Stutz and Rosbash, 1994) the polymeric, particulate form of Ty:Rev VLPs may also be
significant.
Rev-mediated cytotoxicity has also been reported to be a feature of overexpression
in other cell types, for example during transient transfection of transformed cell lines.
Expression of CAEV Rev in COS-1 cells is associated with the appearance of rounded cells
exhibiting reduced viability (Schoborg et at., 1994). Nucleolar deformation has been
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observed in BHK and COS cells expressing high concentrations of HIV Rev (Nosaka et at.,
1993). Subsequent dysfunctional ribosome biogenesis results in nucleolar degradation, and
eventual cell death. An intact nucleolar localisation and multimerisation domain are required
for this activity; integrity of the activation domain is not essential (Nosaka et a!., 1993).
Accumulation of B23 within Rev-deformed nucleoli has recently been demonstrated (Miyazaki
et at., 1995). It has been speculated that sequestration of B23 by Rev may inhibit the nuclear
import activity of the former protein, which in turn would repress ribosome biogenesis. The
relevance of this observation to p1:Rev yeast cytotoxicity is uncertain: although it may be a
contributory mechanism, inhibition of the yeast B23 homologue would not be expected to
result in such rapid structural changes. Nucleolar deformation and cell death were observed in
acutely HIV-infected T lymphocytes, but were not observed in chronically HIV-infected
monocytic cell lines (Nosaka et at., 1993). Rev protein may be expressed at insufficient levels
to promote toxicity in these cells. It is unclear whether Rev plays a significant role in virus-
mediated cytotoxicity in vivo. Although the recent demonstration of the massive turnover of
both virus and host cells in the peripheral circulation of the late stage HIV-infected host
strongly suggests immune-mediated cytopathology (Ho etal., 1995; Wei et at., 1995), other
mechanisms may be important at other periods. Further investigation into the cytotoxic activity
of MVV and HIV Rev proteins may bring valuable insights both into lentiviral pathogenesis and
Rev function.
A structural dissection of the domain requirement of MVV Rev for yeast toxicity would
presumably give an indication of the mechanisms involved. Injection of synthetic peptides
corresponding to the basic domain of HIV-1, -2 and SIV Rev proteins has been shown to
induce specific, lethal neurotoxicity in rodents (Mabrouk etal., 1991). This property is not
shared by the homologous domain of HTLV-1 Rex, but is characteristic of the basic domains of
MVV and HIV Tat proteins (Sabatier et a!., 1991; Phillipon etal., 1994). The proposed
mechanism of Rev toxicity involves disruption of acidic phospholipids within membrane
bilayers, and is associated with the ability of the peptide to form a helical structure in the
inorganic phase. This suggests a further possible mechanism for p1:Rev toxicity in yeast;
insertion into and disruption of cellular membranes. Such activity might be expected to result
in the observed ultrastructural damage occasioned by p1:Rev synthesis. Tentative evidence
for the significance of this property in infected individuals has come from the work of Ranki
and co-workers, who have identified a correlation between expression of Rev and Nef
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proteins in HIV-infected astrocytes and AIDS dementia (1995). Rev toxicity may have a role in
the extensive neurological pathology associated with MVV visna (Petursson etal., 1976).
7.3 Rev/RNA Binding
Evidence has been presented for a high affinity, and relatively specific, interaction
between EV1 GSTRev and an RNA element with complex predicted secondary structure.
The presence of extraneous sequences within the RNA ligand mean that a strict definition of
this region as the EV1 Rev response element is not possible. However, the predicted
secondary structure is highly conserved amongst three ungulate lentivirus strains, strongly
suggestive of functional selective pressure. This structure has been experimentally
confirmed as the site of MVV 1514 binding in in vitro gel mobility shift assays (Tiley and Cullen,
1992). Binding was observed in the presence of 100ng (approximately 200nM) GSTRev,
although a precise comparison with results reported in this thesis is impossible due to the lack
of information regarding the purity of the protein preparation, and the absence of extensive
protein concentration titration experiments. These authors observed distinct multiple band
shifts in the presence of increasing concentrations of GSTRev fusion protein, suggesting that
protein multimerisation on the RNA target can occur, as is demonstrated by HIV-1 Rev.
Moreover, the binding of GSTRev to labelled specific probe RNA could be competed out with
a 400 fold excess unlabelled probe in the presence of excess protein (titration experiments
were not performed). RNase protection assays were performed to analyse the Rev/RRE
interaction. Protection from cleavage was observed throughout the steml, stemll and the base
of steml 11 subregions of the RRE. Comparison of the nucleotides protected by MVV 1514
GSTRev binding with figure 6.3c suggested that these nucleotides were not particularly
highly conserved between the three ungulate lentiviral strains.
Binding of the HIV-1 Rev protein to the asymmetric guanine-rich bulge which forms
the core binding element may be mediated through a protein helical structure (Tan etal.,
1993). Circular dichroism has suggested that the entire binding domain may take helical form
(Auer et at., 1994). The carboxy-terminal proximal section of the EV1 and 1514 Rev basic
domains is predicted to form helical secondary structure (figure 3.3). Helix destabilising
glycine residues may prevent helical formation within the remainder of this domain. Thus, the
MVV protein may use only those residues forming helical structure to mediate recognition, or
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alternatively, a difterent structure may be employed. The use of synthetic peptides derived
from this region in in vitro assays may aid elucidation of the relationship between structure and
function. Furthermore, the effect of the observed substitution of arginine and lysine residues
between the EV1 and 1514 proteins may be investigated by a similar approach.
Much remains to be learned of the interaction between MVV Rev and its target RNA.
In particular, is protein multimerisation required? The work of Tiley and Cullen (1992) would
suggest that multimerisation on RNA does occur. Co-operative binding of Rev monomers is
essential for functional interaction of HIV-1 Rev with the RRE. Daly et al. (1993a) have
demonstrated that the RNA binding half life of a Rev molecule is extended three-fourfold on
binding of a second molecule. Kinetic studies of the MVV Rev/RNA interaction may help
understanding of the mechanism of binding specificity, by comparing the on and off rates for
specific and non-specific interactions.
7.4 Functional Implications of Rev/RNA Interactions
MVV Rev has been shown to control the production of the Env glycoprotein in
infected cells (Tiley et al., 1990). This activity is mediated by the liberation of pre-mRNA
encoding the Env protein from nuclear retention, and is thus homologous to the functional
mechanism of HIV Rev. Chimaeric proteins containing the MVV basic domain and the HIV-1
activation domain were competent to direct trans-activation of MVV structural genes from a
subgenomic fragment, provided a MVV RRE structure was present. The reverse situation was
also found to be true; thus the leucine-rich domain of MVV Rev was defined as an activation
domain which is functionally interchangeable with that of the HIV-1 protein. Mutagenesis of
the MVV Rev protein identified functionally important residues within the activation domain;
the identity and position of such residues was similar to that seen in HIV-1 (Tiley et al., 1991).
However, Tiley et al. found that MVV Rev activation domain mutants possessed poor trans-
dominant inhibitory properties, such that substitution with the activation domain of a HIV-1 TD
mutant was required for efficient inhibition of MVV wild type Rev function. This is suggestive
of a less modular organisation of the MVV protein, such that compensatory interactions from
outside the activation domain could be of relevance. Similar results have been presented for
the CAEV Rev protein, which maintains a conserved domain structure to that of MVV Rev
(Saltarelli et al., 1994). In contrast to an early study of the subcellular localisation of MVV Rev
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protein (Mazarin et a/., 1990), a conventional nuclear/nucleolar distribution ot the Rev proteins
of both MVV and CAEV has been reported (Tiley et at., 1990; Schoborg and Clements, 1994;
Schoborg etal., 1994). The essential requirement of a functional revgene for both MVV and
CAEV viral viability has recently been established (Schoborg and Clements, 1994; Toohey
and Haase, 1994). Thus, the overlap in the biological properties of the ungulate lentiviral Rev
proteins and the HIV protein has so far shown to be almost complete, with the possible
exception of the genesis of inhibitory activation domain mutants.
7.5 Reciprocal Rev/RRE Interactions
The two strains of MVV used in this thesis, EV1 and 1514, were found to be
competent for function through the heterologous RRE. Similarly, both proteins were able to
trans-activate a gene linked to the CAEV RRE. However, the degree of activity was highest
with the cognate RRE. Thus, there appears to have been co-divergence of the Rev/RRE
elements from each of these viruses. Heterologous interactions between retrovirus
Rev/RREs are illustrated by figure 7.1. The HTLV-1 Rex and HIV-1 Rev proteins are
functionally promiscuous, able to mediate activity through the response elements of a range
of other viruses. The more fastidious requirements of these other viruses may be at the level
of RNA binding, multimerisation or co-factor interactions. The CAEV RRE seems particularly
susceptible to the Rev proteins of other viral species (Saltarelli et at., 1994): this does not
extend to the MVV RRE (Tiley etal., 1991). Elucidation of the mechanism behind this
phenomenon may aid the study of the biochemistry of the Rev/RRE interaction.
7.6 Future Prospects
Much remains to be learned about the molecular biology of the MVV Rev/RNA
interaction, and of the functional mechanisms which Rev utilises to exert regulatory control
over viral replication. However, much of this work, though important, may involve recapitulation
of the experimental approaches used thus far to analyse the HIV equivalents. To date, the
observed conservation of the biology of MVV/CAEV and HIV Rev regulatory systems has
been remarkable for such sequence-divergent viruses. It may be suggested that this
functional homology will continue to be observed. Thus, it may be appropriate to concentrate
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Figure 7.1: Compatibility of Rev/RRE Axis of Diverse Complex Retroviruses
Figure illustrates the experimentally defined interactions between the Rev/Rex
proteins of complex retroviruses and the respective response elements. Arrow indicates that
the Rev proteins of the originating virus is competent to mediate function through the
response element of the indicated virus. For example, HIV-1 Rev can function through the
HIV-2 RRE; this function is not reciprocal. Full reciprocity is indicated by a double headed
arrow. For simplicity, no indication of the degree of function is indicated in this diagram. The
EIAV, FIV and BIV proteins have yet to be comprehensively studied, although EIAV and HIV-1
Rev/RRE systems are incompatible (Fridell et al., 1993). Information derived from this thesis,




on topics for which the distinct nature of MVV may be of benefit in the overall study of Rev.
It has been proposed that transgenic sheep expressing a mutant form of the MVV
Rev protein may be protected from viral infection (Tiley et al.,. 1991). Such an experiment
would be of interest for the potential development of gene therapeutical approaches against
human AIDS. The presence, degree and inter-strain nature of protection would be important
variables to consider. Moreover, it would be of interest to identify potential cytotoxic activity in
wild-type and mutant transgenic animals. It is possible that over-expression of a revtransgene
could prove cytotoxic, resulting in a failure to obtain transgenic animals. Sheep expressing a
MVV envtransgene have been reported (Clements etal., 1994).
To date, much of the research on Rev function has been centred on in vitro or cell
culture studies which may not provide fully comprehensive data as to the importance of Rev
for viral replication, persistence and pathogenesis. Experimental infection of sheep with
biological clones of MVV could be developed to identify the presence and functional
significance of rev variation during infection. It would be of interest to determine whether
inactivating rev mutations occur, as has been reported for HIV-1 infection (Iversen et al.,
1995).
Finally, the identification of co-factors for Rev function might allow the effect of
ablation of such factors in an infected host to be studied. The human nucleoporin-like
molecule rip/rab (1.15.2) which acts as a Rev co-factor in the nucleocytoplasmic export of viral
RNA, has been shown to bind the MVV activation domain (Bogerd et al., 1995). Isolation of an
ovine homologue of this protein, and analysis of the requirement of the protein for cell viability
may result in the development of transgenic 'knock-out' animals failing to express this factor.
The susceptibility of such animals to MVV challenge would be of considerable interest in the
development of human gene therapeutics.
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